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Abstract
Equine metabolic syndrome (EMS) is a clustering of clinical signs associated with in-
creased risk of laminitis, a potentially life-threatening condition of the foot. Similar to
human metabolic syndrome (MetS), generalized and/or regional adiposity, hyperinsu-
linemia, insulin resistance and dyslipidemia, are reported components of EMS. However,
there is ongoing debate regarding the definition of EMS, its etiology and pathogenesis,
and the mechanisms linking EMS to its secondary consequences. Conflicting reports
regarding EMS reflect the limitations of prior EMS studies, and that EMS is likely a
complex, multifactorial condition similar to MetS. The primary objectives of this thesis
were to characterize metabolic variation and EMS across horse and pony breeds and to
identify candidate genes for EMS risk.
Chapter 2 details the largest-ever epidemiological investigation of EMS in which 11
metabolic traits were measured in > 600 horses and ponies from 166 farms. The use
of multivariate, multilevel regression modeling allowed, for the first time, quantification
of the relative importance of environmental (farm, dietary composition, exercise, etc.)
and individual (age, breed, sex etc.) factors on these metabolic traits, while accounting
for the often strong correlation between the trait measures. Age, sex, breed, obesity,
prior laminitis status, and time of year were all strongly associated with one or more
metabolic traits. Despite strong associations, these factors only explained 9.6% to 36.3%
of the variation across these 11 traits, thus the majority of the variability in these mea-
sures remained unexplained. Unexplained variation at the farm level after accounting
for diet, exercise, and sampling time of year, suggests that additional unmeasured envi-
ronmental factors explain the similarity in metabolic measures between horses sampled
from the same farm. Similarly, unexplained variation at the individual level suggests
that unmeasured individual characteristics, for example genetics, are responsible for a
large proportion of individual trait variation.
Differences in the incretin response may also contribute to individual trait variation.
The incretin response, defined as the difference in insulinemic responses between an oral
and intravenous glucose challenge, is controlled by intestinal secretion of peptides, such
as GLP-1, that stimulate pancreatic insulin secretion. While the incretin response has
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been hypothesized to play a role in the EMS pathogenesis, this hypothesis has not been
adequately tested. In Chapter 3, the glycemic, insulinemic, and total and active GLP-1
responses to an oral sugar challenge, and the activity of DPP4, the major protease that
breaks down GLP-1, were characterized. The use of a longitudinal analysis, rather than
the traditional area under the curve analysis, allowed for more power to detect differ-
ences in these responses, including variation due to breed, obesity, and prior laminitis
status.
Unexplained individual level variation and breed differences in metabolic phenotypes
support the hypothesis that there is an underlying genetic susceptibility to EMS. The
final objective of this thesis was to identify candidate genes associated with EMS. MetS
is a highly polygenic syndrome where numerous candidate genes have been identified.
Whereas MetS associated variants are typically of small effect size; it was hypothesized
that in EMS a small number of moderate to large effect loci contribute to variation
in metabolic traits due to the fact that horse populations do not randomly mate and
experience substantial selection pressure. 286 Morgan horses were genotyped on the
Illumina SNP50 chip and imputed up to > 800,000 SNPs to perform a genome wide
association study (GWAS) to identify candidate genes for EMS. Additive genetic vari-
ance estimated from a genomic relationship matrix calculated from genotyped SNPs
(“chip heritability”) indicated that the 11 measured metabolic traits were moderately
heritable. Yet initial genome-wide scans using standard linear mixed models failed to
detect significant associations.
In Chapter 4, an improved linear mixed model for mapping polygenic traits in a
population with familial relationships similar to that in many equine GWAS was devel-
oped and validated. The model incorporates a Bayesian variable selection method to
rank SNPs and a stepwise feature selection process to determine the optimal SNPs to
model the random polygenic effect, while including a random effect for each sampled
herd or “familial cluster”. The method was validated using the QTL-MAS 2010 dataset,
and Morgan horse and Welsh pony height datasets, and demonstrated increased power
while controlling the false positive rate.
Using this improved linear mixed model, 76 suggestive and 17 genome-wide signifi-
cant candidate loci were identified for the 11 metabolic traits in the 286 Morgan horse
cohort. Candidate genes had a substantial overlap with MetS candidate genes such as
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VEGFA, NRXN3, GRIK2, and TRIB2. Other interesting candidate genes included ISL,
which encodes insulin enhancer protein that is thought to play an important role in reg-
ulating insulin gene expression; and AHR which encodes the aryl hydrocarbon receptor,
a ligand activated transcription factor known to bind endocrine disrupting chemicals
such as polycyclic aromatic hydrocarbons and dioxins. AHR is an interesting candidate
gene given the potential role of endocrine disrupting chemical in the pathophysiology
of MetS, and unexplained sources of farm level variation in Chapter 2.
A unifying theme of Chapters 2-5 was the similarities between EMS and MetS,
and the complex phenotypic and genetic architecture in both species. The use of ad-
vanced statistical modeling approaches allowed for a more complete understanding of
the metabolic phenotypic variation in Chapters 2 and 3, and for the identification of
many associated genetic loci in Chapter 5. The shared candidate genes for metabolic
syndrome in humans and horses suggests similar underlying pathophysiological mech-
anisms and provides opportunity for exploring similar preventative and therapeutic
management strategies.
v
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Chapter 1
Introduction and Literature
Review
1.1 Introduction
Metabolic syndrome, a constellation of abnormalities, including obesity, dyslipidemia,
glucose intolerance and hypertension, has become a global health concern largely due
to the increase in prevalence and association with increased risk of cardiovascular dis-
ease and type 2 diabetes (T2D). A similar metabolic condition exists in horses and is
associated with increased risk of laminitis, a crippling and potentially life-threatening
condition of the foot. Ongoing debate exists in both the human and veterinary fields
regarding the etiology and pathogenesis of metabolic syndrome and the mechanisms
linking the syndrome to its secondary consequences. In both fields, conflicting reports
generated from different investigations of the etiology and pathogenesis of metabolic
syndrome reflect the complex, multifactorial nature of the condition. In order to de-
velop effective preventative and therapeutic strategies for managing the secondary con-
sequences of the syndrome, further research is warranted to determine the mechanisms
underlying metabolic syndrome.
1
1.2 Review of metabolic syndrome literature
1.2.1 Human metabolic syndrome
Definition of human metabolic syndrome
Metabolic syndrome (MetS) is a growing public-health challenge worldwide coinciding
with urbanization, excess dietary intake, increasing obesity and sedentary lifestyles.
MetS itself does not cause clinical signs but rather comprises a set of risk factors for
diseases that include atherosclerosis, coronary heart disease, stroke, and T2D. MetS
began as a concept rather than a diagnosis and has been evolving for years. In 1920,
Kylin demonstrated the association of hypertension, hyperglycemia, and gout.1 In 1947,
Vague described an association of visceral adiposity with metabolic abnormalities found
with cardiovascular disease (CVD) and type II diabetes.2 At the 1965 meeting of the
European Association for the Study of Diabetes, a syndrome was reported to be com-
prised of hypertension, hyperglycemia, and obesity.3 In 1988 Raeven described a cluster
of risk factors for T2D and CVD and suggested the name “Syndrome X”. He intro-
duced the concept of insulin resistance and compensatory hyperinsulinemia as the main
pathophysiological mechanism underlying MetS.4 Many names have been given to the
syndrome although they all appear to describe different components of the same entity.
Recognized components of MetS include insulin resistance, obesity, dyslipidemia, hy-
pertension, and hyperglycemia.
Establishment of MetS as a disease entity has been impeded by the lack of a con-
sensus regarding criteria for its diagnosis. Several groups including the world health
organization (WHO),5 European Group for the study of Insulin Resistance (EGIR),6
the American Association of Clinical Endocrinologists (AACE),7 the National Choles-
terol Education Program Adult Treatment Panel (NCEP/ATP)8and International Di-
abetes Federation (IDF) have attempted to set forth diagnostic criteria for MetS based
on cut-off points for different MetS component measurements.9,10 A major challenge
in developing criteria that is applicable worldwide is to define obesity cut-off points.
Different populations have different distributions of norms for body weight and weight
circumferences and the relationship between these values and the risk of CVD or T2D
varies in different populations. Because no single definition of metabolic syndrome has
been accepted worldwide, data regarding the prevalence of MetS is variable. Worldwide
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prevalence ranges from < 10% to as much as > 80% depending on the regional environ-
ment, population composition, and the definition of MetS used.11,12 Overall, the IDF
estimates 25% of the world’s adult population has MetS.9
Pathophysiology of human metabolic syndrome
The etiology and pathogenesis of MetS is an area of active debate with many unknowns.
To quote Zimmet on the IDF’s stance “MetS may be an etiologic mystery but far from
myth”.13 Insulin resistance and obesity are the dominant factors cited in the develop-
ment of MetS. The current discussion of MetS pathophysiology is largely based on the
recognition of adipose tissue as a physiologically active organ along with the recognition
of the concept of insulin resistance and its consequences.
The role of adipose tissue in MetS pathophysiology:
Adipose tissue was once considered as merely a storage site for lipids but is now rec-
ognized as a complex, active endocrine tissue that secretes many factors referred to
as adipokines that regulate metabolism and vascular biology. Examples of adipokines
include: adiponectin, leptin, resistin, and pro-inflammatory mediators (tumor necrosis
factor alpha (TNFα) and interleukin-6 (IL-6)), plasminogen activator inhibitor-1 (PAI-
1), and C-reactive protein (CRP).14
Adiponectin regulates lipid and glucose metabolism, increases insulin sensitivity,
regulates food intake and bodyweight, and has anti-inflammatory effects. Adiponectin
inhibits endothelial activation, reduces conversion of macrophages to foam cells, and
inhibits smooth muscle proliferation characteristic in the development of atherosclero-
sis.15 Low adiponectin is a strong independent risk factor for CVD and is inversely
correlated with blood pressure, low-density lipoprotein cholesterol, triglycerides, insulin
resistance, and hyperinsulinemia independent of fat mass.16–18
Leptin secretion is regulated by adipose tissue mass. Plasma leptin levels increase
during the development of obesity and decline with weight loss. Leptin receptor signal-
ing in the hypothalamus and brain stem regulates satiety and energy intake.19 However,
obese individuals exhibit leptin resistance and do not experience appetite suppression
in the presence of elevated leptin levels as expected. Leptin resistance is thought to
play a key role in the pathology of obesity.14 In addition, leptin affects blood pressure
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via activation of the sympathetic nervous system.20 Hyperleptinemia is considered an
independent risk factor for CVD development.21
Resistin expression is linked with insulin resistance and is 15-fold greater in rodent
visceral adipose tissue than subcutaneous adipose tissue.22 Serum resistin is elevated
with rodent obesity and treatment with recombinant resistin in rodents produces insulin
resistance.23 However, human resistin shares limited homology with murine resistin and
is expressed at low levels in human adipocytes. Numerous epidemiological studies in
humans have failed to provide a consistent link between resistin expression in adipose
tissue or circulating levels with adiposity or insulin resistance.22
Adipocyte hypertrophy and hyperplasia occurs in response to nutrient excess. As
the adipocytes enlarge, blood supply is reduced and hypoxic damage to the adipocytes
occurs.24 Necrosis and macrophage infiltration of the adipose tissue leads to the produc-
tion of pro-inflammatory cytokines, which include pro-inflammatory mediators TNFα
and IL-6, PAI-1, and CRP.19 Circulating TNFα is secreted primarily by macrophages in
obese adipose tissue, whereas adipocytes typically produce a membrane bound form.25,26
TNFα stimulates lipolysis and increased levels are highly correlated with insulin resis-
tance, hyperinsulinemia, and hypertension.27–29 TNFα also stimulates expression of
other inflammatory mediators such as leptin and IL-6 and inhibits expression and se-
cretion of adiponectin.30–32 IL-6 has been shown to inhibit insulin action in muscle,
liver, and adipocytes and has been reported to be an important contributor to the
chronic inflammatory state and hepatic insulin resistance of obesity.33,34 PAI-1 is a ser-
ine protease inhibitor secreted from adipocytes, platelets, and vascular endothelium that
inhibits tissue plasminogen activator and is therefore a marker of impaired fibrinolysis
and atherothrombosis.19,35 PAI-1 levels are increased in individuals with abdominal
obesity.36 CRP levels are positively correlated with waist circumference, insulin resis-
tance, body mass index (BMI), and hyperglycemia.37–39 CRP is also more likely to be
elevated in obese insulin resistant individuals than non-obese insulin resistant individ-
uals.40
In summary, adipocytokines affect insulin signaling, energy metabolism, blood co-
agulation, and inflammatory responses demonstrating adipose tissue does much more
than store and mobilize lipids.
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Insulin Resistance:
Insulin resistance is defined as a pathophysiological condition in which a normal insulin
concentration does not produce a normal insulin response in the target tissue such as
muscle, liver, or adipose. Pancreatic β-cells secrete more insulin (hyperinsulinemia) to
compensate to some degree in order to maintain normoglycemia (T2D is the result of
β-cell exhaustion hence inadequate compensating for insulin resistance). However, un-
der hyperinsulinemic conditions, increased insulin levels at target tissues results in the
clinical manifestations of MetS via differential activation of insulin signaling pathways.
Insulin signaling occurs following binding of insulin to the insulin receptor and tyrosine
phosphorylation of downstream substrates and activation of two parallel pathways: the
phosphoinositide 3-kinase (PI3K) pathway and the mitogen activated protein (MAP)
kinase pathway. The PI3K pathway is inhibited under insulin resistant conditions while
the MAP kinase pathway functions normally. Inhibition of the PI3K pathway leads
to a reduction in endothelial nitrous oxide production causing endothelial dysfunction
along with a reduction in GLUT4 translocation resulting in decreased glucose uptake in
skeletal muscle. Since the MAP kinase pathway is still functioning normally, there is con-
tinued endothelin-1(ET-1) production, expression of vascular cell adhesion molecules,
and stimulation of vascular smooth muscle cells leading to the vascular abnormalities
predisposing to atherosclerosis.41 Thus, continued functioning of the MAP kinase in-
sulin signaling pathway combined with inhibition of the PI3K pathway under conditions
of insulin resistance resulting in endothelial dysfunction is a possible mechanism linking
MetS to atherosclerosis.
Obesity enhances insulin resistance. In obese individuals, adipose tissue releases in-
creased amounts of non-esterified fatty acids (NEFA), glycerol, hormones, pro-inflammatory
cytokines and other factors involved in the development of insulin resistance.42 NEFA
are derived mainly from adipose tissue triglyceride stores released through the action of
hormone sensitive lipase. NEFA are also produced through lipolysis of lipoproteins in
tissues by the action of lipoprotein lipase.43 Insulin is involved in both anti-lipolysis and
the stimulation of lipoprotein lipase. The most sensitive pathway of insulin action is
inhibition of lipolysis in adipose tissue. However, when insulin resistance develops, the
increased lipolysis of stored triacylglycerol molecules in adipose tissue produces more
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free fatty acids, further inhibiting the anti-lipolytic effect of insulin and creating ad-
ditional lipolysis.44 In humans, insulin resistance develops within hours of an acute
increase in NEFA levels.45 Moreover, insulin mediated glucose uptake improves with an
acute decrease in NEFA levels following treatment with an anti-lipolytic agent.46 Acute
exposure of skeletal muscle to elevated NEFA levels induces insulin resistance by in-
hibiting insulin-mediated glucose uptake and secondly, chronic exposure of the pancreas
to elevated NEFA levels impairs β-cell function.47
Dyslipidemia:
Insulin resistance leads to an atherogenic dyslipidemia in several ways. First, as de-
scribed above, impaired insulin signaling impairs the normal suppression of lipolysis
by insulin resulting in increased NEFA levels. The NEFA flux to the liver and serve
as a substrate for triglyceride synthesis. NEFA also stabilize the production of apoB,
the major lipoprotein of very low-density lipoproteins (VLDL) particles, resulting in
increased VLDL production. Secondly, since insulin normally degrades apoB through
PI3K-dependent pathways, insulin resistance directly increases VLDL production due
to impairment of the PI3K pathway. Third, insulin regulates the activity of lipoprotein
lipase, which is a major mediator of VLDL clearance. Overall, insulin resistance re-
sults in hypertriglyceridemia via both an increase in VLDL production and a decreased
clearance of VLDL. VLDL is metabolized to small, dense LDL which promote atheroma
formation.48 In summary, the NEFA flux to the liver of insulin resistant individuals is
increased resulting in increased triglyceride synthesis and storage, and excess triglyc-
eride is secreted as VLDL. It is thought that the dyslipidemia associated with insulin
resistance is a direct consequence of increased VLDL secretion by the liver.49–51
Hypertension:
Two mechanisms have been proposed for the hypertension that occurs in insulin resistant
individuals. Both insulin and leptin activate the sympathetic nervous system resulting
in increased vascular tone and hypertension. Secondly, insulin resistance is known to
activate the renin-angiotensin-aldosterone system (RAAS). Renin facilitates conversion
of angiotensinogen to angiotensis I that is subsequently converted to angiotensin II by
6
angiotensin-converting enzyme. Angiotensis II causes blood vessels to constrict result-
ing in increase blood pressure. Aldosterone increases blood pressure mainly through
sodium retention and plasma volume expansion. RAAS may also promote oxidative
stress and endothelial dysfunction.52
Prothrombotic state and endothelial dysfunction:
PAI-1 increases with insulin resistance. PAI-1 inhibits tissue-type plasminogen activa-
tor (t-PA), a serine protease that converts plasminogen to plasmin and is involved in
clot specific fibrinolysis. Thus increased PAI-1 contributes to a prothrombotic state.53
Endothelial dysfunction is characterized by an impaired endothelium-dependent vasodi-
lation. Hyperinsulinemia causes the release of ET-1, a potent vasoconstrictor. Whereas
adiponectin stimulates the production of nitric oxide (anti-inflammatory vasodilator) in
vascular endothelial cells,54 suggesting adiponectin has a protective vascular effect and
that this protective effect is weakened in individuals with low adiponectin levels.55 The
potent vasoprotective effects of nitric oxide counteract various atherogenic processes
such as vascular smooth muscle cell proliferation, platelet adhesion and thrombogene-
sis, lipid peroxidation, and monocyte adhesion to endothelial cells.56
In summary, resistance to the actions of insulin and compensatory hyperinsulinemia
play a central role in MetS, as either the cause or consequence of one or more of its
components.
Genetic susceptibility to human metabolic syndrome
Large variation in MetS susceptibility in individuals with a similar risk profile suggests
an interaction between environmental and genetic factors. For example, some individu-
als who are not obese are insulin resistant where as some individuals who are obese are
not insulin resistant.57 Ethnic variation exists in the pattern of metabolic risk factors.
Expression of metabolic risk factors may be under genetic control, which influences the
response in different types of environments. The “thrifty genotype hypothesis” proposed
by Neel hypothesizes individuals living in harsh environments with a fluctuating food
supply would increase their probability of survival if they were able to maximize storage
of surplus energy. Genetic selection would favor energy-conserving genotypes in these
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environments. However, this genetic adaptation may become unfavorable in alternative
environments.58
Family studies suggest a genetic basis for the components of metabolic syndrome.
Significant genetic correlations among the MetS components have been identified for
BMI, waist circumference, high-density lipoproteins (HDL), triglycerides, insulin, and
PAI-1.59 Candidate gene studies and genome wide association studies have revealed
numerous candidate genes for MetS. In a systematic review, Povel describes the most
studied single nucleotide polymorphisms (SNPs) in relation to MetS suggesting an as-
sociation of MetS with SNPs in the FTO, TCF7L2, IL6, APOA5, APOC3, and CETP
genes.60 The FTO polymorphism is a top GWAS hit for BMI61 and the TCF7L2 poly-
morphism is a top hit for T2D.62 The IL6 polymorphism is associated with increased
BMI and IL-6 levels.63 APOA5, APOC3, and CETP polymorphisms are all associated
with hypertriglyceridemia.64–66
1.2.2 Animal models of human metabolic syndrome
For a complex disease syndrome like MetS no single, ideal animal model can be ex-
pected to meet all of the research needs. Therefore a large number of different species
and strains are used to study causative and pathophysiologic hypotheses related of MetS.
Rodent models are used to test different MetS causative hypotheses such as genetics,
fetal programming, diet, activity, aging, gender, and pollution. The ability to introduce
or eliminate genes from the rodent genomes allows testing of single-gene mutations and
the polygenic basis of MetS. Quantitative trait loci (QTL) mapping conducted in rodents
is used to locate new candidate genes of MetS traits that often become targets of human
candidate gene studies.67 Rodent models are used to determine how and when altered
early nutrition and growth affect adult development of MetS.68 Diet-induced rodent
models are used to examine the role of diet in MetS. The two most commonly studied
models are the high-sucrose fed spontaneously hypertensive rats and the high-fructose
fed Sprague Dawley rats (SD) which develop insulin resistance, hyperinsulinemia, and
hypertension.69 Diet-induced obese rats and mice are commonly used to study the
role of obesity in MetS, although variation in glucose tolerance, insulin resistance, and
triglyceride levels depend on the strain, gender, and source of dietary fat.70 Classic obe-
sity rodent models also include single-gene loss-of-function mutations related to leptin
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metabolism that result in extreme obesity such as obese (ob/ob) mice (Lepob mutation)
and the Zucker (fa/fa) obese rat (Leprfa).71
Other animal species such as sheep, pigs, rabbits, and dogs have also been used
to study the etiology and pathogenesis of MetS. The correlation between visceral adi-
posity and insulin resistance in dogs closely resembles that of humans.72 Rodents and
rabbits do not spontaneously replicate atherosclerosis seen in humans partly due to dif-
ferences in lipoprotein metabolism which include lack of cholesterylester transfer protein,
differences in the apolipoprotein B pathway, and VLDL dominated lipid metabolism
in rabbits. Cholesterol feeding and mechanical endothelial injury are used to induce
atherosclerosis in these models.73 Pigs have LDL-dominated lipid metabolism similar
to humans and do develop atherosclerosis.74
1.2.3 Equine metabolic syndrome
Current definition of equine metabolic syndrome
A condition similar to human metabolic syndrome exists in horses, referred to as equine
metabolic syndrome (EMS), that was first described by Johnson in 200275 and accepted
by a consensus committee in 2010.76 The equine condition resembles the human con-
dition in many aspects, although the vascular consequences differ. In humans, the
vascular structures affected by the condition are typically the coronary vessels whereas
in horses the vasculature of the hoof is affected resulting in laminitis, a potentially
severe, crippling and life-threatening condition. Johnson recognized the primary fea-
tures of the laminitis-prone phenotype shared striking similarities to those described
for human MetS including obesity and insulin resistance. The 2010 American College
of Veterinary Internal Medicine (ACVIM) listed several criteria for EMS based on the
research data available at the time. The three main criteria included:76
• Documented or suspected insulin resistance, ie hyperinsulinemia and/or abnormal
glycemic and insulinemic responses to oral or IV glucose or insulin challenges;
• Generalized obesity and/or increased adiposity in specific locations (regional adi-
posity) including the nuchal ligament (“cresty neck”), the tail head, behind the
shoulder, in the prepuce or mammary gland region;
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• A predisposition toward laminitis that develops in the absence of other recognized
causes, such as grain overload, retained placenta, colitis, colic or pleuropneumonia.
Additional suggested components included:
• Hypertriglyceridemia, dyslipidemia, and increased low density lipoprotein concen-
trations77–79
• Hypertleptinemia80
• Arterial hypertension78,81
• Altered reproductive cycling in mares82,83
• Increased systemic markers of inflammation in association with obesity84
Features of equine metabolic syndrome
Similar to the debate and evolving definition of human MetS, the features that define
EMS are a subject of ongoing debate in the equine veterinary community despite the
earlier consensus statement. Descriptions of the metabolic phenotype of laminitis-prone
horses and ponies have varied among published studies (Table 1.1),77–79,81,85 making a
unifying phenotypic definition difficult. The lack of consensus among study reports may
result from unmeasured explanatory variables, insufficient sample size to detect signif-
icant effects in the presence of confounding variables, and differences in experimental
design including differences in test cohort, breed, time of sample collection (time of
day and or season). Lack of consensus also likely reflects the complexity of the “EMS”
phenotype with multiple factors at both individual and environmental levels likely con-
tributing to variation in metabolic traits.
Insulin resistance is the primary criteria used by clinicians and investigators to
define EMS. However, true insulin resistance is rarely documented in EMS cases. The
diagnosis of insulin resistance in horses is complicated by the fact that “gold standard”
methods for assessing insulin sensitivity (frequently-sampled intravenous glucose toler-
ance test, hyperinsulinemic euglycemic clamps) are labor intensive and not readily used
in clinical practice. Further, the substitution methods for diagnosing insulin resistance
such as fasting insulin levels, combined glucose-insulin tolerance tests, and oral glucose
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Table 1.1: A summary of findings related to obesity, regional adiposity and en-
docrine/metabolic variables in published studies of the equine metabolic syndrome
(EMS) phenotype.
Treiber et al.77 Frank et al.79 Bailey et al.81 Carter et al.78
2006* 2006 2008 2009*
Breed(s) Welsh and
Dartmoor
ponies
6 breeds Mixed-breed
ponies
Welsh and
Dartmoor
ponies
Sample size 160 12 80 74
Obesity (BCS) Yes Yes No Yes
Regional adiposity Yes Yes No Yes
Hyperinsulinemia Yes Yes Yes** Yes
Insulin resistance Yes(RISQI) Yes(CGIT) Yes**(RISQI) Yes(RISQI)
Fasting glucose Not different Higher in EMS Not different Not different
Triglycerides Higher in EMS Not different Higher in
EMS**
Higher in EMS
NEFAs Not different Higher in EMS Not evaluated Not evaluated
*Data obtained from the same population of Welsh and Dartmoor ponies; **serum
insulin and triglyceride concentrations and RISQI differed between ponies with and
without a history of laminitis in summer but not in winter; BCS = body condition
score; RISQI = reciprocal of the square root of the serum insulin concentration; CGIT
= combined glucose-insulin tolerance test; NEFAs = nonesterified fatty acids; Table
adapted from McCue et al.85
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tolerance tests are highly variable and have not been thoroughly evaluated as valid mea-
sures of insulin sensitivity. Thus, while there has been much discussion about insulin
resistance in EMS, very few studies have reported quantitative data on insulin sensitiv-
ity and other aspects of glucose and insulin dynamics in affected animals. Two studies
using minimal model analysis of a frequently-sampled intravenous glucose tolerance test
(FSIGTT) have provided evidence of compensated insulin resistance in laminitis pre-
disposed breeds.86,87
The majority of reports have used “fasting” or “resting” measures of insulin and glu-
cose and/or indices derived from minimal model analysis of FSIGTT measurements as
proxy indicators of insulin resistance,88 with the current consensus view that a fasting in-
sulin concentration >20 mIU/L indicates insulin resistance.76 Fasting hyperinsulinemia
is typically (but not always) accompanied by normoglycemia, which suggests compen-
sated insulin resistance, i.e. increased pancreatic insulin secretion in response to reduced
tissue insulin sensitivity. Two studies in ponies using minimal model analysis of FSIGTT
have provided evidence of compensated insulin resistance, based on indices of insulin
sensitivity and acute insulin response.86,89 Mechanisms other than a compensatory
increase in pancreatic secretion may contribute to the hyperinsulinemia. Decreased
insulin clearance by the liver is a second possible mechanism of hyperinsulinemia. In
one study, reduced insulin clearance was shown to contribute to hyperinsulinemia in
obese horses.90 It has also been proposed that hyperinsulinemia may not necessarily
be secondary to insulin resistance but that the reverse may actually be true,91 leading
some to question whether hyperinsulinemia in EMS is the “cart or the horse”. It has
been considered plausible that horses manifesting chronic hyperinsulinemia may be the
result of an enhanced incretin response (intestinal secretion of incretin hormones that
stimulate insulin secretion in response to oral sugar) with insulin resistance occurring
secondary to chronic hyperinsulinemia.92,93 Hyperinsulinemia has been shown to be a
feature in the EMS phenotype in ponies and Morgan horses,77–79,81 although there is
wide variation in values among studies. The prevalence of hyperinsulinemia (insulin
concentration > 20 mIU/L) was 18% of the obese/over-conditioned horses vs only 1.4%
of the normally conditioned horses in a study of 300 randomly selected mixed-breed
horses in southwest Virginia,94 while another study in Australia reported a 27% preva-
lence of hyperinsulinemia in randomly selected ponies.95 In the pony study, age, body
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condition score (BCS), supplementary feeding and a history of laminitis were identified
as risk factors for hyperinsulinemia.
Evidence of obesity and/or the presence of one or more enlarged subcutaneous fat
deposits (regional adiposity) has been regarded as one of the defining characteristics
of EMS. Horses and ponies diagnosed with EMS may be obese, defined as a Henneke
scales BCS of ≥7/9, and/or have regional adiposity. Common sites of regional fat accu-
mulation include the nuchal ligament region (cresty neck), behind the shoulder (uni- or
bilateral), around the tail-head, and in the preputial or mammary gland regions. Simi-
lar to human MetS, generalized obesity and/or regional adiposity are thought to play a
role in the EMS phenotype. Studies in horses have demonstrated an inverse relationship
between BCS and specific measures of insulin sensitivity and positive correlations be-
tween adiposity, resting insulin concentrations and blood markers of inflammation (e.g.
serum amyloid A, TNF-α, mRNA encoding for IL-1βand TNF-α).78,84,96,97 Induction
of an ∼20% weight gain in Arabian geldings has been shown to result in a reduction in
insulin sensitivity,98 while weight loss in obese ponies resulted in improvement in glucose
tolerance and decreased fasting insulin concentrations.99 Interestingly, moderate weight
gain in Thoroughbred geldings failed to alter insulin sensitivity.100 These observations
reinforce the idea that factors other than BCS and adipose tissue mass contribute to
differences in insulin sensitivity, but also raise the possibility that there are breed dif-
ferences in regards to the impact of obesity on metabolic function.
Increased plasma triglyceride concentrations were a feature of the EMS phenotype
in a closed herd of Welsh ponies77 and was also documented in an out-bred popula-
tion of ponies with a history of recurrent laminitis,81 although hypertriglyceridemia was
variable with season. In a small, mixed-breed group of obese, insulin-resistant horses
increased serum NEFA concentrations (but not triglycerides) were detected, whereas
serum NEFAs were not useful in the differentiation of an EMS phenotype in ponies.77,79
Hypertension, altered serum adipokine concentrations, and systemic inflammation,
all of which are features of metabolic syndrome in humans, may be additional compo-
nents of the EMS phenotype. Bailey and colleagues81 detected arterial hypertension in
mixed-breed, recurrent laminitic ponies during summer but not in winter. Increased
serum leptin has been reported in Welsh ponies with other features of the EMS phe-
notype,78 while other studies have reported a positive association between BCS and
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circulating inflammatory biomarkers84,96 and a significant inverse relationship between
apparent adiposity and serum adiponectin.101,102 Decreased adiponectin levels have
been detected in ponies with prior laminitis history.103 A study of 15 ponies in a weight
reduction program demonstrated a link between plasma adiponectin and insulin resis-
tance, whereas serum leptin was linked to adiposity, independent of insulin sensitivity.104
Features of EMS seem to be more common is some breeds compared to others, espe-
cially pony breeds in comparison to horse breeds. Other breed suggested predispositions
include the Morgan breed, Miniature horses, Spanish Mustang, Saddlebred, Warmblood,
Haflinger, Norwegian Fjord, Peruvian Paso, Paso Fino breeds, and Tennessee Walking
horses.105 EMS has also been reported in some Quarter Horses. Familial clustering of
EMS associated laminitis has also been identified in pony breeding lines supporting a
genetic basis for the condition in horses.77
Laminitis has been demonstrated to be inducible by infusing super physiological
amounts of insulin intravenously over 2-3 day period.106,107 The mechanism linking
insulin and laminitis is unknown with hypotheses stemming from human MetS and
believed links between insulin, insulin resistance, hypertension, and endothelial dys-
function. A possible mechanism being impairment of the PI3K pathway resulting in
decreased nitric oxide synthesis with subsequent reduced digital vasodilator effects, ac-
tivation of the MAPK pathway stimulating ET-1 synthesis and sympathetic nervous
system activation with subsequent digital vasoconstriction effects.76
The horse as a potential animal model of metabolic syndrome
As described above, significant clinical overlap exists between features of human and
equine metabolic syndrome (Table 1.2).85 Both conditions place the individual at a
higher risk of a vascular condition, atherosclerosis in humans and laminitis in horses.
The underlying etiology for both conditions are still unknown and subject of current
debate in both the human and veterinary medical fields. It is possible these two similar
conditions may share a common etiology and pathogenesis and knowledge from one
species may be transferable to the other. As stated earlier, no one animal can be
expected to serve all research needs. Equine models of MetS have the potential to
provide novel insight into the underlying etiology and pathophysiologic mechanisms of
human MetS and its sequelae.
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Table 1.2: Human and equine metabolic syndrome comparison
Human Metabolic Syndrome Equine Metabolic Syndrome
(MetS) (EMS)
Increased BMI or obesity Generalized obesity assessed by body condition score
(BCS)
Intraabdominal or visceral
obesity
Regional adiposity in the nuchal ligament “cresty
neck” phenotype strongly correlated with serum glu-
cose, insulin, triglyceride and leptin concentrations,
and glucose tolerance
Hyperinsulinemia Hyperinsulinemia fasting insulin concentrations >20
mU/L
Impaired fasting glucose Resting plasma glucose concentrations increased in
comparison with normal horses in some studies
Insulin resistance Insulin resistance suggested by various oral and IV
glucose challenge models
Hypertension Hypertension
Dyslipidemia: increased
NEFA, triglycerides, de-
creased VLDL, HDL
Increase in triglycerides, nonesterified fatty acids
(NEFA), HDL cholesterol, decreased VLDL
Proinflammatory state: in-
creased TNF-α, IL-1, IL-6
Increased TNF-α, IL-1, decreased IL-6
Altered adipokines: in-
creased leptin, decreased
adiponectin
Increased leptin, decreased adiponectin
Abbreviation: BMI, body mass index; HDL, high-density lipoprotein; IL, interleukin;
TNF-α, tumor necrosis factor alpha; VLDL, very-low-density lipoprotein; Table adapted
from McCue et al.85
1.3 Review of multilevel modeling: basics and extensions
Careful consideration must be given to experimental design and analytical approaches
directed at understanding the complex, multifactorial basis of metabolic syndrome. As
described in the above literature review, conflicting results have been reported for both
human and equine metabolic syndrome studies, adding to the confusion regarding the
definition and pathophysiology of metabolic syndrome. The following section is intended
to provide a brief overview of an analytical approach utilized in this thesis to address the
analytical challenges presented when studying a complex, multifactorial condition with
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numerous correlated features impacted by both individual and environmental factors.
Table 1.3: Multilevel modeling definitions.
Multilevel model Short explaination
statistical term
Random effect Levels of the factor are a only a “sample” of the total
possible levels.
Fixed effect Levels of the factor are not a “sample” of possible
levels, i.e. all levels are sampled.
Intracluster correlation coef-
ficient (ICC)
A measure of homogeneity of sampled clusters that
can be interpreted two ways: 1) proportion of total
variance of an outcome accounted for by the clusters
or 2) the correlation between measured outcomes for
two randomly drawn individuals in the cluster.
“Null” model Model does not contain explanatory variables, only
decomposes the variance of an outcome.
“Full” model Model contains predictor variables that explain vari-
ance in an outcome.
R2 Proportion of variance explained by predictor vari-
ables.
1.3.1 Reasons for multilevel models
A multilevel statistical model is applied to stratified data in order to elucidate rela-
tionships at more than one level.108 A multilevel linear model (aka hierarchical linear
model,109 random coefficients model,110 mixed effects model,111 growth curve model112)
is a standard method for analyzing outcome data with hierarchical structure such as
observations clustered within individuals and individuals clustered within groups. The
hierarchical structure leads to correlations among the observations within a cluster and
therefore violation of the statistical assumptions of outcome independence. Violating
this assumption leads to inaccurate standard errors and significance tests for fixed ef-
fects. Multilevel models account for the correlation among observations by including
additional error terms (random effects).
Epidemiological investigations often feature a clustered sample design. Modeling the
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outcome dependence is important to control for bias as described above but can also
be of substantive interest. Multilevel models can assess the influence of cluster level
explanatory variables while controlling for individual level explanatory variables. This
thesis describes an epidemiological investigation of metabolic trait variation in horses
sampled with a clustered design; multiple horses sharing a common farm environment
were sampled from numerous farms throughout the United States. Sources of metabolic
trait variation likely include both individual and environmental factors. Examples of
individual factors include genetics, age, and sex where as examples of environmental
factors include diet and season. A multilevel analysis facilitates an investigation of
metabolic syndrome at both an individual and environmental level.
1.3.2 The basic two-level multilevel model
The hierarchical linear model notation writes a separate equation for each level of the
hierarchy and then combines the equation into a single model equation. The first level
of the model for simple regression on the level 1 variable X is written as
Level 1: Yij = β0j + β1x1ij + e0ij , (1.1)
where i (1,...,n) refers to the level 1 (individual) unit and j (1,...,m) to the level 2
(group) unit. The level 1 model appears similar to a typical ordinary least squares
multiple regression model, however, the j subscripts indicate a different level 1 model is
being estimated for each of the j level 2 groups. The intercept and/or slopes are allowed
to randomly vary across level 2 units. An initial step toward modeling between-group
variability is to let the intercept vary between groups. In the case of a random intercept
model each of the different j groups are allowed to have a mean that differs than the
population mean. The level 2 equation is written as
Level 2 random intercept: β0j = γ00 + u0j . (1.2)
The notation for the regression coefficients is changed and the average intercept is called
γ00 while the regression coefficient for X is called γ10. Substitution leads to the combined
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model
Yij = γ00 + γ10xij︸ ︷︷ ︸
fixed
+u0j + e0ij ,︸ ︷︷ ︸
random
(1.3)
where E(u0ij) = 0 and var(u0ij) = σ
2
u0 and E(e0ij) = 0 and var(e0ij) = σ
2
e0 . The
single model equation indicates which part of the model comprises the fixed effects (the
γs) and which part comprises the random effects (u and e). The single model equation
illustrates that the level 1 parameters (β0j , β1j ,β2j) are not directly estimated but are
indirectly estimated through the level 2 gammas γs.108
For example, in a sample population with multiple sampled farms and sampling of
multiple horses per farm the horse is considered level 1 and the farm is considered level
2. A random intercept effect is estimated for each farm, i.e. the difference of the trait
mean for the farm from the trait mean of the entire sample population.
Intracluster correlation coefficient (ICC)
The intracluster correlation coefficient (ICC) measures the proportion of variation ac-
counted for by the group level. The sum of the level 2 and level 1 variances reasonably
estimates the sample variance of the dependent variable.113 The parameter is called a
correlation coefficient because it is equal to the correlation between values of two ran-
domly drawn individuals from the same group where (σ2u0 and σ
2
e0 are estimates of the
level 2 and level 1 variances obtained by fitting a null model (empty model with only
an intercept and no explanatory variables)).108
Null (“empty”) model: Yij = γ00 + u0j + e0ij
ICC: ρ =
σ2u0
(σ2u0 + σ
2
e0)
(1.4)
An ICC greater than zero indicates the observations are not independent and jus-
tifies multilevel modeling of the data. Multilevel modeling relaxes the assumption of
independence and allows for correlated error structures. If ordinary least squares is
used for clustered data with correlated errors, the resulting standard errors are biased
downward resulting in a greater chance of Type 1 errors. Multilevel models estimate the
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appropriate unbiased errors. Therefore it was important to perform a multilevel model
analysis of the data in this study given horses were not sampled randomly and therefore
can not be considered independent observations, an assumption of standard ordinary
least squares regression. If independent observations were assumed, test statistics may
be biased and lead to incorrect inferences.
Assessing model fit
Models fit by restricted maximum likelihood (REML) that are nested and only differ in
their random effects can by assessed for their goodness of fit with the REML statistic.
The Akaike Information Criterion (AIC=-2 loglikelihood + 2*number or parameters,
decreases with goodness of fit) and the loglikelihood (increases with goodness of fit)
can be used for assessment of relative differences in goodness of fit114 and in the case
of model comparisons, the chi-square distributed likelihood ratio and its associated p-
value.108
In ordinary least square regression the fit of a model is assessed by calculating R2
the percentage of variance of the outcome accounted for by explanatory variables in the
model. In multilevel models there is a separate R2 for each level of the model and it
is possible to have smaller or even negative R2 values with inclusion of additional ex-
planatory variables in the model. Alternative R2 approaches for multilevel models often
referred to as a pseudo-R2. The statistic is interpreted as the proportional reduction in
variance or proportion of variance explained for a parameter estimate that results from
the use of one model as compared to a Null model or alternative base model with fewer
explanatory variables.109
pseudo-R2level 2 =
Null model σ2u0 − Full model σ2u0
Null model σ2u0
pseudo-R2level 1 =
Null model σ2e0 − Full model σ2e0
Null model σ2e0
(1.5)
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1.3.3 Extending the basic multilevel model
Longitudinal models
Multilevel modeling can also be applied to longitudinal or repeated measures data where
multiple observations are clustered within a single individual or object and the primary
interest is in modeling the predictors of change over time. Multilevel models are able
to characterize the between and within-individual variability of an outcome trajectory
over time and identify factors that influence the trajectory.
Initially, plots of the data over time should be examined to determine the appro-
priateness of a linear, quadratic, or cubic relationship with time. An ordinary least
squares regression model fit to an unconditional (aka “Null”,“empty”) model with time
included as the only predictor aids in determining whether a linear, quadratic, or cubic
modeling of time best fits the mean population trajectory. Second, multilevel models
are fit sequentially to determine the appropriateness of allowing the intercept, linear
slope, or quadratic slope to vary randomly between the level 2 individuals (AIC and
likelihood ratio tests aid in the selection of the random regression model). For example,
consider a quadratic model of time was determined to best model the mean population
trajectory. The level 1 equation is written
Unconditional Level 1: Yij = β0j + β1j(time)ij + β2j(time
2)ij + e0ij , (1.6)
where i (1,...,n) refers to the level 1 unit (time point) and j (1,...,m) to the level 2
unit (individual). The level 2 equations modeling a random intercept, linear slope, and
quadratic slope are written
Unconditional Level 2: β0j = γ00 + u0j
β1j = γ10 + u1j
β2j = γ20 + u2j ,
(1.7)
where E(u0ij) = E(u1ij) = E(u2ij) = 0, var(u0ij) = σ
2
u0, var(u1ij) = σ
2
u1, var(u2ij) =
σ2u2, cov(σ
2
u0, σ
2
u1) = σu01, cov(σ
2
u0, σ
2
u2) = σu02, cov(σ
2
u1, σ
2
u2) = σu12, E(e0ij) = 0 and
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var(e0ij) = σ
2
e0 . The combined unconditional model is written as
Combined unconditional: Yij = γ00 + γ10(time)ij + γ20(time
2)ij +u0j +u1j +u2j + e0ij .
(1.8)
The next step is to move on to a conditional model where explanatory variables
considered to influence the intercept or slopes are included to the model. It is impor-
tant to note that the interpretation of the intercept and slopes are dependent on the
coding of time. The intercept is the mean value when time=0 and the linear slope is
the rate of change at time=0. For a quadratic model, the quadratic slope remains the
same at all time points. The quadratic slope is equivalent to one half of the accel-
eration/deceleration of the rate of change. Below are examples of level 1 and level 2
equations for a conditional model that includes the effect of level 2 explanatory variable
xj on the intercept, linear slope and quadratic slope.
Conditional Level 1: Yij = β0j + β1j(time)ij + β2j(time
2)ij + e0ij
Conditional Level 2: β0j = γ00 + γ01xj + u0j
β1j = γ10 + γ11xj + u1j
β2j = γ20 + γ21xj + u2j
Combined equation: Yij = γ00 + γ01xj + γ10(time)ij + γ11xj(time)ij
+ γ20(time
2)ij + γ21xj(time
2)ij
+ u0j + u1j + u2j + e0ij
(1.9)
A longitudinal model is used in Chapter 3 to model glucose, insulin and GLP-1
measurements repeated at 7 timepoints (level 1) for each horse (level 2).
Three level models
Multilevel models can be extended to handle more than two levels. Repeated measure-
ments are often collected from individuals that are clustered in groups or alternatively
individuals may be sampled from subgroups of a larger group. For example, if the
repeated observations for individuals modeled in equation (1.8) were correlated at a
higher level due to being sampled in a clustered design the model can be extended to
account for correlation at the third level. The mean for each group is allowed to vary
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randomly across level 3 groups. The level 1, level 2, level 3, and combined model for
repeated measures clustered within individuals clustered within groups where the mean
is allowed to vary randomly across level 3 units and individuals at level 2 are allowed
to have randomly varying intercepts and slopes would be written as
Unconditional Level 1: Yijk = β0jk + β1jk(time)ijk + β2jk(time
2)ijk + e0ijk
Unconditional Level 2: β0jk = δ00k + u0jk
β1jk = γ100 + u1jk
β2jk = γ200 + u2jk
Unconditional Level 3: δ00k = γ000 + v00k
Combined unconditional: Yijk = γ000 + γ100(time)ijk + γ200(time
2)ijk
+ v00k + u0jk + u1jk + u2jk + e0ijk
(1.10)
where i (1,...,n) refers to the level 1 unit (time point), j (1,...,m) to the level 2 unit
(individual), and k (1,...,l) to the level 3 unit (group).
A three level model is used in Chapter 3 to model glucose, insulin and GLP-1
measurements repeated at 7 timepoints (level 1) for each horse (level 2) sampled from
a particular farm (level 3).
Multivariate multilevel models
Multilevel models can be extended to handle more than one dependent outcome. The
dependent variable Yhij is the measurement on the hth variable for individual i in
group j. It is possible to analyze all h variables independently although there are
several reasons for considering analyzing the data in a multivariate manner.113 For
one, partitioning of the covariances between the dependent variables over the different
levels of the model allow conclusions to be drawn about the correlations between the
dependent variables at both group and individual levels. Second, the tests of specific
effects for a single dependent variable will be more powerful in the multivariate analysis
in the situation where individuals are missing data for some of the dependent variables
but the dependent variables are strongly correlated. Third, a multivariate approach
allows one to test whether the effect of an explanatory variable on dependent variable
22
Y1 is larger than its effect on Y2 when Y1 and Y2 were observed on the same individuals.
Finally, a multivariate approach is needed if one desires to carry out a single test of the
joint effect of an explanatory variable on several dependent variables.
The random intercept model for dependent variable Yh with individual-dependent
or group-dependent explanatory variables X1,...,Xp is written as
Yhij = γh00 + γh10x1ij + γh20x1ij + ...+ γhp0xpij + uh0j + e0hij . (1.11)
Three nesting levels are used to represent multivariate data in a multilevel manner.
The first level is the dependent variables indexed by h=1,...,m, the second level is the
individuals i=1,...,nj , and the third level is the groups j =1,...,N. Each measurement of a
dependent variable far a particular individual is represented by a single line of the data
matrix containing Yhij, h, i, j, and explanatory variables x1,...,xp. Dummy variables
d1,...,dm are used to indicate the dependent variable represented on the data line.
dshij =
1 (h = s),0 (h 6= s) (1.12)
The random intercept model for the m dependent variables is combined into one three
level hierarchical linear model. In the sums over s=1,...,m only the term for s=h con-
tributes and all the other terms disappear.
Yhij =
m∑
s=1
γ0sdshij +
p∑
k=1
m∑
s=1
γksdshijxkij +
m∑
s=1
usjdshij +
m∑
s=1
e0sijdshij (1.13)
Since the dependent variables Y1,....Ym are measured on the same individuals their
dependence can be taken into account. The (u)s and the (e)s are components of vectors
uij =

u10j
...
um0j
 , e0ij =

e01ij
...
e0mij
 . (1.14)
There are now residual covariances matrices present at the group and individual level
instead of residual variances.
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
σ2u1 σu1u2 . . . σu1um
σu1u2 σ
2
u2 . . . σu2um
...
...
. . .
...
σu1um σu2um . . . σ
2
um

︸ ︷︷ ︸
between group covariance matrix

σ2e01 σe01e02 . . . σe01e0m
σe01e02 σ
2
e02 . . . σe02e0m
...
...
. . .
...
σe01e0m σe02e0m . . . σ
2
e0m

︸ ︷︷ ︸
within group covariance matrix
(1.15)
A multivariate model is used in Chapters 2 to model the covariance structure of
metabolic phenotypes at both the individual horse and farm level. The multivariate
model is used in Chapter 3 to model the covariance structure of trajectories at individual
horse level.
1.4 Hypothesis and objectives
The underlying molecular mechanism responsible for EMS has not been identified. It is
clear however, that metabolic syndrome itself and its key components, obesity, insulin
resistance and laminitis are influenced by environmental factors, with EMS most com-
monly seen in horses receiving excessive nutrition, often from pasture. On the other
hand, nutritional excess does not result in EMS in all horses. The factors underlying
this difference in susceptibility have not been determined, but recent studies indicate
it may be due to an underlying genetic predisposition. Currently, the genetic variants
underlying this disease phenotype are unknown, which restricts understanding of the
disease pathophysiology, limits the ability to predict disease risk, and hinders the ability
to identify individuals who can benefit from early intervention.
Central hypothesis: An underlying genetic susceptibility to EMS exists and is shared
across horse breeds. The goal is to define the EMS phenotype and shared phenotypic
risk factors across breeds and to identify the underlying genetic component/risk alleles.
Objective 1: Quantify the variation in metabolic phenotypes across horse/pony breeds
and the impact of individual and environmental factors, and to identify differences
in metabolic phenotypes in horses/ponies with obesity and/or a history of laminitis.
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Previous studies of the EMS phenotype have demonstrated variability in phenotypic
measurement across equine populations yet a large scale, across-breed epidemiologic
investigation of EMS has not been performed. In this aim, epidemiologic data includ-
ing signalment/history, environmental (diet and physical activity) and phenotypic data
(morphometric and biochemical measures) will be collected from 5 target breeds and a
total of 600+individuals. Data will be analyzed to:
1. Describe the correlations between morphometric, biochemical, and hormonal mea-
sures used to assess equine metabolic variation.
2. Quantify the proportion of metabolic trait variation between farms and individual
horses within farms.
3. To estimate the effect of measured individual factors (i.e. age, breed, and gender)
and measured environmental factors (i.e. diet, exercise, management practices,
etc.) on metabolic trait measures.
4. To determine how metabolic trait measurements differ between obese and non-
obese horses with and without previous laminitis.
5. Quantify the proportion of explained by environmental and individual factors by
quantifying the variation explained and unexplained variation at the farm and
individual horse level in metabolic trait measurements.
6. Determine the relative importance of age, breed, sex, obesity, prior laminitis sta-
tus, diet, and exercise to the explained variability in metabolic traits.
Objective 2: To examine response to an oral sugar challenge and incretin biology (DPP-
IV activity; insulin secretory and GLP-1 responses; SNPs in GCG and DPP4) in Mor-
gan horses and Welsh ponies. The hypothesis is that DPPIV activity and GLP-1 re-
sponses to oral glucose challenge differ significantly between EMS horses and unaffected
animals, and that these differences in incretin responses are associated with SNPs in
DPP4 and GCG. Objectives include:
1. Characterize DPP-IV activity, insulin secretory and GLP-1 responses to oral glu-
cose challenge in Morgan horses and Welsh ponies; and
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2. Determine if SNPs within GCG and DPP4 are associated with differences in in-
sulin responses, DPP-IV activity and GLP-1 responses.
Objective 3: Identify genetic loci associated with equine metabolic trait variation.
1. Develop and validate an improved linear mixed for mapping polygenic traits in a
population with familial relatedness.
2. Perform a genome-wide association analysis in single breed cohort (genotyped
using the Equine SNP50 Beadchip) with EMS associated phenotypes identified in
Objective 1.
Significance of studying equine metabolic syndrome
In summary, both human and equine metabolic syndrome are increasingly common
conditions with devastating consequences. Knowledge and understanding of the fea-
tures of metabolic syndrome in both species and their link to vascular consequences
are increasing, however much still remains unknown. The ongoing debates evolving in
both human and veterinary fields regarding the etiology and pathogenesis of metabolic
syndrome reflect the complex and likely multifactorial basis of the condition. Further
research directed at characterizing the EMS phenotype and genetic basis of the condi-
tion is warranted and will benefit horses and potentially humans. Determination of the
genetic risk factors underlying the development of EMS and laminitis susceptibility will
lead to an improved understanding of EMS pathophysiology. This will enable identi-
fication of horses at risk for EMS and allow preventative management practices to be
put into place and also aid in the identification of therapeutic strategies.
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Chapter 2
Re-defining the equine metabolic
syndrome phenotype
2.1 Summary
Chapter 2 details the largest-ever epidemiological investigation of equine metabolic syn-
drome (EMS), a clinical syndrome in horses associated with increased risk of laminitis
development. 11 metabolic traits were measured in 610 horses and ponies from 166
farms. The use of multivariate, multilevel regression modeling allowed, for the first
time, quantification of the relative importance of environmental (farm, dietary compo-
sition, exercise, etc.) and individual (age, breed, sex etc.) factors on these metabolic
traits, while accounting for the often strong correlation between the trait measures.
Age, sex, breed, obesity, prior laminitis status, and time of year were all strongly asso-
ciated with one or more metabolic traits. Despite strong associations, these factors only
explained 9.6% to 36.3% of the variation in these traits, thus the majority of the vari-
ability in these measures remains unexplained. Unexplained variation at the farm level
after accounting for diet, exercise, and time of year, suggests that additional environ-
mental factors explain the similarity in metabolic traits measured from horses sharing
the same farm environment. Similarly, unexplained variation at the individual level sug-
gests unmeasured individual characteristics, for example genetics, may be responsible
for metabolic trait variation.
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2.2 Introduction
Equine metabolic syndrome (EMS) is a clinical syndrome associated with increased
risk of laminitis development. Generalized/regional adiposity, hyperinsulinemia, insulin
resistance, dyslipidemia, and predisposition to laminitis development are reported com-
ponents of the syndrome. However, not all studies have consistently reported the same
components for EMS (see Table 1.1). Hyperinsulinemia has been shown to be a feature
of the EMS phenotype in ponies77,81 and Morgan horses,79 however, values vary between
studies.78,81,115 Elevated plasma triglyceride concentrations have been associated with
the EMS phenotype in ponies78,81,116 but not in horses;79 whereas, non-esterified fatty
acid (NEFA) concentrations have been associated with an EMS phenotype in horses,79
but were not useful in the differentiation of an EMS phenotype in ponies.77,78 Morpho-
metric measurements to quantify generalized obesity (girth to height ratio and body
condition score) and regional adiposity (neck circumference to height ratio) have also
been associated with the EMS phenotype in horses79 and proposed as predictors of
laminitis risk in ponies;78 but obesity is not a consistent finding across studies, partic-
ularly in well-managed populations.81
The body of knowledge concerning EMS is growing, however there is a lack of consen-
sus regarding the EMS phenotypic criteria. Potential explanations include differential
in the experimental design between studies. For example, differences in the study co-
hort or time of year of sample collection result in different conclusion due to breed or
season. Insufficient sample size or unmeasured confounding variables may be an ad-
ditional limiting factor of previous studies. In addition, EMS is not likely a singular
condition; multiple factors at both individual and environmental levels likely contribute
to variation in metabolic traits.
The objectives of this chapter are to quantify the variation in metabolic phenotypes
across horse/pony breeds and the impact of individual and environmental factors, and
to identify differences in metabolic phenotype in horses/ponies with obesity and/or a
history of laminitis. To address these objectives, a cross-sectional study of 11 metabolic
traits was performed in 610 horses clustered within 166 farms. A multilevel, multivari-
ate statistical model was utilized to quantify the impact of both individual and farm
characteristics on metabolic measurements in this cohort (trait variation) and determine
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how these measured responses relate to each other (trait co-variation). In a multivari-
ate model, multiple outcome measures are analyzed simultaneously. A multilevel model
partitions the variance of the outcomes into both individual (horse) and group (farm)
levels. By modeling a multivariate, multilevel outcome response one recognizes that the
metabolic traits measured in this cohort are inter-related and that EMS is a complex
condition, measured by several outcome variables (metabolic phenotypes). And further,
that these outcomes are impacted by both individual and environmental factors. Ana-
lyzing data in which samples are clustered by farm environment using ordinary linear
regression is problematic due to violation of the assumptions of independent observa-
tions. Increased similarity of observations from individuals within the same farm leads
to underestimation of the standard errors for regression parameter estimates and inflates
the Type I error.117 Multilevel modeling is well suited to this type of data structure
and is able to model the outcome of interest by examining how farm-level or horse-level
characteristics are related to metabolic trait measures.
When evaluating multiple outcome measurements, one approach would be to per-
form separate multilevel analyses for each trait. However, this option can lead to an
inflation of type 1 error (finding a significant effect where in reality there is no effect),
especially when the measured traits are inter-related as with EMS phenotypes. An alter-
native approach is to model a multivariate, multilevel model. A multivariate model has
several advantages over a series of univariate analyses. By accounting for the possible
relationships between different outcome variables in a multivariate model, one decreases
the chance of making a type 1 error. For example, in a situation where two outcome
measurements are correlated and an explanatory variable effects only one of the out-
come variables; there is a good chance univariate analysis would find an association
with each outcome because of their correlation structure, despite one of the associations
being untrue. A second advantage of a multivariate, multilevel model over a series of
univariate models is that multivariate models typically have greater statistical power.
Finally, the multivariate approach enables us to assess the degree of correlation between
different metabolic traits and the extent to which correlations depend on individual and
environmental factors.
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2.3 Methods
2.3.1 Study Population
Horses were recruited into the study using two mechanisms to ensure an adequate repre-
sentation of horses with varying metabolic phenotypes from different breeds and shared
environments. A 2-step online data survey system was designed to recruit owners of
EMS suspect horses. The initial survey obtained information regarding the horses’ sig-
nalment, previous history of laminitis, and propensity toward being an “easy keeper”.
Exclusion criteria for further participation in the study included suspicion of pars pitu-
itary intermedia dysfunction (PPID) based on age, hair coat, increased thirst/urination,
and/or diagnostic test results for PPID. Inclusion criteria to participate in a second,
more detailed survey included previous history of laminitis (not associated with sys-
temic infection or non-weight bearing lameness in contralateral limb), obesity, and/or
being considered an “easy keeper”. The second survey obtained information from the
EMS suspect horse and along with information from a second horse on the property
not suspected of EMS. Information obtained included digital photos of the horses, body
measurements, diet/exercise information, frequency/treatment of laminitis, and signal-
ment information from the non-EMS suspect horse. Based on survey responses, horse
owners were invited to submit blood and dietary samples from their horses. In ad-
dition to the online recruitment of study participant, Morgan and Welsh pony breed
associations were also contacted to identify farm owners with 1 or more EMS suspect
horses who were willing to allow researchers to visit the farm and sample and obtain
information from multiple horses.
Samples were obtained from 634 horses, 17 horses were eliminated from the study
population due to evidence of hair coat abnormalities and not already defined adreno-
corticotropin hormone (ACTH) elevation (>90pg/ml) suggestive of PPID. Seven horses
were eliminated from the study population due to incomplete data (failure to submit
diet samples, unknown prior laminitis status). The mean study population age was used
for 1 horse with unknown age. A total of 610 horses were included in the analysis.
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2.3.2 Sampling Protocol
Horses were removed from pasture the evening prior to morning (7-10 am) blood sample
collection performed by either the researchers or the horse owner’s veterinarian. Horses
were allowed access to water and provided with 1 flake of hay at 10PM. Horse owners
were also given the opportunity to have the horse participate in an optional oral sugar
test. Following collection of the baseline blood sample, 0.15 ml corn syrup per kg
bodyweight was administered orally and a second blood sample obtained 75 minutes
post oral sugar administration. Blood samples submitted by horse owners were shipped
overnight on ice and centrifuged (1000 x g for 10 minutes) the following morning on
arrival. Plasma and serum were stored at -80oC. Samples collected by researchers were
processed immediately following sample collection.
2.3.3 EMS trait measurements
Measures of obesity
Regional and generalized adiposity were measured using body condition score (BCS),
girth to height ratio and neck circumference to height ratio, respectively. Body condi-
tion scores were assessed using the system developed by Henneke.118 Body condition
scores were assessed by a single investigator (NS) for researcher collected samples and
scored by the same investigator from a standardized set of digital photos for samples
submitted by horse owners. Horses with a body condition score ≥ 7 were considered
obese.118 A standard set of morphometric measurements were collected for each horse.
The neck circumference was measured at one-half the distance between the poll and
the withers with the neck held in a relaxed position.98 To minimize variations due
to muscling and hind leg conformational differences, body length was measured as the
length from the point of shoulder (intermediate tubercle of the humerus) to the point
of the buttock (ischiatic tuberosity), by visualizing a perpendicular line that was drawn
at the point of the buttock.119 Height was measured as the distance from the floor to
the height at the third thoracic vertebra. Heart girth circumference was measured at
the third thoracic vertebra. Neck circumference to height ratios (NH) were calculated
by dividing the neck circumference measured halfway between the poll and withers by
the withers height. Girth to height ratios (GH) were calculated by dividing the girth
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(measured at the heart) by the withers height. Bodyweight was estimated using: Weight
(kg) = girth (cm)2 x length (cm)/11,877.120
Glucose assay
Glucose (GLU) concentrations were determined using YSI glucose and lactate analyzer
(2300 STAT Plus): An enzyme specific for glucose oxidase is immobilized between two
membrane layers, polycarbonate and cellulose acetate. The substrate is oxidized as it
enters the enzyme layer, producing hydrogen peroxide, which passes through cellulose
acetate to a platinum electrode, where the hydrogen peroxide is oxidized. The resulting
current is proportional to the concentration of the substrate.
Insulin assay
Insulin (INS) concentrations were determined using Coat-A-Count from Siemens per
manufacturer’s instructions and validated for equine serum samples as previously vali-
dated by Borer-Weir et al, 2012.121
Triglycerides assay
Serum triglyceride (TG) concentrations were determined using Serum Triglyceride De-
termination kit (TR0100) from Sigma. Assays were run per manufacturer’s protocol
but modified for use in a 96-well microplate format. Briefly, 200 μl of Free Glycerol
Reagent was added to 2.5 μl of standards (serial dilution of Glycerol Standard Solu-
tion, G7793, Sigma), and to samples and a control serum sample and incubated for
5 min at 37C. Absorbance 1 (Abs1) was read at 540 nm using a SpectraMax 340PC
microplate reader. This measurement served as the standard/sample blank. Next, 50 μl
of Triglyceride Reagent was added to each well and incubated at 37◦C for an additional
5 min. Following the incubation, absorbance 2 (Abs2) was read at 540 nm. The final
absorbance for each well was determined by subtracting Abs1 from Abs2. Triglycerides
concentration of each sample was then determined using the constructed linear stan-
dard curve (absorbance vs. concentration). Standards and samples were assayed in
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triplicates.
Nonesterified fatty acids assay
Non-esterified fatty acid (NEFA) concentrations were determined using NEFA-HR from
Wako. Nonesterified fatty acid concentrations were quantified by the enzymatic colori-
metric method, ACS-ACOD (NEFA-HR), as outlined by Panzani et al, 2012,122 and
modified for use in a 96-well microplate format per manufacturer’s instructions. Briefly,
200 μl of color reagent A solution was added to 5.0 μl of standards (serial dilution
of NEFA Standard solution 276-76491), and to samples and a control serum sample
and incubated for 10 min at 37◦C. Absorbance 1 (Abs1) was read at 550/660 nm us-
ing a SpectraMax 340PC microplate reader. This measurement served as the stan-
dard/sample blank. Next, 100 μl of color reagent B solution was added to each well
and incubated at 37◦C for an additional 10 min. Following the incubation, absorbance
2 (Abs2) was read at 550/660 nm. The final absorbance for each well was determined
by subtracting Abs1 from Abs2. Nonesterified fatty acid concentration of each sam-
ple was then determined using the constructed linear standard curve (absorbance vs.
concentration). Standards and samples were assayed in duplicate.
Adrenocorticotropin hormone assay
Adrenocorticotropin hormone (ACTH) concentrations were determined from plasma
samples using an automated chemiluminescent enzyme immunoassay system (Immulite)
validated previously by Perkins et al.123 on the Immulite 1000 (Siemens). Intra assay
variation at the low control (29 pg/ml) was 3% and 2.5% at the high control (367 pg/ml)
for 10 replications.
Leptin assay
Leptin (LEP) concentrations were determined using Multi-Species Leptin Radioim-
munoassay (RIA) (XL-85K) from EMD Millipore per manufacturer’s instructions. This
assay was validated previously by Fitzgerald, B.P., McManus, C.J., (2000),124 and Mc-
Manus and Fitzgerald (2003).125 The kit utilized 125I-labeled recombinant human lep-
tin, a guinea pig multispecies leptin primary antibody, and a goat anti-guinea pig IgG
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serum for the precipitating reagent. Purified recombinant human leptin was used for
the kit standards and quality controls. Samples were run in duplicate and counted for
one minute in a gamma counter.
Adiponectin assay
Serum (APN) adiponectin concentrations were determined using a human high molecu-
lar weight (HMW) adiponectin enzyme-linked immunosorbent assay (ELISA) (EZHMWA-
64K) from EMD Millipore following a protocol validated for equine serum by Wooldridge
et al 2012.101 Samples were run in duplicate.
2.3.4 Signalment and medical history
Signalment information including age, breed, sex, and pregnancy status was docu-
mented. Clinical group status (non-obese/no prior laminitis history, non-obese/prior
laminitis history, obese/no prior laminitis history, and obese/prior laminitis history)
was determined based on medical history and BCS. Supplementation with L-thyroxine
was also documented.
2.3.5 Environment measurements
Geographic latitudes (determined from address informationa) and month of sample col-
lection were documented. Exercise data included average hours of stall confinement per
day, average hours of exercise per week, and description of the type of exercise (see
Table A.2). Average hours per day grazing was also reported. Hay, pasture, and grain
samples were obtained for dietary analysis. Hay samples were collected from 5 bales
of similar hay (same species and cutting) by opening each bale and grabbing a fist full
of hay. These samples were mixed and then a subsample (1 quart sized bag) collected
for testing. The total amount of hay consumed per horse each day was determined by
multiplying the number of flakes of hay consumed per day by the weight per flake of
hay. Weight per flake of hay was determined by weighing of 10 flakes and determining
an average weight.
Pasture samples were collected from pastures grazed by horses by walking a ’Z’ or
ahttp://www.findlatitudeandlongitude.com/
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’M’ pattern throughout the entire pasture and collection of 10 random samples. Sam-
ples included all forage in a one-foot square area cut down to the ground. Areas where
horses had defecated or areas where no grazing occurred were avoided. These samples
were then placed into a bucket and mixed thoroughly and a subsample (1 quart sized
bag) was collected for testing. Because standing forage is approximately 85% water, the
samples were kept out of direct sunlight and placed in a cooled box for shipping to the
laboratory. All diet samples were stored at -20o or -80oC until being shipped to Equi-
Analytical Laboratories for analysis (pasture samples were shipped to Equi-Analytical
Laboratories on dry ice).
Daily caloric consumption (Mcal) and grams crude protein (CP), neutral detergent
fiber (NDF), starch, and water soluble carbohydrates (WSC) consumed per kg body-
weight (bwt) were calculated based on dry matter weight of each dietary component
determined from analysis of dietary samples multiplied by the daily dry matter (DM)
weight fed of each dietary component. Dry matter weight of daily pasture consumption
was calculated by multiplying the determined pasture dry matter proportion by an esti-
mate of the amount of pasture consumed daily based on time spent on pasture. Grams
of dry matter intake per hour spent on pasture was extrapolated from data indicating
horses on pasture for 3,6,9, and 24 hours consumed 1.96, 1.52, 1.12, and 0.57 g DM
intake per kg bwt per hour.126 A linear regression model was fit with log transformed
DM intake values as an outcome and hours on pasture as a predictor to determine the
following prediction estimate equation (r2=0.95).
g dry matter intake per hour = (10[(hrs grazing∗−0.0244)+0.3265])* hrs grazing * kg bwt
(2.1)
Gram dry matter intake estimates where reduced by 75% for horses reported to have
worn grazing muzzles.127
2.3.6 Statistical Methods
A multilevel, multivariate response model in which multiple outcomes are simultane-
ously regressed over a set of explanatory variables was constructed to answer the re-
search questions.128 See Section 1.3 for an overview of multivariate, multilevel models.
35
A multilevel linear model (aka hierarchical linear model) is a standard method for an-
alyzing outcome data with hierarchical structure such as observations clustered within
individuals and individuals clustered within groups. The hierarchical structure leads to
correlations among the observations within a cluster and therefore violation of assump-
tions of outcome independence leading to inaccurate standard errors and significance
test of fixed effects. Multilevel models account for the correlation among observations
by including additional error terms (random effects).
By including multiple outcomes within the multivariate response model, it is possi-
ble to estimate the covariance between different outcomes nested within individuals and
within farms, as well as the variance for each outcome at both the individual and farm
level in a simultaneous manner, see Equation 1.13. Additionally, the Akaike Information
Criterion (AIC)114 and the likelihood ratio test indicated a multivariate response model
provided a better fit than a univariate response model.
First, a “Null” model was fit that contained no explanatory variables in order to es-
timate the amount of metabolic trait variation and co-variation present at the farm and
individual horse level. The multivariate response variables included neck circumference
to height ratio (NH), girth to height ratio (GH), fasting glucose (GLU), fasting insulin
(INS), glucose 75 minutes post oral sugar challenge (GLU OST), insulin 75 minutes post
oral sugar challenge (INS OST), fasting triglycerides (TG), fasting non-esterified fatty
acids (NEFA), fasting adrenocorticotropin hormone (ACTH), fasting leptin (LEP), and
fasting adiponectin (APN). INS, TG, NEFA, ACTH, LEP, and APN exhibited a skewed
distribution and required log or square root transformations to achieve a more normal
distribution with a centrally located mean.
Secondly, a “full” model containing all of the explanatory models was fit to examine
the degree of reduction in variance estimates achieved with inclusion of explanatory
variables, and to estimate the effect size of individual and farm related factors on trait
outcomes. The full model explanatory variables included: age, breed, sex, clinical group,
sampling time of year, latitude, Mcal/kg bwt per day, CP/kg bwt per day, NDF/kg bwt
per day, Starch/kg bwt per day, WSC/kg bwt per day, hours of exercise per day, hours
grazing per day, hours stalled per day, owner submitted versus researcher collected
sample, and L-thyroxine supplementation(yes/no). Correlation estimates and standard
errors are directly provided by the ASReml-R software129 used to perform the analyses,
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95% confidence intervals were calculated as the estimate ±1.96 x standard error. Fixed
effects are expressed as standardized coefficients (represents the effect size in terms of
the number of standard deviations from the reference group, i.e. the grand mean) and
their standard error. The Wald z-test was used to test the significance of a single fixed
effect and a Wald chi-square test was utilized to test the overall significance level of a
categorical explanatory variable such as month of year. The percent reduction in the
“Null” model variance estimate with inclusion of explanatory variables can be thought
of as a pseudo-R squared and an indicator of the model “goodness of fit”. This was used
to determine the proportion of variation explained by explanatory predictor variables
included in the model.
The fractional importance of individual predictor variables in explaining metabolic
trait measures can be estimated by calculating the percent reduction in the variance
estimate for a model that contained all predictor variables relative to a model that
eliminated the predictor variable(s) of interest. However, this approach will not yield
individual explanatory variable estimates of variance explained that sum up to the to-
tal amount of explained variance by the “full” model if correlation exists among the
explanatory variables. In order to obtain estimates of variance explained by each indi-
vidual explanatory variable that sum up to the total amount of variance explained by
the “full” model, a Shapley value regression approach was utilized.130 Shapley value
regression involves fitting numerous models with each possible combination of the ex-
planatory predictor variables ranging from a single explanatory predictor included in
the model to inclusion of all explanatory variables. The Shapley Value is calculated
across all possible combinations of predictors and can be defined as:
ShapleyV aluej =
∑
k
∑
i
γk[ν(Mi|j)− ν(Mi|j(−j))]
Where:
ν(Mi|j) is the pseudo-R2 of a model i containing predictor j and
ν(Mi|j(−j)) is the pseudo-R2 of the same model i without predictor j.
γk =
k!(n− k − 1)!
n!
is a weight based on the number of predictors in total (n)
and the number of predictors in this model (k).
(2.2)
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For the Shapley Value analysis, the explanatory variable clinical group was fit as two
separate explanatory variables 1) obesity status and 2) prior laminitis status in order to
obtain separate estimates of the variance explained obesity and the variance explained
by laminitis versus only obtaining an estimate of the variance explained by clinical
group.
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2.4 Results
2.4.1 Study population descriptive statistics and demographics
Descriptive summary statistics of the metabolic trait response variables NH, GH, GLU,
INS, GLU OST, INS OST, TG, NEFA, ACTH, LEP, and APN are presented in Table
2.1. Descriptive summary statistics for metabolic trait responses for each level of a
categorical explanatory variable are presented in Appendix table ??. INS, TG, NEFA,
ACTH, LEP, and APN exhibited a skewed distribution and required log or square root
transformations to achieve a more normal distribution with a centrally located mean
(mean approximates median). Summary statistics describing continuous explanatory
variables for the population are presented in Table 2.2 and a summary of categorical
explanatory variable population demographics are presented in Table 2.3.
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Table 2.1: Descriptive summary statistics for metabolic trait outcome variables mea-
sured in the study population
Trait N Mean SD Median Range
NH 603 0.66 0.05 0.66 0.50-0.83
GH 608 1.22 0.07 1.22 0.77-1.49
GLU (mg/dl) 608 77.0 10.4 76.8 32.8-153.0
INS (µIU/ml) 609 12.5 35.1 6.7 1.5-632.0
logINS (µIU/ml) 609 0.84 0.41 0.83 0.18-2.80
GLU OST (mg/dl) 513 98.0 18.4 97.4 40.7-203.0
INS OST (µIU/ml) 514 40.0 67.5 22.3 1.5-783.6
logINS OST (µIU/ml) 514 1.35 0.45 1.35 0.18-2.89
TG (mg/dl) 602 31.7 26.8 25.4 3.7-337.3
logTG (mg/dl) 602 1.42 0.26 1.40 0.57-2.53
NEFA (mmol/L) 607 0.23 0.18 0.19 0.00-1.22√
NEFA (mmol/L) 607 0.45 0.19 0.44 0.00-1.10
ACTH (pg/ml) 608 35.4 32.5 26.8 10.0-287.0
logACTH (pg/ml) 608 1.47 0.24 1.43 1.00-2.46
LEP (ng/ml) 600 6.03 3.91 5.18 0.00-26.15√
LEP (ng/ml) 600 2.33 0.78 2.28 0.00-5.11
APN (ng/ml) 609 4349 3088 3728 0-22189√
APN (ng/ml) 609 61.5 23.7 61.1 0.0-149.0
NH: neck circumference to height ratio, GH: girth to height ratio, GLU: glucose, INS:
insulin, log: base 10 log transformation, OST: oral sugar test, sample was obtained 75
minutes following oral sugar administration,
√
: square root transformation, ACTH:
adrenocorticotropin hormone, LEP: leptin, APN: adiponectin
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Table 2.2: Descriptive summary statistics for continuous explanatory variables measured
in the study population
N Mean SD Median Range
WSC g per kg bwt 610 2.0 0.9 1.8 0.2-5.5
Starch g per kg bwt 610 0.6 0.6 0.4 0.0-5.2
NDF g per kg bwt 610 11.2 5.0 9.8 1.7-27.7
CP g per kg bwt 610 2.7 1.3 2.4 0.5-7.3
Mcal g per kg bwt 610 0.042 0.016 0.039 0.007-0.104
Hrs grazing/day 610 10.7 10.7 8.0 0.0-24.0
Hrs exercise/week 610 1.4 2.4 0.0 0.0-20.0
Hrs stall/day 610 3.5 6.7 0.0 0.0-24.0
Latitude 610 40.776 5.022 41.821 26.715-51.314
Age 610 12.6 6.1 12.0 2.0-33.0
WSC: water soluble carbohydrate, bwt: bodyweight, NDF: neutral detergent fiber, CP:
crude protein, Mcal: megacalorie, Hrs: hours
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Table 2.3: Demographic summary of categorical explanatory variables measured in the
study population
Parameter Categorical Variable N
Non-obese, no prior laminitis Group 340
Non-obese, prior laminitis Group 95
Obese, no prior laminitis Group 111
Obese, prior laminitis Group 64
Morgan Breed 288
Arab Breed 63
Pony Breed 96
Quarter Horse Breed 57
Tennessee Walking Horse Breed 45
HR (other high risk breeds) Breed 45
LR (other low risk breeds) Breed 16
Gelding Sex 210
Mare Sex 368
Stallion Sex 32
Owner submitted sample Sample handling 277
Researcher collected sample Sample handling 333
No L-thyroxine supplementation L-thyroxine supplementation 586
Yes L-thyroxine supplementation L-thyroxine supplementation 24
DEC collection Collection month 58
JAN collection Collection month 8
FEB collection Collection month 39
MAR collection Collection month 86
APR collection Collection month 69
MAY collection Collection month 73
JUN collection Collection month 11
JUL collection Collection month 38
AUG collection Collection month 100
SEP collection Collection month 60
OCT collection Collection month 52
NOV collection Collection month 16
Horses with a body condition score <7 were classified as non-obese, horses with a
body condition score ≥7 were classified as obese. High risk breeds includes Mustang,
Warmblood, Haflinger, Fox Trotter, Rocky Mountain Horse, Saddlebred, Paso Fino,
and Peruvian Paso. Low risk breeds includes Thoroughbred and draft breeds. High risk
and low risk breeds were subjectively determined based on clinical judgement/anecdotal
prevalence reports. The Pony breed group is 88.5%Welsh, 5.2%Welsh cross, and 6.3%
other pony breeds.
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2.4.2 Variance decomposition of equine metabolic traits at the farm
and individual horse level
Estimates of metabolic trait variance at the farm and individual horse level from the
Null model (no explanatory variables included) are presented in Table 2.4. The 0.23-0.49
proportion of variation present at the farm level for the metabolic traits indicate homo-
geneity of traits among horses within a farm or intracluster correlation, i.e. metabolic
traits of two horses selected from the same farm are likely to be more similar than
metabolic traits of two horses selected from different farms. Presence of intraclus-
ter correlation indicate farm related characteristics shared by horses sampled from the
same farm such as diet or season at time of sampling may contribute to variation of
metabolic traits. For all traits, the majority of the variation (0.51-0.77) is present at
the individual level indicating that the metabolic measures of individual horses within
a farm vary about the farm mean due to individual level characteristics, e.g. age or sex.
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Table 2.4: Individidual and farm level variance estimates (standard error) for metabolic
phenotypes
individual level variance farm level variance
NH 0.57(0.04) 0.5(0.08)
53% 47%
GH 0.6(0.04) 0.45(0.08)
57% 43%
GLU 0.69(0.05) 0.37(0.07)
65% 35%
logINS 0.69(0.05) 0.39(0.08)
64% 36%
GLU OST 0.61(0.04) 0.45(0.09)
58% 42%
logINS OST 0.71(0.05) 0.35(0.07)
67% 33%
logTG 0.71(0.05) 0.22(0.05)
76% 24%√
NEFA 0.56(0.04) 0.45(0.08)
55% 45%
ACTH 0.56(0.04) 0.54(0.09)
51% 49%√
LEP 0.71(0.05) 0.33(0.07)
68% 32%√
APN 0.78(0.05) 0.23(0.05)
77% 23%
Phenotypes were scaled to zero mean and variance equal to one standard deviation.
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2.4.3 Correlation of equine metabolic traits at the farm and individual
horse level
The correlation (trait co-variation) between the 11 measured outcome variables (i.e.
NH, GH, GLU, INS, GLU OST, INS OST, TG, NEFA, ACTH, LEP, and APN) was
incorporated in the model at both the individual and farm level. Estimates of metabolic
trait correlation from the “Null” model at the individual horse level are presented in
Table 2.5 and estimates of metabolic trait correlation from the “Null” model at the
farm level are presented in Table 2.6 (covariance estimates are reported in Appendix
Tables A.3 to A.4). Cohen’s guidelines131were used to assess the correlation coefficient
strength (> 0.5=strong, 0.3-0.5= moderate, 0.1-0.3=weak).
Trait correlation at the individual level (see Table 2.5) suggests that two measures
are physiologically related due to physiologic factors or characteristics of the individual
(e.g. age, sex). The absolute values of trait correlation coefficients at the individual level
ranged from zero correlation to 0.67. An individual horse’s post-OST GLU or INS levels
were strongly correlated with the individual horse’s fasted levels. Fasted GLU exhibited
moderate, strong correlation with fasted INS, as did post-OST GLU with post-OST
INS. An individual horse’s TG was moderately correlated with the horse’s INS (fasted
and post-OST) level. An individual’s LEP level exhibited a moderate, strong positive
correlation with INS (fasted and post-OST) where as an individual’s APN level exhibited
a moderate, strong negative correlation with INS (fasted and post-OST) and TG. NH, a
measure of regional adiposity was moderately correlated with INS and demonstrated a
weak negative correlation with APN. GH, a measure of regional adiposity was strongly
correlated with LEP. APN and LPN exhibited a very weak correlation.
Correlations between traits at the farm level (see Table 2.6) suggest that shared
farm level factors, such as environment, season of sampling, etc are impacting both
traits. The absolute values of trait correlation coefficients at the farm level ranged from
zero correlation to 0.86. At the farm level, post-oral sugar test GLU or INS levels
were very strongly correlated with the farm’s mean fasted levels. Farm mean post-
OST GLU were very strongly correlated with the farm’s mean post-OST INS levels
where as farm fasted GLU levels were moderately correlated with farm’s fasted INS
levels. Farm TG levels were strongly correlated with farm’s fasting INS and moderately
correlated with the farm’s post OST INS. Farm ACTH levels exhibited a strong positive
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correlation with the farm’s post-OST INS and a strong negative correlation with APN.
Weak moderate, positive correlation existed for farm ACTH levels and farm fasting INS,
TG, post-OST GLU. Farm LEP levels were strongly correlated with farm INS (fasted
and post-OST) levels. Farm APN demonstrated strong negative correlations with GLU
(fasted and post-OST), INS (fasted and post-OST), and TG, which were stronger than
the correlations at the individual level. In contrast, APN showed a moderate positive
correlation with NH, which is the opposite of the moderate negative correlation between
APN and NH at the individual level. Some traits exhibit correlation on one level but
not the other, for example APN is correlated at the farm level with ACTH but not at
the individual level.
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Table 2.5: Individual level correlation estimates, 95% confidence intervals, and p-values for metabolic phenotypes
determined from the “null” model.
NH GH GLU INS GLU OST INS OST TG NEFA ACTH LEP
0.40
GH 0.32,0.48 Correlation
3.0e-23 (-1.0,-0.6)
-0.01 0.00 (-0.6,-0.4)
GLU -0.10,0.09 -0.09,0.09 (-0.4,-0.2)
8.8e-01 9.8e-01 (-0.2,0.0)
0.30 0.22 0.38 (0.0,0.2)
INS 0.21,0.38 0.13,0.31 0.30,0.46 (0.2,0.4)
7.0e-12 1.3e-06 8.0e-21 (0.4,0.6)
0.03 0.04 0.51 0.24 (0.6,1.0)
GLU OST -0.07,0.13 -0.06,0.13 0.44,0.59 0.15,0.33
5.6e-01 4.7e-01 5.6e-45 1.6e-07
0.32 0.22 0.29 0.67 0.42
INS OST 0.23,0.40 0.13,0.31 0.20,0.37 0.62,0.73 0.34,0.50
5.7e-13 2.2e-06 1.5e-10 1.5e-141 1.5e-25
0.21 0.11 0.12 0.33 0.13 0.38
TG 0.13,0.30 0.01,0.20 0.03,0.21 0.25,0.41 0.03,0.22 0.30,0.46
1.8e-06 2.3e-02 1.2e-02 1.8e-15 9.0e-03 9.3e-20
-0.01 -0.02 -0.14 -0.09 0.10 -0.06 -0.03
NEFA -0.10,0.08 -0.11,0.08 -0.23,-0.05 -0.19,0.00 0.00,0.19 -0.16,0.03 -0.12,0.06
8.2e-01 7.2e-01 3.2e-03 4.4e-02 4.0e-02 1.8e-01 5.5e-01
0.06 -0.02 0.05 0.15 0.04 0.08 0.07 0.09
ACTH -0.03,0.16 -0.11,0.07 -0.05,0.14 0.06,0.24 -0.05,0.14 -0.02,0.17 -0.03,0.16 0.00,0.18
1.9e-01 6.4e-01 3.3e-01 1.1e-03 3.7e-01 1.1e-01 1.6e-01 5.0e-02
0.28 0.43 0.16 0.34 0.20 0.40 0.23 -0.18 -0.01
LEP 0.20,0.37 0.36,0.51 0.07,0.25 0.26,0.42 0.10,0.29 0.32,0.48 0.14,0.32 -0.27,-0.09 -0.10,0.08
9.7e-11 3.4e-29 3.5e-04 1.9e-16 2.8e-05 2.2e-23 2.1e-07 8.2e-05 8.2e-01
-0.21 -0.08 -0.09 -0.35 -0.07 -0.37 -0.41 0.12 0.00 -0.11
APN -0.30,-0.12 -0.17,0.01 -0.18,0.00 -0.43,-0.27 -0.17,0.02 -0.45,-0.28-0.49,-0.34 0.03,0.21 -0.09,0.09 -0.20,-0.03
2.5e-06 7.6e-02 4.5e-02 3.1e-18 1.3e-01 1.3e-18 1.4e-27 1.0e-02 9.7e-01 1.2e-02
Bold face cells indicate p-value<0.05. INS, INS OST, TG, and ACTH were log transformed. NEFA, LEP, and APN were square
root transformed.
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Table 2.6: Farm level correlation estimates, 95% confidence intervals, and p-values for metabolic phenotypes determined
from the “null” model.
NH GH GLU INS GLU OST INS OST TG NEFA ACTH LEP
0.50
GH 0.31,0.68 Correlation
1.3e-07 (-1.0,-0.6)
-0.03 -0.09 (-0.6,-0.4)
GLU -0.28,0.22 -0.35,0.16 (-0.4,-0.2)
8.0e-01 4.8e-01 (-0.2,0.0)
0.00 -0.01 0.31 (0.0,0.2)
INS -0.26,0.25 -0.27,0.25 0.06,0.55 (0.2,0.4)
9.7e-01 9.5e-01 1.5e-02 (0.4,0.6)
0.11 0.14 0.78 0.44 (0.6,1.0)
GLU OST -0.14,0.36 -0.12,0.39 0.65,0.90 0.21,0.67
3.9e-01 2.9e-01 5.2e-33 1.8e-04
-0.03 0.07 0.40 0.86 0.70
INS OST -0.30,0.24 -0.20,0.34 0.15,0.64 0.76,0.96 0.54,0.86
8.1e-01 6.1e-01 1.3e-03 3.5e-68 3.9e-18
0.05 0.02 0.14 0.44 0.25 0.30
TG -0.23,0.33 -0.26,0.31 -0.15,0.43 0.19,0.69 -0.03,0.53 0.02,0.58
7.3e-01 8.7e-01 3.4e-01 5.7e-04 8.5e-02 3.3e-02
0.08 0.27 0.03 -0.07 0.38 0.23 0.08
NEFA -0.15,0.31 0.05,0.50 -0.22,0.28 -0.32,0.18 0.15,0.60 -0.02,0.48 -0.20,0.36
5.1e-01 1.9e-02 8.1e-01 5.9e-01 1.3e-03 7.4e-02 5.7e-01
-0.17 -0.11 0.26 0.36 0.35 0.52 0.32 0.26
ACTH -0.40,0.06 -0.34,0.12 0.02,0.50 0.13,0.58 0.12,0.58 0.30,0.74 0.06,0.58 0.04,0.48
1.4e-01 3.4e-01 3.2e-02 1.8e-03 3.0e-03 2.3e-06 1.7e-02 1.8e-02
0.13 0.07 -0.23 0.48 0.05 0.43 0.14 0.10 0.07
LEP -0.12,0.38 -0.19,0.33 -0.50,0.05 0.26,0.70 -0.22,0.33 0.19,0.67 -0.16,0.43 -0.16,0.36 -0.19,0.32
3.2e-01 5.9e-01 1.1e-01 2.4e-05 7.0e-01 4.1e-04 3.5e-01 4.5e-01 6.0e-01
0.39 0.27 -0.56 -0.53 -0.45 -0.50 -0.47 -0.03 -0.46 -0.09
APN 0.13,0.66 0.00,0.54 -0.79,-0.33-0.76,-0.30-0.70,-0.19-0.75,-0.25-0.72,-0.22 -0.31,0.25 -0.71,-0.20 -0.39,0.21
3.6e-03 5.1e-02 2.3e-06 5.1e-06 5.5e-04 7.5e-05 2.5e-04 8.3e-01 3.9e-04 5.4e-01
Bold face cells indicate p-value<0.05. INS, INS OST, TG, and ACTH were log transformed. NEFA, LEP, and APN were square
root transformed.
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2.4.4 Effect of physiologic factors (age, sex, breed, and clinical group
status) on metabolic trait variation
The significance values from a Wald chi-square test of the overall effect of age, sex, breed,
and clinical group status on metabolic trait variation from the full model are presented
in Table 2.7. Fixed effect estimates for the explanatory variables age, sex, breed, and
clinical group status from the full model are reported in Appendix tables A.5-A.15 and
illustrated in Figure 2.1. Additional covariates/explanatory variables in the full model
included diet composition (Mcal, CP, NDF, Starch, and WSC per kg bwt per day),
average hours per day grazing, average hours per day exercising, average hours per day
stalled, month at time of sampling, farm latitude, thyroxine supplementation (yes/no),
and researcher collected sample vs owner submitted. Figure 2.1 illustrates the effect
estimates of age, sex, breed, and clinical group in terms of standard deviations from
the reference group indicated by the red vertical line (non-obese, 12 year old Morgan
geldings with no prior history of laminitis). Several significant effects were identified for
numerous traits and are described in more detail below.
The predicted metabolic trait means for mares, geldings, and stallions determined
from the full model are reported in Table 2.8. Significant overall and pairwise effects
of sex on metabolic trait variation included NH (stallion> gelding>mare), GH (geld-
ings, mares> stallion), GLU fasted and OST (stallions>mares), OST INS (stallion>
gelding>mare), and LEP (mares> geldings).
The predicted metabolic trait means for the different breeds are reported in Table
2.9. Significant overall and pairwise effects of breed on metabolic trait variation included
NH (ponies, Morgan> low risk breeds, Morgan>Arabian), GH (QH> low risk breeds),
INS (Morgan, TW, HR >QH and Ponies>QH, Arabs) and OST INS (Morgan, TW,
HR, ponies>QH), ACTH (ponies>QH, TW, Morgan), LEP (Morgan, ponies, TW,
high risk breeds>QH, Morgan> low risk breeds), and APN (QH>Arabians).
The predicted metabolic trait means according to obesity and/or prior laminitis
status are reported in Table 2.10. Significant overall and pairwise effects of obesity
and/or prior laminitis status on metabolic trait variation included NH (obese+laminitis+
> obese+laminitis− > obese−laminitis+ > obese−laminitis−), GH (obese+laminitis+,
obese+laminitis− > obese−laminitis+, obese−laminitis−), INS (obese+laminitis+ >
obese+laminitis−, obese−laminitis+ > obese−laminitis−) and OST INS
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(obese+laminitis+, obese+laminitis−, obese−laminitis+ > obese−laminitis−),
TG (obese+laminitis+, obese−laminitis+ > obese+laminitis− > obese−laminitis−),
LEP (obese+laminitis+, obese+laminitis− > obese−laminitis+, obese−laminitis−), and
APN (obese−laminitis−, obese+laminitis− > obese−laminitis+, obese+laminitis+).
The predicted effect of age on the median trajectory of insulin and ACTH levels
is illustrated in Figure 2.2. Age correlated positively with INS (fasted and OST) and
ACTH levels.
Table 2.7: Significance results for overall association of physiologic factors (age, breed,
sex, and clinical group) with metabolic trait variation determined from the full multi-
variate, multilevel model
+ 1 SD age sex breed clinical group
NH 7.0e-01 2.1e-07 7.6e-04 9.0e-22
GH 5.2e-02 1.2e-04 9.2e-03 5.0e-18
GLU 3.6e-01 2.7e-03 1.8e-01 5.8e-01
logINS 7.4e-04 2.2e-01 1.4e-05 2.3e-17
GLU OST 6.1e-01 1.2e-02 6.0e-01 3.2e-01
logINS OST 1.1e-02 3.9e-04 2.1e-04 8.2e-12
logTG 5.4e-02 6.5e-02 2.7e-02 7.1e-09√
NEFA 9.2e-01 5.4e-01 4.7e-01 9.1e-01
logACTH 9.6e-20 3.6e-01 7.0e-05 4.4e-01√
Leptin 9.9e-01 3.9e-03 5.2e-08 5.9e-11√
Adiponectin 3.6e-01 4.6e-01 4.7e-02 6.6e-10
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Figure 2.1: Estimated effect of age, sex, breed, and clinical group status on metabolic
trait variation. Vertical line at zero standard deviations indicates the reference
group[non-obese Morgan geldings with no history of laminitis and age equal to the
mean population age].
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Table 2.8: Predicted metabolic trait central means [95% confidence interval] by sex determined from the full multivariate,
multilevel model
NH GH GLU (mg/dl) INS (µIU/ml)
mare 0.65[0.64,0.67]a stallion 1.19[1.16,1.21]a mare 76.1[73.3,78.9]a gelding 7.9[6.2,10.1]a
gelding 0.66[0.65,0.68]b gelding 1.22[1.20,1.23]b gelding 77.8[74.9,80.7]ab mare 8.2[6.5,10.4]a
stallion 0.69[0.67,0.71]c mare 1.23[1.21,1.24]b stallion 81.6[77.3,85.9]b stallion 10.4[7.3,14.8]a
GLU OST (mg/dl) INS OST (µIU/ml) TG (mg/dl) NEFA (mmol/L)
mare 97.7[92.2,103.2]a gelding 24.5[18.2,32.8]a gelding 27.7[24.0,32.0]a gelding 0.20[0.16,0.25]a
gelding 99.6[94.0,105.2]ab mare 28.0[21.0,37.2]a stallion 30.6[24.4,38.3]a mare 0.21[0.17,0.26]a
stallion 106.4[98.5,114.3]b stallion 49.1[32.5,74.4]b mare 31.0[27.0,35.6]a stallion 0.23[0.16,0.30]a
ACTH (pg/ml) LEP (ng/ml) APN (ng/ml)
mare 27.4[24.2,30.9]a stallion 4.54[3.39,5.87]ab mare 2852[2312,3448]a
gelding 27.6[24.3,31.3]a gelding 4.93[4.14,5.79]a gelding 2992[2422,3622]a
stallion 30.6[25.3,37.0]a mare 5.72[4.89,6.61]b stallion 3353[2374,4501]a
Different letters within a column indicate a statistically significant pairwise difference (p<0.05 with holm adjustment
for multiple comparison).
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Table 2.9: Predicted metabolic trait central means [95% confidence interval] by breed determined from the full multi-
variate, multilevel model
NH GH GLU (mg/dl) INS (µIU/ml)
LR 0.64[0.61,0.67]a LR 1.19[1.15,1.22]a QH 75.9[71.7,80.1]a QH 5.2[3.7,7.4]a
Arab 0.65[0.63,0.67]ab HR 1.20[1.17,1.23]ab LR 76.6[70.6,82.5]a Arab 6.6[4.6,9.4]ab
HR 0.66[0.64,0.68]abc TW 1.20[1.18,1.23]ab Morgan 77.5[74.3,80.8]a LR 7.8[4.8,12.8]abc
TW 0.68[0.65,0.70]abc Arab 1.20[1.18,1.23]ab Pony 78.8[74.7,82.8]a Morgan 9.9[7.5,13.0]bc
QH 0.68[0.66,0.70]abc Pony 1.22[1.19,1.24]ab TW 79.1[74.8,83.4]a TW 10.5[7.3,15.2]bc
Pony 0.69[0.67,0.71]bc Morgan 1.22[1.20,1.24]ab HR 80.0[75.9,84.2]a HR 10.6[7.5,15.0]bc
Morgan 0.69[0.67,0.70]c QH 1.24[1.22,1.27]b Arab 81.6[77.4,85.8]a Pony 13.7[9.7,19.2]c
GLU OST (mg/dl) INS OST (µIU/ml) TG (mg/dl) NEFA (mmol/L)
QH 98.1[89.7,106.5]a QH 16.1[10.4,25.0]a LR 23.8[17.5,32.2]a Morgan 0.18[0.14,0.23]a
HR 99.5[90.9,108.0]a LR 28.1[15.4,51.3]ab QH 25.3[20.5,31.3]a Arab 0.19[0.13,0.26]a
Morgan 99.7[93.4,106.0]a Arab 28.3[18.5,43.2]ab Arab 28.2[22.7,34.9]a TW 0.20[0.14,0.28]a
Arab 100.9[92.8,109.0]a Morgan 36.0[25.9,50.0]b Morgan 30.4[25.8,35.8]a HR 0.21[0.14,0.28]a
LR 101.3[89.8,112.8]a HR 40.1[25.7,62.7]b Pony 32.3[26.4,39.6]a Pony 0.22[0.15,0.29]a
TW 102.6[93.9,111.2]a Pony 40.2[26.7,60.6]b TW 34.8[27.9,43.4]a QH 0.22[0.16,0.30]a
Pony 106.6[98.8,114.5]a TW 49.2[31.3,77.3]b HR 35.4[28.6,43.7]a LR 0.29[0.19,0.41]a
ACTH (pg/ml) LEP (ng/ml) APN (ng/ml)
QH 23.8[19.9,28.6]a QH 3.25[2.36,4.29]a Arab 2474[1748,3326]a
TW 24.2[20.0,29.3]a LR 3.79[2.42,5.46]ab TW 2576[1799,3492]ab
Morgan 26.7[23.2,30.9]a Arab 4.71[3.62,5.95]abc LR 2999[1825,4464]ab
LR 27.8[21.5,36.1]ab Pony 5.25[4.15,6.47]bc HR 3076[2243,4039]ab
Arab 30.3[25.2,36.5]ab TW 6.19[4.87,7.68]bc Pony 3164[2398,4036]ab
HR 31.7[26.4,38.1]ab HR 6.27[4.98,7.72]bc Morgan 3281[2609,4029]ab
Pony 36.8[30.8,43.9]b Morgan 6.40[5.39,7.50]c QH 3983[3024,5073]b
Different letters within a column indicate a statistically significant pairwise difference (p<0.05 with holm adjustment
for multiple comparison).
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Table 2.10: Predicted metabolic trait central means [95% confidence interval] by clinical group determined from the
full multivariate, multilevel model
NH GH GLU (mg/dl) INS (µIU/ml)
ob−lam− 0.64[0.63,0.66]a ob−lam+ 1.18[1.17,1.20]a ob−lam− 77.8[74.8,80.7]a ob−lam− 5.5[4.3,7.0]a
ob−lam+ 0.66[0.65,0.68]b ob−lam− 1.19[1.17,1.20]a ob+lam− 78.2[74.8,81.6]a ob+lam− 8.4[6.3,11.2]b
ob+lam− 0.68[0.66,0.69]c ob+lam+ 1.23[1.21,1.25]b ob+lam+ 78.7[75.0,82.3]a ob−lam+ 9.6[7.3,12.5]b
ob+lam+ 0.69[0.68,0.71]d ob+lam− 1.23[1.21,1.25]b ob−lam+ 79.3[76.1,82.6]a ob+lam+ 13.6[10.0,18.4]c
GLU OST (mg/dl) INS OST (µIU/ml) TG (mg/dl) NEFA (mmol/L)
ob−lam− 99.2[93.4,105.0]a ob−lam− 20.3[15.0,27.5]a ob−lam− 24.2[20.8,28.2]a ob+lam− 0.21[0.16,0.27]a
ob−lam+ 101.0[94.6,107.3]a ob+lam− 33.7[24.0,47.2]b ob+lam− 27.3[23.0,32.6]a ob−lam− 0.21[0.16,0.26]a
ob+lam− 102.2[95.8,108.6]a ob−lam+ 36.0[25.8,50.1]b ob−lam+ 34.1[28.9,40.3]b ob−lam+ 0.22[0.17,0.27]a
ob+lam+ 102.6[95.6,109.6]a ob+lam+ 44.1[30.6,63.6]b ob+lam+ 34.6[28.7,41.7]b ob+lam+ 0.22[0.17,0.29]a
ACTH (pg/ml) LEP (ng/ml) APN (ng/ml)
ob−lam− 27.6[24.2,31.4]a ob−lam+ 3.99[3.18,4.90]a ob+lam+ 2318[1669,3074]a
ob+lam+ 27.8[23.7,32.6]a ob−lam− 4.23[3.47,5.06]a ob−lam+ 2402[1801,3089]a
ob+lam− 28.9[24.9,33.6]a ob+lam+ 5.97[4.85,7.20]b ob+lam− 3655[2871,4532]b
ob−lam+ 29.6[25.7,34.2]a ob+lam− 6.22[5.15,7.38]b ob−lam− 4061[3352,4839]b
Different letters within a column indicate a statistically significant pairwise difference (p<0.05 with holm adjustment
for multiple comparison). ob=obese, lam=history of prior laminitis
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Figure 2.2: Predicted effect of age on the median trajectory of insulin(a) and ACTH(b).
Dashed lines represent the 95% confidence interval. Estimate predictions were deter-
mined from the full model (estimates are adjusted for all variables included in the
model).
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2.4.5 Effect of environmental factors (diet, exercise, latitude, and
month of year) on metabolic trait variation
The significance values from a Wald chi-square test of the overall effect of the explana-
tory variables dietary composition (Mcal, CP, NDF, Starch, and WSC per kg bwt per
day), average hours per day grazing, average hours per day exercising, average hours
per day stalled, and month at time of sampling on metabolic trait variation from the
full model are presented in Table 2.11. Fixed effect estimates for diet, exercise, lati-
tude, and month of year from the full model are reported in Appendix tables A.5-A.15.
Additional covariates/explanatory variables in the full model included age, breed, sex,
obesity and prior laminitis status, thyroxine supplementation (yes/no), and researcher
collected sample vs owner submitted.
Figures 2.3 and 2.4 illustrate the relationship of significant environmental factors
on metabolic trait variation. Daily dietary starch intake per kg bwt was negatively
correlated with GLU OST levels. Hours per day spent in a stall was also negatively
correlated with GLU OST levels. Hours per day spent grazing on pasture was positively
correlated with NEFA levels while hours per day spent in a stall was negatively corre-
lated with NEFA levels. ACTH levels correlated positively with latitude.
Metabolic traits that varied significantly with sampling month of the year are fea-
tured in Figure 2.5. GH was significantly lower in horses sampled during the month of
July. Fasting GLU levels tended to rise throughout the spring and summer and then
decrease during the fall and winter with GLU levels being significantly lower during the
months of October, December, and January compared to the month of August. TG
levels were significantly lower in June compared to February, May, August, Septem-
ber, and December The predicted effect of month on girth:height ratio, fasting glucose,
triglyceride, ACTH, leptin, and adiponectin levels are illustrated in Figure 2.5. ACTH
levels were also lowest during the month of June with significantly higher levels being
found during the months of July through November. In addition, LEP levels were also
lowest during the month of June with significantly higher levels observed during the
months of February, May, and October. APN levels were lowest during the month of
May.
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Table 2.11: Significance results for association of environmental factors (Diet, exercise, latitude, and month p-values)
with metabolic trait variation determined from the full multivariate, multilevel model
+1 SD
Mcal/kg
bwt
+1 SD
CP/kg
bwt
+1 SD
NDF/kg
bwt
+1 SD
Starch/kg
bwt
+1 SD
WSC/kg
bwt
Hours
grazing
per day
Hours
exercise
per day
Hours
stalled per
day
Latitude Month
NH 5.7e-01 5.5e-01 5.5e-01 4.2e-01 4.1e-01 5.3e-02 1.1e-01 2.8e-01 8.1e-01 3.2e-01
GH 9.5e-02 1.8e-01 9.5e-02 2.1e-01 2.4e-01 1.1e-01 7.5e-01 2.7e-01 1.5e-01 2.6e-04
GLU 8.1e-01 9.8e-01 6.6e-01 2.0e-01 1.5e-01 2.9e-01 3.5e-01 6.6e-01 6.5e-01 9.9e-04
logINS 9.8e-01 7.5e-01 2.3e-01 7.5e-01 8.8e-02 3.7e-01 6.7e-01 4.9e-01 3.4e-01 5.7e-01
GLU OST 4.9e-01 3.0e-01 2.4e-01 3.7e-02 3.3e-01 9.1e-01 7.3e-01 1.1e-02 8.5e-01 6.1e-01
logINS OST 5.0e-01 5.8e-01 7.0e-01 4.6e-01 2.4e-01 9.2e-01 8.2e-01 6.5e-01 7.1e-01 4.6e-01
logTG 1.7e-01 3.9e-01 4.5e-01 6.0e-01 5.0e-01 2.7e-01 8.8e-01 6.7e-01 4.3e-01 3.6e-03√
NEFA 9.8e-01 3.8e-01 6.1e-01 3.8e-01 9.1e-01 1.3e-05 9.4e-01 6.7e-03 1.6e-01 1.7e-01
logACTH 8.8e-01 5.0e-01 8.1e-01 7.4e-01 8.9e-01 9.4e-01 4.2e-01 1.7e-01 2.6e-02 2.5e-14√
Leptin 7.4e-01 5.3e-01 5.4e-01 3.1e-01 6.5e-01 9.0e-01 5.1e-01 5.7e-01 7.9e-01 2.6e-10√
Adiponectin 9.7e-01 7.6e-01 9.1e-01 6.5e-02 6.9e-01 2.1e-01 7.5e-02 7.0e-01 7.5e-01 1.2e-02
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Figure 2.3: Predicted effects of starch consumption(a) and hours per day spent in stall(b)
on median post-OST glucose and effects of hours per day grazing(c) and hours per day
stalled(d) on median NEFA levels. Dashed lines represent the 95% confidence interval.
Estimate predictions were determined from the full model (estimates are adjusted for
all variables included in the model).
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Figure 2.4: Predicted effect of latitude on ACTH levels. Dashed lines represent the
95% confidence interval. Estimate predictions were determined from the full model
(estimates are adjusted for all variables included in the model).
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Figure 2.5: Predicted effect of month on girth:height ratio(a), fasting glucose(b), triglyc-
eride(c), ACTH(d), leptin(e), and adiponectin(f) levels. Error bars represent the 95%
confidence interval. Different letters indicate a statistically significant pairwise differ-
ence (p<0.05 with holm adjustment for multiple comparison). Estimate predictions
determined from the full model (adjusted for all variables included in the model).
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2.4.6 Relative importance of the full model predictor variables in ex-
plaining metabolic trait variation at the farm and individual
horse level
The results presented in this section report both the percentage of metabolic variation
at the farm and individual level that was explained by inclusion of the full model ex-
planatory variables, in addition to the percent of variation that remained unexplained
in the at the farm and individual level of the study population. These results provide
an indication of the goodness of fit of the model, along with relative importance of the
explanatory variables.
Figure 2.6 illustrates the variance decomposition of the morphometric traits NH and
GH. In the null model, 47% of NH variance was present at the farm level. Inclusion
of explanatory variables in the full model were unable to explain any of the variance
at the farm level. Approximately 25% of the individual level variance was able to be
explained by the model with obesity status accounting for approximately half of the
explained NH variance at the individual level. In the null model, 43% of GH variance
was present at the farm level. Approximately 28% of the farm level variance was able to
be explained with sampling month accounting for half of the explained variance. At the
individual level, similar to NH variance, obesity status contributed the largest amount
to the explained variance. Sex was the second largest contributor to explained variance
at the individual level for both NH and GH variance.
Variance decomposition of GLU (fasted and OST) is presented in Figure 2.7. In
the null model, 35% of fasted GLU variance was present at the farm level. Sampling
month of year was the largest contributor to explained variation at the farm level. Ap-
proximately 80% of fasted GLU variance at the farm level remained unexplained and
variance at the individual level remained largely unexplained (96%). 42% of variance
in post-OST GLU was present at the farm level. Dietary components, especially starch
intake, were important factors in explaining post-OST GLU variance at the farm level.
Although 87% of variance at the farm level remained unexplained and an even higher
percentage remained unexplained at the individual level (97%).
Variance decomposition of INS (fasted and OST) is presented in Figure 2.8. In the
null model, 36% of fasted INS variance was present at the farm level. Approximately
25% of variance at the farm level was explained by factors in the full model. Obesity
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status, breed, and prior laminitis status were important factors in explaining fasted INS
variance at both the farm and individual level. 77% of fasted INS variance at the farm
level remained unexplained. 33% of post-OST variance was present at the farm level.
Breed was the most important factor in explaining post-OST variance at the farm level,
while prior laminitis and obesity status were the most important factors explaining
post-variance at the individual level. About 87% of farm level and 76% of individual
level post-OST variance remained unexplained.
TG and NEFA variance decomposition is presented in Figure 2.9. 24% of TG vari-
ance was present at the farm level. Prior laminitis status was the most important factor
in explaining TG variance at both farm and individual level. 74% of farm level and
83% of TG variance at the individual level remained unexplained. 44% of NEFA vari-
ance was present at the farm level. Hours per day spent grazing accounted for 11% of
farm level NEFA variance. The vast majority of NEFA variance at the individual level
remained unexplained (97%).
A large percentage of ACTH variance occurred at the farm level (49%) (Figure 2.10).
Sampling time of year explained 40% of ACTH variance at the farm level. Age explained
10% of variance at the individual level.
The variance decomposition of adipokines LEP and APN is illustrated in Figure
2.11. 31% of LEP variance was present at the farm level with sampling month and
breed explaining 31% and 22% of LEP variance at the farm level, respectively. Obe-
sity status was the most important factor in explaining LEP variance at the individual
level. 23% of APN variance was present at the farm level. Samples collected by a farm’s
veterinarian and submitted by the farm owner instead of a researcher visiting the farm
and collecting the sample explained 20% of APN variance at the farm level. Breed
and sampling time of year were also important in explaining farm level APN variance.
Prior laminitis status was the most important factor in explaining APN variance at the
individual level.
Total explained variance and explanatory variable contribution to the total vari-
ation is reported in Table 2.12. From Figure 2.11a it can be determined that obe-
sity status accounts for 7.4% of the total variation in leptin levels by multiplying the
Null farm and horse level variance estimates by the percent contribution of the fac-
tor to the farm and horse level variance, respectively, and summing the products (e.g.
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(31.5 ∗ 0.039) + (68.5 ∗ 0.09) = 7.4).
Figure 2.6: Variance decomposition of morphometric traits neck circumference:height
ratio(a) and girth:height ratio(b)
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Figure 2.7: Fasting(a) and post-OST(b) glucose variance decomposition
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Figure 2.8: Fasting(a) and post-OST(b) insulin variance decomposition
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Figure 2.9: Variance decomposition of triglycerides(a) and NEFA(b)
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Figure 2.10: Variance decomposition of ACTH
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Figure 2.11: Variance decomposition of adipokines leptin(a) and adiponectin(b)
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Table 2.12: Explanatory variable contribution to total variation in metabolic traits
Parameter NH GH GLU INS GLU
OST
INS
OST
TG NEFA ACTH LEP APN
Breed 1.4% 3.1% 0.5% 3.4% 0.3% 3.0% 1.6% 0.3% 2.6% 8.3% 4.1%
Sex 2.1% 3.1% 0.7% 0.4% 0.5% 2.2% 0.9% 0.4% 0.3% 1.3% 0.4%
Age 0.2% 1.7% 0.3% 1.0% 0.4% 8.8% 0.3%
Laminitis 1.7% 1.1% 6.6% 0.4% 4.2% 6.2% 0.1% 1.1% 0.2% 7.1%
Obesity 7.3% 8.0% 0.1% 4.9% 0.2% 3.8% 1.4% 0.2% 0.3% 7.4% 0.8%
Month 6.9% 4.6% 0.5% 0.1% 0.6% 2.1% 0.4% 19.6% 11.4% 3.8%
Latitude 0.3% 0.1% 0.1% 0.1% 0.3% 0.3%
Hrs in stall 0.1% 0.3% 0.4% 0.3% 1.4% 0.1% 0.1% 2.1% 0.4%
Hrs exercise 0.3% 0.2% 0.1% 0.1% 0.1% 0.3% 0.5% 0.2%
Hrs grazing 0.6% 0.2% 0.1% 0.2% 5.4%
Mcal 0.1% 0.6% 0.2% 0.4% 0.5% 1.1% 1.3% 0.1% 0.2% 0.6% 0.6%
CP 0.1% 0.4% 0.1% 0.3% 0.6% 0.7% 0.7% 0.2% 0.4% 0.3%
NDF 0.4% 0.2% 0.7% 0.3% 0.7% 0.6% 0.1% 0.1% 0.2% 0.2%
Starch 0.1% 0.3% 0.9% 0.1% 2.0% 0.8% 1.5% 0.1% 0.1% 0.7% 2.0%
WSC 0.1% 0.8% 0.2% 0.3% 0.1% 0.6% 0.4% 0.1% 0.2% 0.1%
Owner submitted 0.1% 0.1% 3.2% 1.1% 0.5% 2.0% 0.1% 4.5%
Thyro-L supplementation 0.1% 0.4% 0.1% 0.7% 0.2% 0.3% 1.6% 1.1%
Total explained variance 13.0% 25.5% 9.6% 23.8% 7.1% 20.6% 19.1% 9.9% 36.3% 31.4% 26.0%
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2.5 Discussion
Although equine metabolic syndrome (EMS) is a term frequently used by veterinary
clinicians, there is a lack of consensus regarding the diagnostic criteria that define EMS.
Generalized/regional adiposity, hyperinsulinemia, insulin resistance, dyslipidemia, and
predisposition to laminitis development are reported components of the syndrome. How-
ever, not all studies have consistently reported the same phenotypic components for
EMS, which may suggest different confounders contributed to the phenotypic variation
among the differing sample cohorts and experimental designs. For example, Measure-
ments to quantify adiposity, GH and NH, have also been associated with the EMS
phenotype in horses79 and proposed as predictors of laminitis risk in ponies;78 however
obesity has not been a consistent finding, particularly in well-managed populations.81
Hyperinsulinemia has been shown to be a feature of the EMS phenotype although the
values vary between studies.78,81,115 Elevated TG have been associated with the EMS
phenotype in ponies78,81,116 but not in horses;79 whereas, NEFA concentrations have
been associated with an EMS phenotype in horses,79 but were not useful in the differen-
tiation of an EMS phenotype in ponies.77,78 The shortfalls of prior EMS studies include
small study populations, studies conducted in a single breed, and/or studies conducted
at a single geographic location, which may prevent translation of findings to the larger
population. Therefore the overarching objective of this study was to investigate varia-
tion and co-variation in metabolic traits in a large population of horses and ponies over
a range of individual and environmental conditions.
2.5.1 Equine metabolic traits cluster at the farm level
A multilevel, multivariate approach made it possible to 1) determine the degree to which
a metabolic trait clusters in horses sampled from the same farm, 2) assess the correlation
of different metabolic traits at both a farm and individual level and 3) determine the
effects of individual and farm level characteristics on metabolic trait variation. All of
the metabolic traits included in the study exhibited substantial clustering at the farm
level with percentage of variance present at the farm level ranging from 23-49% of the
total trait variance (Table 2.4). Clustering of traits at the farm level indicate factors
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shared by horses sampled from the same farm contribute to variation in metabolic traits.
2.5.2 Equine metabolic traits correlate at both the farm and individ-
ual horse level
As expected GLU and INS levels (fasted and post-OST) exhibited a strong, positive
correlation. Interestingly, the correlation was very strong at the farm level indicating
farm related factors play a role in the correlation between GLU and INS measurements.
Inclusion of explanatory variables in the full model revealed farm characteristics such as
sampling time of year, hours spent in a stall and diet (starch in particuular) as impor-
tant factors effecting GLU variation which could in turn explain the strong GLU and
INS correlation at the farm level.
At the individual level, correlation of metabolic traits were similar to that observed
in humans132 with positive correlations among INS, LEP, and TG levels and a negative
correlation of APN with the aforementioned traits. A measure of regional adiposity
(NH), more so than a measure of generalized adiposity (GH), correlated with INS, TG
and APN levels while LEP exhibited a stronger correlation with regional adiposity (GH).
Again, these findings mirror relationships of different fat depots with varying biochem-
ical profiles observed in humans.132 Previous data suggest the nuchal ligament adipose
tissue is more likely than other adipose depots to display an inflammatory phenotype
in the horse and therefore may play a unique role in the pathogenesis of metabolic
dysregulation,133 observing correlation of regional adiposity with biochemical measures
associated with prior laminitis status (INS, TG, APN) supports this hypothesis. In
humans, subcutaneous fat in the neck region has been found to be strongly associated
with insulin resistance.134
Some traits tend to correlate more strongly at the farm level but not at the individual
level. For example, NEFA and post-oral sugar test glucose (GLU OST) were correlated
at the farm level, indicating farm level characteristics may explain variation in energy
production from fat oxidation versus glucose utilization. Also, ACTH and APN were
also correlated at the farm level but not the individual level. From the Shapley value
analysis, it was able to be determined that season was a large contributor to the farm
level variance in both of these traits.
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2.5.3 Clinical group effects metabolic trait measures
Clinical groups based on obesity and prior laminitis status demonstrated divergent pat-
terning of metabolic traits. Elevated TG levels were significantly higher in individuals
with prior laminitis, but were not significantly increased in individuals that were obese
without a history of laminitis. Whereas both obesity and prior laminitis impact INS
and INS OST levels. GH, a measurement of regional adiposity, was only associated with
obesity status and did not vary with prior laminitis status, as opposed to NH, a measure
of regional adiposity, that was greater in both obese horses and those with prior lamini-
tis. Adipokines LEP and APN also exhibited divergent patterns according to clinical
group status. LEP levels were elevated in obese individuals to a similar degree in horses
with and without a prior history of laminitis. APN levels were decreased in horses
with a prior history of laminitis to a similar degree in non-obese and obese individuals.
These findings suggest LEP may be a good indicator of total body fat mass in horses
and decreased APN may indicate the presence of an unhealthy state that predisposes
horse to laminitis. APN and LEP have been identified as key components of human
metabolic syndrome. Interestingly, APN has been identified as a better predictor than
LEP of the presence and degree of coronary atherosclerosis, independent of body mass
index.135
2.5.4 Physiologic factors influence equine metabolic trait variation
Breed differences were observed for several traits (NH, GH, INS (fasted and OST),
ACTH, LEP, APN). The QH breed was the most divergent with lower INS/INS OST,
LEP, and higher APN. Increased muscle mass in the QH breed provides a possible ex-
planation for observing a more insulin sensitive phenotype. A variant involving the
myostatin gene occurs frequently in the QH breed and is associated muscle fiber type
proportions.136 In the mouse, myostatin deficiency has been linked with reduced diet-
induced obesity and a more insulin sensitive phenotype.137–142 Other breed differences
included observing higher ACTH levels in the pony breeds, a finding that has not been
identified in previous studies.143,144 LEP levels were highest in the Morgan breed. LEP
levels are known to be correlated with total body fat mass in humans145 and therefore
may indicate higher total body fat mass in the Morgan breed. Breed differences suggest
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genetic differences as a source of metabolic trait variation and warrants further inves-
tigation of genetic sources of trait variation. Although a drawback of observing breed
differences for metabolic traits is the limitations it poses on the use of a single reference
range for all breeds when utilizing metabolic traits as a diagnostic.
Gender differences were observed for several traits with mares having a significantly
lower measure of regional adiposity (NH) and stallions having a lower measure of gen-
eralized adiposity (GH), suggesting gender differences in equine body fat distribution.
This study included a substantial number of stallions (n=32) which aided in the ability
to detect significantly higher insulinemic responses to an oral glucose challenge than
both mares and geldings. Mares also had higher LEP levels than geldings. Gender
differences in triglyceride levels have been reported to correlate with fat deposition sex
differences in humans.146 Gender differences in LEP levels in humans are accounted for
by percent body fat.147 Similar to previous reports,144,148 age was positively associated
with both fasting and OST INS and to a larger degree with ACTH levels.
2.5.5 Environmental factors influence equine metabolic trait variation
Seasonal variation in metabolic traits observed in our study cohort were similar to what
has been previously reported, despite the fact that samples were obtained from each
horse on only a single day of the year. Elevated ACTH in the fall months has been
previously reported in horses.149–151 However, we report a positive correlation between
latitude on ACTH levels, which is opposite to the relationship observed previously in
horses143 but consistent with the concept of higher latitudes experiencing greater sea-
sonal extremes and thus having larger photoperiod effects. In addition to photoperiod,
differences in ambient temperature may also potentially explain higher ACTH values in
horses from higher latitudes.152
Seasonal variation in GLU levels have been documented in other mammalian species153
with glucose levels reported to be highest in the fall in humans154 similar to our find-
ings. Frank et al.150 also reported higher GLU levels for horses during the month of
September, in addition to elevated insulin concentrations. Similar to Place et al.,149 the
effect of month on insulin levels was not significant in this study, although Schreiber et
al.151 reported insulin levels to be higher in older horses during the month of September.
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Borer et al.155 observed a significant season prior laminitis interaction for insulin levels.
Age x month and age x clinical group interactions were not examined in the current
study but may warrant further investigation.
GH and LEP were lower during the summer months. A possible explanation for this
observation may be seasonal changes in body fat mass. Horses are long day breeders
and exhibit photoperiod responsive changes in hormone levels. Ferrets and mink are
also long day breeders and exhibit bodyweight gain during short days and weight loss
during long days.156,157 Therefore it is plausible weight loss in the summer months
independent of diet and exercise may be due to changes in photoperiod and similar
biologic mechanisms may be responsible in both species. Similar to previous reports,
leptin values were highest in the month of October, at the end of the ACTH rise.158
It is possible increased ACTH levels may have induced leptin resistance in an effort to
prepare for winter.159 The study findings suggest seasonality is an important source of
metabolic trait variation; further evidence of this conclusion is the substantial reduc-
tion in farm level variance achieved for several traits with the inclusion of month as an
explanatory variable. The horse, similar to other long day breeders, seems to switch to
an insulin resistant state during the fall. This “switch” would allow a horse to increase
fat stores to be utilized throughout the winter when food sources may be limited and
increased energy is needed for thermoregulation and to support development of a fetus
in pregnant mares. Increased insulinemic responses have been reported in pregnant
mares compared to non-pregnant mares during an intravenous glucose tolerance test.160
Minimal effects for diet and exercise parameters on metabolic trait variation were de-
tected. Dietary starch intake demonstrated a negative correlation with post-OST GLU
levels. A reduced glycemic response to an oral sugar test has previously been reported
both in horses adapted to a high starch diet,161 similarly, humans are instructed to
consume a higher carbohydrate diet a few day prior to an oral glucose tolerance test in
order to prevent false positives (especially individuals accustomed to a low carb diet).162
Hours per day grazing correlated positively with NEFA levels where as hours per day
spent in a stall correlated negatively with NEFA levels. NEFA levels are influenced
by the availability of food and tend to peak before the next meal. Lower NEFA levels
would be expected in horses that spent more time grazing, however it is possible that
these horses were less acclimated to the fasting period they experienced prior to blood
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sample collection resulting in higher NEFA levels. Testing NEFA levels from non-fasted
samples would be necessary to confirm this hypothesis. Correlations of metabolic traits
with hours of exercise per week were not detected. Power may have been limited to
detect an association with exercise due to only 15% of the population having received
more than 3 hours of exercise per week.
2.5.6 Unexplained equine metabolic trait variation remains at both
the farm and individual horse level
Although a moderate amount of variation in metabolic traits was explained by the ex-
planatory variables included in the full model, the substantial amount or remaining
unexplained variation suggest additional unaccounted for sources of farm and individ-
ual level variance may exist. It is likely that individual genetic differences exist which
contributes to metabolic trait variation. The detection of breed differences in our study
support this hypothesis. Identification of genetic variants associated with metabolic
traits and subsequent genotyping of the individuals in this study cohort for those ge-
netic variants might potentially explain additional metabolic trait variance. Additional
environmental factors not measured in this study may also potentially impact metabolic
trait variation. For example, chemicals present in the environment have endocrine dis-
rupting capabilities and could be a potential unaccounted for source of variation in
equine metabolic traits.163
2.5.7 Diagnostic implications of individual and farm level sources of
metabolic trait variation
The present study identified numerous factors beyond obesity and prior laminitis sta-
tus contribute to variation in metabolic traits, including seasonal effects, breed, age,
sex, and diet. These findings obtained by examining equine metabolic trait variation
in a large population of horses under varying environmental and individual conditions
provide an explanation for the discrepancy in some conclusions drawn from previous
studies regarding the EMS phenotype. However, our findings also draw attention to
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the difficulty in determining appropriate reference ranges for EMS diagnostic criteria in
the presence of multiple sources of “normal” metabolic variation. A potential adjunct
for improving EMS diagnosis prior to laminitis development and monitoring a horse’s
response to management would be to test multiple horses on the same property. A
horse with values dissimilar from the rest of the herd may be at higher risk of laminitis
development. Monitoring additional horses may be even more useful for monitoring
progression of EMS. Instead of only monitoring the affected horse and questioning if
the horse’s values changed due to individual factors (progression/improvement of EMS)
or due to environmental factors, one could monitor additional horses to determine if
all of the horses experienced a similar change in test results due to farm level factors
(season, diet).
2.5.8 Study limitations and future directions
A limitation of the present study is the one-time sampling of the study population. The
present study was not designed to ask questions such as: does metabolic trait variation
and co-variation in previously laminitic horses vary with changes in bodyweight? This
should be a focus area of future research along with identifying additional sources of
variation in metabolic traits in horses with a prior history of laminitis under obese and
non-obese conditions. Further research is needed to identify additional environmental
sources of metabolic trait variation and to dissect sources of individual level metabolic
trait variation. Breed differences were identified by the present study however fur-
ther work is necessary to determine genetic variants responsible for breed variation in
metabolic traits.
In summary, our results indicate multiple sources of variation in equine metabolic
trait variation, in addition to differences in metabolic trait variance and covariance de-
pendent on obesity and prior laminitis status. Given the strong association of adiponectin
with prior laminitis status, incorporation of hypoadiponectinemia into the definition of
EMS should be considered.
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2.5.9 Main findings of Chapter 2 (“Take home messages”)
1. Equine metabolic trait variation is associated with both measured (i.e. age, sex,
breed, obesity status, and prior laminitis status) and unmeasured individual level
factors in addition to measured (i.e. season) and unmeasured environmental level
factors.
2. Obesity and prior laminitis status are associated with divergent metabolic pro-
files. Elevated blood leptin concentration is associated with obesity status where
as decreased adiponectin and increased triglyceride concentration are associated
with prior laminitis status. Thus, blood concentrations of leptin and insulin alone
(insulin is associated with both obesity and prior laminitis status) may not be
ideal biomarkers of laminitis risk. Adiponectin and triglyceride blood concen-
trations may be more appropriate biomarkers of laminitis risk. Moreover, obesity
was not found to be essential in expressing a “metabolically unhealthy” phenotype
characterized by low adiponectin and elevated triglyceride and insulin concentra-
tions; suggesting lean horses may also be at risk for developing endocrinopathic
laminitis.
3. Individual level factors, other than obesity and prior laminitis status (i.e. age,
sex, breed), and environmental level factors (i.e. season) are also associated with
metabolic trait variation and thus present challenges for determining appropriate
diagnostic reference ranges.
4. Undetermined sources of metabolic trait variation at both the individual and
environmental level in horses remains. Potential sources of individual (e.g. genetic
variants) level variation and environmental (e.g. organic pollutants) level variation
warrant investigation.
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Chapter 3
Characterization of the equine
response to an oral sugar
challenge
3.1 Summary
Differences in the incretin response may also contribute to equine metabolic trait vari-
ation. The incretin response, defined as the difference in the insulinemic responses
between an oral and intravenous glucose challenge, is controlled by intestinal secretion
of peptides, such as GLP-1, that stimulate pancreatic insulin secretion. While the in-
cretin response has been hypothesized to play a role in the EMS pathogenesis, this
hypothesis has not been adequately tested. In Chapter 3, the glycemic, insulinemic,
and total and active GLP-1 responses to an oral sugar challenge, and the activity of
DPP4, the major protease that breaks down GLP-1, were characterized. The use of a
longitudinal analysis, rather than the traditional area under the curve analysis, allowed
for increased power to detect differences in these responses, including variation due to
breed, obesity, and prior laminitis status.
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3.2 Introduction
Hyperinsulinemia and insulin resistance are components of equine metabolic syndrome
(EMS), a condition associated with predisposition for laminitis development.76 In-
cretin hormones play a key role in glucose homeostasis and the insulin secretory re-
sponse. The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypepide (GIP) are produced by endocrine cells of the gastrointesti-
nal tract and promote the release of insulin in response to nutrient ingestion.164 Both
GLP-1 and GIP have a short half-life due to rapid inactivation by the enzyme dipep-
tidyl peptidase-4 (DPP4).165 Impairment of the incretin response has been implicated
in human obesity and type 2 diabetes.166 Decreased GLP-1 baseline measurements and
responses to oral glucose have been associated with oral glucose intolerance.167,168 Both
GLP-1 analogs and DPP4 inhibitors are currently used therapeutics for the management
of type 2 diabetes.169 Alteration of the equine incretin response has been hypothesized
to play a role in the pathogenesis of EMS, however limited research has been performed
in terms of testing this hypothesis.92 The objectives of the current study were to 1)
dynamically model the equine response to an oral sugar challenge and 2) identify phys-
iologic and genetic factors associated with variation in this response.
Candidate genes dipeptidyl peptidase-4 (DPP4 ) and proglucagon (GCG) were se-
lected for investigation in this study based on their function, in addition to localizing
to a genomic signature of selection region on chromosome 18 in the Morgan horse.170
The proglucagon gene (GCG) encodes glucagon and several glucagon-like peptides (in-
cluding GLP-1) that are liberated in a tissue specific manner in pancreas, intestine,
and brain. The structure of the proglucagon gene is depicted in Figure 3.1. Pancreatic
islet proglucagon transcription is regulated by enhancer-like elements in the promoter
region.171 Less is known about control of proglucagon transcriptional regulation in the
endocrine gut cells. Based on available rat and human data, a proglucagon gene intesti-
nal enhancer region, designated GUE, has been estimated to reside between -1252 and
-1600 base pairs from the transcriptional start site.171 Alignment of the equine reference
sequence for the 5’ flanking region with other mammalian species revealed an ∼500 base
pair insertion just upstream of the promoter region (Figure B.1). The region was iden-
tified by RepeatMasker172 as an endogenous retrovirus class I long terminal repeat13b
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(ERV class I LTR13b). Thus it is an important region to investigate given ERV LTRs
naturally contain abundant transcriptional regulatory signals and often contribute to
variation in mammalian gene expression, including tissue-specific expression, through
donation of alternative promoters and enhancers.
A multilevel, multivariate longitudinal modeling approach was performed to char-
acterize the variation and covariation of glucose, insulin, and GLP-1 trajectories in 65
Morgan horses and 65 Welsh ponies over a 120 minute time course based on measure-
ments at 0,15, 30, 60, 75, 90, and 120 minutes following the oral sugar challenge. Factors
including age, breed, gender, obesity/prior laminitis status, basal biochemical measure-
ments (triglycerides, NEFA, leptin, adiponectin, DPP4-activity), dietary measurements
(Mcal, CP, NDF, Starch, WSC), and polymorphisms within candidate gene regions were
tested for association with variation of the mean curve trajectory (value at time zero,
initial rate of change, and deceleration rate), in addition to single summary indices of
the curve trajectory, area under the curve. It is common practice to use single summary
measures of oral sugar tests with repeated measurements, however different OST curves
can yield similar single summary measures and information of biological interest may be
lost.173,174 Therefore, investigation of the trajectories was incorporated in an effort to
characterize the mean GLP-1, insulin, and glucose curves, their covariation, and identify
factors associated with variation of the mean curve.
3.3 Methods
3.3.1 Sampling design
Glucose (GLU), insulin (INS), total GLP-1 (GLP1tot), and active GLP-1 (GLP1a)
concentrations were determined in 56 Morgan horses and 56 Welsh Ponies from 7 farms
at 0,15, 30, 60, 75, 90, and 120 minutes following an oral sugar challenge (0.15 ml corn
syrup per kg bodyweight). Triglyceride (TG), non-esterified fatty acid (NEFA), leptin
(LEP), adiponectin (APN), and DPP4 activity blood concentrations were determined
at the zero-minutes time point prior to oral sugar administration. Horses were removed
from pasture the evening prior to the AM blood sample collection. Horses were allowed
access to water and provided with 1 flake of hay at 10PM. Blood collection vials intended
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for GLP-1 measurement contained a DPP4 inhibitora to prevent degradation of GLP-
1. Samples were kept chilled throughout the sample collection period and processed
immediately following completion of the sample collection period. Blood samples were
centrifuged (1000 x g for 10 minutes) and plasma and serum were stored at -80oC. Hay,
pasture, and grain samples were obtained for dietary analysis. Pasture samples were
shipped overnight to our lab on ice. All diet samples were then stored at -20o or -80oC
until being shipped to Equi-Analytical Laboratories (Ithaca, NY) for analysis. Pasture
samples were shipped to the Equi-Analytical laboratory overnight on dry ice.
Body condition scores were assessed using the system developed by Henneke et al.118
Age, breed, sex, and clinical group status (non-obese/no prior laminitis history, non-
obese/prior laminitis history, obese/no prior laminitis history, and obese/prior laminitis
history) were documented. Horses with a BCS ≥ 7 were classified obese.118 Daily caloric
consumption (Mcal) and grams crude protein (CP), neutral detergent fiber (NDF),
starch, and water soluble carbohydrates (WSC) consumed per kg bodyweight (bwt)
were calculated based on dry matter weight of each dietary component determined from
analysis of dietary samples multiplied by the daily dry matter (DM) weight fed of each
dietary component. Dry matter weight of daily pasture consumption was calculated by
multiplying the determined pasture dry matter proportion by an estimate of the amount
of pasture consumed daily based on time spent on pasture. Grams of dry matter intake
per hour spent on pasture was extrapolated from data indicating horses on pasture for
3,6,9, and 24 hours consumed 1.96, 1.52, 1.12, and 0.57 g DM intake per kg bwt per
hour.126 A linear regression model was fit with log transformed DM intake values as
an outcome and hours on pasture as a predictor, see Equation 2.1. Gram dry matter
intake estimates where reduced by 75% for horses wearing grazing muzzles at time of
sampling.127 See Section 2.3.2 for description of GLU, INS, TG, NEFA, LEP, and APN
assays. DPP4 and GLP-1 assays are described below.
DPP4 assay
The DPP4/CD26 Assay kit for Biological Samples [BML-AK498] from Enzo Life Sci-
ences per manufacturer’s instructions and a fluorogenic substrate (H-Gly-Pro-AMC) was
used to determine DPP4 activity in the samples. Each sample was run in duplicates
aMillipore DPP4-010
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and a Spectra Max Genini EM fluorescence plate reader with an excitation/emission
wavelength of 380 nm/460nm was used to capture the changes in fluorescence over
time. Activity is expressed as Relative Fluorescence Units (RFU) per minute and was
calculated by determining the slope of the line of RFU versus time for each sample.
GLP-1 assays
GLP-1 is rapidly metabolized and inactivated by the enzyme DPP4. Thus, it is impor-
tant to distinguish between measurements of the intact active hormone or the sum of
the intact active hormone and its inactive metabolites.
The GLP-1 total ELISA [EZGLP1T-36K] from EMD Millipore Corporation per
manufacturer’s instructions was used. Each sample was run in duplicate. Absorbance
was read at 450nm and 590 nm in a Spectra Max Plus plate reader and the concen-
tration of GLP-1 total was determined using the SoftMax Pro 6.2.1 program with a
4-parameter logistic curve-fit.
The Glucagon-Like Peptide-1 (active) ELISA [EGLP-35K] from EMD Millipore Cor-
poration per manufacturer’s instructions was used to determine the concentration of
GLP-1 active in the samples. Each sample was run in duplicate and a Spectra Max
Genini EM fluorescence plate reader with an excitation/emission wavelength of 355
nm/460nm was used. SoftMax Pro 6.2.1 program was used to fit RFU to the concen-
tration with a cubic-spline curve fit.
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3.3.2 Variant discovery and genotyping
DPP4
The coding region of DPP4 was sequenced from cDNA in 2 EMS suspect cases (muscle)
and 1 horse (liver) of unknown status. Primers used to sequence DPP4 from cDNA
are listed in Table B.1. A single missense mutation identified in exon 11 located at
chr18:42522956 (EquCab2 assembly, dbSNP rs397231534b). The SNP was genotyped
in the entire sample population. Genomic DNA was extracted from whole blood using
a commercially available kit.c NEBcutterd was used to identify differences in restriction
enzyme sites between the reference sequence of DPP4 and the single SNP. An enzyme
Cac81 was determined to cut the variant sequence. The equine reference sequence was
used to design primers to amplify an 830 base pair product encompassing the variant
(primers reported in Table B.1). Standard PCR amplification was performed with 35
cycles and a 58.5◦C annealing temperature. The PCR product was incubated with 0.75
units of Cac81 e enzyme at 37◦C for 6 hours.
GCG
Standard Sanger sequencing of proglucagon (GCG) exons and 5’ flanking region was
performed in two horses with a history of endocrinopathic laminitis (primers reported in
Table B.1). A single variant was identified in non-coding exon 1 (5’UTR). Sequencing of
the region was repeated in 6 additional horses followed by development of an RFLP assay
to genotype the entire sample population. Restriction enzyme BanI was determined to
cut the variant sequence. The variant was genotyped in the entire sample population
using the same PCR amplification protocol described above, the PCR product was
incubated with 3 units of BanI enzyme at 37◦C for 6 hours.
Standard Sanger sequencing of the 5’ GCG flanking region containing the ERV LTR
insertion revealed five variants, therefore Sanger sequencing of the region was elected
over designing restriction fragment length polymorphism genotyping assays to genotype
bDatabase of Single Nucleotide Polymorphisms (dbSNP). Bethesda (MD): National Center for
Biotechnology Information, National Library of Medicine. http://www.ncbi.nlm.nih.gov/SNP/
cPuregene blood core kit, Qiagen Sciences, Germantown, MD.
dhttp://tools.neb.com/NEBcutter2/
eNew England BioLabs, Ipswich, MA.
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Figure 3.1: Proglucagon gene structure (ERV, endogenous retrovirus; LTR, long termi-
nal repeat; GUE, proglucagon upsteam enhancer region; UTR, untranslated region; SP,
signal peptide; GLP, glucagon-like peptide).
Horse ERV class I LTR13b
⇓
⇓
⇓
Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6
GUE Promoter 5’UTR SP Glucagon GLP-1 GLP-2 3’UTR
the entire population.
Haplotypes for the GCG variants were estimated using the implementation of the
EM algorithm coded into the haplo.stats R package.f
3.3.3 Statistical Methods
Single summary statistics:
Area under the curve (AUC) is a common method of integrating a response measured
repeatedly over a period of time into a single summary statistic. AUC calculated by
the trapezoidal method is frequently used to assess insulin and glucose dynamics during
an oral glucose tolerance test.173 The trapezoidal method sums the trapezoidal areas
between measurement time points yielding a single summary statistic, the area under
the curve (Figure 3.2). An integrated assessment often provides more utility than mea-
surement of stimulated insulin secretion at a single time point or peak concentration.
Although AUC is a simple, useful summary statistic it does not adequately describe
the dynamic nature of the responses of interest in oral glucose stimulation. Deficien-
cies of AUC include it being largely influenced by the baseline measurement which can
hinder interpretation of the dynamic response to a stimulus. Two experimental groups
may be misinterpreted as having a significantly different response to a stimulus when
in reality they only differed in their baseline values and had a very similar response
to the stimulus. This issue can be circumvented by calculating a positive incremental
AUC which subtracts the baseline measurement from all values when calculating the
fSinnwell and Schaid, 2005, http://www.mayo.edu/research/documents/manualhaplostatspdf/
doc-10026895.
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Figure 3.2: Area under the curve trapezoidal rule calculation. The area under the curve
is approximated by summing the trapezoidal areas between measurement time points.
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area under the curve. Secondly, it is possible for two different curves to have the same
AUC resulting in a potential loss of important biological information. For example, the
curve featured in Figure 3.3a exhibits a gradual initial increase in insulin without return
to baseline values while the curve featured in Figure 3.3b demonstrates a rapid initial
rate of change and rapid deceleration in order to return to baseline values. Interestingly
these two differently shaped curves have identical area under the curves illustrating the
information lost by assessing the area under the curve.
The effect of variables of interest on the area under the curve were tested one at a
time using a multivariate, multilevel model in which a random intercept was included
for each farm and the covariance of GLU, INS, GLP1a, and GLP1tot area under the
curves was estimated at the farm and individual level. An overall test of the variable
of interest’s effect on the mean AUC was determined by performing a Wald chi-square
test.
Trajectory analysis:
Trajectory analysis (a.k.a. longitudinal analysis, growth curve analysis) models the
response curve as a function of time facilitating a more thorough examination of the
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Figure 3.3: Demonstration of different curves with identical area under the curve (AUC)
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dynamic response to a glucose stimulus. The response variables of interest in an oral
glucose test typically exhibit a “rise-fall” pattern (a quadratic relationship with time).
Multilevel, longitudinal analysis facilitates a more thorough examination of the dynamic
response to a glucose stimulus. Modeling the response curve as a quadratic function of
time is well-suited for examining variation in baseline values, the initial rate of change,
and deceleration of the rate of change. Multilevel longitudinal analyses account for the
correlation of repeated measurements within individuals and correlation of observations
of individuals sampled from the same farm.
Non-linearity in trajectories was checked by plotting and significance tests of quadratic
and cubic fixed time effects. AIC and likelihood ratio tests were performed to determine
inclusion of the appropriate individual and farm level random time effects. The most
parsimonious model included fixed linear and quadratic time effects, a random intercept
at the individual and farm level, and random linear and quadratic time effects at the
individual levels. Covariance of GLU, INS, GLP1a, and GLP1tot intercepts were mod-
eled at the farm level and covariance of GLU, INS, GLP1a, and GLP1tot intercepts,
linear, and quadratic slopes were modeled at the individual level. Time was centered at
time point zero-minutes.
The effect of variables of interest on the mean trajectory were tested one at a time
by modeling their interaction effects with the intercept, linear time slope, and quadratic
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Figure 3.4: Quadratic time function example. When time is centered at zero for a
quadratic function of time (y=B0 + B1time + B2time
2), B0=y value at time zero,
B1=rate of change at time zero, B2=one half of the acceleration or deceleration rate
(degree to which B1 is reduced at each time point)
Ex: insulin= 5 + 4time - 0.3time2
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time slope. See Section 1.3 for an overview of multivariate, longitudinal, multilevel
models. An overall test of the variable of interest’s effect on the mean trajectory was
determined by performing a Wald chi-square test. Accordingly, p values relate to curve
differences in intercept, linear slope, and/or quadratic slope. Estimated marginal means
predicted from the models were used for graphical representation of the trajectories.
Statistical analyses were performed in R (version 15.3)g using ASReml-R129 statistical
software.
gR Core Team (2012). R: A language and environment for statistical computing. R Foundation for
Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, http://www.R-project.org/.
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3.4 Results
3.4.1 Descriptive statistics
Characteristics of the sampled farm populations are presented in Table 3.0. Figure 3.5
illustrates the inter-individual variability in the glucose, insulin, and GLP-1 responses
to an oral sugar challenge. It is readily apparent that individual trajectories are often
not similar to the population mean trajectory indicated by the bold black line. Inter-
individual variability was observed about the intercept (measurement value at time zero
just prior to oral sugar administration), the initial rate of change, and deceleration of
the initial rate of change (determines time till baseline return). The plotted data, in
addition to AIC values, supported the use of random quadratic time effect model.
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Table 3.0: Descriptive statistics of the sampled farms
MorganFarm1 MorganFarm2 MorganFarm3 MorganFarm4 WelshFarm1 WelshFarm2 WelshFarm3
N= 16 20 8 12 12 19 25
Age: mean(sd) 12.1(6.3) 10.2(3.8) 17.8(5.2) 11.9(5.2) 10.2(3.4) 14.4(8.4) 12.4(6.3)
Gender:
gelding/mare/stallion 5/10/1 9/10/1 0/7/1 0/12/0 2/10/0 3/14/2 3/22/0
Clinical group:
O−L−/O−L+/O+L−/O+L+ 10/1/4/1 9/4/5/2 7/1/0/0 5/2/5/0 5/1/4/2 17/2/0/0 0/11/0/14
Diet mean(sd)
Mcal /kg bwt 0.05(0.01) 0.03(0.01) 0.06(0.01) 0.04(0.00) 0.03(0.00) 0.03(0.00) 0.03(0.00)
CP g/kg bwt 2.24(0.66) 1.30(0.40) 2.86(0.25) 3.82(0.10) 1.90(0.00) 2.33(0.19) 3.70(0.30)
NDF g/kg bwt 15.48(2.26) 7.23(1.53) 15.10(2.16) 9.48(0.30) 6.90(0.00) 6.36(0.24) 6.50(0.31)
WSC g/kg bwt 3.84(0.62) 1.41(0.58) 1.32(0.28) 2.02(0.05) 1.64(0.00) 0.86(0.35) 1.05(0.11)
Starch g/kg bwt 0.60(0.17) 1.37(0.32) 0.34(0.15) 0.08(0.01) 0.50(0.00) 0.48(0.01) 0.20(0.02)
Biochemical mean(sd)
TG mg/dl 25.57(10.56) 18.18(5.50) 32.07(9.71) 40.27(31.93) 58.17(33.04) 20.53(7.49) 114.53(89.06)
NEFA mmol/L 0.24(0.18) 0.24(0.11) 0.22(0.09) 0.41(0.17) 0.52(0.14) 0.22(0.11) 0.49(0.13)
LEP ng/ml 6.03(4.23) 3.99(3.68) 7.10(3.68) 5.20(3.88) 3.40(2.43) 7.08(5.02) 5.18(2.28)
APN ng/ml 5557(2626) 7257(1858) 3884(1527) 2955(2633) 6152(4508) 6789(3906) 3770(3110)
DPP4 activity 12.79(3.69) 10.67(2.94) 24.3(3.51) 19.66(3.66) 35.26(13.15) 21.86(11.8) 25.2(7.17)
O−L−=non-obese/no prior laminitis, O−L+=non-obese/prior laminitis, O+L−=obese/no prior laminitis, O+L+=obese/prior
laminitis, Mcal=megacalories, kg=kilogram, bwt=bodyweight, NDF=neutral detergent fiber, WSC=water soluble carbohydrates,
TG=triglycerides, NEFA=non-esterfied fatty acids, LEP=leptin, APN=adiponectin, DPP4= dipeptidyl peptidase-4
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Figure 3.5: Population mean (black) and random sample (grey) of 15 raw trajectories
for glucose (a), insulin (b), active GLP-1 (c), and total GLP-1 (d) during an oral sugar
test (OST). Oral sugar administered at time point zero.
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3.4.2 DPP4 and GCG variants
Table 3.1 reports the location and frequencies of the genotyped variants. A single
missense (Thr>Ala) mutation was identified in exon 11 of the DPP4 gene located at
chr18:42522956 (EquCab2 assembly, dbSNP rs397231534h). Minor allele (G) frequen-
cies in the entire, Welsh pony, and Morgan horse populations were 0.45, 0.54, and 0.36,
respectively.
For the GCG gene, a SNP was identified in non-coding exon 1 (5’UTR) in addition
to five variants identified in the 5’ flanking region containing the ERV LTR insertion.
Haplotypes for the GCG variants were estimated and will be referred to as haplo-
types A-E. Haplotypes A-D had frequencies greater than 5% (haplotype A:CCAGGC,
frequency=0.31; haplotype B :CCAGCC, frequency=0.27; haplotype C :CAATGG, fre-
quency=0.27; haplotype D :GCAGGC, frequency=0.06, haplotype E denotes ten pooled
rare haplotypes (frequency<5%).
Table 3.1: Description of DPP4 and GCG genotyped variants
Minor Allele Frequency
Breed
Gene Location chr:bp Allele
change
Residue
change
Entire
population
Morgan Welsh
Pony
DPP4 exon 11 18:42386473 A>G Thr>Ala 0.45 0.36 0.53
GCG GUE 18:42523969 C>G NA 0.09 0.15 0.02
GCG GUE 18:42523797 C>A NA 0.30 0.23 0.21
GCG GUE 18:42523699 A>G NA 0.04 0.06 0.05
GCG GUE 18:42523690 G>T NA 0.31 0.23 0.23
GCG GUE 18:42523627 G>C NA 0.33 0.50 0.21
GCG 5’UTR 18:42522905 C>G NA 0.33 0.27 0.22
chr, chromosome; bp, base pair; DPP4, dipeptidyl-peptidase 4 gene; GCG, proglucagon
gene; GUE, proglucagon gene upstream enhancer; UTR, untranslated region
hDatabase of Single Nucleotide Polymorphisms (dbSNP). Bethesda (MD): National Center for
Biotechnology Information, National Library of Medicine. http://www.ncbi.nlm.nih.gov/SNP/
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3.4.3 DPP4 activity
DPP4 activity (RFU/min) was tested for association with the following univariate pre-
dictors: age, gender, clinical group, diet , DPP4 genotype, and blood concentration of
triglyceride, NEFA, leptin, and adiponectin (Table 3.2). Age and adiponectin were neg-
atively correlated with DPP4 activity (p< 0.05, p < 0.01; respectively) and DPP4 activ-
ity was significantly higher in Welsh ponies compared to Morgan horses (+10.66(±4.93)
units, p< 0.05).
Table 3.2: DPP4 activity (RFU/min) fixed effect estimate(se)
univariate predictor estimate(se)
Ref group (mean age) 21.41(3.16)
1 SD increase in age -1.64(0.76)*
Ref group (gelding) 20.30(3.48)
mare 1.28(2.00)
stallion 0.73(3.95)
Ref group (Morgan breed) 16.65(3.26)
Welsh Pony 10.66(4.93)*
Ref group (non-obese, no prior laminitis) 22.15(3.26)
non-obese, prior laminitis -2.70(2.38)
obese, no prior laminitis -1.87(2.30)
obese, prior laminitis -0.21(2.84)
Ref group(mean Mcal) 21.42(3.15)
1 SD increase in Mcal -0.42(1.43)
Ref group (mean nutrients) 21.09(4.11)
1 SD increase in Starch -2.17(2.34)
1 SD increase in CP -2.32(2.33)
1 SD increase in NDF -0.65(3.63)
1 SD increase in WSC 3.69(3.33)
Ref group (mean triglycerides) 21.29(3.20)
1 SD increase in triglycerides -0.65(0.95)
Ref group (mean NEFA) 21.34(3.05)
1 SD increase in NEFA 0.44(0.99)
Ref group (mean leptin) 21.33(3.13)
1 SD increase in leptin 0.31(0.77)
Table 3.2 Continued on next page
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Table 3.2 Continued from previous page
univariate predictor estimate(se)
Ref group (mean adiponectin) 21.25(3.06)
1 SD increase in adiponectin -2.30(0.79)**
Ref group (DPP4 0 copies) 20.41(3.18)
DPP4 1 copy minor allele 1.02(1.06)
Ref group (GCG haplotype A) 22.49(3.62)
GCG haplotype B -0.67(1.57)
GCG haplotype C -1.76(1.46)
GCG haplotype D 0.69(2.72)
GCG haplotype E 0.09(2.06)
Asterisks indicate significance of beta estimates (*<0.05, **<0.01, ***<0.001). GCG haplotype
A=highest frequency haplotype, GCG haplotype E=pooled rare haplotypes with frequency <
0.05
3.4.4 Glucose, insulin, and GLP-1 area under the curves and trajec-
tories
Multiple factors were tested for univariate association with glucose (Table 3.3), insulin
(Table 3.4), active GLP-1 (Table 3.5) and total GLP-1 (Table 3.6) area under the
curves and trajectories during an oral sugar test. In numerous instances, trajectory
analysis detected associated factors that went undetected by an area under the curve
analytical approach, hence only the trajectory analysis results are described below. Esti-
mated effects of the different factors on glucose, insulin, active GLP-1, and total GLP-1
AUCs and trajectory intercepts, linear slopes (unit change per 15 minute interval), and
quadratic slopes (1/2 the deceleration rate) from the univariate predictor model are
presented in Tables B.2-B.5. Factors with a p-value significance level <0.2 in the uni-
variate predictor analysis were included in a multiple predictor regression analysis of
glucose, insulin, and GLP-1 trajectories (Appendix Tables B.6 to B.9).
Glucose
Factors demonstrating a significant association with the glucose trajectory included:
age, breed, clinical group, caloric intake, nutrient intake, and NEFA blood concentration
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(Tables 3.3, B.2). Older individuals had a lower initial rate of increase in glucose and
a corresponding reduction in deceleration of the glucose rate (Figure 3.6a). Welsh
ponies had a higher initial rate of increase in glucose and a corresponding increase
in deceleration of the glucose rate in comparison to the Morgan horses (Figure 3.6b).
Glucose trajectories differed by clinical group status. In comparison to the reference
group (non-obese horses with no prior history of laminitis), obese horses with no prior
laminitis history had a higher baseline value of glucose, although their response following
oral sugar administration was not significantly different. Obese horses with a prior
history of laminitis did not differ at the baseline glucose level but did have a higher initial
rate of increase in glucose and a corresponding increase in deceleration of the glucose
rate (Figure 3.6c). The initial glucose rate of increase was positively correlated with
caloric intake per kg bodyweight (Figure 3.7a). Diet composition was not associated
with differences in baseline glucose levels (Figure 3.7b), however higher fiber diets had
a reduced glycemic response whereas diets high in water soluble carbohydrates had an
elevated glycemic response. A high starch diet was associated with a mild reduction in
the glycemic response. Elevated blood concentration of triglycerides and NEFA were
associated with an increased glycemic response (Figure 3.8a,b).
Insulin
The insulin trajectory was significantly associated with breed, clinical group, nutrient
intake, triglycerides, leptin, adiponectin, and DPP4 activity (Tables 3.4, B.3). Baseline
values of insulin were not significantly different by breed, however the insulinemic re-
sponse was much higher in Welsh ponies than in Morgan horses (Figure 3.9a).
Insulin trajectories varied with obesity and prior laminitis status (Figure 3.9b). Obese
horses with a prior history of laminitis had elevated baseline insulin values and a higher
insulinemic response. The insulinemic response was also elevated in non-obese horses
with a prior history of laminitis, although the difference from non-obese horses with
no prior history of laminitis did not reach statistical significance. Horses with higher
starch or higher fiber in their diets tended to have a reduced insulinemic response (Fig-
ure 3.9c). Triglyceride, leptin, and DPP4 activity blood levels were positively correlated
with insulinemic responses whereas adiponectin blood levels were negatively correlated
with the insulinemic response (Figures 3.10a-d).
94
Figure 3.6: Predicted trajectories of glucose during an oral sugar test (OST) by age
(a), breed (b), and clinical group (c). Oral sugar administered at time point zero. Solid
lines are estimated trajectories and dashed lines represent standard error of the mean.
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Table 3.3: Comparison of glucose AUC and trajectory association tests with univariate
predictors of glucose response to an oral sugar test
univariate predictor glucose AUC glucose trajectory
(wald χ2, df) p-value (wald χ2, df) p-value
age (6.7, 1df)=9.4E-03 (9.6, 3df)=2.2E-02
sex (0.2, 2df)=9.1E-01 (3.7, 6df)=7.2E-01
breed (2.2, 1df)=1.4E-01 (12.8, 3df)=5.2E-03
clinical group (17.9, 3df)=4.6E-04 (28.7, 9df)=7.4E-04
caloric intake (4.1, 1df)=4.3E-02 (11.3, 3df)=1.0E-02
nutrient intake (4.8, 4df)=3.1E-01 (30.9, 12df)=2.0E-03
triglycerides (0.4, 1df)=5.4E-01 (8.3, 3df)=4.0E-02
NEFA (6.6, 1df)=1.0E-02 (18.6, 3df)=3.2E-04
leptin (3.3, 1df)=6.9E-02 (1.5, 3df)=6.9E-01
adiponectin (0.0, 1df)=8.4E-01 (2.2, 3df)=5.4E-01
DPP4 activity (1.5, 1df)=2.3E-01 (7.6, 3df)=5.5E-02
DPP4 genotype (0.0, 1df)=8.6E-01 (2.2, 3df)=5.2E-01
GCG haplotype (3.3, 4df)=5.0E-01 (20.1, 12df)=6.5E-02
Results obtained from a multivariate response model (responses included glucose, in-
sulin, active GLP-1 and total GLP-1 measured at 7 time points over a 2 hour period)
GLP-1
Factors associated with GLP-1 trajectories included sex, clinical group, diet compo-
sition, NEFA blood levels, and haplotype at the proglucagon gene (GCG) upstream
enhancer region (GUE) (Tables 3.5, 3.6, B.4, B.5). Active and total GLP-1 unexpect-
edly decreased throughout the duration of the oral sugar tests in stallions, although
baseline GLP-1 levels tended to be higher (Figure 3.11a). Higher starch and higher
protein diets were associated with a reduced GLP-1 response, although individuals with
higher starch diets tended to have higher basal GLP-1 levels and individuals with higher
protein diets tended to have lower basal GLP-1 levels (Figure 3.11b). Basal GLP-1 lev-
els were significantly lower in non-obese horses with a prior history of laminitis and
also trended toward being lower in obese horses with and without a history of lamini-
tis. However, obese horses with no prior laminitis had a significantly greater positive
GLP-1 response following oral sugar administration whereas obese horses with a his-
tory of laminitis had decreasing levels of total GLP-1 throughout the oral sugar test.
GCG haplotype was modestly associated with total GLP-1 trajectory variation (Figure
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Figure 3.7: Predicted trajectories of glucose during an oral sugar test (OST) by caloric
intake (a) and nutrient composition (b) per kg bodyweight. Oral sugar administered
at time point zero. Solid lines are estimated trajectories and dashed lines represent
standard error of the mean.
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3.12a). The most common haplotype (referred to as “haplotype A” in Figure 3.12a)
had the lowest basal total GLP-1 level. “Haplotype E” consisting of a pooling of rare
haplotypes with a frequency less than 5% had a significantly higher basal total GLP-1
level. “Haplotype B” demonstrated decreasing total GLP-1 levels throughout the oral
sugar test similar to obese horses with a history of laminitis.
Correlation of glucose, insulin, and GLP-1 trajectories
Estimate of trajectory variance and covariance from an unconditional multivariate lon-
gitudinal model were used to obtain estimates of correlation. The correlation estimates
of glucose, insulin, and GLP-1 baseline values, initial rate of increase, and deceleration
are presented in Figure 3.13. As expected, given the same overall “rise-fall” pattern
observed for the different trajectories, the initial rate of increase and deceleration rate
were strongly negatively correlated. Individuals with a higher initial rate of increase
experienced faster deceleration in attempt to achieve a return to baseline values in a
timely manner. GLP-1 active and total baseline values, initial rates of change, and
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Figure 3.8: Predicted trajectories of glucose during an oral sugar test (OST) by triglyc-
eride (a) and NEFA (b) concentration. Oral sugar administered at time point zero.
Solid lines are estimated trajectories and dashed lines represent standard error of the
mean.
(a)
●
●
●
●
● ●
●
0 20 40 60 80 100 120
70
80
90
10
0
11
0
minutes post OST
G
L
U
 m
g/
dl
mean triglycerides
1SD increase in triglycerides
(b)
●
●
●
●
● ●
●
0 20 40 60 80 100 120
70
80
90
10
0
11
0
minutes post OST
G
L
U
 m
g/
dl
mean NEFA
1SD increase in NEFA
deceleration rates were also strongly correlated indicated minimal variation in GLP-1
active total ratios throughout the oral sugar test. Insulin and glucose initial rates of
change and deceleration were correlated however appreciably correlation was not evident
between insulin and glucose with GLP-1 active and total trajectories. Active GLP-1
baseline values were correlated with both active and total initial rates of change (posi-
tive correlation) and deceleration (negative correlation). Likewise, total GLP-1 baseline
values were correlated with both active and total initial rate of change and deceleration.
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Figure 3.9: Predicted trajectories of insulin during an oral sugar test (OST) by breed
(a), clinical group (b), and nutrient composition (c). Oral sugar administered at time
point zero. Solid lines are estimated trajectories and dashed lines represent standard
error of the mean.
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Figure 3.10: Predicted trajectories of insulin during an oral sugar test (OST) by triglyc-
eride (a), leptin (b), adiponectin (c), and DPP4 activity (d) blood levels. Oral sugar
administered at time point zero. Solid lines are estimated trajectories and dashed lines
represent standard error of the mean.
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Figure 3.11: Predicted trajectories of active (a, c) and total (b, d) GLP-1 during an
oral sugar test (OST) by sex and nutrient composition. Oral sugar administered at time
point zero. Solid lines are estimated trajectories and dashed lines represent standard
error of the mean.
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Table 3.4: Comparison of insulin AUC and trajectory association tests with univariate
predictors of insulin response to an oral sugar test
univariate predictor insulin AUC insulin trajectory
(wald χ2, df) p-value (wald χ2, df) p-value
age (0.0, 1df)=9.7E-01 (4.0, 3df)=2.7E-01
sex (1.6, 2df)=4.4E-01 (6.4, 6df)=3.8E-01
breed (2.3, 1df)=1.3E-01 (12.8, 3df)=5.2E-03
clinical group (7.2, 3df)=6.5E-02 (28.7, 9df)=7.4E-04
caloric intake (0.8, 1df)=3.8E-01 (3.0, 3df)=3.9E-01
nutrient intake (26.3, 4df)=2.7E-05 (24.5, 12df)=1.7E-02
triglycerides (2.8, 1df)=9.6E-02 (11.9, 3df)=7.8E-03
NEFA (0.0, 1df)=9.5E-01 (5.4, 3df)=1.4E-01
leptin (14.2, 1df)=1.6E-04 (13.0, 3df)=4.6E-03
adiponectin (8.9, 1df)=2.9E-03 (15.1, 3df)=1.7E-03
DPP4 activity (1.1, 1df)=2.9E-01 (10.1, 3df)=1.7E-02
DPP4 genotype (0.2, 1df)=6.3E-01 (6.5, 3df)=8.8E-02
GCG haplotype (1.0, 4df)=9.2E-01 (11.5, 12df)=4.8E-01
Results obtained from a multivariate response model (responses included glucose, in-
sulin, active GLP-1 and total GLP-1 measured at 7 time points over a 2 hour period)
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Table 3.5: Comparison of active GLP-1 AUC and trajectory association tests with
univariate predictors of active GLP-1 response to an oral sugar test
univariate predictor active GLP-1 AUC active GLP-1 trajectory
(wald χ2, df) p-value (wald χ2, df) p-value
age (0.1, 1df)=7.6E-01 (0.8, 3df)=8.4E-01
sex (0.1, 2df)=9.7E-01 (18.1, 6df)=6.0E-03
breed (0.7, 1df)=3.9E-01 (1.7, 3df)=6.5E-01
clinical group (3.5, 3df)=3.3E-01 (15.9, 9df)=6.9E-02
caloric intake (0.6, 1df)=4.3E-01 (1.7, 3df)=6.5E-01
nutrient intake (17.8, 4df)=1.4E-03 (21.7, 12df)=4.1E-02
triglycerides (0.1, 1df)=7.1E-01 (3.7, 3df)=3.0E-01
NEFA (2.6, 1df)=1.1E-01 (3.7, 3df)=2.9E-01
leptin (0.2, 1df)=7.0E-01 (1.0, 3df)=8.0E-01
adiponectin (2.1, 1df)=1.5E-01 (6.2, 3df)=1.0E-01
DPP4 activity (1.6, 1df)=2.1E-01 (2.3, 3df)=5.2E-01
DPP4 genotype (0.0, 1df)=9.9E-01 (0.9, 3df)=8.2E-01
GCG haplotype (2.2, 4df)=7.0E-01 (12.6, 12df)=4.0E-01
Results obtained from a multivariate response model (responses included glucose, in-
sulin, active GLP-1 and total GLP-1 measured at 7 time points over a 2 hour period)
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Table 3.6: Comparison of total GLP-1 AUC and trajectory association tests with uni-
variate predictors of total GLP-1 response to an oral sugar test
univariate predictor total GLP-1 AUC total GLP-1 trajectory
(wald χ2, df) p-value (wald χ2, df) p-value
age (0.2, 1df)=7.0E-01 (2.4, 3df)=4.9E-01
sex (0.7, 2df)=6.9E-01 (22.4, 6df)=1.0E-03
breed (1.2, 1df)=2.8E-01 (4.0, 3df)=2.7E-01
clinical group (4.7, 3df)=1.9E-01 (25.3, 9df)=2.6E-03
caloric intake (0.1, 1df)=7.7E-01 (7.0, 3df)=7.1E-02
nutrient intake (22.0, 4df)=2.0E-04 (48.5, 12df)=2.5E-06
triglycerides (0.8, 1df)=3.8E-01 (6.5, 3df)=8.9E-02
NEFA (3.1, 1df)=7.9E-02 (8.1, 3df)=4.4E-02
leptin (0.0, 1df)=8.8E-01 (4.0, 3df)=2.7E-01
adiponectin (1.9, 1df)=1.7E-01 (3.9, 3df)=2.7E-01
DPP4 activity (0.7, 1df)=4.0E-01 (4.1, 3df)=2.5E-01
DPP4 genotype (0.4, 1df)=5.2E-01 (0.8, 3df)=8.5E-01
GCG haplotype (1.4, 4df)=8.5E-01 (23.3, 12df)=2.5E-02
*Results obtained from a multivariate response model (responses included glucose, in-
sulin, active GLP-1 and total GLP-1 measured at 7 time points over a 2 hour period)
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Figure 3.12: Predicted trajectories of total GLP-1 during an oral sugar test (OST) by
clinical group (a) and GCG haplotypes (b). Oral sugar administered at time point zero.
Solid lines are estimated trajectories and dashed lines represent standard error of the
mean.
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Figure 3.13: Correlation estimates (SE) for glucose, insulin, and GLP-1 trajectories.
Correlation estimates determined from variance and covariance estimates obtained
from an unconditional longitudinal model that included fixed and random linear and
quadratic time effects and a random farm intercept. Time centered at 0 minutes. Stan-
dard errors estimated by the delta method.
Correlation
(-1.0,-0.8)
Glucose 0.30 (-0.8,-0.6)
linear (0.19) (-0.6,-0.4)
quadratic
-0.29 -0.94 (-0.4,-0.2)
(0.19) (0.01) (-0.2,0.0)
Insulin -0.06 0.00 -0.01 (0.0,0.2)
intercept (0.33) (0.27) (0.27) (0.2,0.4)
linear
-0.20 0.43 -0.51 0.36 (0.4,0.6)
(0.14) (0.10) (0.10) (0.28) (0.6,0.8)
quadratic
0.16 -0.46 0.57 -0.51 -0.94
(0.14) (0.10) (0.09) (0.30) (0.01)
GLP1active 0.09 -0.16 0.15 0.24 -0.16 0.13
intercept (0.15) (0.12) (0.12) (0.23) (0.11) (0.11)
linear
-0.13 0.09 -0.05 0.13 0.09 -0.08 0.29
(0.17) (0.15) (0.15) (0.28) (0.13) (0.13) (0.13)
quadratic
0.12 -0.18 0.16 -0.20 -0.18 0.21 -0.41 -0.96
(0.20) (0.17) (0.17) (0.33) (0.15) (0.15) (0.15) (0.02)
GLP1total 0.01 -0.08 0.09 0.29 -0.05 0.03 0.75 0.31 -0.45
intercept (0.14) (0.12) (0.12) (0.22) (0.11) (0.11) (0.05) (0.12) (0.13)
linear
0.02 0.05 -0.03 -0.10 -0.06 0.06 0.32 0.72 -0.67 -0.01
(0.16) (0.13) (0.13) (0.25) (0.11) (0.11) (0.11) (0.07) (0.10) (0.11)
quadratic
-0.05 -0.13 0.13 0.15 -0.02 0.04 -0.34 -0.64 0.65 -0.05 -0.95
(0.17) (0.14) (0.14) (0.27) (0.13) (0.13) (0.12) (0.10) (0.11) (0.12) (0.01)
Glucose Insulin GLP1active GLP1 total
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3.5 Discussion
We hypothesized alteration in the incretin response may play a role in the pathogenesis
of EMS. In this characterization study of the equine incretin response, a number of fac-
tors were found to be associated with the incretin hormone GLP-1 and insulin/glucose
dynamics during the equine response to an oral sugar challenge. In addition, factors were
also observed to be associated with DPP4, the major protease that breaks down GLP-
1. It is important to note that tested factors reported in the main text of the chapter
were included in both the DPP4 activity response model and the glucose/insulin/GLP-1
multivariate response model one at a time due to colinearity, other covariates were not
included in the models. It was beyond the scope of this chapter to build an extensive
prediction model. For the interested reader, estimates from a multiple predictor regres-
sion model are reported in Appendix B but should be interpreted with caution given
the existence of colinearity among the tested predictors. Likewise, estimates reported in
the main text can only be interpreted as correlated factors, not causally related factors.
The objective of this study was to lay the groundwork in identifying factors associated
with variation in the equine response to an oral sugar challenge which can later be built
upon when attempting to determine causal pathways.
3.5.1 DPP4
Age and adiponectin levels were found to be negatively correlated with DPP4 blood
activity levels. Similarly, DPP4 activity has been reported to be negatively correlated
with human adiponectin levels.175 In the current study, the association of DPP4 activity
with clinical group was not significant, which is a little unexpected given the strong neg-
ative correlation of prior laminitis status with adiponectin levels reported in Chapter 2.
DPP4 activity was not associated with baseline insulin levels however it was positively
associated with an increased insulin response to the oral sugar challenge. DPP4 activ-
ity was not associated with glucose and GLP-1 trajectories. The positive association
of DPP4 activity with insulin and the negative association with adiponectin may be
reflective of DPP4’s role as an adipokine.176 The negative association of DPP4 activity
with age has also been previously reported in humans.177,178 DPP4 activity was found
to be higher in Welsh ponies than Morgan horses suggesting a possible genetic basis for
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variation in DPP4 activity, although additive association testing of DPP4 activity with
copy number of a single missense mutation in the DPP4 gene was not significant.
3.5.2 Dynamic responses to the oral sugar test
This study utilized an an analytical approach that is not frequently used for studying
variation in responses to an oral sugar challenge. Most diabetes researchers typically use
a single summary statistic, area under the curve, when assessing variation in the oral
glucose tolerance test. In this chapter, it was pointed out that response curves can be
very different yet have the same area under the curve making it an adequate method for
truly assessing variation in a response. This study found that an alternative approach,
a longitudinal multilevel model, was able to test for differences in the trajectory of the
response and identify factors that were significantly associated with variation in the
trajectory that went undetected when assessing differences in the area under the curve.
Mainstream use of longitudinal multilevel models for assessing oral glucose tolerance
test variation potentially provides additional biologically relevant information and could
improve conclusions drawn from studies that utilize the common oral glucose tolerance
test.
Glucose trajectories
The initial rate of increase in glucose levels was found to decrease with age, a potential
explanation for this finding may be age-related changes in intestinal glucose absorp-
tion.179 Welsh ponies demonstrated an increased glucose response compared to Morgan
horses potentially suggesting a genetic basis for variation in glucose response. Obe-
sity status was associated with variation in the glucose trajectory, elevated baseline
glucose values were observed in obese horses with no prior history of laminitis and
increased glucose responses in obese horses with a prior history of laminitis replicat-
ing findings in human and rodent studies.180,181 Dietary composition was associated
with glucose trajectory variation with individuals on higher fiber diets having a reduced
glycemic response. High fiber diets have been advocated in humans as a management
tool for hyperglycemia.182 Similar to previous equine studies, this study observed ele-
vated glycemic responses in individuals consuming a higher water soluble carbohydrate
diet.183 Biochemical parameters, blood triglyceride and NEFA level, were positively
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associated with glycemic responses. NEFA are known to both decrease insulin medi-
ated glucose transport184 and induce hepatic insulin resistance.185 Insulin resistance
results in failed suppression of NEFA during an oral sugar challenge resulting in in-
creased gluconeogenesis.186 Examining changes in NEFA levels in our study population
has potential to shed additional light on the observed correlation of fasting NEFA levels
with the glycemic response.
Insulin trajectories
Insulinemic responses were found to be significantly greater in Welsh ponies compared
to Morgan horses which again suggest a genetic basis for variation in the equine response
to an oral sugar challenge. Insulin trajectories also varied with clinical group status.
Obese horses had higher baseline insulin values and insulinemic responses, although the
difference only reached significance for obese horses with a prior history of laminitis. In
the larger study population presented in Chapter 2, obesity and laminitis status were
both found to be associated with post-OST insulin levels. Human studies have also
demonstrated elevated fasting insulin and insulinemic responses to oral glucose with
obesity and improvement of the insulinemic response with weight loss.187,188 Similar
to glucose trajectories, horses consuming a higher fiber diet had a reduced insulinemic
response, providing support for dietary modulation as a dysinsulinemia management
tool. Triglyceride and leptin were positively associated with insulinemic responses where
as adiponectin was negatively associated similar to our findings in 75 minute post-
OST insulin in the larger population presented in Chapter 2. Triglyceride, leptin, and
adiponectin have all been shown to be associated with insulin resistance and insulin
responses to oral glucose in humans,189–191 however leptin is correlated with fat mass
and the association with leptin has been shown not to occur independently of obesity.192
GLP-1 trajectories
Only a limited number of stallions (five) were included in the study population, but
significant differences were observed in their active and total GLP-1 trajectories. Stal-
lions exhibited reduced GLP-1 responses to oral sugar, however the baseline values were
higher. Lower GLP-1 responses in the male gender has also been reported in humans.90
GLP-1 trajectories varied with clinical group status. Total basal GLP-1 levels were
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significantly lower in non-obese horses with a prior history of laminitis and also trended
toward being lower in obese horses with and without a prior history of laminitis. In-
terestingly, obese horses with no prior history of laminitis had a significantly greater
positive GLP-1 response where as obese horses with a history of laminitis had decreasing
levels of GLP-1 throughout the oral sugar test. These findings indicate basal GLP-1
and GLP-1 secretory responses to oral glucose are reduced with features of EMS, simi-
lar to decreased GLP-1 secretion observed with features of human metabolic syndrome,
obesity and insulin resistance.168,193–195 Elevated NEFA levels were associated with
decreased basal and secretory GLP-1. Human studies have demonstrated that pharma-
cologic suppression of NEFA levels results in a higher carbohydrate stimulated GLP-1
secretion.193–195 Variation in basal GLP-1 and GLP-1 in response to oral sugar were
correlated with diet nutrient composition. Higher starch and protein diets were associ-
ated with decreased GLP-1 secretory responses.
Variation in the proglucagon gene(GCG) which encodes GLP-1 was tested for as-
sociation with GLP-1 trajectory. Cross-species alignment of 5’ GCG flanking region
nucleotides revealed an endogenous retrovirus long terminal repeat (ERV LTR) inser-
tion located between what is referred to as the proglucagon gene upstream enhancer
region (GUE) and the GCG promoter region. ERV LTRs naturally contain abundant
transcriptional regulatory signals and often contribute to variation in mammalian gene
expression, including tissue-specific expression, through donation of alternative promot-
ers and enhancers. For example, an LTR sequence of a human endogenous retrovirus is
involved in the tissue-specific expression of human salivary amylase.196 The ERV LTR
insertion upstream of three genes of the human amylase gene complex is correlated with
a switch from pancreatic to parotid expression. Haplotype trend regression revealed an
overall modest association with GCG haplotype. Interesting, haplotypes with higher
basal GLP-1 levels tended to exhibit decreased GLP-1 responses to an oral sugar test.
An interesting hypothetical explanation could involve GLP-1 expression in a tissue al-
ternative to intestine due to alternative enhancers/promoters provided by the ERV LTR
or disruption of the intestinal promoter/enhancers as a result of the insertion. Further
experiments would be needed to test these hypotheses.
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Correlation of trajectories
This study’s use of a multivariate response longitudinal multilevel model allowed exam-
ination of the correlation of fasting values with initial rate of increase and deceleration
both within and between each repeated response type. GLP-1 active and total values
were strongly correlated for baseline values, initial rates of change, and deceleration
rates were strongly correlated indicating minimal variation in GLP-1 active total ratios
throughout the oral sugar test. Insulin and glucose were correlated for initial rates of
change and deceleration however appreciable correlation was not evident between in-
sulin and glucose with GLP-1 trajectories. If the equine incretrin response explained a
large amount of the variation in the insulinemic response one would have expected to
have observed stronger correlation of the GLP-1 and insulin trajectories. A possible ex-
planation for the lack of observed correlation may be due to a differential relationship of
GLP-1 secretion with the insulinemic response dependent on clinical group status which
was not specifically tested in the unconditional longitudinal model used to determine
correlation of the trajectories. In humans it has been shown that the incretin effect
accounts for 70% of the variation in the insulin response to an oral sugar challenge in
normal individuals but only 30% percent in individuals affected with type 2 diabetes.197
Although, a recent study that more specifically measured the incretin effect with con-
comitant analysis of oral and intravenous glucose tests also reported a weak correlation
of incretin hormone levels with the incretin effect (potentiation of oral glucose induced
insulin secretion relative to intravenous glucose induced insulin secretion).167
Conclusions
Overall, this study replicated many of the findings associated with human incretin vari-
ation. Previously, it has been considered plausible that the pathophsyiology of equine
hyperinsulinemia may be opposite of that which is believed to occur in humans, with
horses manifesting chronic hyperinsulinemia as a result of an enhanced incretin response
with insulin resistance occurring secondary to chronic hyperinsulinemia.92,93 The re-
sults from our study do not support this hypothesis and suggest the pathophysiology of
equine incretin response impairment may be similar to humans with insulin resistance
playing a primary role. Additional studies that evaluate a horse’s response to an oral
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glucose stimulus compared with their response to an intravenous glucose stimulus are
needed to further assess the incretin role in equine glucose intolerance.
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Chapter 4
Improved linear mixed model of
polygenic traits in populations
with familial relatedness
4.1 Summary
Unexplained individual level variation and breed differences in metabolic phenotypes
identified in Chapters 2 and 3 support the hypothesis that an underlying genetic sus-
ceptibility to EMS exists. Human MetS is a highly polygenic syndrome where numerous
candidate genes have been identified. Whereas MetS associated variants are typically of
small effect size; it was hypothesized that in EMS a small number of moderate to large
effect loci contribute to variation in metabolic traits due to the fact that horse popula-
tions do not randomly mate and experience substantial selection pressure. 286 Morgan
horses were genotyped on the Illumina SNP50 chip and imputed up to > 800,000 SNPs
to perform a genome wide association study (GWAS) to identify candidate genes for
EMS. Additive genetic variance estimated from a genomic relationship matrix calculated
from genotyped SNPs (“chip heritability”) indicated that the 11 measured metabolic
traits were moderately heritable. Yet initial genome-wide scans using standard linear
mixed models failed to detect significant associations. Chapter 4 proposes an improved
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linear mixed model for mapping polygenic traits in a population with familial relation-
ships similar to that in many equine GWAS was developed and validated. The model
incorporates a Bayesian variable selection method to rank SNPs and a stepwise feature
selection process to determine the optimal SNPs to model the random polygenic effect,
while including a random effect for each sampled herd or “familial cluster”. The method
was validated using the QTL-MAS 2010 dataset, and Morgan horse and Welsh pony
height datasets, and demonstrated increased power while controlling the false positive
rate.
4.2 Introduction
Association mapping of complex traits poses several challenges. First, complex traits
are typically polygenic, meaning numerous genes contribute to the variability observed
in a group of individuals measured for a particular trait. Statistical models testing the
association of a trait with a single genetic marker will have reduced power to detect an
association in comparison to a model that simultaneously considers additional loci con-
tributing to variation of the trait. Power of the model will also vary dependent on the
effect size of the causal variant being tested, the frequency of the genetic marker, and
the degree of linkage disequilibrium (LD) between the causal variant and the genetic
marker being tested.
Secondly, a homogeneous mapping population in terms of the level of relatedness
between pairs of individuals is ideal, although unrealistic. Every population has varying
levels of relatedness that may result in spurious associations due to allele frequency dif-
ferences correlated with genetic background or spatial environment. The confounding
structure and/or relatedness must be removed via sample design or accounted for in the
statistical model.
The linear mixed model (LMM) effectively reduces the confounding effect of varying
relatedness among individuals.198–200 Fisher (1918) demonstrated phenotypic covari-
ance between related individuals depends on their genetic relatedness for polygenic
traits.201 The more alleles individuals share, the more similar their phenotype. The
classic Henderson mixed model (1984)202 has been adapted to reduce the confound-
ing effects of genetic background by estimating pairwise relatedness from all single
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nucleotide polymorphisms (SNPs) to build a genetic relationship matrix (GRM) and
model the random genotypic covariance effect on phenotype.203 Relatedness serves as
a proxy for allele sharing at causative loci. Even in ideal study populations without
structure or familial relatedness, mixed linear models can increase power by implicitly
conditioning on associated loci other than the candidate locus by reducing what would
otherwise be considered by the model as random noise (i.e. unaccounted for loci of true
effect would incorrectly be considered random noise resulting in larger error terms and
reduced power).204
The standard LMM approach is based on single-locus tests combined with a diffuse,
overall estimate of the genomic background based on all SNP markers. However, diffuse
modeling of the polygenic term may not be appropriate for traits controlled by multiple
loci of moderate to large effect. Recent LMM innovations aimed at improved model-
ing of the polygenic architecture in effort to increase power include modeling suspected
causal loci as fixed effects205 or building a GRM comprised of select SNPs associated
with the phenotype.206–209 An additional advantage of the select SNP GRM approach
is increased computational efficiency due to using a lower-rank relatedness matrix (the
number of SNPs used to determine the matrix is less than the number of individuals).
Widmer et al208 cautioned building a GRM based on selected SNPs that well predict
the phenotype performed poorly at controlling the type I error rate in the presence of
familial relatedness and recommended including a second GRM comprised of all SNPs
to achieve adequate type I error control. Although, a drawback of this approach is
increased computational time due to full-rank relatedness matrix inclusion.
In this chapter, a LMM approach featuring a novel select SNP GRM building al-
gorithm with increased power and adequate type I error control will be presented and
applied to the QTL mapping and marker assisted selection (QTL-MAS) 2010 workshop
simulated dataset210 and two real datasets featuring familial relatedness.
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4.3 Methods
4.3.1 Description of simulated data
The 2010 QTL-MAS210 simulated dataset features familial relationships (half-sibs, full-
sibs) and is comprised of 3226 individuals from five consecutive generations (F0-F4).
There were 20 founders: 5 males and 15 females. The pedigree structure was created
assuming each female mates once and gives birth to approximately 30 progeny. Almost
non-overlapping generations were created (the parents from every next generation were
selected at random mostly from the current generation). Each of the 2326 individuals
in generation F0 to F3 has phenotypic records on a quantitative trait and were included
in the analysis. A genome consisting of 10,031 biallelic SNPs on 5 chromosomes were
simulated without any missing data and genotyping error. 37 SNPs were selected as
causal variants and the genotypes for 28 QTL were removed from the dataset. The
quantitative trait was simulated with heritability of 0.39. SNPs with a minor allele
frequency less than 0.05 were excluded from the analysis.
4.3.2 Description of real data
The Morgan horse height data consists of 286 individuals sampled from 54 farms located
throughout the United States and a single Canadian farm. The horses were genotyped
on on the Illumina SNP50 array and imputed up to ∼2 million genotypes from a cos-
mopolitan reference population comprised of 384 individuals representing 30+ breeds,
including 43 horses from the Morgan breed using Beagle 4.0 software.211,212 Genotypes
were filtered for MAF < 0.05, and Hardy-Weinberg disequilibrium p-values < 0.00001
yielding 877,608 SNPs. The heritability estimate determined using the GEMMA soft-
ware213 adjusted for age and sex covariates and estimated from a centered GRM com-
prised of all 845,234 autosomal SNPs was 1.00 (standard error: 0.00).
The Welsh pony height data consists of 234 individuals sampled from 27 US farms
genotyped on the Affymetrix 670K array. Genotypes were filtered for SNP missingness
> 0.05 (remaining missing genotypes were imputed using Beagle 4.0 software211,212),
MAF < 0.05, and Hardy-Weinberg disequilibrium p-values < 0.00001 yielding 394,880
SNPs. The heritability estimate determined using the GEMMA software213 adjusted
for age and sex covariates and estimated from a centered GRM comprised of all 379,604
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autosomal SNPs was 0.95 (standard error: 0.03).
4.3.3 The linear mixed model
The linear mixed model decomposes the phenotype (y) into the phenotype mean (µ),
fixed covariate (βcov) and fixed genetic marker (βgenetic marker) effects, random genetic
effect (u), and residual () as follows:
y = 1nµ+Wβcov + xβgenetic marker + u+ ;
u ∼MVNn(0, λτ−1K),
 ∼MVNn(0, τ−1In),
(4.1)
where 1n is a n-vector of ones; µ is a scalar representing the intercept; W=(w1,...,wc)
is a n x c matrix of covariates; βcov is a c-vector of covariate effect sizes; x is a n-vector
of marker genotypes; βgenetic marker is the effect size of the marker; u is a n-vector of
unknown random polygenic effects;  is a n-vector of random residual effects; τ−1 is
the variance of the residual errors; λ is the ratio between the two variance components;
K is a known n x n relatedness matrix with element Kij (i,j=1,2,...,n) calculated from
genetic markers and In is a n x n identity matrix. MVNn denotes the n-dimensional
multivariate normal distribution. Solving equation (4.3) involves determining all the
unknown parameters under which the observations (y) have the maximum likelihood,
defined as follows:
L(y|µ, βcov, βgenetic marker, λ, τ−1). (4.2)
The alternative hypothesis H 1 : βgenetic marker 6= 0 is tested for each genetic marker
(SNP) in turn against the null hypothesis H 0 : βgenetic marker = 0.
4.3.4 The bayesian sparse linear mixed model
The bayesian sparse linear mixed model (BSLMM), as described in Zhou et al 2013,207
is a hybrid between a linear mixed model (assumes all genetic markers have an effect)
and bayesian variable selection regression (BVSR) that assumes genetic marker effects
come from a mixture of two normal distributions where all genetic markers have a small
effect while a portion of the genetic markers have additional larger effects and has the
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following form:
y = 1nµ+Xβ + u+ ;
βi ∼ piN(0, σ2aτ
−1) + (1− pi)δ0,
u ∼MVNn(0, σ2bτ
−1K),
 ∼MVNn(0, τ−1In),
(4.3)
X is a n x p matrix of genotypes measured on n individuals at p genetic markers,
β is the corresponding p-vector of the genetic marker effects, pi is the proportion of
genetic markers with large effects, δ0 denotes a point mass at zero (no large effect), σa
is the variance of the large SNP effects, σb is the variance of the small SNP effects,
and other parameters are the same as defined in the standard linear mixed model in
the previous section. Setting pi = 0 is equivalent to running a LMM whereas setting
σb = 0 is equivalent to BVSR. When K = XX
T/p (centered relationship matrix), the
SNP effect sizes are decomposed into two parts: 1) α captures the small effect that all
SNPS have and 2) β capture the additional large effects of some SNPs. u = Xα is
the combined effect of all small effects. The total effect for a given SNP is αi + βi.
Hyper-parameters µ, τ, pi, σa, σb are estimated in a Bayesian framework by specifying
prior distributions for the parameters and using Markov chain Monte Carlo (MCMC) to
obtain approximate samples from their posterior distribution given the observed data.
4.3.5 Description of improved linear mixed model algorithm for map-
ping polygenic traits in populations with familial relatedness
The improved LMM algorithm is a basic 3 step process:
• Step 1: Bin each chromosome into 500 kilobase (KB) segments and select the
most influential SNP in addition to the two immediately adjacent SNPs to repre-
sent each bin (inclusion of adjacent SNPs demonstrated superior control over the
false positive rate in comparison to including only a single SNP to represent a bin
in the simulated dataset (see Table 4.1)).
• Step 2: Perform stepwise feature (bin) selection to build the select SNP GRM.
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• Step 3: Perform LMM GWAS with select SNP GRM in place of an all SNP
GRM.
In Step 1, BSLMM was performed to rank SNPs based on model frequency (the propor-
tion of iterations that the SNP was included in the subset of markers deemed to have a
large effect). The SNP with the highest BSLMM model frequency in each 500KB bin
was deemed the most influential and selected to represent the bin along with the two im-
mediately adjacent SNPs. The GEMMA software207 was used to perform the BSLMM.
The phenotypes were first adjusted for covariates (sex in the simulated dataset; age and
sex in the real dataset) prior to the BSLMM analysis as the software does not incorpo-
rate inclusion of covariates. Covariate effects were estimated from a linear mixed effect
model including a random intercept for the clusters. Adjusting for covariates prior to
the BSLMM assumes the covariate effects are unrelated to genetic effects which may
not be a correct assumption in all situations. 550,000 MCMC iterations were performed
(including 50,000 burn-in iterations). The number of iterations selected was influenced
by computation speed. Variation in results dependent on number of iterations was not
assessed in the current study and is left to the user to determine the appropriate balance
between computational speed and accuracy.
Step 2 involves a stepwise feature selection model building process to determine the
ideal bins to be included in the select SNP GRM. A schematic illustrating Step 2 is
presented in Figure 4.1. First, a null model which includes fixed effect covariates and a
random intercept term for each genetic cluster (full-sib families in the simulated data;
farm in the real datasets) is compared with an alternative model that includes an ad-
ditional polygenic random effect determined from a select SNP GRM calculated from
the SNPs representing the top ranked bin from the BSLMM. A second GRM composed
of all SNPs, similar to Widmer et al’s208 recommendation was considered in place of
the random intercept, however there was no gain in power or false positive control (see
Table 4.1). Therefore, due to improved computational speed, the background random
intercept was elected over a second GRM composed of all SNPs. A likelihood ratio test
is performed to determine if inclusion of SNPs representing the bin into the select SNP
GRM significantly improve the model. The degrees of freedom are determined from the
difference in the effective degrees of freedom of each model.214,215 If inclusion of the bin
is significant, the alternative model becomes the new null model and is tested against
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an alternative model that is the same as the new null model with the exception that the
SNPs representing the next highest ranked bin are also included in the calculation of the
select SNP GRM. Under the condition where the alternative model is not significantly
improved over the null model, the SNPs representing the current bin are removed from
the select SNP GRM in exchange for the SNPs representing the next ranked bin. The
process continues until all bins have been tested for inclusion in the select SNP GRM.
After completion of Step 2, the select SNP GRM is built and ready for inclusion in
Step 3, the improved LMM GWAS. During the testing of a SNP in the final improved
LMM GWAS, SNPs within 1MB of a test SNP are removed from the select SNP GRM
to avoid proximal contamination.206,216 Exclusion of SNPs from the select SNP GRM
based on LD with test SNPs, similar to Wang et al.209 was considered however false
positive control was reduced and computational time increased (data not shown). The
final GWAS model includes covariates and a random intercept for each genetic clus-
ter in addition to the select SNP GRM. The FaST-LMM software is used to estimate
parameters in steps 2 and 3 by maximizing the log-likelihood using the algorithms of
Lippert et al.206,217 and Widmer et al.208
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Figure 4.1: Schematic illustration of feature selection process to build select SNP ge-
nomic relationship matrix for inclusion in improved linear mixed model GWAS.
y = 1nµ+Wβcov + ucluster + 
LL=-3009, df=58.05
Null
model
y = 1nµ+Wβcov + ucluster + uselect SNPs + 
uselect SNPs = polygenic effect of bin1
LL=-2971, df=60.82
Alternate
model
y = 1nµ+Wβcov + ucluster + uselect SNPs + 
uselect SNPs = polygenic effect of bin1
LL=-2971, df=60.82
Null
model
y = 1nµ+Wβcov + ucluster + uselect SNPs + 
uselect SNPs = polygenic effect of bin1,bin2
LL=-2970, df=63.20
Alternate
model
LRT p-value < 0.05
y = 1nµ+Wβcov + ucluster + uselect SNPs + 
uselect SNPs = polygenic effect of bin1
LL=-2971, df=60.82
Null
model
y = 1nµ+Wβcov + ucluster + uselect SNPs + 
uselect SNPs = polygenic effect of bin1, bin3
LL=-2919, df=62.02
Alternate
model
LRT p-value > 0.05
y = 1nµ+Wβcov + ucluster + uselect SNPs + 
uselect SNPs = polygenic effect of bin1, bin3
LL=-2919, df=62.02
Null
model
LRT p-value < 0.05
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4.3.6 Validation of the improved linear mixed model
For the QTL-MAS simulated data, the comparison criteria was similar to that used by
the 2010 QTL-MAS workshop; a true QTL was considered mapped if one or more of the
deemed QTL positions were within 1 MB distance from the simulated QTL. If two or
more of the deemed QTL positions were within 1 Mb distance from a simulated QTL,
they were considered to map the same true QTL. Reported positions exceeding 1MB
from the true QTL were considered to be false positives. For both the standard and im-
proved LMM, Wald test statistics with p-values <1x10−5 were considered statistically
significant. The QTL positions were determined by starting with the position of the
top ranked statistically significant SNPs and removing any other statistically significant
SNPs in linkage disequilibrium (r2 > 0.2) with the top ranked SNP, the process was
repeated for the 2nd top ranked and continued for all remaining statistically significant
SNPs.
For the horse height datasets, the true QTL locations are unknown in the real
datasets therefore it is not possible to report the number of detected true and false pos-
itives, however replication in independent datasets is considered the gold standard for
validation of GWAS hits and therefore was used as a method of validating the improved
algorithm in the real datasets. Both replication of previously reported horse loci and
height loci in other species were considered. A randomized permutation test was used
to formerly test for enrichment of human height QTL by evaluating how likely it was to
produce the number of QTL observed within 2MB of an equine ortholog to the human
gene nearest one of the 180 statistically significant SNPs identified in a human height
GWAS218 by chance. SNPs in a quantity equal to the observed number of horse height
QTL detected were selected at random and the number of SNPs located within 2MB of
an equine ortholog to a human height gene were determined. 10,000 random tests were
performed.
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4.4 Results
4.4.1 Application and optimization of the improved linear mixed model
using simulated data
The improved linear mixed model (LMM) described above was applied to the simulated
2010 QTL-MAS dataset.210 Principal component analysis (PCA) was performed and
the familial structure of the data is illustrated in Figure 4.2a. Individuals from the
same familial cluster share the same color and it is easy to see from the figure that
colors are not randomly distributed. As expected, individuals from the same familial
cluster are more genetically similar. In an effort to quantify the differences in average
allele sharing for pairs of individuals sampled from the same familial cluster versus
pairs of individuals from different familial clusters, the mean identity by state (IBS)
was calculated for pairs of individuals from the same familial cluster versus pairs of
individuals from different clusters. Mean IBS for pairs sampled from the same familial
cluster was 0.82 in comparison to 0.69 in individuals sampled from different familial
clusters. Figure 4.3a illustrates the differences in the distribution of IBS values for pairs
of individuals belonging to the same familial cluster versus different familial clusters.
Wald tests from the improved LMM were compared with the standard LMM imple-
mented in GEMMA213 in terms of power (number of mapped true QTL) and number
of falsely reported QTLs. Manhattan plots for the standard LMM and improved LMM
for the simulated data are presented in Figure 4.4. At the suggestive significance level
(p-values < 1x10−5), the standard LMM mapped 6 true QTL with zero false discover-
ies (genome-wide Bonferonni corrected p-values yielded 5 true QTL detections and zero
false discoveries). The improved LMM detected 13 true QTL along with a single false
discovery at the suggestive significance threshold (12 true positives and a single false
positive detected at the genome-wide Bonferonni threshold).
Utilizing a Bayesian model to initially rank the SNPs in the improved LMM al-
gorithm performed superior to using an initial standard LMM to rank the SNPs prior
to performing feature selection for inclusion in the select SNP GRM in the final GWAS
(see Table 4.1). Manhattan plots of the initial BSLMM posterior inclusion probabilities
(model frequency) used to initially rank the SNPs are presented in Appendix figure C.3
and a manhattan plot of GWAS results from an improved LMM model that substitutes
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Figure 4.2: Familial relatedness. Principal components 1-3 for a) QTL-MAS simulated
dataset, b) Morgan horse real height dataset, and c) Welsh pony real height dataset.
Individuals sampled from the same family or farm are identified by a similar color (Note:
colors are repeated for different clusters, an enlarged version of the horse PCA plots is
presented in Figures C.1 and C.2 with numeric representation of different farms).
(a)
(b)
(c)
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Figure 4.3: Illustration of IBS distribution difference for individuals sampled from the
same cluster (farm) versus different clusters (farms) for the a) QTL-MAS simulated
dataset, b) Morgan horse real height dataset, and c) Welsh pony real height dataset.
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a LMM for the BSLMM in the first step to rank the SNPs is presented in Figure 4.5.
A smaller bin size, 200KB instead of 500KB, was also evaluated and yielded similar
results, see Appendix Figure C.4.
Table 4.1: Optimization of improved LMM.
Initial top SNP representing bin top SNP + adjacent SNPs
SNP ranking True QTL False True QTL False
model detected positives detected positives
LMM 10 5 9 2
BSLMM 13 4 13 1
Note: bin size=500KB; LMM=standard linear mixed model, BSLMM=Bayesian sparse
linear mixed model.
4.4.2 Application of the improved linear mixed model to equine datasets
The performance of the improved LMM algorithm was also compared to the standard
LMM algorithm in 2 real datasets. Both datasets feature height, a classic polygenic
trait) sampled in two different equine populations, the Morgan horse and the Welsh
pony. These datasets are also characterized by familial relationships. Horses and ponies
sampled from the same farms were genetically more similar to each other than indi-
viduals sampled from different farms. Principal component analysis in Figures 4.2b,c
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Figure 4.4: Manhattan plot displaying the a) standard and b) improved linear mixed
model results for the simulated QTL-MAS dataset. Red vertical lines indicate the
location of true QTL. Genome-wide p-value < 0.05 (solid grey horizontal line) and
suggestive (dashed grey horizontal line) thresholds are also shown.
(a)
(b)
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Figure 4.5: Manhattan plot displaying the improved linear mixed model results for the
simulated QTL-MAS dataset using an initial standard linear mixed model to rank SNP.
Red vertical lines indicate the location of true QTL. Genome-wide p-value <0.05 (solid
grey horizontal line) and suggestive (dashed grey horizontal line) thresholds are also
shown.
illustrate the family structure present in these datasets. Pairs of individuals from the
same farm share a similar color and similar to the simulated data it is easy to observe
the non-random distribution of colors. Again, similar to the simulated data, mean IBS
is higher in pairs of individuals sampled from the same farm in comparison to pairs of
individuals sampled from different farms. Illustration of differences in the average pro-
portion of alleles identical by state for individuals sampled from the same farm versus
different genetic clusters is presented in Figure 4.3b,c.
Manhattan plots of GWAS results from the standard and improved LMMs are pre-
sented in Figures 4.6 and 4.7 for the Morgan horses and Welsh ponies, respectively.
Since the true QTL locations are unknown in the real datasets it is not possible to
report the number of detected true and false positives, however replication in indepen-
dent datasets is considered the gold standard for validation of GWAS hits and therefore
was used as a method of validating the improved algorithm in the real datasets. The
top ranked QTL in both the Morgan horse and Welsh pony data for both the standard
and improved LMM models are located within 1MB of genes (ZFAT and HMGA2, re-
spectively) previously identified as QTL in horse,219–221 human,218 and cattle222 GWAS
and candidate gene studies. P-values for the ZFAT locus in the standard and improved
LMM in the Morgan horse population were 2.21x10−7 and 1.44x10−18, respectively,
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while p-values for the HMGA2 locus in the standard and improved LMM in the Welsh
population were 1.80x10−26 and 7.74x10−87, respectively.
Similar to evaluations in the simulated data, the improved LMM identified substan-
tially more QTL than the standard LMM for the real datasets. In the Morgan horses, 8
genome-wide significant loci (including 4 human candidate loci) and 13 suggestive loci
(including 4 human candidate loci) were identified by the improved LMM (Table 4.2)
in comparison to zero genome-wide significant loci and 10 suggestive loci (including 3
human candidate loci) identified by the standard LMM. In the Welsh ponies, 9 genome-
wide significant loci (including 4 human candidate loci) and 6 suggestive loci (including
3 human candidate loci) were identified by the improved LMM (Table 4.3) in comparison
to 2 genome-wide significant loci (including 1 human candidate locus) and 2 suggestive
loci (including 1 human candidate locus) identified by the standard LMM. The top
ranked loci overlapped for the improved and standard LMMs in both the Morgan horse
and Welsh ponies. In addition, the ZNF462 locus was detected at the genome-wide and
suggestive significance level in the Morgan horse and Welsh pony, respectively, providing
further support of ZNF462 being a true QTL for height variation in horses. The IPPK
and GPR126 loci detected in the Morgan horse population have also been reported as
QTL for cattle height in addition to human height.222 Additional candidate genes for
horse height may localize to the identified QTL that did not harbor a human candidate
height gene and these loci are provided in Tables 4.2 to 4.3 for the interested reader.
A search for potential height candidate genes was not conducted since mapping height
QTL was not the objective of the current study.
A randomized permutation test was used to formerly test for enrichment of human
height QTL by evaluating how likely it was to produce the number of QTL observed
within 2MB of an equine ortholog to the human gene nearest one of the 180 statistically
significant SNPs identified in a human height GWAS218 by chance. Only 20% and 9% of
the randomized permutation tests in Morgan horses and Welsh pony data, respectively,
produced the number of QTL equal to or exceeding the results observed at the sugges-
tive (p-values < 1x10−5) significance level and only 14% and 22%, at the Bonferonni
genome-wide significance level. Therefore, it is unlikely that the results reported here
for height in Morgan horse and Welsh ponies arose by chance. In addition, evaluation
of Q-Q plots in Figure 4.8a-c illustrate the observed test statistic distribution with the
128
expected null distribution and demonstrate effective control of the type 1 error rate with
genomic inflation factors less than one for the simulated and real datasets.
Figure 4.6: Manhattan plot displaying the a) standard and b) improved linear
mixed model results for the Morgan horse real height dataset. Genome-wide p-
value<5.70x10−8 (solid grey horizontal line) and suggestive p-value<1x10−5(dashed
grey horizontal line) thresholds are also shown.
(a)
(b)
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Table 4.2: Height QTL identified in Morgan horse population by the improved lin-
ear mixed model. Bonferonni threshold: p-value<5.70x10−8 Suggestive threshold:
p-value<1x10−5
chromosome position beta standard p-value human height
estimate error candidate gene
9 75674706 0.259 0.029 1.44E-18 ZFAT
2 54258131 -0.237 0.031 1.17E-14 ADAM28
15 73417660 -0.194 0.027 1.21E-12
9 69065870 -0.186 0.027 9.91E-12
15 41710938 -0.193 0.029 5.88E-11
10 34921358 -0.172 0.027 2.01E-10 FAM46A
7 11470079 -0.175 0.028 4.14E-10
23 54928132 -0.162 0.027 9.35E-10 IPPK
25 12606038 -0.157 0.029 7.31E-08 ZNF462
3 73225735 -0.138 0.027 3.92E-07
21 12777073 -0.135 0.027 5.48E-07
29 6735168 0.126 0.025 5.84E-07
28 36628887 -0.133 0.027 6.11E-07
5 98798764 0.133 0.027 1.33E-06
16 33334177 0.142 0.03 1.69E-06 RFT1
1 152515464 0.131 0.028 2.27E-06
18 58850432 -0.12 0.026 3.40E-06
18 69763301 -0.127 0.028 5.21E-06
31 22766464 -0.13 0.029 6.30E-06 GPR126
21 586856 0.112 0.025 8.27E-06 MYO9B
3 23442441 -0.125 0.028 9.29E-06
Note: ZFAT is a previously identified QTL for height in horses.220,221
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Figure 4.7: Manhattan plot displaying the a) standard and b) improved linear mixed
model results for the Welsh pony real height dataset. Genome-wide p-value<1.27x10−7
(solid grey horizontal line) and suggestive p-value<1x10−5(dashed grey horizontal line)
thresholds are also shown.
(a)
(b)
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Table 4.3: Height QTL identified in Welsh pony population by the improved linear
mixed model. Bonferonni threshold: p-value<1.27x10−7 Suggestive threshold: p-
value<1x10−5
chromosome position beta standard p-value human height
estimate error candidate gene
6 81413254 0.466 0.024 7.74E-87 HMGA2
3 81805228 0.122 0.019 1.50E-10
4 26707485 -0.116 0.019 2.04E-09
5 68039446 0.108 0.018 4.47E-09
6 66913666 0.112 0.02 1.43E-08
8 60233394 -0.119 0.021 1.94E-08
12 26848333 -0.126 0.022 2.08E-08 RHOD
9 70148789 0.12 0.022 2.64E-08 GSDMC
6 28058021 0.107 0.02 4.74E-08 SEPT2
22 11893884 0.097 0.019 2.43E-07
1 75767477 0.09 0.018 7.31E-07
1 161563724 -0.105 0.021 8.47E-07 NFATC4
6 9239939 -0.092 0.019 1.41E-06 IHH
25 12661868 0.105 0.023 4.67E-06 ZNF462
16 46179071 0.091 0.021 9.63E-06
Note: HMGA2 is a previously identified QTL for height in ponies.219,220
4.4.3 Variance decomposition during the stepwise feature SNP selec-
tion process
During step 2 of the improved LMM (stepwise feature SNP selection process) a majority
of the bin representative SNPs selected for inclusion in the select SNP GRM are chosen
in the beginning of the feature selection process with very with SNPs representing lower
ranked bins being included in the select SNP GRM, see Appendix Figure C.5. This is
not surprising given SNPs were initially ranked by the BSLMM based on their model
inclusion probability of having more than a small effect on the trait. Also, the cluster
level variance is reduced to zero as SNPs are selected that presumably explain pheno-
typic variation between the clusters, i.e. correlation of the cluster allele frequency with
the phenotype. A total of 38 bins were selected for the simulated dataset and explained
47% of the total phenotypic variance. In the Morgan horse data, 41 bins were selected,
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Figure 4.8: Q-Q plot of observed p-values against the expected p-values for a) QTL-MAS
simulated dataset, b) Morgan horse real dataset, and c) Welsh pony real dataset.
(a) (b) (c)
explaining 85% of height variation and in the Welsh pony data 26 bins were selected
explaining 91% of height variation.
4.5 Discussion
Linear mixed models (LMM) are regarded as the method of choice for association testing
in genome-wide association studies (GWAS) as they account for population structure,
familial and cryptic relatedness while achieving increased statistical power by jointly
modeling all of the genotyped markers.198,199,203,205,206,213,216,223–226 However, the
standard LMM assumes that all genetic markers are causal (the so-called “infinitesi-
mal model’) with small effect sizes drawn from an independent Gaussian distribution
which is unlikely to be true, especially in domesticated animal populations. Recently,
efforts to more accurately model a non-infinitesimal genetic architecture have been pro-
posed. Segura et al.205 proposed identifying and conditioning out loci of large effect
as fixed effects while others have recommended applying the mixed model to only a
selected subset of phenotype associated markers.208,209,214,216,224,227 Widmer et al.208
cautioned using only phenotype associated markers in the LMM genomic relationship
matrix (GRM) led to insufficient control of the type I error rate in populations with
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familial relatedness, therefore recommending inclusion of a second GRM composed of all
genetic markers to correct for familial structure while still maintaining statistical power
to detect causal variants with the caveat that inclusion of a second GRM composed of
all SNPs is much more computationally intensive. Chapter 4 described a new algorithm
that builds upon these recent advances while maintaining computational feasibility and
demonstrated the increased power of the improved LMM algorithm over the standard
LMM while still maintaining control of the false positive rate.
The improved LMM algorithm is an advance for multiple reasons. First, the im-
proved LMM more accurately models the true genetic architecture by applying a Bayesian
method to initially rank SNPs combined with stepwise feature selection to select an op-
timal subset of SNPs for inclusion in the GRM. Recently, Bayesian methods have been
developed that apply non-infinitesimal model assumptions to produce improved genetic
prediction accuracy.207,228 The improved LMM extends this concept to association test-
ing but still provides the traditional GWAS frequentist test statistic.
Secondly, the improved LMM harnesses the power of phenotype specific variant
inclusion in the GRM while avoiding the computationally intensive inclusion of a sec-
ond GRM composed of all SNPs to correct for familial relationships. The improved
LMM simply includes a random intercept effect for each genetic cluster of individuals
while selecting feature SNPs for inclusion in the select SNP GRM and when calculat-
ing the GWAS test statistics. Individuals clustered in similar environments are often
more similar genetically, especially in domesticated animal populations. The random
intercept effectively captures shared environment and genetic background effects when
attempting to select SNPs tagging causal variants that explain phenotypic differences
in individuals that share a common environment or genetic background, simultaneously
increasing power and correcting for non-independent observations. In situations where
family structure is not correlated with shared environment it may be necessary to in-
clude a second GRM determined from all autosomal SNPs to adequately model the
family structure and prevent inflation of test statistics.
Finally, the improved LMM algorithm presented in this chapter shares many simi-
larities with the BOLT-LMM method proposed by Loh et al.229 in terms of employing a
Bayesian framework yet providing a frequentist test statistic, however the BOLT-LMM
method recommends randomly ascertained observations and has not been studied in
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datasets with family structure. Compared with currently available advances in LMM
for GWAS, the improved LMM described in this work offers increased statistical power
while maintaining control of the false positive rate in populations with family structure
in a computationally efficient manner.
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Chapter 5
Genome wide association study of
equine metabolic trait variation
5.1 Summary
Chapter 5 utilizes the improved linear mixed model described in Chapter 4 to identify
genetic variants influencing metabolic syndrome in horses. Using this improved linear
mixed model, 76 suggestive and 17 genome-wide significant candidate loci were identi-
fied for the 11 metabolic traits in the 286 Morgan horse cohort. Candidate genes sub-
stantially overlapped with human MetS candidate genes including: VEGFA, NRXN3,
GRIK2, and TRIB2. Other interesting candidate genes included ISL, which encodes
insulin enhancer protein that is thought to play an important role in regulating insulin
gene expression; and AHR which encodes the aryl hydrocarbon receptor, a ligand acti-
vated transcription factor known to bind endocrine disrupting chemicals such as poly-
cyclic aromatic hydrocarbons and dioxins. AHR is an interesting candidate gene given
the potential role of endocrine disrupting chemical in the pathophysiology of MetS, and
unexplained sources of farm level variation in Chapter 2. The shared candidate genes
for metabolic syndrome in humans and horses suggests similar underlying pathophys-
iological mechanisms and provides opportunity for exploring similar preventative and
therapeutic management strategies.
136
5.2 Introduction
Equine metabolic syndrome (EMS) is a complex disease influenced by genetic and en-
vironmental factors and their interactions. This study presents findings from a GWAS
designed to identify genetic variants influencing metabolic syndrome in horses. Eleven
metabolic phenotypes described in Chapter 2 representing not only obesity, but also
biological processes associated with obesity were tested for association with a dense
panel of 877,608 single nucleotide polymorphisms (SNP)s in a population of 286 Mor-
gan horses sampled from 55 herds. Horses sampled from the same farms exhibited
similar phenotypes and increased genetic similarity, thus the improved linear mixed
model (LMM) described in Chapter 4 was utilized to test for associations while control-
ling for shared environment and polygenic background. Loci identified to be associated
with equine metabolic phenotypes (p-value< 1x10−5) were investigated for overlap
with loci identified in human GWAS of obesity and its comorbidities. Identification
of genetic variants contributing to metabolic variation will aid in understanding the
pathophysiologic mechanisms underlying equine metabolic syndrome ultimately leading
to the discovery of preventative measures and therapeutic targets in horses, in addition
to potentially shedding light on the molecular basis of metabolic trait variation in other
mammalian species.
5.3 Methods
5.3.1 Phenotyping
The Morgan horse data consists of 286 individuals sampled from 54 herds located
throughout the United States and a single Canadian herd. Eleven phenotypes were
tested for SNP associations and included morphometric measurements: neck circum-
ference to height ratio (NH) and girth to height ratio (GH); and blood concentration
measurements: fasting glucose (GLU), fasting insulin (INS), glucose 75 minutes post
oral sugar administration (GLU OST), insulin 75 minutes post oral sugar administration
(INS OST), triglycerides (TG), non-esterified fatty acids (NEFA), adrenocorticotropin
hormone (ACTH), leptin (LEP), and adiponectin (APN). A more detailed description
of the phenotypic measurements can be found in Section 2.3.3. INS, TG, NEFA, ACTH,
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LEP, and APN exhibited a skewed distribution and required log or square root trans-
formations to achieve a more normal distribution. Phenotypes were scaled to zero mean
and standard deviation equal to one.
5.3.2 Genotyping
The horses were genotyped on on the Illumina SNP50 array and imputed up to ∼2
million genotypes from a cosmopolitan reference population comprised of 384 individuals
representing 30+ breeds, including 43 horses from the Morgan breed using Beagle 4.0
software211,212). Genotypes were filtered with MAF > 0.05, and Hardy-Weinberg
disequilibrium p-values > 0.00001 yielding 877,608 SNPs.
5.3.3 Polygenic and shared environment variance estimates
The polygenic variance (a.k.a.“chip heritability”) and shared environment variance es-
timates were determined using the GEMMA software.213 Polygenic variance estimates
were determined from a mean centered genomic relationship matrix comprised of all
845,234 autosomal SNPs and adjusted for age and sex covariates. Shared environment
estimates were determined from a pairwise relationship matrix where pairwise relation-
ships between individuals sharing an environment were represented by 1 and pairwise
relationships between individuals not sharing an environment were represented by zero.
Shared environment estimates were also adjusted for age and sex covariates.
5.3.4 Association testing
The improved linear mixed model as described in Section 4.3.5 was used to determine
phenotype-genotype associations. The improved LMM more accurately models the true
genetic architecture by applying a Bayesian method to initially rank SNPs combined
with stepwise feature selection to select an optimal subset of SNPs for inclusion in the
GRM. Recently, Bayesian methods have been developed that apply non-infinitesimal
model assumptions to produce improved genetic prediction accuracy.207,228 The im-
proved LMM extends this concept to association testing but still provides the traditional
GWAS frequentist test statistic. Briefly, the improved LMM algorithm is a basic 3 step
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process:
• Step 1: Bin each chromosome into 500 kilobase (KB) segments and select the
most influential SNP in addition to the two immediately adjacent SNPs to repre-
sent each bin.
• Step 2: Perform stepwise feature (bin) selection to build the select SNP GRM.
• Step 3: Perform LMM GWAS with select SNP GRM in place of an all SNP
GRM.
In Step 1, BSLMM was performed to rank SNPs based on model frequency (the propor-
tion of iterations that the SNP was included in the subset of markers deemed to have a
large effect). The SNP with the highest BSLMM model frequency in each 500KB bin
was deemed the most influential and selected to represent the bin along with the two im-
mediately adjacent SNPs. The GEMMA software207 was used to perform the BSLMM.
The phenotypes were first adjusted for covariates age and sex prior to performing the
BSLMM analysis as the software does not incorporate inclusion of covariates. Covariate
effects were estimated from a linear mixed effect model including a random intercept
for the clusters. 550,000 MCMC iterations were performed (including 50,000 burn-in
iterations).
Step 2 involves a stepwise feature selection model building process to determine the
ideal bins for inclusion in the select SNP GRM. First, a null model which includes fixed
effect covariates and a random intercept term for each genetic cluster (farm) is compared
with an alternative model that includes an additional polygenic random effect deter-
mined from a select SNP GRM calculated from the SNPs representing the top ranked
bin from the BSLMM. A likelihood ratio test is performed to determine if inclusion of
SNPs representing the bin into the select SNP GRM significantly improve the model.
The degrees of freedom are determined from the difference in the effective degrees of
freedom of each model.214,215 If inclusion of the bin is significant, the alternative model
becomes the new null model and is tested against an alternative model that is the same
as the new null model with the exception that the SNPs representing the next highest
ranked bin are also included in the calculation of the select SNP GRM. Under the con-
dition where the alternative model is not significantly improved over the null model, the
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SNPs representing the current bin are removed from the select SNP GRM in exchange
for the SNPs representing the next ranked bin. The process continues until all bins have
been tested for inclusion in the select SNP GRM.
After completion of Step 2, the select SNP GRM is built and ready for inclusion
in Step 3, the improved LMM GWAS. During the testing of a SNP in the final im-
proved LMM GWAS, SNPs within 1MB of a test SNP are removed from the select
SNP GRM to avoid proximal contamination.206,216 The final GWAS model includes
covariates and a random intercept for each genetic cluster in addition to the select SNP
GRM. The FaST-LMM software is used to estimate parameters in steps 2 and 3 by
maximizing the log-likelihood using the algorithms of Lippert et al.206,217 and Widmer
et al.208 Bonferroni correction was used to set the genome-wide significance thresh-
old (p-value< 5.70x10−8), however Bonferroni corrections are considered conservative
since Bonferroni assumes independence among SNPs and linkage disequilibrium violates
this assumption. Therefore, a suggestive threshold was set at p-value< 1x10−5, similar
with previous equine genome-wide studies.230–232
5.3.5 Investigation of EMS candidate loci overlap with human metabolic
syndrome loci
Human GWAS data were obtained from the PheGenI database (http://www.ncbi.nlm.
nih.gov/gap/phegeni accessed on December 1 2015) using default search parameters.
The genes nearest the top p-value for all EMS associated loci above the suggestive
significance threshold were searched against the following human GWAS phenotype
terms for 11 different metabolic syndrome components and co-morbities:
1. adiposity (Abdominal Fat, Intra-Abdominal Fat)
2. body mass (Body Mass Index, Obesity, Waist Circumference, Waist-Hip Ratio,
Body Weight Changes, Body Weights and Measures, Body Weight)
3. diabetes (Diabetes Mellitus, Type 1 Diabetes, Type 2 Diabetes, Diabetic Nephropa-
thy, Diabetic Retinopathy)
4. glucose (Glucose, Glycosylated Hemoglobin A)
5. insulin and insulin resistance
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6. lipids (Apolipoprotein A-I, Apolipoproteins C, Cholesterol, HDL, LDL, Lipopro-
teins, VLDL, Triglycerides)
7. cardiovascular (Arteries, Atrial Fibrillation, Blood Flow Velocity, Blood Pressure,
Coronary Artery Disease, Echocardiography, Heart Failure, Heart Rate, Hemat-
ocrit, Hypertension, Myocardial Infarction, Blood Coagulation Factors, Left Ven-
tricular Hypertrophy)
8. stroke
9. adiponectin
10. C-Reactive Protein
11. monocytes (Monocyte Chemoattractant Protein-1, Monocytes)
5.4 Results
5.4.1 Heritability estimation in a population featuring familial rela-
tionships and shared environments
Increased genetic similarity existed among individuals sampled form the same farm,
illustrated in the PCA plot presented in Figure 5.1. Individuals sampled from the same
farm are identified by the same number and share a similar color. It is easy to see
the non-random allocation of numbers and colors, indicating individuals sampled from
the same farm are more genetically similar than two individuals sampled from different
farms.
Metabolic traits were also more similar among individuals sampled from the same
farm. Figure 5.2 illustrates clustering of metabolic trait values near the farm median
value. A linear relationship should not be easily discernible between individual trait
values and the farm median in the case of independent observations. In Table 5.1,
the “Farm ICC” column quantifies the increased phenotype similarity of individuals
sampled from the same farm in comparison to individuals sampled from different farms.
The farm intracluster correlation coefficient (ICC) is interpreted as 1) the proportion
of variance at the farm level and 2) the correlation between measured outcomes for two
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Figure 5.1: PCA illustration of increased genetic similarity at the farm level, each farm
is represented by a different numeric value. Horses sampled from the same environment
are identified with the same color (note: colors are repeated for the 55 herds).
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randomly drawn individuals from the same cluster (farm), see (Section 1.3) for review
of ICC.
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Figure 5.2: Illustration of metabolic trait clustering in shared environments: neck cir-
cumference:height ratio(a), girth:height ratio(b), fasting glucose(c), fasting insulin(d),
post-OST glucose(e) and post-OST insulin(f). Trait values centered to zero mean and
scaled to one standard deviation variance.
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(c) GLU
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(d) logINS
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(e) GLU post-OST
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(f) logINS post-OST
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Figure 5.2 Continued from previous page: Illustration of metabolic trait cluster-
ing in shared environments: triglycerides(g), NEFA(h), ACTH(i), leptin(j), and
adiponectin(k). Trait values centered to zero mean and scaled to one standard deviation
variance.
(g) logTG
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
−2 −1 0 1 2
−
4
0
2
4
farm median value
in
di
vi
du
al
 v
al
ue
(h)
√
NEFA
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(i) logACTH
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Adiponectin
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Polygenic variance estimates (“narrow sense chip heritability”) are presented in Ta-
ble 5.1. The polygenic variance estimate is an estimate of the amount of trait variance
attributable to shared genetic backgrounds (“heritability”) and is determined from a
SNP based genomic relationship matrix, i.e. the degree to which individuals with in-
creased genotype sharing are also more phenotypically similar.
An accurate estimate of heritability is not possible due to confounding of envi-
ronmental factors correlated with the population structure in this dataset. Polygenic
variance and environmental variance (farm ICC) are not mutually exclusive. Individuals
sampled from the same farm may be more phenotypically similar due to both shared
environmental factors and shared genetic background. Therefore, it is important to note
that this estimate of heritability may be upwardly biased if environmental factors in-
fluence the trait and individuals with increased genotype similarity also share the same
environment. Polygenic variance estimates (“heritability”) obtained from a model that
also simultaneously partitions the farm level variance are presented in Table 5.2.
It is important to note heritability estimates adjusted for farm effects will be con-
servative given increased genetic similarity of individuals sampled from the same farm.
Variance decomposition of fasting glucose illustrates the confounding effect of shared en-
vironment and genetic background. The genetic background (polygenic variance=0.22)
and environment level variance (farm ICC=0.17) for fasting glucose are fairly similar
when determined separately in Table 5.1. However, in a model that simultaneously
estimates the polygenic variance and farm environment variance (Table 5.2) one can
easily see that the two variance estimates are correlated as the polygenic variance es-
timate goes to zero and the farm level variance remains at 0.18. On the other hand,
the polygenic variance is relatively high for adiponectin (“heritability”=0.70) and the
farm environment variance is relatively low (0.12) when estimated separately in Ta-
ble 5.1. Likewise, in a model that simultaneously estimates the polygenic variance and
farm environment variance (Table 5.2) for adiponectin, the polygenic variance remains
relatively high (“heritability”=0.64) since the farm level variance was not large.
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Table 5.1: Genetic and environmental variance estimates.
Trait N= Polygenic variance estimate Farm
a.k.a “chip heritability” ICC
(standard error) (standard error)
NH 285 0.59(0.15) 0.44(0.08)
GH 285 0.55(0.18) 0.43(0.08)
GLU 284 0.22(0.12) 0.17(0.07)
INS 285 0.62(0.15) 0.39 (0.09)
GLU OST 268 0.54(0.15) 0.29(0.08)
INS OST 268 0.38(0.15) 0.23(0.08)
TG 284 0.29(0.14) 0.17(0.06)
NEFA 286 0.65(0.18) 0.31(0.07)
ACTH 284 0.49(0.20) 0.41(0.09)
LEP 280 0.54(0.13) 0.26(0.07)
APN 285 0.70(0.17) 0.12(0.05)
ICC=Intracluster correlation coefficient is a measure of homogeneity of sampled clus-
ters that can be interpreted two ways: 1) proportion of total variance of an outcome
accounted for by the clusters or 2) the correlation between measured outcomes for two
randomly drawn individuals in the cluster.
Table 5.2: Polygenic variance estimate (“heritability”) adjusted for farm effects.
polygenic farm residual
variance variance variance
NH 0.22(0.11) 0.43(0.08) 0.34(0.11)
GH 0.20(0.12) 0.44(0.08) 0.36(0.12)
GLU 0.00(0.00) 0.18(0.07) 0.82(0.07)
INS 0.25(0.12) 0.39(0.09) 0.36(0.11)
GLU OST 0.13(0.13) 0.30(0.08) 0.57(0.14)
INS OST 0.20(0.13) 0.25(0.08) 0.55(0.13)
TG 0.00(0.00) 0.18(0.06) 0.82(0.06)
NEFA 0.00(0.00) 0.32(0.08) 0.68(0.08)
ACTH 0.25(0.11) 0.44(0.08) 0.30(0.11)
LEP 0.18(0.13) 0.24(0.08) 0.58(0.13)
APN 0.64(0.16) 0.05(0.05) 0.31(0.15)
Note: polygenic variance estimates (“heritability”) adjusted for farm effects is a conser-
vative estimate of heritability given increased genetic similarity of horses sampled from
the same farm.
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5.4.2 GWAS results
GWAS was performed on 286 Morgan horses from 55 different herds for 11 metabolic
traits. The improved linear mixed model (LMM) described in Chapter 4 was utilized to
test for associations while controlling for shared environment and polygenic background.
Regional plots of candidate loci for all traits featuring color-coded r2 correlation values
with the top SNP in the region are illustrated in Appendix Figures D.1 to D.11. Results
determined from a standard LMM are reported in Section D.2.
Measures of adiposity
Manhattan plots for measures of regional adiposity (NH) and more generalized adiposity
(GH), in addition to a listing of suggestive (p-value<1x10−5) and genome-wide (p-
value<5.70x10−8) significant loci are presented in Figures 5.3 and 5.4. Genome-wide
significant variants were not detected for NH or GH, although several loci attained
suggestive significance.
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Figure 5.3: Manhattan plot of GWAS results for neck circumference to height ratio.
Bonferonni threshold: p-value<5.70x10−8; suggestive threshold (dashed line): p-
value<1x10−5. Loci reaching genome-wide and/or suggestive significance are listed
below.
chromosome position alleles maf beta standard p-value nearest
estimate error gene
17 75543887 C\T 0.30 0.210 0.040 1.86E-07 FAM155A
2 93491935 A\G 0.36 0.201 0.041 1.04E-06 PCDH18
4 59620539 A\G 0.08 0.200 0.042 1.96E-06 CREB5
19 32821180 C\T 0.23 0.198 0.042 2.53E-06 SENP5
2 23825094 A\C 0.08 -0.194 0.041 2.74E-06 ZNF362
1 85359274 A\C 0.09 0.192 0.042 4.85E-06 CCSER2
1 128863092 C\T 0.06 -0.180 0.039 5.23E-06 RAB8B
3 96066755 G\A 0.08 -0.194 0.043 6.66E-06 PCDH7
10 52269721 C\T 0.11 -0.189 0.043 9.32E-06 GRIK2
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Figure 5.4: Manhattan plot of GWAS results for girth to height ratio.
Bonferonni threshold: p-value<5.70x10−8; suggestive threshold (dashed line): p-
value<1x10−5. Loci reaching genome-wide and/or suggestive significance are listed
below.
chromosome position alleles maf beta standard p-value nearest
estimate error gene
7 26154989 G\A 0.490 -0.198 0.038 1.95E-07 MPZL2
22 10321507 A\G 0.200 0.189 0.039 1.44E-06 SEL1L2
1 78254375 G\A 0.250 0.186 0.04 3.19E-06 MAP10
14 67885725 C\A 0.080 0.165 0.036 4.52E-06 SLCO4C1
6 50144883 A\C 0.440 -0.173 0.038 6.42E-06 SOX5
3 48758732 T\C 0.140 -0.184 0.041 7.34E-06 GPRIN3
20 46160950 A\G 0.280 -0.172 0.039 8.29E-06 GPR115
1 181616615 T\C 0.380 -0.174 0.039 9.21E-06 MDGA2
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Glucose and insulin
Manhattan plots and listing of suggestive and genome-wide significant candidate loci
for both fasting and 75 minutes post-oral sugar challenge glucose and insulin levels are
presented in Figures 5.5 to 5.9. Two genome-wide significant loci were detected for
fasting insulin. The GRIK2 locus on Equus caballus (ECA) autosome 10 illustrated in
Figure 5.7 was the top reported fasting insulin locus in addition to reaching suggestive
significance for neck circumference to height ratio (Figure D.1i). A second variant near
ATG14 on ECA 24 (see Figure D.4b) also reached genome-wide significance. Three
loci presented in Figure D.6a-c located on ECA 21, 10, and 13 reached genome-wide
significance for insulin levels 75 minutes following an oral sugar challenge. The variant
on ECA 21 is near ISL-1 (Figure 5.10) which encodes insulin gene enhancer protein.
SNPs located within FAM155A on ECA 17 (Figures D.4g and D.1a) reached suggestive
significance for both fasting insulin and NH.
Figure 5.5: Manhattan plot of GWAS results for fasting glucose.
Bonferonni threshold: p-value<5.70x10−8; suggestive threshold (dashed line): p-
value<1x10−5. Loci reaching genome-wide and/or suggestive significance are listed
below.
chromosome position alleles maf beta standard p-value nearest
estimate error gene
8 9312611 T\C 0.31 0.240 0.046 1.55E-07 CRYBA4
22 26963686 A\G 0.35 0.231 0.046 5.48E-07 DLGAP4
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Figure 5.6: Manhattan plot of GWAS results for fasting insulin.
Bonferonni threshold (solid line): p-value<5.70x10−8; suggestive threshold (dashed
line): p-value<1x10−5. Loci reaching genome-wide and/or suggestive significance are
listed below.
chromosome position alleles maf beta standard p-value nearest
estimate error gene
10 53891179 T\C 0.15 0.192 0.034 9.54E-09 GRIK2
24 3597984 C\T 0.06 0.193 0.034 1.02E-08 ATG14
19 18465605 G\A 0.19 0.173 0.033 2.27E-07 MFN1
19 4295255 C\T 0.36 -0.177 0.034 2.32E-07 OTOL1
1 128192334 A\G 0.25 0.167 0.033 4.13E-07 DAPK2
4 49751990 A\G 0.48 0.176 0.035 4.53E-07 AHR
17 75473022 A\G 0.42 -0.163 0.034 1.35E-06 FAM155A
20 4333850 G\A 0.35 0.168 0.036 2.41E-06 FAM50B
12 2818242 A\G 0.21 0.164 0.035 2.94E-06 COMMD9
9 58656992 T\C 0.31 -0.157 0.034 4.63E-06 TRPS1
2 81787272 T\C 0.43 -0.149 0.033 4.79E-06 GATB
30 24253197 C\T 0.42 -0.150 0.034 7.78E-06 KCNT2
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Figure 5.7: Regional plot of GRIK2 locus association with fasting insulin. Color-coding represents correlation (r2 value)
with the reference SNP (dashed line)
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Figure 5.8: Manhattan plot of GWAS results for glucose 75 minute post-oral sugar test.
Bonferonni threshold : p-value<5.70x10−8; suggestive threshold (dashed line): p-
value<1x10−5. Loci reaching genome-wide and/or suggestive significance are listed
below.
chromosome position alleles maf beta standard p-value nearest
estimate error gene
6 4059449 G\A 0.15 -0.211 0.044 1.30E-06 SPAG16
2 24516703 T\C 0.19 0.218 0.045 1.44E-06 HDAC1
4 21624394 T\C 0.22 -0.219 0.046 2.49E-06 COBL
17 20363782 T\G 0.05 -0.212 0.045 2.67E-06 DLEU7
20 63223615 T\C 0.32 0.230 0.052 9.47E-06 RIMS1
26 15146523 C\T 0.08 0.198 0.045 9.84E-06 USP25
154
Figure 5.9: Manhattan plot of GWAS results for insulin 75 minute post-oral sugar test.
Bonferonni threshold (solid line): p-value<5.70x10−8; suggestive threshold (dashed
line): p-value<1x10−5. Loci reaching genome-wide and/or suggestive significance are
listed below.
chromosome position alleles maf beta standard p-value nearest
estimate error gene
21 20162158 C\A 0.12 -0.226 0.034 3.11E-11 ISL1
10 71766565 G\A 0.17 0.225 0.036 3.39E-10 RNF217
13 22385480 C\T 0.07 0.190 0.034 2.13E-08 ZKSCAN2
4 17084310 T\C 0.16 -0.175 0.033 1.16E-07 TNS3
15 71121201 T\C 0.42 -0.175 0.035 3.99E-07 NCOA1
10 16809864 A\C 0.34 -0.163 0.032 4.93E-07 DACT3
20 42730981 G\T 0.08 0.160 0.033 1.51E-06 VEGFA
5 39031828 C\T 0.18 0.154 0.034 4.10E-06 OR10K1
17 1746473 C\A 0.24 0.163 0.036 5.26E-06 XPO4
14 65684935 A\G 0.13 -0.155 0.034 5.67E-06 NUDT12
2 16703018 G\A 0.15 0.150 0.033 6.10E-06 HIVEP3
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Figure 5.10: Regional plot of ISL1 locus association with 75 minute post-oral sugar test insulin levels. Color-coding
represents correlation (r2 value) with the reference SNP (dashed line)
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Lipids
Manhattan plots and listing of suggestive and genome-wide significant candidate loci for
triglyceride and NEFA levels are presented in Figures 5.11 to 5.13. A variant within FRK
on ECA 10 (Figure 5.12) attained near genome-wide significance (p-value = 7.8x10−08)
for triglyceride levels. Seven loci reached genome-wide significance for NEFA levels
including variants in ALK, NOVA1, FLVCR2, KLHDC1, SOX6, and ADAD1, (see
Figures D.8b-g). A SNP near TSN on ECA 18 (Figure 5.14) was the top ranked locus
(p-value = 4.36x10−12) for NEFA levels.
Figure 5.11: Manhattan plot of GWAS results for trigylcerides.
Bonferonni threshold (solid line): p-value<5.70x10−8; suggestive threshold (dashed
line): p-value<1x10−5. Loci reaching genome-wide and/or suggestive significance are
listed below.
chromosome position alleles maf beta standard p-value nearest
estimate error gene
10 64538148 T\C 0.15 0.207 0.038 7.80E-08 FRK
9 12293620 T\C 0.18 -0.190 0.038 8.18E-07 JPH1
4 95568021 T\C 0.17 0.179 0.037 1.08E-06 TRBV19
15 47489715 A\G 0.40 0.181 0.038 2.29E-06 GPR75-
ASB3
24 43212532 A\C 0.28 -0.174 0.037 2.79E-06 DIO3
2 17237220 A\G 0.08 -0.183 0.040 6.35E-06 CTPS1
1 15523210 C\T 0.41 0.167 0.037 7.31E-06 PNLIPRP1
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Figure 5.12: Regional plot of FRK locus association with triglycerides. Color-coding represents correlation (r2 value)
with the reference SNP (dashed line)
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Figure 5.13: Manhattan plot of GWAS results for non-esterified fatty acids.
Bonferonni threshold (solid line): p-value<5.70x10−8; suggestive threshold (dashed
line): p-value<1x10−5. Loci reaching genome-wide and/or suggestive significance are
listed below.
chromosome position alleles maf beta standard p-value nearest
estimate error gene
18 8562608 G\A 0.33 0.227 0.033 4.36E-12 TSN
15 66792714 G\T 0.11 0.212 0.031 8.33E-12 ALK
1 164702224 A\G 0.18 0.206 0.031 2.35E-11 NOVA1
24 20975408 G\T 0.35 0.200 0.031 1.83E-10 FLVCR2
1 183728003 G\A 0.23 -0.192 0.031 9.68E-10 KLHDC1
7 84765240 T\C 0.46 0.180 0.032 1.16E-08 SOX6
2 105684803 G\T 0.11 0.165 0.030 4.03E-08 ADAD1
10 13860272 G\A 0.33 0.163 0.030 7.87E-08 LYPD4
2 1779499 T\C 0.08 0.155 0.031 4.75E-07 OMA1
30 19352250 T\G 0.09 0.145 0.031 1.98E-06 BRINP3
9 74443615 C\T 0.22 -0.139 0.030 3.40E-06 ST3GAL1
11 56669565 A\G 0.21 -0.145 0.031 3.50E-06 HS3ST3B1
14 80043766 C\T 0.09 0.146 0.032 3.54E-06 RN7SKP34
1 35305763 C\T 0.29 0.144 0.032 5.46E-06 LGI1
18 75270775 G\A 0.14 -0.136 0.030 6.47E-06 KCTD18
30 5917999 G\A 0.44 -0.136 0.031 8.83E-06 CNST
159
Figure 5.14: Regional plot of TSN locus association with NEFA. Color-coding represents correlation (r2 value) with
the reference SNP (dashed line)
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ACTH
Manhattan plots and listing of suggestive and genome-wide significant candidate loci for
ACTH levels are presented in Figure 5.15. Three loci reached genome-wide significance
for ACTH levels, two of the loci contain candidate regions related to growth hormone.
The nearest gene to the top ranked variant is SNORD12 (Figure 5.16) which lies in a
region identified to be associated with growth hormone deficiency in humans.233 The
third ranked locus contains a variant ∼100KB from GHR on ECA 21 (Figure 5.17)
that encodes the growth hormone receptor. SEPP1 encodes selenoprotein P and is the
nearest gene to the variant, however GHR is a more obvious biological candidate given
growth hormone is also an anterior pituitary hormone and growth hormone receptor
mutations impair growth hormone autofeedback signaling in pituitary tumors.234
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Figure 5.15: Manhattan plot of GWAS results for adrenocorticotropin hormone.
Bonferonni threshold (solid line): p-value<5.70x10−8; suggestive threshold (dashed
line): p-value<1x10−5. Loci reaching genome-wide and/or suggestive significance are
listed below.
chromosome position alleles maf beta standard p-value nearest
estimate error gene
22 37596454 C\T 0.23 0.219 0.033 2.14E-11 SNORD12
21 10999900 A\G 0.13 0.223 0.035 1.90E-10 KIF2A
21 23724278 T\C 0.18 -0.182 0.033 4.04E-08 SEPP1
25 14650611 T\C 0.09 0.164 0.032 4.05E-07 EPB41L4B
13 24087845 C\T 0.25 0.184 0.037 8.73E-07 SCNN1B
3 101439577 G\A 0.26 0.167 0.034 9.52E-07 GBA3
20 28706883 T\C 0.22 -0.152 0.032 1.79E-06 OR2H1
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Figure 5.16: Regional plot of SNORD12 locus association with ACTH. Color-coding represents correlation (r2 value)
with the reference SNP (dashed line)
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Figure 5.17: Regional plot of GHR locus association with ACTH. Color-coding represents correlation (r2 value) with
the reference SNP (dashed line)
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Adipokines
Manhattan plots and listing of suggestive and genome-wide significant candidate loci
for leptin and adiponectin levels are presented in Figures 5.18 to 5.19. Genome-wide
significant loci were not detected for leptin, although two loci on ECA 15 (Figure D.11a)
and 22 (Figure D.11b) did reach genome-wide significance for adiponectin levels. In
addition, a variant located within NRXN3 (Figure 5.20) on ECA 24 attained near
genome-wide significance (p-value = 1.88x10−07) for adiponectin levels.
Figure 5.18: Manhattan plot of GWAS results for leptin.
Bonferonni threshold : p-value<5.70x10−8; suggestive threshold (dashed line): p-
value<1x10−5. Loci reaching genome-wide and/or suggestive significance are listed
below.
chromosome position alleles maf beta standard p-value nearest
estimate error gene
19 49581025 G\A 0.23 -0.187 0.037 5.42E-07 CCDC54
19 11111059 T\C 0.42 -0.180 0.038 2.56E-06 RPL22L1
14 47283907 G\A 0.23 0.181 0.039 2.79E-06 MEGF10
1 54004249 G\A 0.21 0.175 0.038 5.43E-06 CTNNA3
2 51826889 A\G 0.10 0.161 0.036 5.78E-06 RHOBTB2
3 25187849 C\T 0.18 -0.173 0.038 5.92E-06 CNTNAP4
6 38093791 G\A 0.13 0.155 0.035 9.32E-06 KLRC1
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Figure 5.19: Manhattan plot of GWAS results for adiponectin.
Bonferonni threshold (solid line): p-value<5.70x10−8; suggestive threshold (dashed
line): p-value<1x10−5. Loci reaching genome-wide and/or suggestive significance are
listed below.
chromosome position alleles maf beta standard p-value nearest
estimate error gene
15 21018128 A\G 0.11 -0.200 0.033 1.85E-09 ST6GAL-
NAC2
22 18132778 C\T 0.15 -0.194 0.035 2.83E-08 SLC23A2
24 24582154 G\A 0.15 -0.171 0.033 1.88E-07 NRXN3
6 68035083 G\A 0.11 0.178 0.035 2.71E-07 DIP2B
2 85771023 G\A 0.17 -0.169 0.034 8.62E-07 TTC29
4 37502360 C\T 0.23 -0.165 0.033 8.96E-07 GNGT1
20 3585516 G\T 0.35 -0.155 0.033 2.85E-06 RIPK1
2 17691609 T\C 0.11 -0.161 0.035 3.91E-06 ZFP69B
19 44097058 C\A 0.10 -0.154 0.034 4.86E-06 GRAMD1C
15 80933450 G\A 0.13 -0.151 0.034 8.17E-06 TRIB2
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Figure 5.20: Regional plot of NRXN3 locus association with adiponectin. Color-coding represents correlation (r2 value)
with the reference SNP (dashed line)
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5.4.3 Control for false positives and prioritization of GWAS candidate
genes
Q-Q plots of the observed versus expected test statistics presented in Figure 5.21 indi-
cate absence of genomic inflation. In addition, overlap of candidate genes for human
metabolic syndrome with candidate genes for equine metabolic syndrome (included all
equine loci above the suggestive threshold) was investigated since population structure
is unlikely to cause the same false positives in two different species and would provide
strong evidence for a biological connection between the trait and the SNP in linkage
disequilibrium with the candidate gene. Results of the human-equine metabolic syn-
drome candidate gene overlap investigation are reported in Table 5.3. The 93 identified
equine metabolic syndrome candidate genes overlapped with 156 reported human gene
metabolic trait associations (some genes associate with more than one human MetS
trait). A similar investigation was performed on candidate genes identified using a
standard linear mixed model GWAS and reported in Table D.12, the standard GWAS
analysis also identified 93 candidate genes, however overlap with only 118 human gene
metabolic trait associations were detected. In addition, 17 of the improved LMM GWAS
reached genome-wide significance where as zero loci reached genome-wide significance
using the standard LMM. 29 loci were identified by both the standard and improved
LMM methods. The increased genome-wide significant findings and improved enrich-
ment for human MetS candidate genes provided by using the improved LMM suggest
the method is more powerful than a standard LMM in this study population.
168
Figure 5.21: Q-Q plots for EMS traits: neck circumference:height ratio(a), girth:height
ratio(b), fasting glucose(c), fasting insulin(d), post-OST glucose(e) and post-
OSTinsulin(f).
(a) NH (b) GH (c) GLU
(d) logINS (e) GLU post-OST (f) logINS post-OST
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Figure 5.21 Continued from previous page: Q-Q plots for EMS traits: triglycerides(g),
NEFA(h), ACTH(i), leptin(j), and adiponectin(k).
(g) logTG (h)
√
NEFA (i) logACTH
(j)
√
Leptin (k)
√
Adiponectin
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Table 5.3: Replication of human GWAS candidate genes for metabolic traits. Hu-
man GWAS data were obtained from the PheGenI database (http://www.ncbi.nlm.nih.
gov/gap/phegeni accessed on December 1 2015) using default search parameters. The
genes nearest the top p-value for all EMS associated loci above the suggestive signif-
icance threshold were searched against the following human GWAS phenotype terms
for 11 different metabolic syndrome components and co-morbities: 1) adiposity (Ab-
dominal Fat, Intra-Abdominal Fat), 2) body mass (Body Mass Index, Obesity, Waist
Circumference, Waist-Hip Ratio, Body Weight Changes, Body Weights and Measures,
Body Weight), 3) diabetes (Diabetes Mellitus, Type 1 Diabetes, Type 2 Diabetes, Dia-
betic Nephropathy, Diabetic Retinopathy), 4) glucose (Glucose, Glycosylated Hemoglobin
A), 5) insulin and insulin resistance, 6) lipids (Apolipoprotein A-I, Apolipoproteins C,
Cholesterol, HDL, LDL, Lipoproteins, VLDL, Triglycerides), 7) cardiovascular (Ar-
teries, Atrial Fibrillation, Blood Flow Velocity, Blood Pressure, Coronary Artery Dis-
ease, Echocardiography, Heart Failure, Heart Rate, Hematocrit, Hypertension, Myocar-
dial Infarction, Blood Coagulation Factors, Left Ventricular Hypertrophy), 8) stroke, 9)
adiponectin, 10) C-Reactive Protein, and 11) monocytes (Monocyte Chemoattractant
Protein-1, Monocytes).
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TSN NEFA 4.4E-12 X X X X X
ALK NEFA 8.3E-12 X X X X X X
SNORD12 ACTH 2.1E-11
NOVA1 NEFA 2.4E-11 X X X
ISL1 INS OST 3.1E-11 X X
FLVCR2 NEFA 1.8E-10 X X
KIF2A ACTH 1.9E-10 X X X
RNF217 INS OST 3.4E-10 X
KLHDC1 NEFA 9.7E-10
ST6GALNAC2 APN 1.9E-09
GRIK2 INS 9.5E-09 X X X X
ATG14 INS 1.0E-08
SOX6 NEFA 1.2E-08 X X X
ZKSCAN2 INS OST 2.1E-08
Table 5.3 Continued on next page
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SLC23A2 APN 2.8E-08 X
ADAD1 NEFA 4.0E-08 X
SEPP1 ACTH 4.0E-08
FRK TG 7.8E-08 X X X X X
LYPD4 NEFA 7.9E-08
TNS3 INS OST 1.2E-07 X X X
CRYBA4 GLU 1.6E-07
FAM155A NH 1.9E-07 X X X X X
NRXN3 APN 1.9E-07 X X X X X X X
MPZL2 GH 2.0E-07
MFN1 INS 2.3E-07
OTOL1 INS 2.3E-07 X X X X X
DIP2B APN 2.7E-07
NCOA1 INS OST 4.0E-07 X X
EPB41L4B ACTH 4.1E-07
DAPK2 INS 4.1E-07
AHR INS 4.5E-07 X X
OMA1 NEFA 4.8E-07 X
DACT3 INS OST 4.9E-07
CCDC54 LEP 5.4E-07 X X X
DLGAP4 GLU 5.5E-07
JPH1 TG 8.2E-07 X X X
TTC29 APN 8.6E-07 X X
SCNN1B ACTH 8.7E-07
GNGT1 APN 9.0E-07
GBA3 ACTH 9.5E-07 X X
PCDH18 NH 1.0E-06 X X
TRBV19 TG 1.1E-06
Table 5.3 Continued on next page
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SPAG16 GLU OST 1.3E-06 X X X
FAM155A INS 1.4E-06 X X X X X
SEL1L2 GH 1.4E-06
HDAC1 GLU OST 1.4E-06
VEGFA INS OST 1.5E-06 X X X X X
OR2H1 ACTH 1.8E-06 X
CREB5 NH 2.0E-06 X X X
BRINP3 NEFA 2.0E-06 X X X X X X
GPR75-ASB3 TG 2.3E-06
FAM50B INS 2.4E-06
COBL GLU OST 2.5E-06 X X X X X
SENP5 NH 2.5E-06
RPL22L1 LEP 2.6E-06 X X
DLEU7 GLU OST 2.7E-06 X X
ZNF362 NH 2.7E-06
DIO3 TG 2.8E-06
MEGF10 LEP 2.8E-06 X X X
RIPK1 APN 2.9E-06
COMMD9 INS 2.9E-06
MAP10 GH 3.2E-06
ST3GAL1 NEFA 3.4E-06 X X X X
HS3ST3B1 NEFA 3.5E-06 X
RN7SKP34 NEFA 3.5E-06
ZFP69B APN 3.9E-06
OR10K1 INS OST 4.1E-06
SLCO4C1 GH 4.5E-06 X X
TRPS1 INS 4.6E-06 X X X X X X X
GATB INS 4.8E-06
Table 5.3 Continued on next page
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CCSER2 NH 4.9E-06
GRAMD1C APN 4.9E-06
RAB8B NH 5.2E-06 X
XPO4 INS OST 5.3E-06 X X
CTNNA3 LEP 5.4E-06
LGI1 NEFA 5.5E-06 X
NUDT12 INS OST 5.7E-06 X X X
RHOBTB2 LEP 5.8E-06 X
CNTNAP4 LEP 5.9E-06
HIVEP3 INS OST 6.1E-06 X
CTPS1 TG 6.4E-06
SOX5 GH 6.4E-06 X X X X
KCTD18 NEFA 6.5E-06 X
PCDH7 NH 6.7E-06 X X X X X X
PNLIPRP1 TG 7.3E-06
GPRIN3 GH 7.3E-06 X X
KCNT2 INS 7.8E-06 X X X X X X
TRIB2 APN 8.2E-06 X X X X X
GPR115 GH 8.3E-06
CNST NEFA 8.8E-06
MDGA2 GH 9.2E-06 X X
GRIK2 NH 9.3E-06 X X X X
KLRC1 LEP 9.3E-06
RIMS1 GLU OST 9.5E-06 X X
USP25 GLU OST 9.8E-06 X X
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5.5 Discussion
Extensive phenotyping combined with high density genotypes enabled localization of
genetic loci associated with the pathophysiology of metabolic syndrome in horses. The
results suggest substantial overlap of the biological processes underlying human and
equine metabolic syndrome. Examples exist for monogenic traits where mutations in
the same gene result in similar phenotypes in different species, such as mutations in
the MC1R gene causing differences in hair color in humans235 and variation in haircoat
in horses and feathers in chickens.236 Shared candidate genes have also been identified
among humans, horses, and cattle for height, a classic polygenic trait.220,222 Identifica-
tion of shared candidate genes for metabolic syndrome in both humans and horses both
provides validation for the gene as causal in each species since population stratification
is unlikely to cause the same false positive in different species and secondly, potentially
provides opportunity for exploring similar preventative and therapeutic management
strategies.
Genome-wide and suggestive genetic variants were associated with measures of re-
gional and generalized adiposity. The FAM155 locus associated with neck circumference
to height ratio (NH) in horses, in addition to equine fasting insulin levels. The FAM155
locus has also demonstrated associations with human metabolic traits including: obesity
in adults who received cranial radiation therapy as a child cancer patient,237 C-reactive
protein levels,238 and suggestive associations with human body mass,239 lipoproteins,240
and hypertension241 in the Framingham Heart Studies. Similar to the FAM155 locus,
the GRIK2 locus was also associated with equine NH and fasting insulin levels, in addi-
tion to associations with human metabolic traits body mass,239 cholesterol,240 lipopro-
teins,240 and hypertension241 in the Framingham Heart Studies. The equine NH locus
PCDH7 is associated with human cholesterol levels242 and body mass index.239 PCDH7
is also a paralog of PCDH18 another protocadherin gene associated with equine NH,
providing evidence for protocadherins playing a role in equine regional adiposity.
Several genome-wide and suggestive genetic variants were associated with glucose
and insulin fasting and post-oral sugar test levels. A genetic variant near AHR which
encodes the aryl hydrocarbon receptor, a ligand activated transcription factor known
to bind natural plant flavanoids in addition to endocrine disrupting chemicals such as
175
polycyclic aromatic hydrocarbons and dioxins making it an interesting candidate gene
to pursue given increased interest in the potential role of endocrine disrupting chemical
in the pathophysiology of metabolic syndrome. The AHR locus is also associated with
human caffeine consumption243 and heart rate.244 Equine fasting insulin levels were
also associated with the TRPS1 locus which has demonstrated association with human
cholesterol levels.245,246 Equine fasting insulin KCNT2 locus is associated with human
adiponectin levels.247,248 The top ranked SNP for insulin levels following an oral sugar
challenge in horses is ISL1, which encodes insulin enhancer protein that binds to the
enhancer region of the insulin gene and may play an important role in regulating insulin
gene expression. The VEGFA equine post-OST insulin locus is another interesting can-
didate gene given associations with human adiponectin levels249 and waist-hip ratio.250
The top ranked SNP for triglycerides located within the FRK gene has been asso-
ciated with obesity in the Korean population,251 in addition to a reported association
with cholesterol level.245 Numerous variants located within genes were associated with
equine NEFA levels and also happen to be associated with multiple human metabolic
syndrome phenotypes, for example, the ALK locus is associated with human body mass
and diabetes-related traits in the Framingham Heart Study239,248 and NOVA1 is asso-
ciated with body weight and cholesterol levels.239,240
Genome-wide and suggestive genetic variants were associated with adipokines leptin
and adiponectin. The equine adiponectin locus NRXN3 is also associated with human
body mass index,252 obesity253 and waist circumference.254 Human associations also
exist for the equine adiponectin locus TRIB2 with cholesterol and apolipoprotein C
levels.240
The current study is limited by a relatively small sample size for detecting variants
of small effect contributing to a polygenic trait. The statistical algorithm incorporates
Bayesian methodology and has demonstrated increased power to detect polygenic vari-
ants. However, the method may provide varying results depending on initial parameter
settings, thus it is important not to assume all identified associations are causal with-
out additional validation studies. Replication of candidate genes observed in humans
provides support for identified equine loci being causal, however a statistical test for
enrichment of human metabolic syndrome candidate genes was not performed. Per-
forming a test of this nature and also investigating enrichment of metabolic syndrome
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related pathways are recommended and would aid in prioritization of GWAS candidate
genes for more in depth analysis.
An additional point of discussion is the use of only the nearest gene relative to the
top ranked locus SNP to search for overlapping human MetS GWAS identified loci. It
is well known that the top ranked SNP for a particular locus tags a haplotype that may
contain multiple genes and the gene harboring the causal variant may not necessarily
be the closest gene. The procedure used in this study to identify overlapping horse
and human metabolic syndrome loci circumvents this issue to a degree. For a given
gene list, the PheGenI database (http://www.ncbi.nlm.nih.gov/gap/phegeni) reports
human genes nearest or containing SNPs identified significant by GWAS. Therefore the
reported human gene may not be the gene nearest the top ranked SNP for a particular
human locus, it is simply a gene within a human associated locus. For both human
and horse loci, the nearest gene is a place to begin further investigations, especially if
the gene function is known to be biologically relevant to the trait. However, one must
be mindful to consider genes more distal to the tag SNP when performing enrichment
or sequence analysis. Future analyses could specifically test for increased enrichment
of the genes nearest tag SNPs compared to other genes in the locus to support further
investigation (sequence analysis) of the nearest gene.
A final limitation of the current study is the performance of only a univariate re-
sponse model. Many of the metabolic syndrome phenotypes are correlated which may
in part be due to genetic correlation, for example in the current study the GRIK2
and FAM155A loci were associated with both NH and fasting insulin. Incorporating a
multivariate response model may increase power to detect additional loci, however the
source code for the improved LMM algorithm presented in Chapter 4 has not yet been
modified to include multivariate responses.
In summary, the current study identified several genome-wide and suggestive ge-
netic variants associated with equine metabolic syndrome phenotypes suggesting the
syndrome has a highly polygenic architecture similar to human metabolic syndrome.
Furthermore, numerous overlapping candidate genes were observed for equine and hu-
man metabolic traits, indicating similar biological processes may underly metabolic
syndrome pathophysiology in both species. Future work will require validation of
equine candidate genes in a second population. Haplotypic association analysis with
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high-density genotypes will aid in narrowing the associated regions and identifying all
positional candidate genes to include in sequence analysis to identify the causal variants.
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Chapter 6
Conclusions and future directions
Human metabolic syndrome (MetS) is a global health concern due to the increase in
prevalence and association with increased risk of cardiovascular disease and type 2
diabetes (T2D). Horses suffer from a similar metabolic condition associated with in-
creased risk of laminitis, a crippling and potentially life-threatening condition of the
foot. Debate exists in both the human and veterinary fields regarding the etiology and
pathogenesis of metabolic syndrome and the mechanisms linking the syndrome to its
secondary consequences. In both fields, conflicting reports generated from different in-
vestigations of the etiology and pathogenesis of metabolic syndrome reflect the complex,
multifactorial nature of the condition. It is possible these two similar conditions may
share some common underlying biological processes and pathogenesis and knowledge
from one species may be transferable to the other.
In order to develop effective preventative and therapeutic strategies for managing
the secondary consequences of these syndromes, further research is warranted to de-
termine the underlying mechanisms. The objectives of this thesis were to 1) quantify
the variation in metabolic phenotypes across horse/pony breeds and the impact of in-
dividual and environmental factors, and to identify differences in metabolic phenotype
in horses/ponies with obesity and/or a history of laminitis, 2) to examine response to
an oral sugar challenge and incretin biology (DPP-IV activity; insulin secretory and
GLP-1 responses; SNPs in GCG and DPP4) in Morgan horses and Welsh ponies, and
3) identify genetic loci associated with equine metabolic trait variation.
179
6.1 Characterization of the EMS phenotype
6.1.1 Benefits of a multilevel, multivariate analysis of metabolic syn-
drome
In Chapter 2 a multilevel, multivariate cross-sectional analysis of metabolic trait vari-
ation was performed in a large cohort (610) of horses and ponies sampled from 166
farms located throughout the US in addition to a single Canadian farm. Metabolic trait
measurements were found to cluster at the farm level, i.e. horses sampled from the
same farm were more likely to have similar metabolic trait measurements than horses
sampled from different farms. The multilevel, multivariate analytic approach accounts
for the sampling bias (nuisance factor) due to violating the assumption of independent
observation but simultaneously facilitates a much deeper analysis, including quantify-
ing the impact of both individual and farm related factors on metabolic trait variation
and determining the degree of variation and correlation (co-variation) between equine
metabolic traits at the farm and individual horse level. Traits that exhibit a more pro-
nounced correlation at the farm level compared to the individual horse level indicate
factors shared at the farm level (e.g. sampling time of year, pasture composition) may
also explain co-variation in metabolic traits.
6.1.2 Regional vs generalized adiposity correlate with different bio-
chemical profiles
Analysis of trait co-variation revealed triglyceride (TG), insulin (INS), and adiponectin
(APN) levels correlated more strongly with a measure of regional adiposity (neck cir-
cumference to height ratio [NH]) than a measure of generalized adiposity (girth to height
ratio [GH]). Previous data suggest the nuchal ligament adipose tissue is more likely than
other adipose depots to display an inflammatory phenotype in the horse and therefore
may play a unique role in the pathogenesis of metabolic dysregulation,133 data from
Chapter 2 support this hypothesis. Interestingly, in humans, subcutaneous fat in the
neck region has been found to be strongly associated with insulin resistance suggesting
the possibility of shared underlying mechanisms.134
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6.1.3 Equine metabolic traits vary with obesity and laminitis status
Adipokine measurements, leptin (LEP) and APN, exhibited divergent patterns of vari-
ation according to obesity and prior laminitis status. LEP levels were elevated in obese
horses to a similar degree with and without a prior history of laminitis whereas APN
levels were decreased in horses with a prior history of laminitis to a similar degree in
non-obese and obese horses. In addition, LEP correlated more strongly with generalized
adiposity than regional adiposity. These findings suggest LEP may be a good indicator
of body fat mass in horses and APN may indicate the presence of “unhealthy” adipose.
Horses with a history of laminitis exhibiting significant differences in regional adiposity,
insulin, triglycerides, and adiponectin levels independent of obesity status, providing
further support for these components as laminitis risk factors and indicating obesity is
not an essential component affecting variation in these metabolic traits. The effect of
obesity on INS and LEP levels may limit the utility of these biochemical markers as
a diagnostic test for metabolic disturbances due to causes other than over nutrition.
In our population, TG and APN levels were less affected by obesity and may have an
increased utility for diagnosing metabolic disturbances resulting from causes other than
over nutrition.
6.1.4 Equine metabolic traits vary with breed, gender, age, season,
and diet
Breed differences were observed for several traits, for example, the Quarter Horse (QH)
breed was the most divergent with lower INS/INS OST, TG, and LEP. Increased muscle
mass in the QH breed may explain the observation of a more insulin sensitive pheno-
type. Breed differences provide support for genetic variation as a source of metabolic
trait variation. However, breed differences for metabolic traits may pose limitations on
the use of a single reference range for all breeds when utilizing metabolic traits as a
diagnostic.
Gender differences were observed for several traits with mares having a significantly
lower measure of regional adiposity (NH) and stallions having a lower measure of gen-
eralized adiposity (GH), suggesting gender differences in equine body fat distribution.
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Mares also had higher TG and LEP levels. The gender differences observed in horses
share similarity with human gender differences. Triglyceride levels have been reported
to correlate with fat deposition sex differences in humans146 and gender differences in
LEP levels in humans are accounted for by percent body fat.147Similar to previous re-
ports,144,148 age was positively associated with INS and to a larger degree with ACTH
levels.
Seasonal variation in traits was similar to previous reports, although the current
study is limited by the fact that samples were obtained from each horse on only a single
day of the year. Elevated ACTH in the fall months has been previously reported in
horses.149,150 However, in our study positive effects of latitude on ACTH levels were
observed which is opposite of the relationship observed previously in horses143 but con-
sistent with the concept of higher latitudes experiencing greater seasonal extremes and
thus having more pronounced photoperiod effects. Similar to previous reports, leptin
values were highest in the month of October, at the end of the ACTH rise.158 It is pos-
sible increased ACTH levels may have induced leptin resistance in an effort to prepare
for winter. Fasted NEFA levels were higher during the winter months and may indi-
cate decreased glucose utilization in favor of fat oxidation. The study findings suggest
seasonality is an important source of metabolic trait variation; further evidence of this
conclusion is the substantial reduction in farm level variance achieved for several traits
with the inclusion of month as an explanatory variable. The horse, similar to other
long day breeders, seems to switch to an insulin resistant state during the fall which
would allow a horse to increase fat stores to be utilized throughout the winter when
food sources may be limited and increased energy is needed for thermoregulation and
to support development of a fetus in pregnant mares. Mild effects for diet and exercise
parameters on metabolic trait variation were detected. Power may have been limited to
detect an association with diet due to the one time sampling and limited power to detect
associations with exercise due to only 15% of the population having received more than
3 hours of exercise per week.
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6.1.5 Impact of EMS phenotype characterization findings and future
directions
In summary, numerous factors beyond obesity and prior laminitis status were found
to contribute to variation in metabolic traits, including seasonal effects, breed, age,
sex, and diet. These findings obtained by examining equine metabolic trait variation
in a large population of horses under varying environmental and individual conditions
provide an explanation for the discrepancy in some conclusions drawn from previous
studies regarding the EMS phenotype. However, these findings also draw attention to
the difficulty in determining appropriate reference ranges for EMS diagnostic criteria in
the presence of multiple sources of “normal” metabolic variation. A potential adjunct
for improving EMS diagnosis prior to laminitis development and monitoring a horse’s
response to management would be to test multiple horses on the same property. A
horse with values dissimilar from the rest of the herd may be at higher risk of laminitis
development. Monitoring additional horses may be even more useful for monitoring
progression of EMS. Instead of only monitoring the affected horse and questioning if
the horse’s values changed due to individual factors (progression/improvement of EMS)
or due to environmental factors, one could monitor additional horses to determine if
all of the horses experienced a similar change in test results due to farm level factors
(season, diet).
Although parameters included in the analysis explained a moderate amount of vari-
ation in metabolic traits, the results also suggest additional unaccounted for sources
of farm and individual horse level variance exist. It is likely that individual genetic
differences exist which contributes to metabolic trait variation. The detection of breed
differences in our study support this hypothesis. Additional environmental factors not
measured in this study may also potentially impact metabolic trait variation. For ex-
ample, chemicals present in the environment have endocrine disrupting capabilities and
could be a potential unaccounted for source of variation in equine metabolic traits.163
A limitation of the present study is the one-time sampling of the population. The
present study was not designed to ask questions such as: does metabolic trait variation
and co-variation in horses with a prior history of laminitis vary with changes in body-
weight? This should be a focus area of future research along with identifying additional
sources of variation in metabolic traits in horses with a prior history of laminitis in both
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obese and non-obese individuals. Further research is needed to identify additional envi-
ronmental sources of metabolic trait variation and to dissect sources of individual level
metabolic trait variation. Breed differences identified in Chapter 2 support the need for
additional genetic studies, such as the GWAS performed in Chapter 5, and GWAS in
multiple breeds to determine variants responsible for breed variation in metabolic traits.
The findings from Chapter 2 indicate both individual level factors (age, gender, ge-
netics, obesity, and prior laminitis status) and environmental level factors (season, diet)
are sources of equine metabolic trait variation. The metabolic trait profile of obese
horses with and without a prior history of laminitis also vary providing further evidence
adipose is more than just a fat storage site and the possibility an individual may have
“healthy fat” vs “unhealthy fat”.
6.2 Characterization of the equine response to an oral
sugar challenge
Alteration of the equine incretin response (intestinal secretion of GLP-1 to stimulate
insulin secretion in response to oral sugar) has been hypothesized to play a role in the
pathogenesis of EMS however limited research has been performed in terms of testing
this hypothesis. The objective of Chapter 3 was to characterize the equine response to
an oral sugar challenge and identify factors associated with variation in this response.
A longitudinal analysis was performed to test for association of different factors with
variation in glucose, insulin, GLP-1 trajectories during an oral sugar test. The tra-
jectory analysis is more informative than a traditional area under the curve summary
statistic given the possibility for two different curves to have the same AUC resulting
in a potential loss of important biological information. A number of factors were found
to be associated with the incretin hormone GLP-1 and insulin/glucose dynamics during
the equine response to an oral sugar challenge. In addition, factors associated with
DPP4 activity, the major protease that breaks down GLP-1, were also identified.
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6.2.1 Insulinemic response varies with breed, obesity, and prior lamini-
tis status
Welsh ponies had a greater insulin response compared to Morgan horses suggesting a ge-
netic basis for variation in the equine response to an oral sugar challenge. Obese horses
with a prior history of laminitis also exhibited a greater insulin response. Triglycerides
and leptin, biochemical factors found to be positively correlated with obesity and lamini-
tis status in Chapter 2, also demonstrated a positive correlation with insulin response.
Likewise, adiponectin demonstrated a negative correlation with the insulin response.
The observed increased insulinemic response is likely due to an insulin resistant state
in obese, prior laminitic horses, as the response is associated with biochemical variation
consistent with insulin resistance.
6.2.2 Equine GLP-1 trajectories are not strongly correlated with the
insulinemic response during an oral sugar test
GLP-1 trajectories were not strongly correlated with insulin trajectories. A potential
explanation for the lack of correlation may be due to the use of a statistical model
that assumes correlation of trajectories is the same in obese and non-obese horses and
in horses with and without a prior history of laminitis. In humans the incretin effect
accounts for 70% of the variation in the insulin response to an oral sugar challenge in
normal individuals but only 30% percent in individuals affected with type 2 diabetes.197
Estimation of trajectory correlation separately for obese and non-obese horses and in
horses with and without a prior history of laminitis was not examined in Chapter 3 but
should be investigated further in the future.
6.2.3 DPP4 activity is not associated with equine GLP-1 trajectories
during an oral sugar test
An unexpected finding of Chapter 3 was the lack of association of DPP4 activity with
equine GLP-1 trajectories given DPP4’s role in degrading GLP-1 and the success of
DPP4 inhibitors to modulate human GLP-1 levels and improve the incretin response.
However, DPP4 activity was positively associated with the insulin response and neg-
atively correlated with age and adiponectin levels, suggesting insulin resistance as the
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mechanism for the increased insulin response and not modulation of GLP-1 levels by
DPP4. The positive association of DPP4 activity with an insulin resistance type of
response may reflect DPP4’s role as an adipokine.176
6.2.4 Basal GLP-1 and GLP-1 secretory responses to oral glucose are
reduced with features of EMS
Similar to decreased GLP-1 secretion observed with features of human metabolic syn-
drome (obesity and insulin resistance), basal GLP-1 and GLP-1 secretory responses to
oral glucose are reduced with features of equine metabolic syndrome.168,193–195 Haplo-
type variation in the promoter region of GCG, which encodes for the GLP-1 peptide,
among other proteins was tested for association with GLP-1 and demonstrated a mod-
est association. Haplotypes with higher basal GLP-1 levels tended to exhibit decreased
GLP-1 responses to an oral sugar test. Testing additional horses would be necessary
to confirm the haplotype as a causal source of GLP-1 variation. Although the role of
variation in GLP-1 in the equine incretin response still remains to be questioned given
the minimal correlation observed between insulin and GLP-1 trajectories. Future re-
search should investigate a horse’s response to an oral glucose stimulus compared with
their response to an intravenous glucose stimulus to further assess the role of incretins
in equine glucose intolerance.
6.3 Identification of candidate gene associated with metabolic
syndrome phenotypes
6.3.1 Development of an improved linear mixed model to map poly-
genic traits in populations with familial relationships
The final objective of this thesis was to identify candidate genes associated with equine
metabolic syndrome by performing a genome-wide association study of quantitative
metabolic phenotypes. Human metabolic syndrome is a highly polygenic syndrome
where numerous candidate genes have been identified but only explain a fraction of the
heritability. Associated variants are typically of small effect size and require a large
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sample size to detect associations. Horse populations do not randomly mate and expe-
rience substantial selection pressure, therefore it was hypothesized that a small number
of moderate to large effect loci contribute to variation in metabolic traits and would be
detectable with a relatively small population sample size (∼300) in comparison to the
very large (10,000+) sample sizes needed to detect candidate genes for human polygenic
traits. The Morgan horse breed was selected for the GWAS given the reportedly higher
prevalence of metabolic syndrome in this breed of horses. Estimation of “chip heri-
tability” determined from a genomic relationship matrix calculated from all genotyped
SNPs indicated metabolic traits were heritable, however initial genome-wide scans us-
ing standard linear mixed models failed to detect genome-wide significant SNPs, thus
indicating causal variants were not well tagged by the SNPs or metabolic trait variation
in the Morgan breed is due to several loci of small to moderate effect.
The standard LMM approach is based on single-locus tests combined with a diffuse,
overall estimate of the genomic background based on all SNP markers. However, diffuse
modeling of the polygenic term may not be appropriate for traits controlled by multiple
loci of moderate effect. Recent LMM innovations aimed at improved modeling of the
polygenic architecture by building a genomic relationship matrix (GRM) comprised of
select SNPs associated with the phenotype have demonstrated increased power to map
polygenic traits.206–209 However, Widmer et al208 cautioned building a GRM based
on selected SNPs that well predict the phenotype performed poorly at controlling the
type I error rate in the presence of familial relatedness and recommended inclusion of
a second GRM comprised of all SNPs to achieve adequate type I error control. The
drawback of this approach is increased computational time due to full-rank relatedness
matrix inclusion. The Morgan horse population used for the GWAS performed in Chap-
ter 5 featured familial relatedness, thus the objective of Chapter 4 was to develop and
validate an improved linear mixed model for mapping polygenic traits in a population
with familial relationships. The proposed model incorporated a Bayesian variable se-
lection method to rank SNPs and a stepwise feature selection process to determine the
optimal SNPs to model the random polygenic effect while including a random effect
for each sampled herd or “familial cluster”. The method was validated using the QTL-
MAS 2010 dataset and real datasets for Morgan horse and Welsh pony height. The
proposed method demonstrated increased power while controlling the false positive rate
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and maintaining computational feasibility.
6.3.2 93 candidate loci identified for equine metabolic syndrome ex-
hibit substantial overlap with human MetS candidate genes
The improved linear mixed model was applied to the 286 Morgan horse dataset geno-
typed on the Illumina SNP50 chip and imputed up to >800,000 SNPs to identify can-
didate genes for metabolic syndrome. 76 suggestive and 17 genome-wide significant
candidate loci were identified and exhibited substantial overlap with human metabolic
syndrome candidate genes such as VEGFA, NRXN3, GRIK2, and TRIB2. Additional
interesting candidate genes include the top ranked loci for insulin levels following an
oral sugar challenge, ISL, which encodes insulin enhancer protein that binds to the en-
hancer region of the insulin gene and may play an important role in regulating insulin
gene expression. A insulin associated genetic variant near AHR which encodes the aryl
hydrocarbon receptor, a ligand activated transcription factor known to bind endocrine
disrupting chemicals such as polycyclic aromatic hydrocarbons and dioxins make it an
interesting candidate gene to pursue given increased interest in the potential role of
endocrine disrupting chemical in the pathophysiology of metabolic syndrome. Research
already underway involves validation of the identified equine candidate genes in a second
population and sequence analysis to identify the causal variants.
6.4 Summarizing statements
In summary, this work has increased knowledge and understanding of metabolic trait
variation in horses and its relationship with the metabolic syndrome phenotype. A
unifying theme of Chapter 2-5 was the repeated finding of similarities between horse
and human metabolic syndrome and similar genetic architecture of complex traits in
both species. Unexplained metabolic trait variation remains at the environmental level
for horses after accounting for diet and exercise. Caloric intake and sedentary lifestyle
have often been blamed for the obesity epidemic and obesity-related diseases in humans
living in industrialized regions, however findings from this work indicate the possibility
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of additional environmental sources of metabolic trait variation exist. Organic pollu-
tants and endocrine disrupting chemicals have been proposed as playing a role in human
obesity and type 2 diabetes and findings from this study warrant additional investiga-
tion. Identification of shared candidate genes for metabolic syndrome in both humans
and horses both indicates the possibility of similar underlying pathophysiological mech-
anisms and provides opportunity for exploring similar underlying biological processes
along with similar preventative and therapeutic management strategies.
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Figure A.1: Initial online survey for Equine Metabolic Syndrome.
CONTACT INFORMATION
Your Name: (fill in the blank)
Phone Number: (fill in the blank)
Your e-mail: (fill in the blank)
Horse’s Call (Barn) Name: (fill in the blank)
Horse’s Registered Name: (fill in the blank)
VETERINARIAN’S CONTACT INFORMATION
Veterinarian Name: (fill in the blank)
Clinic Name: (fill in the blank)
Clinic Address: (fill in the blank)
Clinic Phone: (fill in the blank)
Veterinarian/Clinic e-mail: (fill in the blank)
SIGNALMENT
1. Horse’s (approximate) year of birth? (drop down choices: 1975-2015)
2. What breed is the horse? (drop down choices: 56 different breeds and “other”)
If you chose other please provide breed(s) (fill in the blank)
3. What is the horse’s gender? (drop down choices: male intact/ male castrated/
female intact/ female spayed)
4. Would you describe your horse as an “easy keeper” (tends to gain weight
easily)? (drop down choices: Yes/No/Not Sure)
LAMINITIS STATUS
5. Has your horse been previously diagnosed with laminitis? (drop down
choices: Yes/No/Not Sure)
6. Please fill in the blank with any additional medical conditions occurring
at the time of laminitis if ”yes” was selected for the previous question? (fill
in the blank)
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Figure A.1 Continued from previous page: Initial online survey for Equine Metabolic
Syndrome.
PHENOTYPE
7. Is your horse overweight? (drop down choices: Yes/No/Not Sure)
8. Is your horse underweight? (drop down choices: Yes/No/Not Sure)
9. Does your horse have a thick, cresty neck? (drop down choices: Yes/No/Not
Sure)
10. Does your horse have fat pads on its rump? (drop down choices: Yes/No/Not
Sure)
11. Does your horse have hair coat that sheds later in the year? (drop down
choices: Yes/No/Not Sure)
12. Does your horse have thick or long curly hair coat? (drop down choices:
Yes/No/Not Sure)
13. Does your horse urinate more than normal? (drop down choices:
Yes/No/Not Sure)
14. Does your horse drink more than normal? (drop down choices: Yes/No/Not
Sure)
PREVIOUS LAB WORK
15. Has your horse had any of the following lab work done?
Insulin Level: (drop down choices: Yes, High /Yes, Normal /Yes, Low /Not
performed)
Glucose Level: (drop down choices: Yes, High /Yes, Normal /Yes, low /Not
performed)
Dexamethasone Suppression Test: (drop down choices: Yes, Normal Suppression
/Yes, Abnormal Suppression /Not Performed)
OTHER INFORMATION
16. How many other horses are kept on the same property as your horse?
(fill in the blank)
17. How many other horses kept on the same property have experienced
laminitis in the past? (fill in the blank)
18. How many other horses on the same property are overweight or have
been diagnosed with equine metabolic syndrome? (fill in the blank)
19. May we contact you for more information? (drop down choices: Yes/No)
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Figure A.2: Second online survey for Equine Metabolic Syndrome.
Based on results from the initial survey, owners were given a link to access a second
online survey to gather information about a potential metabolic syndrome horse and a
second suitable control on the property.
CONTACT INFORMATION
Owner Last Name: (fill in the blank)
Owner First Name: (fill in the blank)
Owner Email: (fill in the blank)
Horse’s Call (Barn) Name: (fill in the blank)
Horse’s Registered Name: (fill in the blank)
Owner Address: (fill in the blank)
City: (fill in the blank)
State: (fill in the blank)
Zip: (fill in the blank)
*contact information was used to link first and second survey results
HORSE MEASUREMENTS*
*online description and diagrams of requested measurements were available on the
survey website
1. What is your horse?s body condition score on a scale of 1-9? (drop down
choices 1-9 in 0.5 unit increments / not sure)
2. Horse Photos: horse owners were asked to upload digital photos for 4 standard
views of horses
3. What is your horse’s body length? (in inches) (fill in the blank)
4. What is your horse’s neck circumference measurement? (in inches) (fill
in the blank)
5. What is your horse’s girth measurement? (in inches) (fill in the blank)
6. What is your horse’s weight? (in pounds) (fill in the blank)
7. How long has the horse been considered overweight? Not applicable (horse
is not overweight) /less than 1 year /1 year /2 years /three years /4-6 years /more
than 6 years /not sure
8. How was this weight determined? Estimate /scale /weight tape /not sure
9. What is your horse’s height at the withers (measured in inches)? fill in
the blank
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Figure A.2 Continued from previous page: Second online survey for Equine Metabolic
Syndrome.
PREVIOUS DIAGNOSIS
10. Has the horse been diagnosed with metabolic syndrome? (drop down
choices: Yes/No/Not Sure)
11. Has the horse ever been diagnosed with Cushings disease (pituitary
pars intermedia dysfunction, PPID)? (drop down choices: Yes/No/Not Sure)
PREVIOUS LABORATORY DATA
Please work with your veterinarian to enter the horse’s values for any of the following
laboratory data if available (please provide units of measure):
12. Insulin concentration: fill in the blank
13. When was the sample for insulin concentration taken? drop down choices:
• not applicable (test not performed)
• the horse was not fasted
• after a complete fast (no hay or grain) of greater than 6 hours
• after a complete fast (no hay or grain) of greater than 10 hours
• after a partial fast (hay but no grain) of greater than 6 hours
• after a partial fast (hay but no grain) of greater than 10 hours
• not sure
14. The insulin concentration was compared to normal values. (drop
down choices: not applicable (test not performed) /high low /normal /not sure)
15. Glucose concentration: fill in the blank
16. When was the sample for glucose concentration taken? drop down choices:
• not applicable (test not performed)
• the horse was not fasted
• after a complete fast (no hay or grain) of greater than 6 hours
• after a complete fast (no hay or grain) of greater than 10 hours
• after a partial fast (hay but no grain) of greater than 6 hours
• after a partial fast (hay but no grain) of greater than 10 hours
• not sure
17. The glucose concentration was compared to normal values. (drop
down choices: not applicable (test not performed) /high low /normal /not sure)
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Figure A.2 Continued from previous page: Second online survey for Equine Metabolic
Syndrome.
PREVIOUS LABORATORY DATA continued
18. Triglyceride concentration: fill in the blank
19. When was the sample for triglyceride concentration taken? drop down
choices:
• not applicable (test not performed)
• the horse was not fasted
• after a complete fast (no hay or grain) of greater than 6 hours
• after a complete fast (no hay or grain) of greater than 10 hours
• after a partial fast (hay but no grain) of greater than 6 hours
• after a partial fast (hay but no grain) of greater than 10 hours
• not sure
20. The triglyceride concentration was compared to normal values.
(drop down choices: not applicable (test not performed) /high low /normal /not sure)
21. Nonesterified fatty acids (NEFA) concentration: fill in the blank
22. When was the sample for NEFA concentration taken? drop down choices:
• not applicable (test not performed)
• the horse was not fasted
• after a complete fast (no hay or grain) of greater than 6 hours
• after a complete fast (no hay or grain) of greater than 10 hours
• after a partial fast (hay but no grain) of greater than 6 hours
• after a partial fast (hay but no grain) of greater than 10 hours
• not sure
23. The NEFA concentration was compared to normal values. (drop
down choices: not applicable (test not performed) /high low /normal /not sure)
24. ACTH concentration: fill in the blank
25. What time of day was the sample for ACTH concentration taken? drop
down choices:
• not applicable (test not performed)
• early morning
• mid-day
• evening
• not sure
26. What month was the ACTH concentration taken? drop down (January-
December)
27. The ACTH concentration was compared to normal values. (drop
down choices: not applicable (test not performed) /high low /normal /not sure)
214
Figure A.2 Continued from previous page: Second online survey for Equine Metabolic
Syndrome.
PREVIOUS LABORATORY DATA continued
28. Cortisol concentration: fill in the blank
29. What time of day was the cortisol concentration measured? drop down
choices:
• not applicable (test not performed)
• early morning
• mid-day
• evening
• not sure
30. What month was the cortisol concentration taken? Drop down (January-
December)
31. The cortisol concentration was compared to normal values. (drop
down choices: not applicable (test not performed) /high low /normal /not sure)
LAMINITIS STATUS
Please answer the following questions regarding the horse’s laminitis (if applicable):
32. Was the horse experiencing laminitis when any of the above tests were
performed? (drop down choices: Yes/No/Not Sure)
33. Has the horse had any of the following endocrine testing done? (please
choose all that apply)
• 24 hour dexamathasone suppression test
• overnight dexamathasone suppression test
• ACTH stimulation test
• combined dexamathasone suppression and ACTH stimulation test
• thyrotropin-releasing hormone stimulation test
• glucose tolerance test
• insulin tolerance test
• not sure
• Other:
34. Has your horse been previously diagnosed with laminitis? (drop down
choices: Yes/No/Not Sure)
35. If so, at what age did your horse first develop laminitis? fill in the blank
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Figure A.2 Continued from previous page: Second online survey for Equine Metabolic
Syndrome.
LAMINITIS STATUS continued
36. In what year did the most recent laminitis episode occur? drop down
choices:
• not applicable (horse has not had laminitis)
• 2010
• 2009
• 2008
• 2007
• 2006 2005 2004 .... 1991 1990 1989
• not sure
37. In what month did the most recent laminitis episode occur? (drop down
choices: not applicable (horse has not had laminitis) / months January-December / not
sure)
38. Which limbs are affected? drop down choices:
• not applicable (horse has not had laminitis)
• forelimbs
• hindlimbs
• all four limbs
• not sure
39. How have the horse’s symptoms changed over time? drop down choices:
• improved
• worsened
• stayed the same
• not applicable
• not sure
40. What treatments has the horse received for laminitis? (Pick all that apply)
• no treatment
• corrective shoeing
• phenylbutazone (bute)
• flunixin meglumine (Banamine)
• not sure
41. Do you think your horse’s laminitis problems are related to grazing
on lush green pastures? (drop down choices: not applicable (horse has not had
laminitis) / Yes /No /not sure)
42. How frequently does you horse have bouts of laminitis? drop down choices:
• not applicable (horse has not had laminitis)
• once every 2-3 years
• once per year
• 2 times per year
• 3 times per year
• more than 3 time per year
• occurs year long
• not sure 216
Figure A.2 Continued from previous page: Second online survey for Equine Metabolic
Syndrome.
PREVIOUS TREATMENTS
43. What treatments has the horse received for its metabolic syn-
drome/obesity? (Choose all that apply) (drop down)
• chromium supplementation
• magnesium supplementation
• thyroid supplementation
• metformin
• dietary change
• management change
• not sure Other:
44. Has the diet been changed? (drop down choices: decreased /increased /not
changed /not sure)
45. Has the amount of turnout been changed? (drop down choices: decreased
/increased /not changed /not sure)
46. Has the amount of exercise changed? (drop down choices: decreased
/increased /not changed /not sure)
DIET AND MANAGEMENT
Please answer the following questions about the horse’s diet and management when
**signs consistent with metabolic syndrome** were first apparent:
47. How much hay did the horse receive per day? (drop down)
• less than 10 lbs
• 10-14 lbs
• 15-19 lbs
• more than 20 lbs
• not sure
48. What type of hay was fed? (drop down)
• grass hay
• legume (alfalfa)
• mix (predominantly grass)
• mix (predominantly alfalfa)
• not sure
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Figure A.2 Continued from previous page: Second online survey for Equine Metabolic
Syndrome.
DIET AND MANAGEMENTcontinued
49. How much grain did the horse receive per day? (drop down)
• none
• less than 1 lb
• 1-2 lbs
• 3-4 lbs
• more than 5 lbs
• not sure
50. What supplements did the horse receive? (Choose all that apply)
• No supplements
• Vitamin E
• Fat/oil
• Selenium
• Mineral block
• Salt block
• Electrolyte
• Joint supplement
• not sure
• Other:
51. How much time did the horse spend in a stall on average? (drop down)
• 0 - 1 hour/day
• 1 - 6 hours/day
• 6 - 12 hours/day
• 12+ hours/day
• not sure
52. How much riding/forced exercise did the horse get per week? (drop down)
• none
• less than 30 minutes
• 30 min to 60 min
• 60 min to 120 min
• 120 min to 180 min
• 180 min to 240 min
• more than 240 min
• not sure
53. How much grass pasture turnout did the horse receive? (drop down)
• none
• less than 1 hour per day
• 1-3 hours per day
• 3-6 hours per day
• 6-9 hours per day
• more than 9 hours per day
• 100% turnout
• not sure
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Figure A.2 Continued from previous page: Second online survey for Equine Metabolic
Syndrome.
DIET AND MANAGEMENTcontinued
Please answer the following questions about the horse’s **current** diet and manage-
ment:
54. How much hay does the horse receive per day? (drop down)
• less than 10 lbs
• 10-14 lbs
• 15-19 lbs
• more than 20 lbs
• not sure
55. What type of hay is fed? (drop down)
• grass hay
• legume (alfalfa)
• mix (predominantly grass)
• mix (predominantly alfalfa)
• not sure
56. How much grain does the horse receive per day? (drop down)
• none
• less than 1 lb
• 1-2 lbs
• 3-4 lbs
• more than 5 lbs
• not sure
57. What supplements does the horse receive? (Choose all that apply) (drop
down)
• No supplements
• Vitamin E
• Fat/oil
• Selenium
• Mineral block
• Salt block
• Electrolyte
• Joint supplement
• not sure
• Other:
58. How much time does the horse spend in a stall on average? (drop down)
• 0 - 1 hour/day
• 1 - 6 hours/day
• 6 - 12 hours/day
• 12+ hours/day
• not sure
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Figure A.2 Continued from previous page: Second online survey for Equine Metabolic
Syndrome.
DIET AND MANAGEMENTcontinued
Please answer the following questions about the horse’s **current** diet and manage-
ment:
59. How much riding/forced exercise does the horse get per week? (drop
down)
• none
• less than 30 minutes
• 30 min to 60 min
• 60 min to 120 min
• 120 min to 180 min
• 180 min to 240 min
• more than 240 min
• not sure
60. How much grass pasture turnout does the horse receive? (drop down)
• none
• less than 1 hour per day
• 1-3 hours per day
• 3-6 hours per day
• 6-9 hours per day
• more than 9 hours per day
• 100% turnout
• not sure
61. What other chronic health problems does the horse have? fill in the
blank/short answer
62. What is the horse used for? (Choose all that apply)
• Pleasure/trail riding
• Lounging
• Driving
• Dressage
• Eventing
• Hunter/jumper
• Racing
• Roping
• Cutting
• Barrel racing
• Halter
• Other:
63. Do any related horses have similar symptoms? (drop down)
• Yes
• No
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Figure A.2 Continued from previous page: Second online survey for Equine Metabolic
Syndrome.
CONTROL HORSE INFORMATION
Please answer the remaining questions for a second horse on the same
property not suspected of having EMS (to serve as “control”)
Owner name (required): (fill in the blank)
Address: (fill in the blank)
phone: (fill in the blank)
e-mail (required): (fill in the blank)
Horse’s call (barn) name: (fill in the blank)
Horse’s Registered name (if registered): (fill in the blank)
Control Horse Photos: (submitted as above)
CONTROL HORSE SIGNALMENT
1. Horse’s year of birth? (drop down choices: 1975-2015)
2. What breed is the horse? (drop down choices: 56 different breeds and “other”)
If you chose other please provide breed(s) (fill in the blank)
3. What is the horse’s gender? (drop down choices: male intact/ male castrated/
female intact/ female spayed)
4. Would you describe your horse as an ”easy keeper”(tends to gain weight
easily)? (drop down choices: Yes/No/Not Sure)
CONTROL HORSE PHENOTYPE
Which of the following descriptions apply to your horse (control) now or in the past?
5. Overweight (drop down choices: Yes/No/Not Sure)
6. Underweight (drop down choices: Yes/No/Not Sure)
7. Thick, cresty neck (drop down choices: Yes/No/Not Sure)
8. Fat pads on rump (drop down choices: Yes/No/Not Sure)
9. Hair coat that sheds later in year (drop down choices: Yes/No/Not Sure)
10. Thick or long curly hair coat (drop down choices: Yes/No/Not Sure)
11. Urinates more than normal (drop down choices: Yes/No/Not Sure)
12. Drinks more than normal (drop down choices: Yes/No/Not Sure)
13. Sweats more than normal (drop down choices: Yes/No/Not Sure)
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Figure A.2 Continued from previous page: Second online survey for Equine Metabolic
Syndrome.
CONTROL HORSE MEASUREMENTS*
*online description and diagrams of requested measurements were available on the
survey website
14. What is your horse’s body condition score on a scale of 1-9? (drop down
choices 1-9 in 0.5 unit increments / not sure)
15. Horse Photos: horse owners were asked to upload digital photos for 4 standard
views of horses
16. What is your horse’s body length? (in inches) (fill in the blank)
17. What is your horse’s neck circumference measurement? (in inches) (fill in
the blank)
18. What is your horse’s girth measurement? (in inches) (fill in the blank)
19. What is your horse’s weight? (in pounds) (fill in the blank)
20. How long has the horse been considered overweight? Not applicable (horse
is not overweight) /less than 1 year /1 year /2 years /three years /4-6 years /more
than 6 years /not sure
21. How was this weight determined? Estimate /scale /weight tape /not sure
22. What is your horse’s height at the withers (measured in inches)? fill in
the blank
CONTROL HORSE PREVIOUS DIAGNOSIS
23. Has the horse been diagnosed with metabolic syndrome? (drop down
choices: Yes/No/Not Sure)
24. Has the horse ever been diagnosed with Cushings disease (pituitary
pars intermedia dysfunction, PPID)? (drop down choices: Yes/No/Not Sure)
25. Has your horse been previously diagnosed with laminitis? (drop down
choices: Yes/No/Not Sure)
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Figure A.2 Continued from previous page: Second online survey for Equine Metabolic
Syndrome.
CONTROL HORSE DIET AND MANAGEMENT
Please answer the following questions about the control horse’s current diet and man-
agement:
26. How much hay does the horse receive per day? (drop down)
• less than 10 lbs
• 10-14 lbs
• 15-19 lbs
• more than 20 lbs
• not sure
27. What type of hay is fed? (drop down)
• grass hay
• legume (alfalfa)
• mix (predominantly grass)
• mix (predominantly alfalfa)
• not sure
28. How much grain does the horse receive per day? (drop down)
• none
• less than 1 lb
• 1-2 lbs
• 3-4 lbs
• more than 5 lbs
• not sure
29. What supplements does the horse receive? (Choose all that apply) (drop
down)
• No supplements
• Vitamin E
• Fat/oil
• Selenium
• Mineral block
• Salt block
• Electrolyte
• Joint supplement
• not sure
• Other:
223
Figure A.2 Continued from previous page: Second online survey for Equine Metabolic
Syndrome.
CONTROL HORSE DIET AND MANAGEMENT continued
30. How much time does the horse spend in a stall on average? (drop down)
• 0 - 1 hour/day
• 1 - 6 hours/day
• 6 - 12 hours/day
• 12+ hours/day
• not sure
31. How much riding/forced exercise does the horse get per week? (drop
down)
• none
• less than 30 minutes
• 30 min to 60 min
• 60 min to 120 min
• 120 min to 180 min
• 180 min to 240 min
• more than 240 min
• not sure
32. How much grass pasture turnout does the horse receive? (drop down)
• none
• less than 1 hour per day
• 1-3 hours per day
• 3-6 hours per day
• 6-9 hours per day
• more than 9 hours per day
• 100% turnout
• not sure
33. What chronic health problems does the horse have? fill in the blank/short
answer
34. What is the horse used for? (Choose all that apply)
• Pleasure/trail riding
• Lounging
• Driving
• Dressage
• Eventing
• Hunter/jumper
• Racing
• Roping
• Cutting
• Barrel racing
• Halter
• Other:
35. May we contact you for more information? (drop down choices Yes / No)
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Table A.1: Metabolic phenotype descriptive summary statistics for all levels of categor-
ical explanatory variables. Mean (SD), median, number of individuals.
Categorical explanatory variable NH GH
Non-obese, no prior laminitis 0.65(0.05),0.64, n=335 1.20(0.06),1.21, n=339
Non-obese, prior laminitis 0.66(0.05),0.67, n=95 1.20(0.09),1.22, n=95
Obese, no prior laminitis 0.68(0.06),0.68, n=110 1.27(0.06),1.27, n=111
Obese, prior laminitis 0.68(0.06),0.68, n=63 1.26(0.08),1.26, n=63
Morgan 0.67(0.05),0.67, n=288 1.23(0.06),1.23, n=288
Arabian 0.63(0.05),0.63, n=62 1.19(0.06),1.20, n=62
Other high risk breeds 0.64(0.06),0.63, n=45 1.20(0.08),1.21, n=45
Other low risk breeds 0.61(0.05),0.62, n=16 1.19(0.08),1.17, n=16
Pony 0.67(0.05),0.66, n=96 1.25(0.07),1.25, n=96
Quarter Horse 0.65(0.07),0.65, n=53 1.24(0.07),1.24, n=57
Tennessee Walking Horse 0.64(0.04),0.64, n=43 1.18(0.08),1.20, n=44
Gelding 0.65(0.05),0.65, n=206 1.21(0.07),1.21, n=209
Mare 0.66(0.05),0.66, n=365 1.23(0.07),1.24, n=367
Stallion 0.69(0.05),0.69, n=32 1.18(0.05),1.17, n=32
Owner submitted sample 0.67(0.05),0.67, n=333 1.23(0.07),1.23, n=333
Researcher collected sample 0.64(0.06),0.64, n=270 1.21(0.07),1.21, n=275
No L-thyroxine supplementation 0.66(0.05),0.66, n=579 1.22(0.07),1.23, n=584
Yes L-thyroxine supplementation 0.64(0.06),0.64, n=24 1.19(0.06),1.17, n=24
DEC collection 0.66(0.04),0.66, n=58 1.23(0.06),1.23, n=58
JAN collection 0.63(0.05),0.64, n=8 1.23(0.03),1.24, n=7
FEB collection 0.68(0.05),0.67, n=35 1.25(0.06),1.25, n=39
MAR collection 0.65(0.05),0.66, n=86 1.22(0.05),1.21, n=86
APR collection 0.66(0.05),0.66, n=69 1.23(0.07),1.24, n=69
MAY collection 0.66(0.06),0.67, n=72 1.21(0.06),1.22, n=72
JUN collection 0.67(0.05),0.67, n=11 1.23(0.05),1.22, n=11
JUL collection 0.63(0.06),0.64, n=36 1.16(0.13),1.21, n=38
AUG collection 0.65(0.05),0.65, n=100 1.20(0.06),1.21, n=100
SEP collection 0.67(0.06),0.67, n=60 1.26(0.07),1.25, n=60
OCT collection 0.65(0.06),0.65, n=52 1.22(0.07),1.23, n=52
NOV collection 0.66(0.08),0.66, n=16 1.25(0.08),1.26, n=16
Table A.1 – Continued on next page
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Table A.1 Continued from previous page
Categorical explanatory variable GLU (mg/dl) INS (µIU/ml)
Non-obese, no prior laminitis 76.1(10.5),76.1, n=339 7.1(8.6),4.8, n=339
Non-obese, prior laminitis 79.7(12.3),78.6, n=95 26.7(82.8),10.3, n=95
Obese, no prior laminitis 76.8(8.3),77.2, n=110 10.6(7.1),9.1, n=111
Obese, prior laminitis 78.0(9.4),78.0, n=64 23.4(23.6),14.5, n=64
Morgan 75.9(9.7),76.2, n=286 9.1(11.2),6.0, n=287
Arabian 82.0(12.6),80.2, n=63 10.2(10.1),6.5, n=63
Other high risk breeds 78.6(7.6),78.4, n=45 17.6(20.2),10.9, n=45
Other low risk breeds 75.7(7.4),76.8, n=16 10.8(11.4),5.8, n=16
Pony 75.6(12.6),73.8, n=96 23.1(82.4),7.9, n=96
Quarter Horse 76.0(10.5),75.8, n=57 6.4(5.3),5.1, n=57
Tennessee Walking Horse 80.2(6.8),80.0, n=45 17.8(21.4),11.9, n=45
Gelding 78.7(11.1),77.9, n=209 17.1(57.0),6.7, n=210
Mare 76.0(10.1),76.5, n=367 10.1(11.8),6.9, n=367
Stallion 77.7(7.5),74.7, n=32 10.4(20.1),5.3, n=32
Owner submitted sample 75.9(9.4),76.2, n=331 7.7(8.5),5.6, n=332
Reseacher collected sample 78.3(11.4),77.7, n=277 18.2(50.7),9.3, n=277
No L-thyroxine supplementation 76.8(10.4),76.6, n=584 12.1(35.5),6.3, n=585
Yes L-thyroxine supplementation 81.1(8.9),83.5, n=24 21.3(20.2),16.7, n=24
DEC collection 70.3(7.4),70.7, n=58 7.6(4.1),6.9, n=58
JAN collection 69.3(9.0),70.1, n=8 25.4(38.6),11.9, n=8
FEB collection 76.0(7.8),76.3, n=39 12.1(7.9),10.9, n=39
MAR collection 77.4(10.7),77.5, n=86 10.0(14.0),5.9, n=86
APR collection 78.2(8.1),77.3, n=69 8.9(13.6),5.2, n=69
MAY collection 76.7(7.8),76.6, n=72 10.0(14.5),5.7, n=72
JUN collection 78.8(6.5),78.5, n=11 12.5(12.0),9.6, n=11
JUL collection 80.4(8.4),79.9, n=38 9.8(11.6),5.3, n=38
AUG collection 79.5(14.1),79.6, n=100 16.0(64.0),5.1, n=100
SEP collection 78.7(12.1),76.8, n=60 20.7(66.2),7.7, n=60
OCT collection 75.5(9.4),75.5, n=52 14.3(11.3),11.1, n=52
NOV collection 74.6(7.6),73.4, n=15 13.3(15.5),6.5, n=16
Table A.1 – Continued on next page
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Table A.1 Continued from previous page
Categorical explanatory variable GLU OST (mg/dl) INS OST (µIU/ml)
Non-obese, no prior laminitis 94.8(16.8),94.2, n=294 22.8(22.8),16.2, n=296
Non-obese, prior laminitis 102.0(24.7),98.2, n=69 80.2(137.5),37.3, n=68
Obese, no prior laminitis 101.2(15.8),102.2, n=98 42.7(34.7),29.7, n=98
Obese, prior laminitis 104.5(18.2),106.5, n=52 80.4(100.5),56.4, n=52
Morgan 94.9(17.2),95.4, n=268 34.3(59.9),20.3, n=268
Arabian 103.5(17.1),104.5, n=53 40.3(32.5),34.6, n=53
Other high risk breeds 97.4(16.5),91.2, n=28 49.6(50.5),29.7, n=28
Other low risk breeds 99.5(15.8),104.7, n=11 52.4(86.7),14.9, n=12
Pony 102.8(23.0),101.0, n=87 51.5(105.2),26.4, n=87
Quarter Horse 97.0(17.1),97.7, n=36 17.7(13.2),17.1, n=36
Tennessee Walking Horse 102.7(14.1),99.8, n=30 70.6(70.4),45.7, n=30
Gelding 101.0(19.2),98.3, n=159 52.5(108.4),21.1, n=159
Mare 96.8(18.3),96.8, n=324 34.4(35.5),23.2, n=324
Stallion 95.2(12.2),96.5, n=30 35.2(33.1),24.7, n=31
Owner submitted sample 97.3(17.3),97.2, n=330 29.1(28.3),19.7, n=330
Reseacher collected sample 99.1(20.1),97.4, n=183 59.6(103.6),27.1, n=184
No L-thyroxine supplementation 97.9(18.4),97.4, n=497 39.1(67.8),21.8, n=498
Yes L-thyroxine supplementation 101.3(18.4),98.7, n=16 69.5(48.3),66.1, n=16
DEC collection 89.2(12.5),89.4, n=58 28.5(24.0),22.3, n=57
JAN collection 90.2(15.4),93.0, n=6 46.1(48.9),31.4, n=6
FEB collection 97.5(16.4),97.2, n=32 39.0(29.2),34.6, n=32
MAR collection 99.8(15.8),99.8, n=78 28.4(32.5),19.6, n=78
APR collection 105.9(17.2),105.2, n=54 35.0(35.8),21.8, n=55
MAY collection 91.2(16.8),90.5, n=64 29.2(30.4),16.7, n=64
JUN collection 103.4(11.7),108.5, n=7 23.8(14.7),25.6, n=7
JUL collection 103.9(16.1),105.0, n=35 35.7(35.3),19.9, n=35
AUG collection 93.5(20.2),91.7, n=84 37.9(77.0),17.2, n=84
SEP collection 106.9(23.3),108.5, n=56 77.9(150.3),39.5, n=56
OCT collection 99.3(14.4),100.3, n=27 62.5(63.0),48.9, n=28
NOV collection 100.4(18.8),101.7, n=12 58.9(61.1),37.8, n=12
Table A.1 – Continued on next page
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Table A.1 Continued from previous page
Categorical explanatory variable TG (mg/dl) NEFA (mmol/L)
Non-obese, no prior laminitis 24.6(14.1),21.2, n=337 0.23(0.19),0.18, n=338
Non-obese, prior laminitis 43.2(32.3),37.0, n=91 0.21(0.16),0.18, n=94
Obese, no prior laminitis 31.8(17.2),27.6, n=110 0.25(0.15),0.22, n=111
Obese, prior laminitis 53.1(53.7),38.1, n=64 0.27(0.20),0.23, n=64
Morgan 27.0(16.5),23.1, n=286 0.23(0.19),0.19, n=288
Arabian 30.3(15.8),25.7, n=61 0.21(0.15),0.20, n=62
Other high risk breeds 36.0(26.6),29.8, n=44 0.16(0.14),0.12, n=45
Other low risk breeds 23.5(11.4),21.6, n=16 0.33(0.17),0.28, n=16
Pony 47.3(51.0),31.3, n=95 0.31(0.19),0.30, n=96
Quarter Horse 27.5(16.6),22.7, n=57 0.23(0.19),0.18, n=56
Tennessee Walking Horse 35.1(18.8),33.1, n=43 0.18(0.12),0.16, n=44
Gelding 28.9(16.3),25.4, n=208 0.20(0.16),0.16, n=209
Mare 34.3(31.9),26.5, n=363 0.25(0.19),0.22, n=366
Stallion 20.4(8.4),19.2, n=31 0.24(0.20),0.22, n=32
Owner submitted sample 31.8(31.8),23.6, n=332 0.27(0.19),0.23, n=333
Reseacher collected sample 31.7(19.1),28.3, n=270 0.19(0.16),0.15, n=274
No L-thyroxine supplementation 31.0(26.3),25.0, n=578 0.24(0.18),0.20, n=583
Yes L-thyroxine supplementation 48.6(34.1),43.5, n=24 0.18(0.11),0.16, n=24
DEC collection 29.3(19.4),26.2, n=58 0.27(0.16),0.26, n=58
JAN collection 29.3(11.9),31.3, n=8 0.27(0.22),0.16, n=8
FEB collection 36.4(18.7),32.2, n=37 0.19(0.11),0.21, n=39
MAR collection 27.9(22.0),20.2, n=86 0.23(0.18),0.20, n=86
APR collection 27.6(16.5),23.1, n=68 0.28(0.19),0.23, n=69
MAY collection 28.0(15.5),24.9, n=73 0.20(0.17),0.16, n=73
JUN collection 17.9(7.4),15.0, n=11 0.08(0.08),0.06, n=11
JUL collection 33.0(17.4),25.6, n=38 0.24(0.16),0.26, n=38
AUG collection 31.2(23.7),25.0, n=97 0.22(0.22),0.16, n=97
SEP collection 52.9(59.9),33.3, n=60 0.28(0.20),0.30, n=60
OCT collection 29.3(12.0),27.6, n=50 0.21(0.16),0.15, n=52
NOV collection 23.9(11.2),26.6, n=16 0.25(0.14),0.28, n=16
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Table A.1 Continued from previous page
Categorical explanatory variable Leptin (ng/ml) Adiponectin (ng/ml)
Non-obese, no prior laminitis 5.3(3.5),4.4, n=335 5017(2760),4504, n=340
Non-obese, prior laminitis 5.1(2.9),4.5, n=93 3106(3455),1613, n=95
Obese, no prior laminitis 8.3(4.5),7.8, n=109 4335(3263),3502, n=110
Obese, prior laminitis 7.5(4.1),6.9, n=63 2667(2684),1612, n=64
Morgan 6.8(4.2),5.6, n=282 4938(3018),4537, n=287
Arabian 5.5(2.8),4.9, n=63 2795(2166),2463, n=63
Other high risk breeds 7.4(4.4),7.3, n=43 3357(2514),2743, n=45
Other low risk breeds 4.2(3.4),2.9, n=16 3602(2994),3266, n=16
Pony 5.4(3.7),4.4, n=96 4944(3645),3899, n=96
Quarter Horse 3.5(2.4),2.7, n=57 4466(3042),4018, n=57
Tennessee Walking Horse 5.9(3.1),5.7, n=43 2602(2302),1750, n=45
Gelding 5.4(3.3),4.7, n=209 4064(3076),3330, n=210
Mare 6.5(4.2),5.6, n=360 4345(2984),3742, n=367
Stallion 4.4(2.8),3.5, n=31 6254(3720),5174, n=32
Owner submitted sample 6.1(4.1),5.1, n=329 5142(3050),4573, n=333
Reseacher collected sample 5.9(3.7),5.2, n=271 3392(2860),2895, n=276
No L-thyroxine supplementation 6.0(3.9),5.1, n=578 4424(3074),3772, n=585
Yes L-thyroxine supplementation 6.8(3.8),5.9, n=22 2523(2930),1333, n=24
DEC collection 6.3(4.5),5.1, n=58 5351(3191),4765, n=58
JAN collection 6.7(4.6),5.7, n=8 2171(1753),1778, n=8
FEB collection 7.3(5.1),6.1, n=38 3702(2832),3037, n=39
MAR collection 5.5(4.0),4.1, n=86 5895(3409),5638, n=86
APR collection 6.7(3.6),5.5, n=69 4671(3149),4295, n=69
MAY collection 7.5(4.0),6.8, n=73 3257(1969),3294, n=73
JUN collection 3.1(1.4),2.7, n=11 3700(3127),3333, n=11
JUL collection 5.0(2.5),4.8, n=38 3693(2414),3353, n=38
AUG collection 3.9(2.7),3.1, n=91 4449(3100),4098, n=99
SEP collection 4.9(3.1),4.0, n=60 4111(3715),3429, n=60
OCT collection 8.7(3.3),9.1, n=52 3357(2437),3050, n=52
NOV collection 6.8(2.8),7.1, n=16 4157(2441),3125, n=16
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Table A.1 Continued from previous page
Categorical explanatory variable ACTH (pg/ml)
Non-obese, no prior laminitis 31.0(25.0),25.1, n=339
Non-obese, prior laminitis 46.0(48.1),30.1, n=94
Obese, no prior laminitis 33.6(29.5),26.4, n=111
Obese, prior laminitis 45.8(39.2),33.3, n=64
Morgan 30.3(27.7),23.1, n=286
Arabian 45.0(44.4),32.2, n=63
Other high risk breeds 36.7(27.5),28.1, n=45
Other low risk breeds 51.5(51.6),36.8, n=16
Pony 41.8(31.7),32.5, n=96
Quarter Horse 35.9(33.1),27.0, n=57
Tennessee Walking Horse 32.6(34.0),24.5, n=45
Gelding 35.3(31.0),27.1, n=210
Mare 35.5(34.6),25.8, n=366
Stallion 34.3(12.7),33.2, n=32
Owner submitted sample 30.4(21.9),24.1, n=332
Researcher collected sample 41.3(41.2),29.4, n=276
No L-thyroxine supplementation 35.1(32.8),26.6, n=584
Yes L-thyroxine supplementation 40.9(25.8),29.0, n=24
DEC collection 26.6(12.6),22.5, n=57
JAN collection 31.6(13.3),28.0, n=8
FEB collection 26.8(12.8),22.9, n=39
MAR collection 25.3(14.2),21.6, n=86
APR collection 23.3(19.8),20.3, n=69
MAY collection 29.7(28.5),24.1, n=73
JUN collection 18.9(5.8),17.5, n=11
JUL collection 44.3(46.4),28.8, n=38
AUG collection 41.5(28.0),34.4, n=100
SEP collection 61.1(56.7),41.6, n=60
OCT collection 45.6(38.0),36.1, n=51
NOV collection 43.5(37.4),28.5, n=16
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Table A.2: Exercise demographics
N=
Type of exericse
Dressage 43
Driving 13
Eventing/Hunter Jumper 10
Pleasure/trail 183
Longline 1
Other 7
Hours exercise/week
0 353
0.01-3 164
3.01-5 61
> 5 32
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Table A.3: Individual level covariance estimates(SE) for metabolic phenotypes from the null multivariate, multilevel
model.
NH GH GLU INS GLU OST INS OST TG NEFA ACTH LEP APN
NH 0.57
(0.04)
GH 0.23 0.60
(0.03) (0.04)
GLU 0.00 0.00 0.69
(0.03) (0.03) (0.05)
INS 0.19 0.14 0.26 0.69
(0.03) (0.03) (0.03) (0.05)
GLU OST 0.02 0.02 0.33 0.16 0.61
(0.03) (0.03) (0.04) (0.03) (0.04)
INS OST 0.20 0.14 0.20 0.47 0.28 0.71
(0.03) (0.03) (0.04) (0.04) (0.04) (0.05)
TG 0.14 0.07 0.08 0.23 0.08 0.27 0.71
(0.03) (0.03) (0.03) (0.03) (0.03) (0.04) (0.05)
NEFA -0.01 -0.01 -0.09 -0.06 0.06 -0.04 -0.02 0.56
(0.03) (0.03) (0.03) (0.03) (0.03) (0.03) (0.03) (0.04)
ACTH 0.04 -0.01 0.03 0.09 0.03 0.05 0.04 0.05 0.56
(0.03) (0.03) (0.03) (0.03) (0.03) (0.03) (0.03) (0.03) (0.04)
LEP 0.18 0.28 0.11 0.24 0.13 0.29 0.16 -0.11 -0.01 0.71
(0.03) (0.03) (0.03) (0.03) (0.03) (0.04) (0.03) (0.03) (0.03) (0.05)
APN -0.14 -0.06 -0.07 -0.26 -0.05 -0.27 -0.31 0.08 0.00 -0.09 0.78
(0.03) (0.03) (0.03) (0.04) (0.03) (0.04) (0.04) (0.03) (0.03) (0.03) (0.05)
All phenotypes were scaled to zero mean and variance equal to one standard deviation. INS, INS OST, TG, and ACTH were log
transformed. NEFA, LEP, and APN were square root transformed.
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Table A.4: Farm level covariance estimates(SE) for metabolic phenotypes from the null multivariate, multilevel model.
NH GH GLU INS GLU OST INS OST TG NEFA ACTH LEP APN
NH 0.50
(0.08)
GH 0.24 0.45
(0.06) (0.08)
GLU -0.01 -0.04 0.37
(0.06) (0.05) (0.07)
INS 0.00 0.00 0.12 0.39
(0.06) (0.05) (0.06) (0.08)
GLU OST 0.05 0.06 0.32 0.18 0.45
(0.06) (0.06) (0.07) (0.06) (0.09)
INS OST -0.01 0.03 0.14 0.32 0.28 0.35
(0.06) (0.06) (0.06) (0.07) (0.07) (0.07)
TG 0.02 0.01 0.04 0.13 0.08 0.08 0.22
(0.05) (0.05) (0.04) (0.05) (0.05) (0.05) (0.05)
NEFA 0.04 0.12 0.01 -0.03 0.17 0.09 0.03 0.45
(0.06) (0.06) (0.05) (0.05) (0.06) (0.05) (0.04) (0.08)
ACTH -0.09 -0.06 0.12 0.16 0.17 0.23 0.11 0.13 0.54
(0.06) (0.06) (0.06) (0.06) (0.06) (0.06) (0.05) (0.06) (0.09)
LEP 0.05 0.03 -0.08 0.17 0.02 0.15 0.04 0.04 0.03 0.33
(0.05) (0.05) (0.05) (0.05) (0.05) (0.05) (0.04) (0.05) (0.06) (0.07)
APN 0.13 0.09 -0.16 -0.16 -0.14 -0.14 -0.11 -0.01 -0.16 -0.03 0.23
(0.05) (0.05) (0.05) (0.05) (0.05) (0.05) (0.04) (0.05) (0.05) (0.04) (0.05)
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Table A.5: Fixed effect estimates for neck circumference to height ratio (NH) from the
full multivariate, multilevel model.
Parameter scaled estimate(SE) unscaled estimate(SE) p-value
Intercept 0.235(0.296) 0.670(0.016)
+1 SD age(yrs) 0.013(0.033) 0.001(0.002) 7.0e-01
Sex:gelding Reference Reference Reference
Sex:mare -0.197(0.073) -0.011(0.004) 7.1e-03
Sex:stallion 0.518(0.149) 0.028(0.008) 5.3e-04
Breed:Morgan Reference Reference Reference
Breed:Arab -0.662(0.186) -0.035(0.010) 3.8e-04
Breed:Pony -0.002(0.189) 0.000(0.010) 9.9e-01
Breed:TW -0.214(0.213) -0.011(0.011) 3.1e-01
Breed:QH -0.175(0.182) -0.009(0.010) 3.4e-01
Breed:HR -0.484(0.205) -0.026(0.011) 1.8e-02
Breed:LR -0.855(0.256) -0.046(0.014) 8.4e-04
Group:obese−laminitis− Reference Reference Reference
Group:obese−laminitis+ 0.331(0.092) 0.018(0.005) 3.2e-04
Group:obese+laminitis− 0.652(0.086) 0.035(0.005) 3.2e-14
Group:obese+laminitis+ 0.957(0.121) 0.051(0.006) 2.6e-15
+1 SD g Mcal/kg bwt per day 0.192(0.340) 0.010(0.018) 5.7e-01
+1 SD g CP/kg bwt per day -0.095(0.161) -0.005(0.009) 5.5e-01
+1 SD g NDF/kg bwt per day -0.115(0.192) -0.006(0.010) 5.5e-01
+1 SD g Starch/kg bwt per day -0.065(0.081) -0.003(0.004) 4.2e-01
+1 SD g WSC/kg bwt per day -0.089(0.109) -0.005(0.006) 4.1e-01
+1 SD hours grazing per day 0.121(0.063) 0.006(0.003) 5.3e-02
+1 SD hours exercise per day 0.067(0.041) 0.004(0.002) 1.1e-01
+1 SD hours stalled per day -0.046(0.043) -0.002(0.002) 2.8e-01
Month:DEC Reference Reference Reference
Month:JAN -0.197(0.529) -0.011(0.028) 7.1e-01
Month:FEB 0.353(0.383) 0.019(0.020) 3.6e-01
Month:MAR -0.492(0.356) -0.026(0.019) 1.7e-01
Month:APR -0.373(0.379) -0.020(0.020) 3.2e-01
Month:MAY 0.055(0.358) 0.003(0.019) 8.8e-01
Month:JUN 0.490(0.505) 0.026(0.027) 3.3e-01
Month:JUL -0.315(0.425) -0.017(0.023) 4.6e-01
Month:AUG -0.227(0.339) -0.012(0.018) 5.0e-01
Month:SEP -0.081(0.358) -0.004(0.019) 8.2e-01
Month:OCT -0.241(0.351) -0.013(0.019) 4.9e-01
Month:NOV -0.042(0.456) -0.002(0.024) 9.3e-01
+1 SD latitude 0.019(0.079) 0.001(0.004) 8.1e-01
Oral thyroxine (no) Reference Reference Reference
Oral thyroxine (yes) 0.025(0.178) 0.001(0.009) 8.9e-01
Researcher collected sample Reference Reference Reference
Owner submitted sample -0.368(0.204) -0.020(0.011) 7.1e-02
Metabolic traits were mean centered and variance scaled to 1 standard deviation. Scaled fixed ef-
fect estimates represent the number of standard deviations change in the metabolic trait relative
to the reference group.
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Table A.6: Fixed effect estimates for girth to height ratio (GH) from the full multivari-
ate, multilevel model.
Parameter scaled estimate(SE) unscaled estimate(SE) p-value
Intercept 0.026(0.250) 1.223(0.018)
+1 SD age(yrs) 0.065(0.033) 0.005(0.002) 5.2e-02
Sex:gelding Reference Reference Reference
Sex:mare 0.134(0.073) 0.010(0.005) 6.7e-02
Sex:stallion -0.438(0.153) -0.031(0.011) 4.1e-03
Breed:Morgan Reference Reference Reference
Breed:Arab -0.213(0.175) -0.015(0.012) 2.2e-01
Breed:Pony -0.055(0.172) -0.004(0.012) 7.5e-01
Breed:TW -0.246(0.196) -0.017(0.014) 2.1e-01
Breed:QH 0.301(0.168) 0.021(0.012) 7.3e-02
Breed:HR -0.268(0.190) -0.019(0.013) 1.6e-01
Breed:LR -0.468(0.245) -0.033(0.017) 5.6e-02
Group:obese−laminitis− Reference Reference Reference
Group:obese−laminitis+ -0.026(0.093) -0.002(0.007) 7.8e-01
Group:obese+laminitis− 0.666(0.087) 0.047(0.006) 1.5e-14
Group:obese+laminitis+ 0.651(0.120) 0.046(0.009) 6.2e-08
+1 SD g Mcal/kg bwt per day -0.530(0.317) -0.038(0.022) 9.5e-02
+1 SD g CP/kg bwt per day 0.199(0.147) 0.014(0.010) 1.8e-01
+1 SD g NDF/kg bwt per day 0.298(0.179) 0.021(0.013) 9.5e-02
+1 SD g Starch/kg bwt per day 0.097(0.077) 0.007(0.005) 2.1e-01
+1 SD g WSC/kg bwt per day -0.120(0.101) -0.008(0.007) 2.4e-01
+1 SD hours grazing per day 0.095(0.059) 0.007(0.004) 1.1e-01
+1 SD hours exercise per day -0.013(0.040) -0.001(0.003) 7.5e-01
+1 SD hours stalled per day -0.045(0.041) -0.003(0.003) 2.7e-01
Month:DEC Reference Reference Reference
Month:JAN 0.330(0.467) 0.023(0.033) 4.8e-01
Month:FEB 0.082(0.322) 0.006(0.023) 8.0e-01
Month:MAR -0.244(0.301) -0.017(0.021) 4.2e-01
Month:APR -0.306(0.321) -0.022(0.023) 3.4e-01
Month:MAY -0.024(0.305) -0.002(0.022) 9.4e-01
Month:JUN 0.220(0.437) 0.016(0.031) 6.1e-01
Month:JUL -1.447(0.358) -0.103(0.025) 5.3e-05
Month:AUG -0.238(0.288) -0.017(0.020) 4.1e-01
Month:SEP 0.082(0.305) 0.006(0.022) 7.9e-01
Month:OCT -0.170(0.300) -0.012(0.021) 5.7e-01
Month:NOV 0.309(0.391) 0.022(0.028) 4.3e-01
+1 SD latitude 0.100(0.069) 0.007(0.005) 1.5e-01
Oral thyroxine (no) Reference Reference Reference
Oral thyroxine (yes) -0.143(0.176) -0.010(0.012) 4.2e-01
Researcher collected sample Reference Reference Reference
Owner submitted sample -0.183(0.175) -0.013(0.012) 2.9e-01
Metabolic traits were mean centered and variance scaled to 1 standard deviation. Scaled fixed ef-
fect estimates represent the number of standard deviations change in the metabolic trait relative
to the reference group.
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Table A.7: Fixed effect estimates for fasting glucose (mg/dl) from the full multivariate,
multilevel model.
Parameter scaled estimate(SE) unscaled estimate(SE) p-value
Intercept -0.711(0.258) 69.581(2.685)
+1 SD age(yrs) -0.036(0.040) -0.380(0.413) 3.6e-01
Sex:gelding Reference Reference Reference
Sex:mare -0.161(0.087) -1.680(0.905) 6.3e-02
Sex:stallion 0.365(0.184) 3.806(1.914) 4.7e-02
Breed:Morgan Reference Reference Reference
Breed:Arab 0.387(0.197) 4.027(2.052) 5.0e-02
Breed:Pony 0.117(0.189) 1.215(1.973) 5.4e-01
Breed:TW 0.148(0.217) 1.546(2.264) 4.9e-01
Breed:QH -0.158(0.189) -1.642(1.973) 4.1e-01
Breed:HR 0.240(0.213) 2.499(2.217) 2.6e-01
Breed:LR -0.092(0.282) -0.955(2.940) 7.5e-01
Group:obese−laminitis− Reference Reference Reference
Group:obese−laminitis+ 0.153(0.111) 1.590(1.157) 1.7e-01
Group:obese+laminitis− 0.046(0.103) 0.478(1.076) 6.6e-01
Group:obese+laminitis+ 0.087(0.141) 0.905(1.472) 5.4e-01
+1 SD g Mcal/kg bwt per day -0.086(0.356) -0.899(3.713) 8.1e-01
+1 SD g CP/kg bwt per day 0.003(0.162) 0.035(1.691) 9.8e-01
+1 SD g NDF/kg bwt per day -0.088(0.202) -0.913(2.099) 6.6e-01
+1 SD g Starch/kg bwt per day -0.113(0.088) -1.176(0.918) 2.0e-01
+1 SD g WSC/kg bwt per day 0.161(0.113) 1.682(1.180) 1.5e-01
+1 SD hours grazing per day 0.072(0.067) 0.750(0.702) 2.9e-01
+1 SD hours exercise per day -0.043(0.046) -0.448(0.483) 3.5e-01
+1 SD hours stalled per day -0.021(0.048) -0.220(0.495) 6.6e-01
Month:DEC Reference Reference Reference
Month:JAN -0.365(0.484) -3.803(5.045) 4.5e-01
Month:FEB 0.452(0.334) 4.710(3.475) 1.8e-01
Month:MAR 0.493(0.311) 5.140(3.239) 1.1e-01
Month:APR 0.606(0.332) 6.317(3.456) 6.8e-02
Month:MAY 0.700(0.315) 7.295(3.279) 2.6e-02
Month:JUN 0.475(0.461) 4.944(4.800) 3.0e-01
Month:JUL 0.405(0.375) 4.218(3.905) 2.8e-01
Month:AUG 1.144(0.298) 11.918(3.105) 1.2e-04
Month:SEP 0.740(0.318) 7.710(3.308) 2.0e-02
Month:OCT 0.331(0.314) 3.444(3.267) 2.9e-01
Month:NOV 0.033(0.410) 0.340(4.274) 9.4e-01
+1 SD latitude -0.033(0.074) -0.348(0.771) 6.5e-01
Oral thyroxine (no) Reference Reference Reference
Oral thyroxine (yes) 0.244(0.206) 2.542(2.149) 2.4e-01
Researcher collected sample Reference Reference Reference
Owner submitted sample 0.170(0.184) 1.768(1.915) 3.6e-01
Metabolic traits were mean centered and variance scaled to 1 standard deviation. Scaled fixed ef-
fect estimates represent the number of standard deviations change in the metabolic trait relative
to the reference group.
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Table A.8: Fixed effect estimates for fasting log insulin (µIU/ml) from the full multi-
variate, multilevel model.
Parameter scaled estimate(SE) unscaled estimate(SE) p-value
Intercept -0.660(0.246) 0.568(0.101)
+1 SD age(yrs) 0.121(0.036) 0.050(0.015) 7.4e-04
Sex:gelding Reference Reference Reference
Sex:mare 0.042(0.078) 0.017(0.032) 5.9e-01
Sex:stallion 0.285(0.164) 0.117(0.067) 8.2e-02
Breed:Morgan Reference Reference Reference
Breed:Arab -0.432(0.183) -0.178(0.075) 1.8e-02
Breed:Pony 0.340(0.178) 0.140(0.073) 5.6e-02
Breed:TW 0.066(0.202) 0.027(0.083) 7.4e-01
Breed:QH -0.681(0.175) -0.280(0.072) 1.0e-04
Breed:HR 0.071(0.197) 0.029(0.081) 7.2e-01
Breed:LR -0.247(0.259) -0.102(0.106) 3.4e-01
Group:obese−laminitis− Reference Reference Reference
Group:obese−laminitis+ 0.590(0.100) 0.242(0.041) 3.5e-09
Group:obese+laminitis− 0.454(0.093) 0.187(0.038) 1.0e-06
Group:obese+laminitis+ 0.961(0.128) 0.395(0.053) 5.9e-14
+1 SD g Mcal/kg bwt per day -0.007(0.332) -0.003(0.136) 9.8e-01
+1 SD g CP/kg bwt per day -0.048(0.152) -0.020(0.063) 7.5e-01
+1 SD g NDF/kg bwt per day -0.223(0.187) -0.091(0.077) 2.3e-01
+1 SD g Starch/kg bwt per day 0.026(0.081) 0.011(0.033) 7.5e-01
+1 SD g WSC/kg bwt per day 0.180(0.106) 0.074(0.043) 8.8e-02
+1 SD hours grazing per day 0.056(0.062) 0.023(0.026) 3.7e-01
+1 SD hours exercise per day -0.018(0.042) -0.007(0.017) 6.7e-01
+1 SD hours stalled per day -0.030(0.044) -0.012(0.018) 4.9e-01
Month:DEC Reference Reference Reference
Month:JAN 0.128(0.455) 0.052(0.187) 7.8e-01
Month:FEB 0.497(0.317) 0.204(0.130) 1.2e-01
Month:MAR 0.197(0.297) 0.081(0.122) 5.1e-01
Month:APR -0.161(0.316) -0.066(0.130) 6.1e-01
Month:MAY 0.202(0.299) 0.083(0.123) 5.0e-01
Month:JUN -0.302(0.434) -0.124(0.178) 4.9e-01
Month:JUL -0.094(0.355) -0.038(0.146) 7.9e-01
Month:AUG 0.104(0.284) 0.043(0.117) 7.1e-01
Month:SEP -0.050(0.302) -0.021(0.124) 8.7e-01
Month:OCT 0.173(0.297) 0.071(0.122) 5.6e-01
Month:NOV -0.182(0.387) -0.075(0.159) 6.4e-01
+1 SD latitude 0.066(0.069) 0.027(0.029) 3.4e-01
Oral thyroxine (no) Reference Reference Reference
Oral thyroxine (yes) 0.107(0.187) 0.044(0.077) 5.7e-01
Researcher collected sample Reference Reference Reference
Owner submitted sample 0.667(0.174) 0.274(0.071) 1.2e-04
Metabolic traits were mean centered and variance scaled to 1 standard deviation. Scaled fixed ef-
fect estimates represent the number of standard deviations change in the metabolic trait relative
to the reference group.
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Table A.9: Fixed effect estimates for 75 minute post oral sugar test glucose (mg/dl)
from the full multivariate, multilevel model.
Parameter scaled estimate(SE) unscaled estimate(SE) p-value
Intercept -0.662(0.281) 85.827(5.159)
+1 SD age(yrs) -0.020(0.040) -0.374(0.729) 6.1e-01
Sex:gelding Reference Reference Reference
Sex:mare -0.103(0.089) -1.884(1.636) 2.5e-01
Sex:stallion 0.370(0.181) 6.803(3.317) 4.0e-02
Breed:Morgan Reference Reference Reference
Breed:Arab 0.064(0.211) 1.184(3.884) 7.6e-01
Breed:Pony 0.379(0.206) 6.958(3.779) 6.6e-02
Breed:TW 0.158(0.250) 2.894(4.586) 5.3e-01
Breed:QH -0.086(0.219) -1.584(4.017) 6.9e-01
Breed:HR -0.012(0.250) -0.212(4.588) 9.6e-01
Breed:LR 0.089(0.309) 1.636(5.683) 7.7e-01
Group:obese−laminitis− Reference Reference Reference
Group:obese−laminitis+ 0.096(0.116) 1.763(2.138) 4.1e-01
Group:obese+laminitis− 0.164(0.103) 3.006(1.883) 1.1e-01
Group:obese+laminitis+ 0.184(0.148) 3.386(2.720) 2.1e-01
+1 SD g Mcal/kg bwt per day 0.262(0.381) 4.817(6.992) 4.9e-01
+1 SD g CP/kg bwt per day -0.181(0.173) -3.329(3.187) 3.0e-01
+1 SD g NDF/kg bwt per day -0.259(0.222) -4.752(4.078) 2.4e-01
+1 SD g Starch/kg bwt per day -0.190(0.091) -3.489(1.674) 3.7e-02
+1 SD g WSC/kg bwt per day 0.120(0.123) 2.208(2.252) 3.3e-01
+1 SD hours grazing per day 0.008(0.072) 0.148(1.331) 9.1e-01
+1 SD hours exercise per day 0.018(0.053) 0.332(0.979) 7.3e-01
+1 SD hours stalled per day -0.125(0.049) -2.304(0.904) 1.1e-02
Month:DEC Reference Reference Reference
Month:JAN -0.217(0.545) -3.988(10.016) 6.9e-01
Month:FEB 0.559(0.369) 10.266(6.775) 1.3e-01
Month:MAR 0.327(0.341) 5.997(6.256) 3.4e-01
Month:APR 0.540(0.379) 9.914(6.960) 1.5e-01
Month:MAY 0.573(0.348) 10.524(6.398) 1.0e-01
Month:JUN 0.639(0.539) 11.738(9.897) 2.4e-01
Month:JUL 0.264(0.411) 4.853(7.541) 5.2e-01
Month:AUG 0.600(0.329) 11.028(6.042) 6.8e-02
Month:SEP 0.770(0.347) 14.133(6.366) 2.6e-02
Month:OCT 0.516(0.358) 9.481(6.573) 1.5e-01
Month:NOV 0.279(0.464) 5.122(8.526) 5.5e-01
+1 SD latitude -0.017(0.086) -0.305(1.579) 8.5e-01
Oral thyroxine (no) Reference Reference Reference
Oral thyroxine (yes) 0.207(0.229) 3.798(4.205) 3.7e-01
Researcher collected sample Reference Reference Reference
Owner submitted sample 0.092(0.206) 1.697(3.777) 6.5e-01
Metabolic traits were mean centered and variance scaled to 1 standard deviation. Scaled fixed ef-
fect estimates represent the number of standard deviations change in the metabolic trait relative
to the reference group.
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Table A.10: Fixed effect estimates for 75 minute post oral sugar test log insulin (µIU/ml)
from the full multivariate, multilevel model.
Parameter scaled estimate(SE) unscaled estimate(SE) p-value
Intercept -0.399(0.253) 1.173(0.115)
+1 SD age(yrs) 0.095(0.037) 0.043(0.017) 1.1e-02
Sex:gelding Reference Reference Reference
Sex:mare 0.129(0.083) 0.059(0.038) 1.2e-01
Sex:stallion 0.667(0.169) 0.303(0.077) 7.5e-05
Breed:Morgan Reference Reference Reference
Breed:Arab -0.231(0.195) -0.105(0.089) 2.4e-01
Breed:Pony 0.107(0.189) 0.049(0.086) 5.7e-01
Breed:TW 0.299(0.229) 0.136(0.104) 1.9e-01
Breed:QH -0.769(0.201) -0.349(0.091) 1.3e-04
Breed:HR 0.104(0.229) 0.047(0.104) 6.5e-01
Breed:LR -0.237(0.285) -0.108(0.129) 4.1e-01
Group:obese−laminitis− Reference Reference Reference
Group:obese−laminitis+ 0.546(0.109) 0.248(0.049) 5.4e-07
Group:obese+laminitis− 0.483(0.096) 0.219(0.044) 5.0e-07
Group:obese+laminitis+ 0.741(0.138) 0.337(0.062) 7.2e-08
+1 SD g Mcal/kg bwt per day -0.237(0.351) -0.108(0.159) 5.0e-01
+1 SD g CP/kg bwt per day 0.087(0.159) 0.040(0.072) 5.8e-01
+1 SD g NDF/kg bwt per day -0.079(0.204) -0.036(0.093) 7.0e-01
+1 SD g Starch/kg bwt per day -0.062(0.084) -0.028(0.038) 4.6e-01
+1 SD g WSC/kg bwt per day 0.134(0.113) 0.061(0.051) 2.4e-01
+1 SD hours grazing per day -0.007(0.067) -0.003(0.030) 9.2e-01
+1 SD hours exercise per day 0.011(0.049) 0.005(0.022) 8.2e-01
+1 SD hours stalled per day -0.021(0.046) -0.010(0.021) 6.5e-01
Month:DEC Reference Reference Reference
Month:JAN -0.420(0.495) -0.191(0.225) 4.0e-01
Month:FEB 0.256(0.333) 0.116(0.151) 4.4e-01
Month:MAR -0.282(0.307) -0.128(0.139) 3.6e-01
Month:APR -0.145(0.342) -0.066(0.155) 6.7e-01
Month:MAY -0.096(0.314) -0.044(0.143) 7.6e-01
Month:JUN -0.728(0.489) -0.331(0.222) 1.4e-01
Month:JUL -0.415(0.371) -0.189(0.169) 2.6e-01
Month:AUG -0.249(0.296) -0.113(0.135) 4.0e-01
Month:SEP -0.032(0.313) -0.015(0.142) 9.2e-01
Month:OCT 0.175(0.323) 0.080(0.147) 5.9e-01
Month:NOV -0.172(0.420) -0.078(0.191) 6.8e-01
+1 SD latitude 0.030(0.078) 0.013(0.036) 7.1e-01
Oral thyroxine (no) Reference Reference Reference
Oral thyroxine (yes) 0.122(0.212) 0.056(0.096) 5.6e-01
Researcher collected sample Reference Reference Reference
Owner submitted sample 0.497(0.186) 0.226(0.085) 7.5e-03
Metabolic traits were mean centered and variance scaled to 1 standard deviation. Scaled fixed ef-
fect estimates represent the number of standard deviations change in the metabolic trait relative
to the reference group.
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Table A.11: Fixed effect estimates for fasting log triglycerides (mg/dl) from the full
multivariate, multilevel model.
Parameter scaled estimate(SE) unscaled estimate(SE) p-value
Intercept -0.223(0.209) 1.359(0.054)
+1 SD age(yrs) -0.070(0.037) -0.018(0.009) 5.4e-02
Sex:gelding Reference Reference Reference
Sex:mare 0.188(0.080) 0.048(0.021) 1.9e-02
Sex:stallion 0.164(0.173) 0.042(0.045) 3.4e-01
Breed:Morgan Reference Reference Reference
Breed:Arab -0.129(0.175) -0.033(0.045) 4.6e-01
Breed:Pony 0.104(0.163) 0.027(0.042) 5.2e-01
Breed:TW 0.230(0.194) 0.059(0.050) 2.4e-01
Breed:QH -0.307(0.167) -0.079(0.043) 6.6e-02
Breed:HR 0.254(0.189) 0.066(0.049) 1.8e-01
Breed:LR -0.414(0.253) -0.107(0.065) 1.0e-01
Group:obese−laminitis− Reference Reference Reference
Group:obese−laminitis+ 0.576(0.105) 0.149(0.027) 3.8e-08
Group:obese+laminitis− 0.205(0.096) 0.053(0.025) 3.2e-02
Group:obese+laminitis+ 0.599(0.129) 0.155(0.033) 3.6e-06
+1 SD g Mcal/kg bwt per day -0.427(0.309) -0.110(0.080) 1.7e-01
+1 SD g CP/kg bwt per day 0.119(0.138) 0.031(0.036) 3.9e-01
+1 SD g NDF/kg bwt per day 0.131(0.175) 0.034(0.045) 4.5e-01
+1 SD g Starch/kg bwt per day -0.040(0.078) -0.010(0.020) 6.0e-01
+1 SD g WSC/kg bwt per day 0.065(0.098) 0.017(0.025) 5.0e-01
+1 SD hours grazing per day 0.066(0.060) 0.017(0.016) 2.7e-01
+1 SD hours exercise per day 0.006(0.042) 0.002(0.011) 8.8e-01
+1 SD hours stalled per day -0.018(0.043) -0.005(0.011) 6.7e-01
Month:DEC Reference Reference Reference
Month:JAN -0.332(0.407) -0.086(0.105) 4.1e-01
Month:FEB 0.298(0.276) 0.077(0.071) 2.8e-01
Month:MAR -0.266(0.252) -0.069(0.065) 2.9e-01
Month:APR -0.273(0.269) -0.071(0.070) 3.1e-01
Month:MAY -0.062(0.257) -0.016(0.066) 8.1e-01
Month:JUN -1.301(0.386) -0.336(0.100) 7.5e-04
Month:JUL -0.044(0.309) -0.011(0.080) 8.9e-01
Month:AUG -0.024(0.243) -0.006(0.063) 9.2e-01
Month:SEP -0.047(0.260) -0.012(0.067) 8.6e-01
Month:OCT -0.325(0.260) -0.084(0.067) 2.1e-01
Month:NOV -0.789(0.338) -0.204(0.087) 2.0e-02
+1 SD latitude -0.050(0.063) -0.013(0.016) 4.3e-01
Oral thyroxine (no) Reference Reference Reference
Oral thyroxine (yes) 0.437(0.189) 0.113(0.049) 2.1e-02
Researcher collected sample Reference Reference Reference
Owner submitted sample 0.127(0.153) 0.033(0.040) 4.1e-01
Metabolic traits were mean centered and variance scaled to 1 standard deviation. Scaled fixed ef-
fect estimates represent the number of standard deviations change in the metabolic trait relative
to the reference group.
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Table A.12: Fixed effect estimates for fasting
√
NEFA (mmol/L) from the full multi-
variate, multilevel model.
Parameter scaled estimate(SE) unscaled estimate(SE) p-value
Intercept 0.235(0.268) 0.490(0.051)
+1 SD age(yrs) -0.004(0.036) -0.001(0.007) 9.2e-01
Sex:gelding Reference Reference Reference
Sex:mare 0.071(0.080) 0.013(0.015) 3.8e-01
Sex:stallion 0.159(0.167) 0.030(0.032) 3.4e-01
Breed:Morgan Reference Reference Reference
Breed:Arab 0.051(0.192) 0.010(0.037) 7.9e-01
Breed:Pony 0.201(0.189) 0.038(0.036) 2.9e-01
Breed:TW 0.138(0.215) 0.026(0.041) 5.2e-01
Breed:QH 0.232(0.185) 0.044(0.035) 2.1e-01
Breed:HR 0.142(0.207) 0.027(0.039) 4.9e-01
Breed:LR 0.579(0.267) 0.110(0.051) 3.0e-02
Group:obese−laminitis− Reference Reference Reference
Group:obese−laminitis+ 0.043(0.102) 0.008(0.019) 6.7e-01
Group:obese+laminitis− 0.000(0.095) 0.000(0.018) 1.0e+00
Group:obese+laminitis+ 0.088(0.131) 0.017(0.025) 5.0e-01
+1 SD g Mcal/kg bwt per day 0.009(0.347) 0.002(0.066) 9.8e-01
+1 SD g CP/kg bwt per day -0.141(0.160) -0.027(0.030) 3.8e-01
+1 SD g NDF/kg bwt per day 0.101(0.195) 0.019(0.037) 6.1e-01
+1 SD g Starch/kg bwt per day 0.074(0.085) 0.014(0.016) 3.8e-01
+1 SD g WSC/kg bwt per day -0.012(0.111) -0.002(0.021) 9.1e-01
+1 SD hours grazing per day 0.286(0.066) 0.054(0.012) 1.3e-05
+1 SD hours exercise per day 0.003(0.044) 0.001(0.008) 9.4e-01
+1 SD hours stalled per day -0.122(0.045) -0.023(0.009) 6.7e-03
Month:DEC Reference Reference Reference
Month:JAN -0.090(0.492) -0.017(0.093) 8.5e-01
Month:FEB -0.426(0.345) -0.081(0.066) 2.2e-01
Month:MAR -0.491(0.324) -0.093(0.061) 1.3e-01
Month:APR -0.285(0.345) -0.054(0.065) 4.1e-01
Month:MAY -0.597(0.326) -0.113(0.062) 6.7e-02
Month:JUN -1.372(0.470) -0.260(0.089) 3.5e-03
Month:JUL -0.821(0.386) -0.156(0.073) 3.3e-02
Month:AUG -0.305(0.310) -0.058(0.059) 3.2e-01
Month:SEP -0.594(0.328) -0.113(0.062) 7.0e-02
Month:OCT -0.504(0.323) -0.096(0.061) 1.2e-01
Month:NOV -0.152(0.420) -0.029(0.080) 7.2e-01
+1 SD latitude 0.105(0.074) 0.020(0.014) 1.6e-01
Oral thyroxine (no) Reference Reference Reference
Oral thyroxine (yes) 0.154(0.192) 0.029(0.036) 4.2e-01
Researcher collected sample Reference Reference Reference
Owner submitted sample -0.112(0.188) -0.021(0.036) 5.5e-01
Metabolic traits were mean centered and variance scaled to 1 standard deviation. Scaled fixed ef-
fect estimates represent the number of standard deviations change in the metabolic trait relative
to the reference group.
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Table A.13: Fixed effect estimates for fasting log ACTH (pg/ml) from the full multi-
variate, multilevel model.
Parameter scaled estimate(SE) unscaled estimate(SE) p-value
Intercept -0.691(0.221) 1.303(0.052)
+1 SD age(yrs) 0.302(0.033) 0.071(0.008) 9.6e-20
Sex:gelding Reference Reference Reference
Sex:mare -0.015(0.073) -0.004(0.017) 8.3e-01
Sex:stallion 0.190(0.154) 0.045(0.036) 2.2e-01
Breed:Morgan Reference Reference Reference
Breed:Arab 0.233(0.166) 0.055(0.039) 1.6e-01
Breed:Pony 0.588(0.159) 0.138(0.037) 2.2e-04
Breed:TW -0.184(0.184) -0.043(0.043) 3.2e-01
Breed:QH -0.211(0.160) -0.050(0.038) 1.9e-01
Breed:HR 0.314(0.180) 0.074(0.042) 8.1e-02
Breed:LR 0.075(0.237) 0.018(0.056) 7.5e-01
Group:obese−laminitis− Reference Reference Reference
Group:obese−laminitis+ 0.133(0.094) 0.031(0.022) 1.6e-01
Group:obese+laminitis− 0.088(0.087) 0.021(0.020) 3.1e-01
Group:obese+laminitis+ 0.015(0.119) 0.004(0.028) 9.0e-01
+1 SD g Mcal/kg bwt per day -0.044(0.298) -0.010(0.070) 8.8e-01
+1 SD g CP/kg bwt per day 0.091(0.136) 0.021(0.032) 5.0e-01
+1 SD g NDF/kg bwt per day 0.040(0.169) 0.009(0.040) 8.1e-01
+1 SD g Starch/kg bwt per day 0.024(0.074) 0.006(0.017) 7.4e-01
+1 SD g WSC/kg bwt per day 0.013(0.095) 0.003(0.022) 8.9e-01
+1 SD hours grazing per day -0.005(0.057) -0.001(0.013) 9.4e-01
+1 SD hours exercise per day -0.032(0.039) -0.008(0.009) 4.2e-01
+1 SD hours stalled per day -0.055(0.040) -0.013(0.009) 1.7e-01
Month:DEC Reference Reference Reference
Month:JAN 0.104(0.414) 0.024(0.098) 8.0e-01
Month:FEB -0.064(0.285) -0.015(0.067) 8.2e-01
Month:MAR -0.076(0.266) -0.018(0.063) 7.7e-01
Month:APR -0.168(0.284) -0.039(0.067) 5.5e-01
Month:MAY 0.187(0.269) 0.044(0.063) 4.9e-01
Month:JUN -0.851(0.394) -0.200(0.093) 3.1e-02
Month:JUL 0.829(0.320) 0.195(0.075) 9.6e-03
Month:AUG 0.863(0.255) 0.203(0.060) 7.1e-04
Month:SEP 1.050(0.272) 0.247(0.064) 1.1e-04
Month:OCT 0.793(0.268) 0.187(0.063) 3.1e-03
Month:NOV 0.618(0.350) 0.146(0.082) 7.7e-02
+1 SD latitude 0.141(0.063) 0.033(0.015) 2.6e-02
Oral thyroxine (no) Reference Reference Reference
Oral thyroxine (yes) -0.161(0.173) -0.038(0.041) 3.5e-01
Researcher collected sample Reference Reference Reference
Owner submitted sample 0.437(0.157) 0.103(0.037) 5.4e-03
Metabolic traits were mean centered and variance scaled to 1 standard deviation. Scaled fixed ef-
fect estimates represent the number of standard deviations change in the metabolic trait relative
to the reference group.
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Table A.14: Fixed effect estimates for fasting
√
leptin (ng/ml) from the full multivariate,
multilevel model.
Parameter scaled estimate(SE) unscaled estimate(SE) p-value
Intercept -0.041(0.198) 2.296(0.154)
+1 SD age(yrs) 0.000(0.036) 0.000(0.028) 9.9e-01
Sex:gelding Reference Reference Reference
Sex:mare 0.220(0.079) 0.171(0.061) 5.2e-03
Sex:stallion -0.114(0.170) -0.089(0.132) 5.0e-01
Breed:Morgan Reference Reference Reference
Breed:Arab -0.462(0.167) -0.359(0.130) 5.8e-03
Breed:Pony -0.307(0.154) -0.239(0.120) 4.6e-02
Breed:TW -0.054(0.186) -0.042(0.145) 7.7e-01
Breed:QH -0.932(0.162) -0.726(0.126) 8.2e-09
Breed:HR -0.032(0.183) -0.025(0.143) 8.6e-01
Breed:LR -0.749(0.247) -0.583(0.192) 2.4e-03
Group:obese−laminitis− Reference Reference Reference
Group:obese−laminitis+ -0.075(0.102) -0.058(0.079) 4.7e-01
Group:obese+laminitis− 0.561(0.094) 0.437(0.073) 2.6e-09
Group:obese+laminitis+ 0.497(0.127) 0.387(0.099) 9.4e-05
+1 SD g Mcal/kg bwt per day 0.098(0.297) 0.076(0.232) 7.4e-01
+1 SD g CP/kg bwt per day -0.083(0.133) -0.065(0.103) 5.3e-01
+1 SD g NDF/kg bwt per day -0.103(0.169) -0.080(0.132) 5.4e-01
+1 SD g Starch/kg bwt per day -0.077(0.075) -0.060(0.059) 3.1e-01
+1 SD g WSC/kg bwt per day -0.043(0.094) -0.034(0.073) 6.5e-01
+1 SD hours grazing per day 0.007(0.058) 0.006(0.045) 9.0e-01
+1 SD hours exercise per day -0.027(0.041) -0.021(0.032) 5.1e-01
+1 SD hours stalled per day 0.024(0.041) 0.018(0.032) 5.7e-01
Month:DEC Reference Reference Reference
Month:JAN 0.042(0.390) 0.033(0.303) 9.1e-01
Month:FEB 0.211(0.259) 0.164(0.202) 4.2e-01
Month:MAR -0.138(0.238) -0.108(0.185) 5.6e-01
Month:APR -0.112(0.254) -0.087(0.198) 6.6e-01
Month:MAY 0.409(0.244) 0.318(0.190) 9.4e-02
Month:JUN -1.107(0.369) -0.862(0.288) 2.7e-03
Month:JUL -0.438(0.294) -0.341(0.229) 1.4e-01
Month:AUG -0.642(0.231) -0.500(0.180) 5.5e-03
Month:SEP -0.175(0.247) -0.136(0.192) 4.8e-01
Month:OCT 0.505(0.246) 0.393(0.192) 4.0e-02
Month:NOV 0.144(0.322) 0.112(0.251) 6.5e-01
+1 SD latitude 0.016(0.060) 0.012(0.047) 7.9e-01
Oral thyroxine (no) Reference Reference Reference
Oral thyroxine (yes) 0.129(0.189) 0.101(0.147) 4.9e-01
Researcher collected sample Reference Reference Reference
Owner submitted sample 0.127(0.146) 0.099(0.114) 3.8e-01
Metabolic traits were mean centered and variance scaled to 1 standard deviation. Scaled fixed ef-
fect estimates represent the number of standard deviations change in the metabolic trait relative
to the reference group.
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Table A.15: Fixed effect estimates for fasting
√
adiponectin (ng/ml) from the full mul-
tivariate, multilevel model.
Parameter scaled estimate(SE) unscaled estimate(SE) p-value
Intercept 0.469(0.168) 72.661(3.973)
+1 SD age(yrs) -0.035(0.038) -0.820(0.891) 3.6e-01
Sex:gelding Reference Reference Reference
Sex:mare -0.055(0.082) -1.298(1.943) 5.0e-01
Sex:stallion 0.135(0.181) 3.205(4.301) 4.6e-01
Breed:Morgan Reference Reference Reference
Breed:Arab -0.318(0.159) -7.534(3.778) 4.6e-02
Breed:Pony -0.043(0.135) -1.029(3.189) 7.5e-01
Breed:TW -0.275(0.179) -6.526(4.232) 1.2e-01
Breed:QH 0.246(0.159) 5.832(3.765) 1.2e-01
Breed:HR -0.077(0.178) -1.819(4.227) 6.7e-01
Breed:LR -0.106(0.249) -2.512(5.903) 6.7e-01
Group:obese−laminitis− Reference Reference Reference
Group:obese−laminitis+ -0.621(0.108) -14.717(2.560) 9.0e-09
Group:obese+laminitis− -0.138(0.099) -3.277(2.356) 1.6e-01
Group:obese+laminitis+ -0.657(0.131) -15.582(3.111) 5.5e-07
+1 SD g Mcal/kg bwt per day -0.010(0.273) -0.235(6.460) 9.7e-01
+1 SD g CP/kg bwt per day 0.036(0.118) 0.847(2.790) 7.6e-01
+1 SD g NDF/kg bwt per day 0.018(0.158) 0.422(3.738) 9.1e-01
+1 SD g Starch/kg bwt per day 0.131(0.071) 3.097(1.680) 6.5e-02
+1 SD g WSC/kg bwt per day 0.034(0.086) 0.815(2.029) 6.9e-01
+1 SD hours grazing per day -0.070(0.056) -1.670(1.324) 2.1e-01
+1 SD hours exercise per day -0.074(0.041) -1.749(0.982) 7.5e-02
+1 SD hours stalled per day 0.016(0.040) 0.369(0.960) 7.0e-01
Month:DEC Reference Reference Reference
Month:JAN -0.269(0.366) -6.374(8.668) 4.6e-01
Month:FEB -0.241(0.224) -5.703(5.299) 2.8e-01
Month:MAR 0.295(0.197) 6.993(4.663) 1.3e-01
Month:APR 0.024(0.208) 0.563(4.930) 9.1e-01
Month:MAY -0.396(0.208) -9.376(4.921) 5.7e-02
Month:JUN 0.213(0.341) 5.061(8.080) 5.3e-01
Month:JUL 0.144(0.253) 3.410(6.000) 5.7e-01
Month:AUG -0.196(0.196) -4.657(4.653) 3.2e-01
Month:SEP 0.180(0.212) 4.265(5.020) 4.0e-01
Month:OCT 0.034(0.217) 0.817(5.152) 8.7e-01
Month:NOV 0.208(0.289) 4.920(6.841) 4.7e-01
+1 SD latitude 0.017(0.055) 0.413(1.306) 7.5e-01
Oral thyroxine (no) Reference Reference Reference
Oral thyroxine (yes) -0.243(0.191) -5.770(4.537) 2.0e-01
Researcher collected sample Reference Reference Reference
Owner submitted sample -0.399(0.130) -9.468(3.077) 2.1e-03
Metabolic traits were mean centered and variance scaled to 1 standard deviation. Scaled fixed ef-
fect estimates represent the number of standard deviations change in the metabolic trait relative
to the reference group.
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Table B.1: GCG and DPP4 PCR primers
Primer Sequence (5’ to 3’)
DPP4 cDNA 1F TGCAGACAGTGTGGAAGGTG
DPP4 cDNA 1R CAAAGGCAGGAGCTGTGAAT
DPP4 cDNA 2F GATCACGTGGAATGGGAAAG
DPP4 cDNA 2R CAGCAATGAAGCAGGCTACA
DPP4 cDNA 3F CGTGACATGGGTAACCACAG
DPP4 cDNA 3R GGTATCAGATGATCTTGCCTCC
DPP4 cDNA 4F TGCACAGCAGCAGGAATGAT
DPP4 cDNA 4R AAGTGGCGTGTTCAAGTGTG
DPP4 cDNA 5F CCTTGCAAGCACAGAAAACA
DPP4 cDNA 5R CCACATGAGCCACTTCATACA
DPP4 exon 11F AATCTTGAGCCATGGTGT
DPP4 exon 11R CAGAGTGAATGGCTGGGAAT
GCG promoter/exon 1F GAAGCCAGGCTGAAAAAGG
GCG promoter/exon 1R GGTTTGGGGCACAGTTAAGT
GCG exon 2F AAACATGGTTGCCTGTCTCC
GCG exon 2R GCACAATGGTTAGAATACAGCC
GCG exon 3F CCTTCCAGCTTCATGTGGTC
GCG exon 3R GCTCATCAAATAGTGCCCAT
GCG exon 4F GAATCCTGAACCCAAAGCTG
GCG exon 4R GAAATAAGTCCCATTGGTGGG
GCG exon 5F CGTTTTCTCAATGACCCTCAC
GCG exon 5R GTTCCCAATGTGAGGGAGAG
GCG exon 6F TTGACAAGTCCACAAGACTAAGG
GCG exon 6R GATATGGAAGGACTGGCAGC
GUE F GACACTCAAACGAAGCCAGG
GUE R ACTGGCAGGTCACAAAGCTC
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Figure B.1: Proglucagon upstream enhancer, promoter region, and exon 1 cross species
nucleotide alignment
horse CATAT- AGAGGTGATGAGAAGATTGTTA- - - - - - - - - - - - - - - - - - - - - -
cat CGTAGGGGTGGGGATGAGAAAATTCTGA- - - - - - - - - - - - - - - - - - - - - -
dog CGTAG- AGTGGGGTTGAGAAGATTCTTA- - - - - - - - - - - - - - - - - - - - - -
pig CATAT- AGTGTAAATTAGAAGATATTTTTTCTTTCTTTCTTTTTTTTAAT
sheep CACAT- AGTGTTGATGAGAAGATCCCTA- - - - - - - - - - - - - - - - - - - - - -
cow CACAT- AACGTTGATGAGAAGATCCCTA- - - - - - - - - - - - - - - - - - - - - -
chimp CATGT- TGTGAGGAAGAGAGGATTTTTA- - - - - - - - - - - - - - - - - - - - - -
human CACGT- TGTGAGGAAGAGAGGATTTTTA- - - - - - - - - - - - - - - - - - - - - -
rabbit CATAC- AATGGAGAGGATAGAATTTTTA- - - - - - - - - - - - - - - - - - - - - -
mouse CATAC- AATGTGGATGAGTGGGTTATTG- - - - - - - - - - - - - - - - - - - - - -
rat CATAC- AAAGTAGATGAGTGGGTTATTG- - - - - - - - - - - - - - - - - - - - - -
*
horse snp
C>G
horse - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
dog - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
pig TTCATGGCCGCACTGGCAGTATATGGAAGTTCCTGTGCCAGAGATTGAAT
sheep - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cow - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
chimp - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
human - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rabbit - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
mouse - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
horse - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
dog - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
pig TCGAGCCACAGCTGTGACCTACAGCTGTAGCAATGCCAGATCATTTAACC
sheep - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cow - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
chimp - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
human - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rabbit - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
mouse - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
horse - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
dog - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
pig CACTGCCCTGGCTGGGATCAAACCCACACTTCTGCAGCTACCCAAGTCGC
sheep - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cow - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
chimp - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
human - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rabbit - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
mouse - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Figure B.1 Continued on next page
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horse - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
dog - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
pig TACAGTCAGATTCTTAACCCACTGTGCCTCAGCGGGAACTCCAGGAAAAT
sheep - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cow - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
chimp - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
human - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rabbit - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
mouse - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
horse - - - - - - - - - - - ATACATATGTGTTG- - - - - - - - AT- - TTATTA- - - TCTG
cat - - - - - - - - - - - TTAAGTATGTGTTGAGCAAATGAT- - TTATTA- - - CTTG
dog - - - - - - - - - - - TTAAGTATGTGTTGAGTGAATGAT- - TTATTA- - - TTTG
pig TCTTGATGAGT- - - - - - ATGTTTTGAGTGAGTGAT- - TCATTA- - - TTTG
sheep - - - - - - - - - - - - - - - - - ATGTTTTGAGTGAGTGAT- - TTATTA- - - TTTG
cow - - - - - - - - - - - - - - - - - ATGTTTTGAGTGAGTGAT- - TTATTA- - - TTTG
chimp - - - - - - - - - - - ATACATATGTGTTGAATGAATGATCA- - - TTA- - - TTTA
human - - - - - - - - - - - ATACATATGTGTTGAATGAATGATCA- - - TTA- - - TTTA
rabbit - - - - - - - - - - - ATAAGTATGTGTAGAATTAATGAT- - - - - TTGCTATTTT
mouse - - - - - - - - - - - ATATGTGTGTACTGGGTGAGTGAT- - - - - TTG- - - TTTG
rat - - - - - - - - - - - ATATGTGTGCACTGGGTGAGCGAT- - - - - TTG- - - TTTG
horse GGTAGACAAAAGAATGAATTGATTA- - - TATTCAGATTAAATTCAT- - - -
cat GGTAGATGATAGAATGAACTGATTACTGCATTCAGAT- GAATGCAT- - - -
dog GGTAGGTGATAGAATGAACTGATTATTGCATTCAGAT- AAATTTAT- - - -
pig GATATATGAAAAGATGAACCGATTATTACATTAAGAT- ACATTCAT- - - -
sheep GGTAGACAAAAGAATGAATTGATTATTCTATTAAGAT- AAATTCAT- - - -
cow GGTAGATGAAAGAATGAATTGATTATTCTATTAAGAT- AAATTCAT- - - -
chimp GATAAATGAATGACTGAAGTGATTGTTATATTCAGGT- AAATTCAT- - - -
human GATAAATGAATGACTGAAGTGATTGTTATATTCAGGT- AAATTCAT- - - -
rabbit AATAAATGGATGAATTAATAAAT- - - - - TATTA- - - - - - AACTCAATAAA
mouse CCTAGATGAATGAT- CTATCACT- - - - - TATTCAGG- - - AACTCAGGA- -
rat CCTAGATGAATGGT- CCATCAGT- - - - - TATTCAGG- - - AACTCAGGA- -
horse - - - - - CATAACTAAATAGTGATGAAAATAATAAAAAAATTTTCACATATT
cat - - - - - CATAATGAA- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
dog - - - - - CAAAACTAA- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
pig - - - - - CATAACTAA- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
sheep - - - - - TATAACTAA- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cow - - - - - TATCACTAA- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
chimp - - - - - CATGGCTAG- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
human - - - - - CATGGCTAG- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rabbit TCCATCATATCTAA- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
mouse - - - - - TATAGCCAA- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rat - - - - - - - TGGCCAA- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
————————ERV class I LTR13b————————
horse GAGGTATATGGGGAAGCCATTCTGGTTTAAACCTGATTCGACCTAAACTT
cat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
dog - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
pig - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
sheep - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cow - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
chimp - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
human - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rabbit - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
mouse - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
—————————————–ERV class I LTR13b————————————–
*
horse snp
C>A
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horse ATTTTTCCCAGAGCAGCCTGACTTATAGCCTGTCAATCATGCACTGTGCA
cat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
dog - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
pig - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
sheep - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cow - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
chimp - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
human - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rabbit - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
mouse - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
—————————————–ERV class I LTR13b————————————–
horse TCTGCTTTAAACATTAAACATCATCCCAAAGTAAAGGAGGCGCTCTTTCA
cat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
dog - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
pig - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
sheep - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cow - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
chimp - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
human - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rabbit - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
mouse - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
—————————————–ERV class I LTR13b————————————–
* *
horse snp horse snp
A>G G>T
horse AGATAGGAATGGATGCCTCCCCTCTTCTAACATCAATATCAGTACTCTTT
cat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
dog - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
pig - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
sheep - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cow - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
chimp - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
human - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rabbit - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
mouse - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
—————————————–ERV class I LTR13b————————————–
horse CGAAGAGAAGTTTTTCTTCTCAGAAACCAGGGCCAGGTCTACCTAGTGTG
cat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
dog - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
pig - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
sheep - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cow - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
chimp - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
human - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rabbit - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
mouse - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
—————————————–ERV class I LTR13b————————————–
*
horse snp
G>C
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horse TATGTGCTAAACTTCAGTAGACTAGCTCCTTGTGACTTTGAGAAAAAAAT
cat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
dog - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
pig - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
sheep - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cow - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
chimp - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
human - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rabbit - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
mouse - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
—————————————–ERV class I LTR13b————————————–
horse ATATCCCTGTCATGCTTCATGTATGTTCTTTGCTCTGAAATGGTATGTAA
cat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
dog - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
pig - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
sheep - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cow - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
chimp - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
human - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rabbit - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
mouse - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
—————————————–ERV class I LTR13b————————————–
horse TCATGCCACAAATCGTGCTTCTCCGAAACGTTTTCTCCCTTTGTGGAGAC
cat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
dog - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
pig - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
sheep - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cow - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
chimp - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
human - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rabbit - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
mouse - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
—————————————–ERV class I LTR13b————————————–
horse TGCCTTCCCAGCTCAAGTAAAATTCACTGTATCTCTCTTATCTATAGAAT
cat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
dog - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
pig - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
sheep - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
cow - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
chimp - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
human - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rabbit - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
mouse - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
rat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
—————————————–ERV class I LTR13b————————————–
horse GGTTATTGGTTATTTGCATGGACAATAGCAAACAGAAGGACTCATAAGAC
cat - - - - - - - - - - - - - - - - - - - - - - - - ACAACAAACGGGAGGACTTGTAAGAC
dog - - - - - - - - - - - - - - - - - - - - - - - - ACAGCAAAAGGCAGGACTTGTAAGAC
pig - - - - - - - - - - - - - - - - - - - - - - - - ATAGCAAA- - GAAGGGCTTATAAGGC
sheep - - - - - - - - - - - - - - - - - - - - - - - - ATAGCAAA- - GAAGGGCTTATAAGAC
cow - - - - - - - - - - - - - - - - - - - - - - - - AGAGCAAA- - AAAGGGCTTCTAAGAC
chimp - - - - - - - - - - - - - - - - - - - - - - - - GTAGCAAACCA- AAGGCTTGTAAGAA
human - - - - - - - - - - - - - - - - - - - - - - - - GTAGCAAACCA- AAGACTTGTAAGAA
rabbit - - - - - - - - - - - - - - - - - - - - - - - - GTATTAAAACT- - - - - - - - GAAAGAC
mouse - - - - - - - - - - - - - - - - - - - - - - - - ATACCAAATCAAGGG- - - - ATAAGAC
rat - - - - - - - - - - - - - - - - - - - - - - - - ATAGCACATCAAGGG- - - - ACAAGAC
———–ERV class I LTR13b———–
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horse ACTCAAACGAAG- - - CCAGGCTGAAAAAGGGGTTAGTCATGGACTATGTT
cat CCCCAAATGAGG- - - CCCTGCTCAAAGTGAGGTTAGCCATAGTCTATGTA
dog CCTCAAATGAAG- - - CCCTGCTCAACATGGGGTTAGCCATAAACTATGTA
pig CCTCAAATAAGG- - - CT- - - - - - - - - - - - - - - - - - - - - ACGGACTATATA
sheep CCTCAAATAAGG- - - CTATGCTCA- - AAGAGGTTGGCCATGGACTATATA
cow CCTGAAATAAGG- - - CTATGCTCA- - AAGAGGTTGGCCACGGACTATATA
chimp CCTCAAATGAGG- - - CCATGCACAAAACAGGGCTGGCCATGGGCTACGTA
human CCTCAAATGAGG- - - ACATGCACAAAACAGGGATGGCCATGGGCTACGTA
rabbit TCTCAAA- GAGG- - - CCATGCTAAAAATGGGGCTAGCTACAGACTACATA
mouse CCTCAAATGAGA- - - CTAGGCTCA- - - - - - - - - - - - - - - - - - - - - - - - - -
rat CCTCAAATGACTCCTCTAGGCTCA- - - - - - - - - - - - - - - - - - - - - - - - - -
horse ATTTCAAGT- T- - - - - - - - - - CATTCG- TCTTCAATATCAAAATTCATTT
cat ATTTCACGGGT- - - - - - - - - - TTTTTG- TCTTCGGCATCAAAATTCACTT
dog ATTTCAAGGTTGTTTTTTTTTTTTTAA- TCTTCGGCATCAGAATCCACTT
pig ATCTCACCT- T- - - - - - - - - - CTTTTG- TCTGCAGCATAAAAATTCACTT
sheep ATTTCACAT- T- - - - - - - - - - CTTTAG- TCTGCAACATAAACATTCACAT
cow ACTTCACAT- T- - - - - - - - - - CTTTTGTTCTGCAACCTAAAAATTCACAT
chimp ATTTCAAGG- T- - - - - - - - - - CTTTTG- TCTTCAACATCAAAATTCACTT
human ATTTCAAGG- T- - - - - - - - - - CTTTTG- TCTTCAACGTCAAAATTCACTT
rabbit ATATCAAGT- T- - - - - - - - - - CTTTTT- TCCTCAACATCAAAATTTACGT
mouse - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - TTTGACGTCAAAATTCACTT
rat - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - TTTGACGTCAAAATTCACTT
horse TAGAAGACTTACGT- AATTTTCATGCCTGACTGAGAGTGAAAGGTGATTT
cat TAGAGTACTTAAGT- GATTTTCATGCCTGACTGAGGGTGAAGGGTGAATT
dog TAGATGACTTAAGT- GATTTTTATGCCTGACTGAGAGTGGAGGGTGAATT
pig TAGAGTACTTAAGT- GATTTTCATGCCTGACCAAGAGTGAAAGGTGAATT
sheep CAGAGTACTTAAAT- GATTTTCATTCCTGATCAAGAGTGA- AGGTGAATT
cow CAGAGTACTTAAGT- GATTTTCTTTCCCGATCAAGAGTGA- AGGTGAATT
chimp TAAAGAACTTAAGT- GATTTTCATGCGTGATTGAAAGTAGAAGGTGGATT
human TAGAGAACTTAAGT- GATTTTCATGCGTGATTGAAAGTAGAAGGTGGATT
rabbit CAGATAAC- - AAGT- GAATTTCATGCCTGAATG- - - - - - - - - - - - - AATT
mouse GAGAGAACTTTAGCAGTTTTTCGTGCCTGACTGAGACCGAAGGGTGGATC
rat CAGAGAGCTGAAGTAGTTTTTCACGCCTGACTGAGATTGAAGGGTGTATT
* * * * * * *
TF site
Pax6
horse TTCAAACTGCCCTTTCCATTCCCAACAA- - - - - - - - - - - - - - - - - - - - - A
cat TCCAAACTGCCCTTTCCATTCCCAACAACA- - - - - - - - - - - - A- - - - - CA
dog GCCAAACTGCCCTTTCCATTCCCAACAACA- - - - - - - - - - - - A- - - - - CA
pig TCCAAACTGCTCTTTCCATTCTCAGCAAAA- - - - - - - - - - - - A- - - - - AA
sheep TCCAAACTTCCCTTTCCATTCTCAGCCAAA- - - - - - - - - - - - A- - - - - AA
cow TCCAAACTTCCCTTTCCATTCTCAGCCAAA- - - - - - - - - - - - A- - - - - AA
chimp TCCAAGCTGCTCTCTCCATTCCCAACCAAAATCAAAAAAAAAA- AAAAAA
human TCCAAGCTGCTCTCTCCATTCCCAACCAAA- - - - - - - - - - - - - - - - AAAA
rabbit TCCAAACTGTCCTTTCCATTCCCAACAAAA- - - - - - - - - - - - - - - - - ACA
mouse TCCAAACTGCCCTTTCCATTCCCAAA- - - - - - - - - - - - - - - - - - - - - - CA
rat TCCAAACTACCCTTTCCATTCCCAAA- - - - - - - - - - - - - - - - - - - - - - CA
horse - - - - - - - - - - - - - - - - - - - - - - AAAAGGCATGAGAGTAAATAAAAAGTTT
cat - - - - - - - - - - - - - - - - - - - - - - AAAAAGCAAGAGAGTAAATAAAAAGTTT
dog - - - - - - - - - - - - - ACAA- - - - - AAAAAGCAGGAAAGTAAATAAGAAGTTT
pig - - - - AAAAAAAAA- - - - - - - - - AAAAAGCAACAGAGTAAATAAAAAGGTT
sheep AAAA- - - - - - - - - - - - - - - - - - AAAAAGCA- - AGAGTAAATAAAAAGTTT
cow - - - - - - - - - - - - - - - - - - - - - - AAAAAGCA- - AGAGTAAATAAAAAGTTT
chimp - - - - - - - - - - - - - - - - - AAAAAAAAAGACACAAGAGTGCATAAAAAGTTT
human - - - - - - - - - - - - - - - - - AAAAAAAAAGATACAAGAGTGCATAAAAAGTTT
rabbit - - - - - - - - - - - - - - - - - AAAGGAAAAGGCACAAGAGTCAATAAAAAGTTT
mouse - - - - - - - - - - - - - - - - - - - - - - GAAAGGCACAAGAGTAAATAAAATGTTT
rat - - - - - - - - - - - - - - - - - - - - - - GAAAGGCACAAGAGTAAATAAAAAGTTT
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* * * * * * * * * * * *
TF site
HNF-3β
horse CCTGCTCTCTGAGGTC- - TCACCCAACATAAGCGTAGAATGCAGATGAGC
cat CCTGGTCTCCGAGGTC- - CCACCCAATATAAGCTTAGAATGCAGATGAGC
dog CCTGGTCTCAGAGGTC- - CCACCCAATATAAGCACAGAATGCAGATGAGC
pig CCT- - - - - - - - - - - - - - - - - - CCCAATATAAGCATAGAATGCAGAGGAGC
sheep CCTGGTTTCTGAGTTC- - CCACCCAATATAAGCTTATTATGCAGATGAGC
cow CCTGGTCTCTGAGTTC- - CCACCCAATATAAGCTTATTATGCAGATGAGC
chimp CCAGGTCTCTAAGGTCTCTCACCCAATGTAAGCATAGAATGCAGATGAGC
human CCAGGTCTCTAAGGTCTCTCACCCAATATAAGCATAGAATGCAGATGAGC
rabbit CCGGGTCTCTGATGTCCCA- - CCCAATACGGGCAGAGAATGCAGATGAGC
mouse CCGGGCCTCTGCGGTCTCA- ACCCGGTATCAGCGTAAAAAGCAGATGAGC
rat CCGGGCCTCTGAGGTCTCA- CCCCGGTATCAGCGTGAGGAGCAGATGAGC
horse AAAGTGAGTAGGCGAGTGAAATCGTTTGTAACAAAAACCCATTATTTACA
cat AAAGTGAGTAGGCGAGTGAAATCGTTTGTAACAAAAACTCATTATTTACA
dog AAAGTGAGTGGGCGAGTGAAATCGTTTGTAACAAAAACTCATTATTTACA
pig AAAGTGAGTGGGCGAGTGAAATTGTTTGTAACAAAAACTCATTATTTACA
sheep GAAGTGAGTGGGCGAGTGAAATCGTTTGTAACAAAAACCCATTATTCACA
cow AAAGTGAGTGGGCGAGTGAAATCGTTTGTAACAAAAACCCATTATTCACA
chimp AAAGTGAGTGGGAGAGGGAAGTCATTTGTAACAAAAACTCATTATTTACA
human AAAGTGAGTGGGAGAGGGAAGTCATTTGTAACAAAAACTCATTATTTACA
rabbit AAACTGAGTGGGCGAGTGAAATCATTTGTAACAAAGACCCATTATTTACA
mouse AAAGTGAGTGGGCGAGTGAAATCATTTG- AACAAAACCCCATTATTTACA
rat A- - - - GAGTGGGCGAGTGAAATCATTTG- AACAAAACCCCATTATTTACA
* * * * * *
TF site
Brn-4
horse GATGAGAAATTTATATTGTCAGCATAATATCTGTGAGGCTAAACAACGCT
cat GATGAGAAATTTATACTGTCAGCGTAATATCTGTGAGTCTAAACAACGCT
dog GATGAGAAATTTATATTGTCAGCGTAATATCTGTGAGTCTGAACAATGCT
pig GATGAAAAATTTATATTGTCAGCGTAATATCTGCGAGGCTAAACAACGCT
sheep GATGAAAAATTTATATTGTCAGCGTAATATCTGCAAGGCTAAACACCACT
cow GATGAAAAATTTATATTGTCAGCGTAATATCTGCAAGGCTAAACACCACT
chimp GATGAGAAATTTATATTGTCAGCGTAATATCTGTGAGGCTAAACAGAGCT
human GATGAGAAATTTATATTGTCAGCGTAATATCTGTGAGGCTAAACAGAGCT
rabbit GTTGAGAAATTTATATTGTCAGCATAATATCTGG- GGGCTAGGAGA- GCT
mouse GATGAGAAATTTATATTGTCAGCGTAATATCTGCAAGGCTAAACAG- CCT
rat GATGAGAAATTTATATTGTCAGCGTAATATCTGCAAGGCTAAACAG- CCT
* * * * * * * * * * *
TF site TF site
cdx-2/3 isl-1
horse GGGGAGTATATAAAAGCAGCGCACTTTGCTGCAGAAGTAGAGAGCTCAGG
cat G- AGAGTATATAAATACAGTGCACTGTGCTGCAGAAGTACAGGGCTCAGG
dog G- AGAGTATATAAATGCAGTAGGCTCTGCTGCAGAAGTACAGAGCTCAGG
pig GGGGAGTATATAAAAGCAGCACGCTGTGGTGCAGAACTACAGGGCTCAGG
sheep GGAGAATATATAAAGGCAGTAAGCTTTGGTGCACAGCTACAGAGCTCAGG
cow GGAGAGTATATAAAGGCAGTGAGCTTTGGTGCACAACTACAGAGCTCAGG
chimp GGAGAGTATATAAAAGCAGTACGGCTTGGTGCAGAAGTGCAGAGCTTAGG
human GGAGAGTATATAAAAGCAGTGCGCCTTGGTGCAGAAGTACAGAGCTTAGG
rabbit GGAGAGTATATAA- AGCAGTGTGGTCTGCTGCAGAAGTGCAGAGTCCAGG
mouse GGAGAGCATATAAAAGCACAGCACCCTGGTGCAGAAGGGCAGAGCTT- GG
rat GGAGACTATATAAAAGCACAGCACCCTGGTGCAGAAGGGCAGAGCTT- GG
*
human/rat intestine
transcription start site
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horse AGACA- - GCACATCCAAAGTTCTGAAAGGAGGGCGCCCTCTCTCTCCACC
cat ACACA- - - CACATCCAAAGTTCCGAAAAGAGGGCTCGCTCTCTCTCCACC
dog ACACA- - GCACAGCCAAAGTTCCGAAAAGAGGGCTCGCTCTCTCCCCACC
pig ACACT- - GCACACACGAAGTTCTGA- AAAGAGTCTCACTCTCTTTCCACC
sheep ACACT- - GCACACCCAA- - - - - - - - - ACGAGGGCTCACTCTCTCTCCACC
cow ACACT- - GCACACCCAA- - - - - - - - - ACGAGGGCTCACTCTCTCTTCACC
chimp ACACAGAGCACATCAAAAGTTCCCA- AAGAGGGCTTGCTCTCTCTTCACC
human ACACAGAGCACATCAAAAGTTCCCA- AAGAGGGCTTGCTCTCTCTTCACC
rabbit GCACAGAGCACATCCAGTGTCCACA- - - GAGGGCTTGCTCTCTCTCCACC
mouse GCCCAGGACACACTCAAAGTTCCCA- A- GGGGACTCCCTCTGTCTACACC
rat GCGCAGAACACACTCAAAGTTCCCA- A- AGGAGCTCCACCTGTCTACACC
*
horse snp
C>G
horse TGCTCTGCTCCACATCACAGT- GTCAGAAG
cat TGCTCTGTTCCA- GTC- AAGT- GTCAGAAG
dog TGCTCTGTTCCA- ATCGCGGT- GTCAGAAG
pig TGCCCTGTTCCACCTTCTGGT- GTCAAAAG
sheep TGCTCTGTTCCACCTCCTGGT- GTCAGAAG
cow TGCTCTGTTCCACCTCCTGGT- GTCAGAAG
chimp TGCTCTGTTCTACAGCACACT- ACCAGAAG
human TGCTCTGTTCTACAGCACACT- ACCAGAAG
rabbit TGCTCTGTTCCACACGCCAGTACTCAGAAG
mouse TGTTCG- - - - - - CAGCTCAGG- CTCACAAG
rat TCCTCT- - - - - - CAGCTCAGT- CCCACAAG
*
human/rat
final nucleotide non-
coding exon 1
Horse nucleotide sequence=reverse complement of Ensembl generated EquCab2.0 assembly
chr18:42522863-42523969. Cross species alignments generated with Ensembl.255 Putative tran-
scription factor (TF) binding sites obtained from Nian et al 1999171 and transcription start site
obtained from Novak et al 1987.256 Identification of horse endogenous retrovirus class I long
terminal repeat 13b (ERV class I LTR13b) obtained using RepeatMasker.172
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Table B.2: Glucose mg/dl area under the curve and trajectory fixed effect estimate(se)
Univariate AUC Trajectory
predictor intercept linear slope quadratic
slope
Ref group (mean age) 11417.12(252.38) 74.10(0.89) 10.67(0.56) -0.98(0.07)
1 SD increase in age -349.42(134.50)** -1.25(0.72) -1.27(0.56)* 0.14(0.07)*
Ref group (gelding) 11313.48(413.53) 74.43(1.83) 9.75(1.30) -0.89(0.15)
mare 97.47(355.15) -0.68(1.87) 1.17(1.46) -0.10(0.17)
stallion 289.10(707.92) 2.24(3.81) 0.51(3.03) -0.19(0.36)
Ref group (Morgan breed) 11035.56(371.09) 74.35(1.48) 8.74(0.77) -0.77(0.09)
Welsh Pony 824.63(555.46) -0.39(2.18) 3.86(1.09)*** -0.41(0.13)**
Ref group (non-obese, no lam) 11284.10(310.79) 73.32(1.12) 9.41(0.80) -0.84(0.09)
non-obese, prior laminitis -720.99(384.73) -2.44(1.92) 0.04(1.48) 0.00(0.17)
obese, no prior laminitis 988.58(381.17)** 5.01(2.03)* 2.65(1.60) -0.26(0.19)
obese, prior laminitis 508.64(449.68) 2.80(2.07) 4.87(1.57)** -0.56(0.18)**
Ref group(mean Mcal) 11440.93(253.30) 74.12(1.02) 10.67(0.56) -0.98(0.07)
1 SD increase in Mcal -380.35(187.59)* 0.10(0.87) -1.44(0.56)* 0.12(0.07)
Ref group (mean nutrients) 11462.49(256.36) 74.35(1.17) 10.67(0.53) -0.98(0.06)
1 SD increase in Starch -228.87(258.30) 0.45(1.27) -1.67(0.76)* 0.20(0.09)*
1 SD increase in CP 0.88(253.25) -0.13(1.25) 0.23(0.76) -0.04(0.09)
1 SD increase in NDF -637.61(341.97) -1.76(1.63) -3.21(0.92)*** 0.36(0.11)***
1 SD increase in WSC 374.37(348.35) 2.30(1.66) 2.32(0.93)* -0.32(0.11)**
Ref group (mean triglycerides) 11393.58(314.44) 74.03(1.15) 10.67(0.57) -0.98(0.07)
1 SD increase in triglycerides -100.65(163.38) -1.53(0.81) 1.00(0.57) -0.08(0.07)
Ref group (mean NEFA) 11428.23(200.16) 74.16(1.00) 10.67(0.55) -0.98(0.07)
1 SD increase in NEFA 386.43(150.73)* -0.27(0.81) 1.89(0.55)*** -0.16(0.07)*
Ref group (mean leptin) 11385.18(323.23) 74.08(1.08) 10.67(0.57) -0.98(0.07)
1 SD increase in leptin 246.06(135.33) 0.19(0.74) 0.64(0.57) -0.07(0.07)
Ref group (mean adiponectin) 11400.07(294.23) 74.09(0.99) 10.67(0.57) -0.98(0.07)
1 SD increase in adiponectin 29.49(144.38) -0.14(0.75) -0.49(0.58) 0.08(0.07)
Ref group (mean DPP4 activity) 11397.33(276.57) 74.08(1.01) 10.67(0.56) -0.98(0.07)
1 SD increase in DPP4 activity 197.73(164.01) 0.16(0.80) 1.52(0.56)** -0.17(0.07)*
Ref group (DPP4 0 copies) 11371.27(337.26) 74.92(1.33) 10.19(0.90) -0.95(0.11)
DPP4 1 copy minor allele 32.27(189.49) -0.93(1.01) 0.54(0.80) -0.03(0.09)
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Table B.2 Continued from previous page
Univariate AUC Trajectory
predictor intercept linear slope quadratic
slope
Ref group (GCG haplotype A) 11513.16(435.94) 72.75(1.89) 11.09(1.26) -0.95(0.15)
GCG haplotype B 99.05(267.83) 2.24(1.34) -1.19(1.00) 0.11(0.12)
GCG haplotype C -185.83(252.70) -0.73(1.28) 0.70(0.96) -0.13(0.11)
GCG haplotype D -645.89(476.14) -0.55(2.47) 0.01(1.90) -0.21(0.22)
GCG haplotype E -20.67(362.77) 2.55(1.90) -0.89(1.47) 0.05(0.17)
Asterisks indicate significance of beta estimates (*<0.05, **<0.01, ***<0.001). AUC estimates
were calculated in minutes. Time was coded in 15 minute intervals and centered at zero minutes
for the trajectory estimates. Results obtained from a multivariate response model (responses
included glucose, insulin, active GLP-1 and total GLP-1 measured at 7 time points over a 2
hour period). GCG haplotype A=highest frequency haplotype, GCG haplotype E=pooled rare
haplotypes with frequency < 0.05
Table B.3: Insulin μIU/ml area under the curve and trajectory fixed effect estimate(se)
Univariate AUC Trajectory
predictor intercept linear slope quadratic
slope
Ref group (mean age) 3526.22(537.69) 6.16(1.07) 11.74(1.12) -1.06(0.12)
1 SD increase in age -8.45(247.87) 1.24(0.62)* -0.07(1.12) -0.01(0.12)
Ref group (gelding) 2902.20(729.54) 4.61(1.69) 7.43(2.49) -0.65(0.27)
mare 757.26(629.65) 1.79(1.60) 5.35(2.79) -0.50(0.31)
stallion 1104.12(1267.99) 2.94(3.25) 5.40(5.79) -0.63(0.64)
Ref group (Morgan breed) 2877.62(655.87) 4.98(1.36) 8.26(1.51) -0.71(0.17)
Welsh Pony 1474.56(981.09) 2.66(2.02) 6.95(2.14)** -0.70(0.24)**
Ref group (non-obese, no lam) 2991.86(536.77) 5.11(1.01) 9.15(1.57) -0.79(0.17)
non-obese, prior laminitis 1100.66(706.11) 0.54(1.68) 5.05(2.90) -0.45(0.32)
obese, no prior laminitis 390.10(716.33) 0.19(1.76) 0.51(3.11) -0.05(0.34)
obese, prior laminitis 2124.56(804.10)** 6.91(1.84)*** 8.89(3.05)** -1.04(0.33)**
Ref group(mean Mcal) 3563.08(534.22) 6.07(1.16) 11.74(1.11) -1.06(0.12)
1 SD increase in Mcal -313.00(355.82) 0.24(0.82) -1.78(1.11) 0.16(0.12)
Table B.3 Continued on next page
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Univariate AUC Trajectory
predictor intercept linear slope quadratic
slope
Ref group (mean nutrients) 3640.25(243.34) 6.27(1.03) 11.74(1.03) -1.06(0.11)
1 SD increase in Starch -531.69(349.22) -0.21(1.07) -2.05(1.47) 0.18(0.16)
1 SD increase in CP 627.25(347.10) 0.63(1.06) 2.47(1.46) -0.28(0.16)
1 SD increase in NDF -730.15(421.01) -1.18(1.41) -2.70(1.78) 0.27(0.20)
1 SD increase in WSC 32.86(423.75) 1.02(1.42) 0.08(1.79) -0.03(0.20)
Ref group (mean triglycerides) 3564.52(475.35) 6.23(0.96) 11.74(1.09) -1.06(0.12)
1 SD increase in triglycerides 463.22(278.13) -0.03(0.68) 2.47(1.09)* -0.16(0.12)
Ref group (mean NEFA) 3521.08(534.73) 6.20(0.91) 11.74(1.11) -1.06(0.12)
1 SD increase in NEFA 18.55(291.54) 1.26(0.68) 1.43(1.11) -0.15(0.12)
Ref group (mean leptin) 3511.34(528.02) 6.16(1.09) 11.74(1.07) -1.06(0.12)
1 SD increase in leptin881.39(233.76)*** 0.31(0.63) 3.20(1.08)** -0.27(0.12)*
Ref group (mean adiponectin) 3508.46(476.93) 6.15(1.08) 11.74(1.06) -1.06(0.12)
1 SD increase in adiponectin -735.02(246.82)** 0.26(0.64) -3.79(1.06)*** 0.33(0.12)**
Ref group (mean DPP4 activity) 3512.55(517.39) 6.10(1.04) 11.74(1.09) -1.06(0.12)
1 SD increase in DPP4 activity 307.07(289.48) 1.26(0.69) 2.68(1.09)* -0.31(0.12)**
Ref group (DPP4 0 copies) 3377.04(608.34) 5.15(1.31) 9.56(1.74) -0.76(0.19)
DPP4 1 copy minor allele 164.92(340.29) 1.14(0.86) 2.48(1.53) -0.35(0.17)*
Ref group (GCG haplotype A) 3728.59(763.73) 5.28(1.67) 12.04(2.47) -1.04(0.27)
GCG haplotype B -53.04(473.38) 1.86(1.14) -1.23(1.95) 0.08(0.21)
GCG haplotype C -245.52(447.63) 0.47(1.09) 0.75(1.87) -0.07(0.20)
GCG haplotype D 295.95(853.69) -0.29(2.10) 3.02(3.70) -0.50(0.40)
GCG haplotype E -415.28(653.02) -1.81(1.62) -2.22(2.87) 0.20(0.31)
Asterisks indicate significance of beta estimates (*<0.05, **<0.01, ***<0.001). AUC estimates
were calculated in minutes. Time was coded in 15 minute intervals and centered at zero minutes
for the trajectory estimates. Results obtained from a multivariate response model (responses
included glucose, insulin, active GLP-1 and total GLP-1 measured at 7 time points over a 2
hour period).
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Table B.4: Active GLP-1 pM area under the curve and trajectory fixed effect esti-
mate(se)
Univariate AUC Trajectory
predictor intercept linear slope quadratic
slope
Ref group (mean age) 1377.16(221.86) 7.31(1.52) 2.32(0.28) -0.26(0.03)
1 SD increase in age 41.04(132.80) 0.55(0.97) -0.17(0.28) 0.02(0.03)
Ref group (gelding) 1333.04(351.12) 4.91(2.65) 2.70(0.61) -0.24(0.06)
mare 67.20(340.28) 2.30(2.50) -0.30(0.69) -0.04(0.07)
stallion -60.61(687.86) 9.17(5.03) -3.27(1.42)* 0.23(0.15)
Ref group (Morgan breed) 1536.88(298.64) 8.80(2.22) 2.38(0.39) -0.26(0.04)
Welsh Pony -379.17(443.00) -3.18(3.29) -0.11(0.55) 0.00(0.06)
Ref group (non-obese, no lam) 1464.45(258.74) 9.36(1.97) 2.06(0.39) -0.23(0.04)
non-obese, prior laminitis -295.17(378.01) -3.99(2.80) -0.02(0.71) -0.01(0.08)
obese, no prior laminitis 251.88(385.87) -2.12(2.84) 2.18(0.77)** -0.21(0.08)*
obese, prior laminitis -634.42(427.78) -6.38(3.19)* -0.52(0.75) 0.04(0.08)
Ref group(mean Mcal) 1364.58(212.14) 7.25(1.59) 2.32(0.28) -0.26(0.03)
1 SD increase in Mcal 131.16(165.17) 1.64(1.27) 0.01(0.28) 0.00(0.03)
Ref group (mean nutrients) 1364.91(127.51) 7.26(1.56) 2.32(0.28) -0.26(0.03)
1 SD increase in Starch 29.26(182.99) 1.43(1.61) -0.53(0.40) 0.03(0.04)
1 SD increase in CP -294.08(181.87) -2.25(1.59) -0.43(0.39) 0.01(0.04)
1 SD increase in NDF -43.42(220.61) 0.06(2.12) -0.23(0.48) 0.02(0.05)
1 SD increase in WSC 447.46(222.04)* 3.74(2.13) 0.39(0.48) -0.04(0.05)
Ref group (mean triglycerides) 1371.64(217.67) 7.28(1.53) 2.32(0.28) -0.26(0.03)
1 SD increase in triglycerides -55.89(148.80) -1.56(1.09) 0.08(0.28) -0.02(0.03)
Ref group (mean NEFA) 1358.47(209.18) 7.27(1.48) 2.32(0.28) -0.26(0.03)
1 SD increase in NEFA -234.00(146.38) -1.93(1.09) -0.21(0.28) 0.02(0.03)
Ref group (mean leptin) 1380.04(220.38) 7.32(1.51) 2.32(0.28) -0.26(0.03)
1 SD increase in leptin 51.66(132.68) -0.08(0.98) 0.26(0.28) -0.02(0.03)
Ref group (mean adiponectin) 1383.98(208.24) 7.36(1.44) 2.32(0.28) -0.26(0.03)
1 SD increase in adiponectin 196.36(136.04) 1.60(1.00) -0.06(0.28) 0.02(0.03)
Ref group (mean DPP4 activity) 1378.22(198.80) 7.24(1.58) 2.32(0.28) -0.26(0.03)
1 SD increase in DPP4 activity -183.79(146.34) -0.71(1.12) -0.18(0.28) 0.01(0.03)
Table B.4 Continued on next page
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Univariate AUC Trajectory
predictor intercept linear slope quadratic
slope
Ref group (DPP4 0 copies) 1378.27(275.31) 7.60(1.93) 2.42(0.43) -0.28(0.05)
DPP4 1 copy minor allele -2.95(182.93) -0.35(1.35) -0.11(0.38) 0.02(0.04)
Ref group (GCG haplotype A) 1262.47(345.63) 4.85(2.43) 2.97(0.60) -0.29(0.06)
GCG haplotype B -79.35(243.08) 1.63(1.79) -0.86(0.48) 0.06(0.05)
GCG haplotype C 141.75(232.49) 0.77(1.72) -0.31(0.46) 0.01(0.05)
GCG haplotype D 352.84(448.35) 3.05(3.30) 0.57(0.90) -0.10(0.10)
GCG haplotype E 280.91(345.26) 4.88(2.54) -0.48(0.70) 0.02(0.07)
Asterisks indicate significance of beta estimates (*<0.05, **<0.01, ***<0.001). AUC estimates
were calculated in minutes. Time was coded in 15 minute intervals and centered at zero minutes
for the trajectory estimates. Results obtained from a multivariate response model (responses
included glucose, insulin, active GLP-1 and total GLP-1 measured at 7 time points over a 2
hour period). GCG haplotype A=highest frequency haplotype, GCG haplotype E=pooled rare
haplotypes with frequency < 0.05
Table B.5: Total GLP-1 pM area under the curve and trajectory fixed effect estimate(se)
Univariate AUC Trajectory
predictor intercept linear slope quadratic
slope
Ref group (mean age) 2430.76(421.09) 16.94(3.12) 2.04(0.34) -0.25(0.03)
1 SD increase in age 89.98(230.12) 0.79(1.85) -0.24(0.34) 0.04(0.03)
Ref group (gelding) 2066.28(634.84) 9.89(4.91) 3.39(0.74) -0.33(0.07)
mare 443.67(587.35) 7.51(4.64) -1.42(0.83) 0.08(0.08)
stallion 788.41(1191.32) 22.30(9.34)* -5.84(1.73)*** 0.44(0.17)**
Ref group (Morgan breed) 2797.17(539.02) 19.22(4.26) 2.53(0.48) -0.29(0.05)
Welsh Pony -864.40(801.39) -5.40(6.33) -0.98(0.68) 0.07(0.07)
Ref group (non-obese, no lam) 2819.31(451.16) 21.21(3.72) 2.02(0.47) -0.24(0.05)
non-obese, prior laminitis -1086.52(644.91) -10.48(5.27)* -0.34(0.86) 0.01(0.08)
obese, no prior laminitis -146.40(664.49) -7.08(5.36) 2.75(0.93)** -0.24(0.09)**
obese, prior laminitis -1339.43(721.11) -10.20(5.99) -2.03(0.91)* 0.17(0.09)
Table B.5 Continued on next page
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Univariate AUC Trajectory
predictor intercept linear slope quadratic
slope
Ref group(mean Mcal) 2402.46(415.35) 16.97(3.26) 2.04(0.34) -0.25(0.03)
1 SD increase in Mcal 86.41(298.70) -0.83(2.47) 0.82(0.34)* -0.08(0.03)**
Ref group (mean nutrients) 2363.22(222.69) 16.56(2.23) 2.04(0.33) -0.25(0.03)
1 SD increase in Starch 254.28(319.59) 5.12(2.75) -1.05(0.47)* 0.06(0.05)
1 SD increase in CP -729.35(317.64)* -3.72(2.73) -1.02(0.46)* 0.03(0.05)
1 SD increase in NDF 352.12(385.28) 2.56(3.43) 0.23(0.56) -0.02(0.06)
1 SD increase in WSC 161.31(387.79) 0.04(3.46) 0.92(0.57) -0.08(0.06)
Ref group (mean triglycerides) 2413.86(391.24) 16.72(2.92) 2.04(0.34) -0.25(0.03)
1 SD increase in triglycerides -223.01(252.03) -1.46(2.08) -0.71(0.34)* 0.05(0.03)
Ref group (mean NEFA) 2405.93(370.96) 16.80(2.68) 2.04(0.34) -0.25(0.03)
1 SD increase in NEFA -436.79(248.57) -2.98(2.06) -0.63(0.34) 0.04(0.03)
Ref group (mean leptin) 2440.56(420.92) 16.96(3.12) 2.04(0.34) -0.25(0.03)
1 SD increase in leptin 34.48(230.06) -0.98(1.85) 0.66(0.34) -0.06(0.03)
Ref group (mean adiponectin) 2447.49(385.32) 17.04(2.92) 2.04(0.34) -0.25(0.03)
1 SD increase in adiponectin 320.24(235.27) 1.41(1.91) 0.38(0.34) -0.02(0.03)
Ref group (mean DPP4 activity) 2441.65(385.32) 16.89(3.09) 2.04(0.34) -0.25(0.03)
1 SD increase in DPP4 activity -216.44(254.85) -0.12(2.14) -0.47(0.34) 0.03(0.03)
Ref group (DPP4 0 copies) 2611.37(498.50) 18.88(3.79) 1.98(0.54) -0.25(0.05)
DPP4 1 copy minor allele -202.48(316.61) -2.23(2.55) 0.08(0.48) 0.00(0.05)
Ref group (GCG haplotype A) 2055.48(635.51) 10.29(4.80) 3.33(0.74) -0.32(0.07)
GCG haplotype B 194.23(424.51) 5.37(3.40) -1.40(0.58)* 0.10(0.06)
GCG haplotype C 258.81(404.03) 3.17(3.24) -0.91(0.56) 0.05(0.05)
GCG haplotype D 171.80(780.58) 0.93(6.21) 0.96(1.11) -0.12(0.11)
GCG haplotype E 679.67(600.37) 10.68(4.77)* -0.82(0.86) 0.00(0.08)
Asterisks indicate significance of beta estimates (*<0.05, **<0.01, ***<0.001). AUC estimates
were calculated in minutes. Time was coded in 15 minute intervals and centered at zero minutes
for the trajectory estimates. Results obtained from a multivariate response model (responses
included glucose, insulin, active GLP-1 and total GLP-1 measured at 7 time points over a 2
hour period). GCG haplotype A=highest frequency haplotype, GCG haplotype E=pooled rare
haplotypes with frequency < 0.05
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Factors with a p-value significance level < 0.2 in the univariate predictor analysis
were included in a multiple predictor regression analysis of glucose, insulin, and GLP-1
trajectories. In the multiple regression analysis glucose trajectories were significantly as-
sociated with clinical group, caloric intake, diet nutrient composition, and NEFA blood
concentrations (Table B.6). The different clinical group glucose trajectories differed at
the intercept (measurement at time zero) with obese, no prior laminitis horses having a
higher baseline glucose measurement. Insulin trajectories were associated with leptin,
triglycerides, and DPP4 genotype (Table B.7). Horses with higher leptin levels also
exhibited a higher initial rate of change in insulin and subsequently a faster deceler-
ation in the initial rate of change in attempt to prevent a delayed return to baseline
insulin levels. DPP4 genotype was also positively associated with insulin initial rate of
change and deceleration rate. GLP-1 active and total responses were less dynamic in
stallions (Tables B.8,B.9). Total GLP-1 trajectories were also associated with clinical
group, dietary nutrient composition, and haplotype at the GCG upstream enhancer
region (Table B.9). Obese horses with no prior laminitis exhibited a higher initial rate
of change in total GLP-1 and subsequently a faster deceleration in the initial rate of
change in attempt to prevent a delayed return to baseline levels.
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Table B.6: Glucose mg/dl trajectory multiple regression association tests
intercept time time2 overall signficance
parameter estimate(se) estimate(se) estimate(se) (wald χ2, df) pval
mean trajectory 72.88(2.50) 9.38(1.22) -0.78(0.14)
age -1.06(0.74) -0.51(0.51) 0.05(0.06) (3.7, 3df)=3.0E-01
breed
Morgan Reference Reference Reference
Welsh Pony 0.74(3.83) 2.82(1.80) -0.34(0.21) (2.8, 3df)=4.3E-01
clinical group
obese−lam− Reference Reference Reference
obese−lam+ -1.92(2.31) -2.04(1.65) 0.15(0.19)
obese+lam− 4.91(2.22)* 1.46(1.61) -0.16(0.19)
obese+lam+ 3.32(2.70) 0.24(1.91) -0.16(0.23) (20.0, 9df)=1.8E-02
Mcal 4.83(5.19) -8.13(2.84)** 0.85(0.32)** (8.6, 3df)=3.6E-02
nutrients
CP -0.99(2.45) 2.80(1.31)* -0.34(0.15)*
NDF -5.59(5.48) 6.54(3.09)* -0.64(0.35)
WSC 0.93(1.95) 0.79(0.99) -0.19(0.12)
Starch 0.33(1.88) 0.41(1.04) -0.02(0.12) (21.4, 12df)=4.5E-02
DPP4 activity -0.10(0.96) 0.64(0.65) -0.08(0.08) (1.1, 3df)=7.8E-01
NEFA -0.62(0.97) 0.76(0.66) 0.00(0.08) (10.1, 3df)=1.7E-02
triglycerides -0.84(0.90) -0.77(0.65) 0.13(0.08) (5.2, 3df)=1.6E-01
Asterisks indicate significance of beta estimates (*<0.05, **<0.01, ***<0.001). Re-
sults obtained from a multivariate response model (responses included glucose, in-
sulin, active GLP-1 and total GLP-1 measured at 7 time points over a 2 hour pe-
riod). Time was coded in 15 minute intervals and centered at zero minutes for the
trajectory estimates. Continuous predictors are scaled to zero mean and 1 standard
deviation. obese−lam−=non-obese/no prior laminitis, obese−lam+=non-obese/prior
laminitis, obese+lam−=obese/no prior laminitis, obese+lam+=obese/prior laminitis
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Table B.7: Insulin μIU/ml trajectory multiple regression association tests
intercept time time2 overall signficance
parameter estimate(se) estimate(se) estimate(se) (wald χ2, df) pval
mean trajectory 3.59(3.43) 6.96(2.67) -0.43(0.29)
breed
Morgan Reference Reference Reference
Welsh Pony -0.10(5.18) 0.92(3.51) -0.09(0.38) (0.1, 3df)=1.0E+00
clinical group
obese−lam− Reference Reference Reference
obese−lam+ 1.28(2.00) 3.72(3.01) -0.40(0.34)
obese+lam− 1.11(1.93) 1.11(3.08) -0.14(0.34)
obese+lam+ 7.10(2.37)** 5.88(3.35) -0.86(0.37)* (16.6, 9df)=5.5E-02
nutrients
CP -0.91(1.69) 1.81(1.66) -0.24(0.19)
NDF -0.68(2.60) -3.16(2.15) 0.30(0.24)
WSC 1.92(2.27) 1.33(1.82) -0.15(0.20)
Starch 0.30(1.62) -0.91(1.66) 0.06(0.18) (6.8, 12df)=8.7E-01
DPP4 activity 1.21(0.88) 0.26(1.30) -0.06(0.14) (2.1, 3df)=5.5E-01
adiponectin -0.30(0.76) -2.31(1.14)* 0.20(0.12) (4.9, 3df)=1.8E-01
leptin 0.30(0.64) 2.88(0.94)** -0.25(0.10)* (10.8, 3df)=1.3E-02
NEFA 1.36(0.88) -0.97(1.32) 0.08(0.14) (2.7, 3df)=4.4E-01
triglycerides -0.80(0.82) -0.78(1.27) 0.22(0.14) (8.6, 3df)=3.5E-02
DPP4 genotype 1.31(0.86) 2.76(1.29)* -0.39(0.14)** (11.8, 3df)=8.1E-03
Asterisks indicate significance of beta estimates (*<0.05, **<0.01, ***<0.001). Re-
sults obtained from a multivariate response model (responses included glucose, in-
sulin, active GLP-1 and total GLP-1 measured at 7 time points over a 2 hour pe-
riod). Time was coded in 15 minute intervals and centered at zero minutes for the
trajectory estimates. Continuous predictors are scaled to zero mean and 1 standard
deviation. obese−lam−=non-obese/no prior laminitis, obese−lam+=non-obese/prior
laminitis, obese+lam−=obese/no prior laminitis, obese+lam+=obese/prior laminitis
262
Table B.8: Active GLP-1 pM trajectory multiple regression association tests
intercept time time2 overall signficance
parameter estimate(se) estimate(se) estimate(se) (wald χ2, df) pval
mean trajectory 4.58(3.08) 2.73(0.77) -0.25(0.08)
sex
Gelding Reference Reference Reference
Mare 4.16(2.59) -0.46(0.74) -0.01(0.08)
Stallion 9.02(4.94) -3.09(1.42)* 0.24(0.15) (13.7, 6df)=3.3E-02
clinical group
obese−lam− Reference Reference Reference
obese−lam+ -0.93(2.95) -0.34(0.81) 0.04(0.09)
obese+lam− -1.12(2.86) 1.84(0.81)* -0.18(0.09)*
obese+lam+ -2.72(3.37) -0.87(0.88) 0.09(0.09) (8.9, 9df)=4.4E-01
nutrients
CP -2.71(1.90) -0.10(0.45) -0.01(0.05)
NDF -0.91(2.37) -0.05(0.49) 0.01(0.05)
WSC 3.74(2.38) 0.04(0.48) -0.01(0.05)
Starch 1.16(1.81) -0.23(0.40) 0.01(0.04) (11.0, 12df)=5.3E-01
adiponectin 0.54(0.68) -0.27(0.22) 0.03(0.02) (1.6, 3df)=6.5E-01
Asterisks indicate significance of beta estimates (*<0.05, **<0.01, ***<0.001). Re-
sults obtained from a multivariate response model (responses included glucose, in-
sulin, active GLP-1 and total GLP-1 measured at 7 time points over a 2 hour pe-
riod). Time was coded in 15 minute intervals and centered at zero minutes for the
trajectory estimates. Continuous predictors are scaled to zero mean and 1 standard
deviation. obese−lam−=non-obese/no prior laminitis, obese−lam+=non-obese/prior
laminitis, obese+lam−=obese/no prior laminitis, obese+lam+=obese/prior laminitis
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Table B.9: Total GLP-1 pM trajectory multiple regression association tests
intercept time time2 overall signficance
parameter estimate(se) estimate(se) estimate(se) (wald χ2, df) pval
mean trajectory 8.63(6.18) 3.91(0.98) -0.41(0.10)
sex
Gelding Reference Reference Reference
Mare 8.72(4.97) -1.21(0.83) 0.10(0.08)
Stallion 15.81(9.65) -5.11(1.62)** 0.47(0.17)** (14.9, 6df)=2.1E-02
clinical group
obese−lam− Reference Reference Reference
obese−lam+ -8.06(5.59) 0.15(0.91) 0.01(0.09)
obese+lam− -5.36(5.46) 2.45(0.90)** -0.23(0.09)*
obese+lam+ -6.33(6.38) -1.54(1.01) 0.17(0.10) (16.9, 9df)=5.0E-02
nutrients
CP -5.83(3.48) -0.06(0.51) -0.06(0.05)
NDF -0.82(4.21) 0.63(0.55) -0.06(0.06)
WSC 1.28(4.22) 0.33(0.55) -0.01(0.06)
Starch 4.17(3.23) -0.58(0.45) 0.00(0.05) (35.5, 12df)=3.9E-04
NEFA 0.45(1.51) 0.00(0.30) -0.01(0.03) (1.5, 3df)=6.8E-01
triglycerides 0.07(1.43) -0.53(0.28) 0.05(0.03) (5.3, 3df)=1.5E-01
GCG haplotype
haploptype A Reference Reference Reference
haploptype B 4.63(2.16)* -0.96(0.42)* 0.09(0.05)*
haploptype C 1.34(2.05) -0.33(0.40) 0.02(0.04)
haploptype D -2.18(3.82) 0.01(0.75) 0.00(0.08)
haploptype E 5.81(3.10) -1.06(0.61) 0.03(0.07) (22.2, 12df)=3.6E-02
Asterisks indicate significance of beta estimates (*<0.05, **<0.01, ***<0.001). Re-
sults obtained from a multivariate response model (responses included glucose, in-
sulin, active GLP-1 and total GLP-1 measured at 7 time points over a 2 hour pe-
riod). Time was coded in 15 minute intervals and centered at zero minutes for the
trajectory estimates. Continuous predictors are scaled to zero mean and 1 standard
deviation. obese−lam−=non-obese/no prior laminitis, obese−lam+=non-obese/prior
laminitis, obese+lam−=obese/no prior laminitis, obese+lam+=obese/prior laminitis
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Figure C.1: Enlarged version of Figure 4.2b Morgan horse PCA plot with numeric
representation of different farms.
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Figure C.2: Enlarged version of Figure 4.2c Welsh pony PCA plot with numeric repre-
sentation of different farms.
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Figure C.3: Manhattan plot displaying the standard bayesian sparse linear mixed model
results for the simulated QTL-MAS dataset. Red vertical lines indicate the location of
true QTL.
Figure C.4: Manhattan plot displaying the improved linear mixed model results for the
simulated QTL-MAS dataset using a 200 kilobase bin size. Red vertical lines indicate
the location of true QTL. Genome-wide p-value <0.05 (solid grey horizontal line) and
suggestive (dashed grey horizontal line) thresholds are also shown.
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Figure C.5: Illustration of variance decomposition throughout the stepwise feature SNP
selection process for the a) QTL-MAS simulated dataset, b) Morgan horse real height
dataset, and c) Welsh pony real height dataset. Tick marks along the X-axis represent
selected bins.
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Figure D.10: Leptin loci
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Figure D.11: Adiponectin loci
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Table D.1: Significance values for all SNPs above suggestive threshold
chromosome position alleles maf beta standard p-value nearest
estimate error gene
17 75543887 C\T 0.3 0.21 0.04 1.86E-07 FAM155A
17 76068467 C\T 0.36 0.199 0.04 7.15E-07 TNFSF13B
17 75572753 A\G 0.3 0.201 0.041 7.53E-07 FAM155A
2 93491935 A\G 0.36 0.201 0.041 1.04E-06 PCDH18
2 93340896 G\A 0.27 0.201 0.042 1.46E-06 PCDH18
17 75578441 G\T 0.28 0.197 0.041 1.64E-06 FAM155A
4 59620539 A\G 0.08 0.2 0.042 1.96E-06 CREB5
19 32821180 C\T 0.23 0.198 0.042 2.53E-06 SENP5
4 59489648 G\A 0.09 0.194 0.041 2.60E-06 CREB5
2 23825094 A\C 0.08 -0.194 0.041 2.74E-06 ZNF362
4 59182669 T\C 0.08 0.198 0.042 2.87E-06 CREB5
17 76828542 T\C 0.49 0.195 0.042 2.88E-06 MYO16
2 93336327 G\A 0.28 0.194 0.041 2.95E-06 PCDH18
2 93500820 G\T 0.36 0.193 0.041 2.95E-06 PCDH18
4 59494006 A\G 0.09 0.192 0.041 3.04E-06 CREB5
17 75473022 A\G 0.42 -0.196 0.042 3.18E-06 FAM155A
17 75578145 C\A 0.29 0.191 0.041 3.31E-06 FAM155A
2 93581546 G\A 0.19 0.204 0.044 3.88E-06 PCDH18
19 32811045 A\C 0.23 0.193 0.042 4.10E-06 SENP5
4 59548966 T\C 0.15 0.192 0.042 4.15E-06 CREB5
4 59134336 A\C 0.08 0.194 0.042 4.26E-06 CREB5
4 59229403 A\C 0.08 0.194 0.042 4.26E-06 CREB5
4 59290113 A\G 0.08 0.194 0.042 4.26E-06 CREB5
1 85359274 A\C 0.09 0.192 0.042 4.85E-06 CCSER2
17 76846954 C\T 0.49 0.191 0.042 4.93E-06 MYO16
17 75618350 C\T 0.27 0.189 0.041 4.94E-06 FAM155A
2 93345379 A\G 0.26 0.195 0.043 5.20E-06 PCDH18
1 128863092 C\T 0.06 -0.18 0.039 5.23E-06 RAB8B
2 93390516 A\C 0.25 0.194 0.043 5.69E-06 PCDH18
2 93382353 T\C 0.39 0.189 0.042 5.70E-06 PCDH18
4 60008165 T\C 0.08 0.187 0.041 6.55E-06 CPVL
3 96066755 G\A 0.08 -0.194 0.043 6.66E-06 PCDH7
2 93488668 A\G 0.28 -0.187 0.042 6.66E-06 PCDH18
1 85323285 T\C 0.08 0.188 0.042 6.98E-06 CCSER2
19 32853596 C\T 0.23 0.188 0.042 7.15E-06 SENP5
2 23825921 A\C 0.08 -0.184 0.041 7.50E-06 ZNF362
1 85357726 C\T 0.09 0.187 0.042 7.60E-06 CCSER2
2 93334445 A\G 0.24 0.19 0.042 7.61E-06 PCDH18
2 93348200 T\C 0.24 0.19 0.042 7.61E-06 PCDH18
2 93363325 T\G 0.24 0.19 0.042 7.61E-06 PCDH18
2 93366016 T\G 0.24 0.19 0.042 7.61E-06 PCDH18
2 93379462 A\G 0.24 0.19 0.042 7.61E-06 PCDH18
2 93393451 C\A 0.24 0.19 0.042 7.61E-06 PCDH18
2 93407104 A\G 0.24 0.19 0.042 7.61E-06 PCDH18
2 93440446 G\A 0.24 0.19 0.042 7.61E-06 PCDH18
2 93466920 A\G 0.24 0.19 0.042 7.61E-06 PCDH18
2 93482049 A\G 0.24 0.19 0.042 7.61E-06 PCDH18
2 93524852 T\C 0.24 0.19 0.042 7.61E-06 PCDH18
17 76326041 C\A 0.38 0.176 0.039 7.86E-06 MYO16
19 32950281 G\T 0.25 0.184 0.041 7.87E-06 PAK2
2 93613121 A\G 0.19 0.198 0.044 7.90E-06 PCDH18
17 75301675 G\A 0.43 0.179 0.04 8.26E-06 FAM155A
4 59887211 C\T 0.09 0.185 0.042 8.63E-06 CPVL
4 59504852 A\G 0.08 0.188 0.042 8.65E-06 CREB5
4 59362148 A\C 0.1 0.187 0.042 8.66E-06 CREB5
2 93418906 T\C 0.26 0.189 0.042 8.78E-06 PCDH18
Table D.1 Continued on next page
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Table D.1 Continued from previous page
chromosome position alleles maf beta standard p-value nearest
estimate error gene
2 93897287 A\G 0.19 0.198 0.045 8.93E-06 HADHB
2 93968327 T\G 0.19 0.198 0.045 8.93E-06 HADHB
2 93985100 G\T 0.19 0.198 0.045 8.93E-06 HADHB
2 93562757 T\C 0.25 0.188 0.042 9.04E-06 PCDH18
10 52269721 C\T 0.11 -0.189 0.043 9.32E-06 GRIK2
17 75656566 A\G 0.27 0.184 0.042 9.82E-06 FAM155A
Table D.2: Significance values for all girth:height SNPs above suggestive threshold
chromosome position alleles maf beta standard p-value nearest
estimate error gene
7 26154989 G\A 0.49 -0.198 0.038 1.95E-07 MPZL2
7 26155211 G\A 0.49 0.197 0.038 2.00E-07 MPZL2
7 26138800 T\C 0.43 -0.194 0.039 4.96E-07 MPZL2
7 26153883 C\T 0.48 -0.189 0.038 8.93E-07 MPZL2
7 23150348 C\T 0.07 -0.19 0.039 9.98E-07 NXPE2
7 22091943 C\T 0.1 -0.187 0.039 1.32E-06 TMPRSS5
22 10321507 A\G 0.2 0.189 0.039 1.44E-06 SEL1L2
7 26144328 T\C 0.44 -0.182 0.038 1.96E-06 MPZL2
22 9808709 C\T 0.06 0.189 0.041 2.91E-06 FLRT3
7 23139980 T\C 0.06 -0.18 0.039 2.98E-06 NXPE2
1 78254375 G\A 0.25 0.186 0.04 3.19E-06 MAP10
7 26148134 A\G 0.45 -0.176 0.038 3.75E-06 MPZL2
14 67885725 C\A 0.08 0.165 0.036 4.52E-06 SLCO4C1
22 11401249 T\C 0.15 0.176 0.038 4.95E-06 ISM1
22 11406977 T\G 0.15 0.175 0.039 5.51E-06 ISM1
6 50144883 A\C 0.44 -0.173 0.038 6.42E-06 SOX5
1 78195470 C\T 0.26 0.181 0.04 6.47E-06 MAP10
7 23131620 G\A 0.06 -0.175 0.039 7.25E-06 NXPE2
3 48758732 T\C 0.14 -0.184 0.041 7.34E-06 GPRIN3
20 46160950 A\G 0.28 -0.172 0.039 8.29E-06 GPR115
1 78578265 G\A 0.29 0.179 0.04 8.58E-06 SIPA1L2
22 11403577 G\A 0.15 0.173 0.039 8.70E-06 ISM1
1 181616615 T\C 0.38 -0.174 0.039 9.21E-06 MDGA2
7 26147791 C\A 0.38 0.166 0.038 9.49E-06 MPZL2
Table D.3: Significance values for all fasting glucose SNPs above suggestive threshold
chromosome position alleles maf beta standard p-value nearest
estimate error gene
8 9312611 T\C 0.31 0.24 0.046 1.55E-07 CRYBA4
22 26963686 A\G 0.35 0.231 0.046 5.48E-07 DLGAP4
22 26976287 T\C 0.35 0.228 0.046 7.04E-07 DLGAP4
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Table D.4: Significance values for all fasting insulin SNPs above suggestive threshold
chromosome position alleles maf beta standard p-value nearest
estimate error gene
10 53891179 T\C 0.15 0.192 0.034 9.54E-09 GRIK2
24 3597984 C\T 0.06 0.193 0.034 1.02E-08 ATG14
24 3595302 C\T 0.07 0.19 0.034 1.57E-08 ATG14
24 3595016 G\A 0.09 0.186 0.034 4.62E-08 ATG14
24 3597697 G\A 0.07 0.18 0.035 1.92E-07 ATG14
19 18465605 G\A 0.19 0.173 0.033 2.27E-07 MFN1
19 4295255 C\T 0.36 -0.177 0.034 2.32E-07 OTOL1
19 4296223 C\T 0.33 -0.173 0.034 3.39E-07 OTOL1
1 128192334 A\G 0.25 0.167 0.033 4.13E-07 DAPK2
4 49751990 A\G 0.48 0.176 0.035 4.53E-07 AHR
24 3593543 T\C 0.08 0.172 0.034 5.41E-07 ATG14
1 128205038 G\A 0.26 0.163 0.033 7.02E-07 DAPK2
19 4295476 A\G 0.34 -0.165 0.033 8.06E-07 OTOL1
4 49764439 C\T 0.47 0.173 0.035 9.28E-07 AHR
1 128156735 T\C 0.26 0.159 0.033 1.21E-06 DAPK2
17 75473022 A\G 0.42 -0.163 0.034 1.35E-06 FAM155A
1 128228461 G\A 0.25 0.154 0.032 1.36E-06 DAPK2
4 49752757 C\T 0.46 0.172 0.036 1.50E-06 AHR
4 49755552 T\C 0.45 0.172 0.036 1.58E-06 AHR
4 49767207 A\G 0.47 0.167 0.035 1.68E-06 AHR
1 128212104 T\C 0.26 0.157 0.033 1.70E-06 DAPK2
20 4333850 G\A 0.35 0.168 0.036 2.41E-06 FAM50B
4 49765839 G\A 0.45 0.169 0.036 2.47E-06 AHR
12 2818242 A\G 0.21 0.164 0.035 2.94E-06 COMMD9
9 58656992 T\C 0.31 -0.157 0.034 4.63E-06 TRPS1
10 53881774 T\C 0.14 0.155 0.034 4.66E-06 GRIK2
2 81787272 T\C 0.43 -0.149 0.033 4.79E-06 GATB
4 49754549 C\T 0.46 0.167 0.037 5.20E-06 AHR
19 4306032 A\G 0.35 -0.153 0.034 6.52E-06 OTOL1
19 4308928 C\A 0.33 -0.152 0.034 7.76E-06 OTOL1
30 24253197 C\T 0.42 -0.15 0.034 7.78E-06 KCNT2
12 2358224 A\G 0.17 0.158 0.036 9.18E-06 TRIM44
2 81787453 A\G 0.42 -0.145 0.033 9.70E-06 GATB
Table D.5: Significance values for all 75 minute post-OST glucose SNPs above suggestive
threshold
chromosome position alleles maf beta standard p-value nearest
estimate error gene
6 4059449 G\A 0.15 -0.211 0.044 1.30E-06 SPAG16
2 24516703 T\C 0.19 0.218 0.045 1.44E-06 HDAC1
2 24505077 T\C 0.19 0.214 0.045 2.43E-06 HDAC1
4 21624394 T\C 0.22 -0.219 0.046 2.49E-06 COBL
17 20363782 T\G 0.05 -0.212 0.045 2.67E-06 DLEU7
4 21702929 T\C 0.22 -0.214 0.047 4.41E-06 COBL
4 21650242 T\G 0.22 -0.212 0.047 6.06E-06 COBL
4 21658375 A\G 0.22 -0.212 0.047 6.06E-06 COBL
17 21698394 C\T 0.06 -0.202 0.045 7.26E-06 CAB39L
17 21713297 G\A 0.06 -0.202 0.045 7.26E-06 CAB39L
20 63223615 T\C 0.32 0.23 0.052 9.47E-06 RIMS1
26 15146523 C\T 0.08 0.198 0.045 9.84E-06 USP25
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Table D.6: Significance values for all 75 minute post-OST insulin SNPs above suggestive
threshold
chromosome position alleles maf beta standard p-value nearest
estimate error gene
21 20162158 C\A 0.12 -0.226 0.034 3.11E-11 ISL1
10 71766565 G\A 0.17 0.225 0.036 3.39E-10 RNF217
10 71762350 T\C 0.17 0.225 0.036 4.37E-10 RNF217
13 22385480 C\T 0.07 0.19 0.034 2.13E-08 ZKSCAN2
13 22420537 A\G 0.06 0.187 0.034 2.76E-08 ZKSCAN2
13 22421004 A\G 0.06 0.185 0.034 4.03E-08 ZKSCAN2
13 22437535 G\A 0.06 0.186 0.034 4.40E-08 AQP8
13 22452201 A\G 0.06 0.178 0.033 9.48E-08 AQP8
4 17084310 T\C 0.16 -0.175 0.033 1.16E-07 TNS3
10 70974737 A\C 0.09 0.184 0.035 1.59E-07 TRDN
10 71750321 C\T 0.21 0.186 0.036 2.26E-07 RNF217
4 17092940 T\G 0.15 -0.172 0.033 2.59E-07 TNS3
15 71121201 T\C 0.42 -0.175 0.035 3.99E-07 NCOA1
13 22463159 G\T 0.05 0.17 0.034 4.09E-07 LCMT1
10 16809864 A\C 0.34 -0.163 0.032 4.93E-07 DACT3
13 22419198 A\C 0.06 0.168 0.034 6.15E-07 ZKSCAN2
10 71796588 A\G 0.12 0.183 0.037 6.16E-07 RNF217
21 20164143 G\A 0.19 -0.179 0.036 6.42E-07 ISL1
10 71858123 C\T 0.13 0.182 0.037 9.55E-07 RNF217
21 20163997 T\C 0.16 -0.174 0.036 1.12E-06 ISL1
15 71183475 T\C 0.43 -0.168 0.035 1.21E-06 NCOA1
13 22369126 C\T 0.07 0.167 0.035 1.36E-06 ZKSCAN2
20 42730981 G\T 0.08 0.16 0.033 1.51E-06 VEGFA
15 71182984 C\T 0.44 -0.165 0.034 1.56E-06 NCOA1
10 71679132 A\G 0.11 0.177 0.037 1.84E-06 RNF217
4 17129514 C\T 0.24 -0.157 0.033 1.87E-06 TNS3
13 22444899 A\G 0.05 0.158 0.034 2.90E-06 AQP8
15 70830218 A\G 0.37 0.16 0.034 2.94E-06 EFR3B
4 17085239 C\T 0.16 -0.156 0.033 3.06E-06 TNS3
10 71826868 G\A 0.13 0.172 0.037 3.63E-06 RNF217
5 39031828 C\T 0.18 0.154 0.034 4.10E-06 OR10K1
4 17189808 A\G 0.16 -0.151 0.033 4.88E-06 TNS3
13 22430351 G\A 0.05 0.154 0.034 4.94E-06 ZKSCAN2
4 17182445 G\A 0.41 -0.154 0.034 5.01E-06 TNS3
17 1746473 C\A 0.24 0.163 0.036 5.26E-06 XPO4
14 65684935 A\G 0.13 -0.155 0.034 5.67E-06 NUDT12
15 71094746 G\A 0.36 0.155 0.034 5.99E-06 NCOA1
15 71174950 G\A 0.36 0.155 0.034 5.99E-06 NCOA1
15 71209535 G\A 0.36 0.155 0.034 5.99E-06 NCOA1
2 16703018 G\A 0.15 0.15 0.033 6.10E-06 HIVEP3
13 22512385 C\T 0.06 0.153 0.034 6.89E-06 LCMT1
13 22326057 A\G 0.12 0.161 0.036 7.11E-06 ZKSCAN2
15 71016734 A\G 0.46 -0.154 0.035 8.82E-06 ADCY3
15 71018294 T\C 0.46 -0.154 0.035 8.82E-06 ADCY3
15 71041540 G\A 0.46 -0.154 0.035 8.82E-06 ADCY3
21 20289132 G\T 0.16 -0.156 0.035 9.19E-06 ISL1
10 16768683 T\C 0.16 -0.153 0.035 9.31E-06 DACT3
14 65168563 A\G 0.1 -0.154 0.035 9.41E-06 EFNA5
4 16972268 G\T 0.12 -0.152 0.034 9.69E-06 TNS3
15 71059523 G\T 0.37 0.148 0.034 9.86E-06 ADCY3
10 71840480 A\C 0.13 0.163 0.037 9.98E-06 RNF217
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Table D.7: Significance values for all triglyceride SNPs above suggestive threshold
chromosome position alleles maf beta standard p-value nearest
estimate error gene
10 64538148 T\C 0.15 0.207 0.038 7.80E-08 FRK
10 64250362 T\C 0.11 0.193 0.038 2.92E-07 FRK
9 12293620 T\C 0.18 -0.19 0.038 8.18E-07 JPH1
9 12289659 A\G 0.18 -0.19 0.039 8.55E-07 JPH1
10 64589149 G\A 0.13 0.187 0.038 9.39E-07 FRK
4 95568021 T\C 0.17 0.179 0.037 1.08E-06 TRBV19
10 64305449 T\C 0.13 0.183 0.038 1.71E-06 FRK
10 64391361 T\G 0.13 0.181 0.038 2.14E-06 FRK
15 47489715 A\G 0.4 0.181 0.038 2.29E-06 GPR75-ASB3
24 43212532 A\C 0.28 -0.174 0.037 2.79E-06 DIO3
10 64616202 T\C 0.13 0.18 0.039 2.99E-06 FRK
10 64257474 C\T 0.14 0.178 0.038 3.08E-06 FRK
10 64644659 A\G 0.15 0.177 0.038 3.44E-06 FRK
9 12361673 C\T 0.14 -0.179 0.039 4.04E-06 JPH1
10 64157652 A\G 0.17 0.174 0.038 4.35E-06 FRK
9 12258786 G\A 0.12 -0.17 0.037 4.44E-06 GDAP1
10 64295072 G\T 0.1 0.17 0.037 5.85E-06 FRK
2 17237220 A\G 0.08 -0.183 0.04 6.35E-06 CTPS1
10 64339819 G\A 0.14 0.171 0.038 6.74E-06 FRK
9 12360677 T\C 0.15 -0.173 0.039 7.23E-06 JPH1
1 15523210 C\T 0.41 0.167 0.037 7.31E-06 PNLIPRP1
2 17209134 A\G 0.08 -0.182 0.041 7.31E-06 SCMH1
2 17213809 T\C 0.08 -0.182 0.041 7.31E-06 SCMH1
2 17215838 G\T 0.08 -0.182 0.041 7.31E-06 SCMH1
10 64256124 C\T 0.12 0.172 0.038 8.04E-06 FRK
2 16742567 A\G 0.08 -0.179 0.04 8.83E-06 HIVEP3
2 16751948 T\C 0.08 -0.179 0.04 8.83E-06 HIVEP3
2 16756518 A\G 0.08 -0.179 0.04 8.83E-06 HIVEP3
2 17045837 A\C 0.08 -0.179 0.04 8.83E-06 SCMH1
2 17048652 T\C 0.08 -0.179 0.04 8.83E-06 SCMH1
2 17087976 A\G 0.08 -0.179 0.04 8.83E-06 SCMH1
2 17119097 T\C 0.08 -0.179 0.04 8.83E-06 SCMH1
2 17124058 A\G 0.08 -0.179 0.04 8.83E-06 SCMH1
2 17151276 A\G 0.08 -0.179 0.04 8.83E-06 SCMH1
2 17261734 T\G 0.08 -0.179 0.04 8.83E-06 CTPS1
2 17268072 C\T 0.08 -0.179 0.04 8.83E-06 CTPS1
2 17269106 G\T 0.08 -0.179 0.04 8.83E-06 CTPS1
2 17274166 A\G 0.08 -0.179 0.04 8.83E-06 CTPS1
2 17275705 T\G 0.08 -0.179 0.04 8.83E-06 CTPS1
2 17282903 G\A 0.08 -0.179 0.04 8.83E-06 CTPS1
Table D.8: Significance values for all NEFA SNPs above suggestive threshold
chromosome position alleles maf beta standard p-value nearest
estimate error gene
18 8562608 G\A 0.33 0.227 0.033 4.36E-12 TSN
15 66792714 G\T 0.11 0.212 0.031 8.33E-12 ALK
18 8545866 A\G 0.33 0.221 0.033 1.73E-11 TSN
15 66684047 T\G 0.1 0.208 0.031 2.06E-11 ALK
15 66696394 A\G 0.1 0.208 0.031 2.06E-11 ALK
15 66738686 G\A 0.1 0.208 0.031 2.06E-11 ALK
15 66742079 A\G 0.1 0.208 0.031 2.06E-11 ALK
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15 66744419 T\G 0.1 0.208 0.031 2.06E-11 ALK
15 66772783 A\C 0.1 0.208 0.031 2.06E-11 ALK
15 66787386 T\C 0.1 0.208 0.031 2.06E-11 ALK
15 66791464 G\A 0.1 0.208 0.031 2.06E-11 ALK
15 66806634 T\C 0.1 0.208 0.031 2.06E-11 ALK
15 66834278 G\A 0.1 0.208 0.031 2.06E-11 ALK
15 66894519 T\C 0.1 0.208 0.031 2.06E-11 ALK
15 66916531 G\A 0.1 0.208 0.031 2.06E-11 ALK
1 164702224 A\G 0.18 0.206 0.031 2.35E-11 NOVA1
15 66625413 C\T 0.1 0.207 0.031 2.81E-11 ALK
15 66954402 A\G 0.1 0.207 0.031 2.81E-11 ALK
15 66978254 A\G 0.1 0.207 0.031 2.81E-11 ALK
18 8576176 C\A 0.33 0.219 0.033 3.59E-11 TSN
15 66621192 A\G 0.1 0.206 0.031 3.82E-11 ALK
15 66619562 C\T 0.1 0.206 0.031 4.01E-11 ALK
15 66592272 A\G 0.1 0.204 0.031 5.40E-11 YPEL5
15 66604806 G\A 0.1 0.204 0.031 5.40E-11 YPEL5
15 66427077 A\G 0.1 0.202 0.031 6.00E-11 LBH
15 66853554 C\T 0.1 0.204 0.031 8.19E-11 ALK
18 8583757 T\C 0.36 0.215 0.033 1.01E-10 TSN
15 66432918 G\T 0.1 0.199 0.031 1.39E-10 LBH
18 8494580 G\A 0.33 0.212 0.033 1.74E-10 TSN
18 8498505 T\C 0.37 0.211 0.033 1.78E-10 TSN
24 20975408 G\T 0.35 0.2 0.031 1.83E-10 FLVCR2
15 66980572 T\C 0.1 0.2 0.031 1.83E-10 ALK
18 8510544 T\C 0.32 0.213 0.034 1.95E-10 TSN
18 8526404 T\C 0.33 0.209 0.033 2.44E-10 TSN
15 66363627 A\G 0.1 0.196 0.031 2.57E-10 LBH
15 66315808 T\C 0.1 0.196 0.031 2.65E-10 LBH
15 66364189 A\G 0.1 0.196 0.031 2.65E-10 LBH
15 66230520 G\A 0.11 0.196 0.031 3.57E-10 LCLAT1
18 8522040 G\T 0.33 0.208 0.033 4.39E-10 TSN
15 66360884 C\T 0.1 0.193 0.031 4.56E-10 LBH
15 66257969 C\T 0.1 0.193 0.031 5.65E-10 LCLAT1
15 66263349 T\C 0.1 0.193 0.031 5.65E-10 LCLAT1
15 66281832 G\A 0.1 0.193 0.031 5.65E-10 LCLAT1
15 66312187 C\T 0.1 0.193 0.031 5.65E-10 LBH
18 8552881 A\G 0.37 0.202 0.033 6.20E-10 TSN
15 66353731 G\A 0.1 0.192 0.031 6.25E-10 LBH
15 66354719 C\T 0.1 0.192 0.031 6.25E-10 LBH
15 66362587 T\C 0.1 0.192 0.031 6.25E-10 LBH
15 66368420 T\G 0.1 0.192 0.031 6.25E-10 LBH
15 66370910 C\A 0.1 0.192 0.031 6.25E-10 LBH
15 66897447 A\G 0.06 0.199 0.032 9.44E-10 ALK
1 183728003 G\A 0.23 -0.192 0.031 9.68E-10 KLHDC1
18 8541982 A\G 0.37 0.204 0.033 9.88E-10 TSN
18 8518139 G\A 0.4 0.196 0.032 1.06E-09 TSN
18 8868366 C\T 0.31 0.205 0.034 1.07E-09 TSN
15 66271610 A\G 0.1 0.188 0.031 1.27E-09 LCLAT1
18 8898085 A\G 0.3 0.205 0.034 1.44E-09 TSN
15 66451849 A\G 0.07 0.194 0.032 1.53E-09 LBH
15 66203067 C\A 0.12 0.188 0.031 2.23E-09 LCLAT1
15 66189967 C\T 0.12 0.185 0.031 3.26E-09 LCLAT1
15 67012184 T\C 0.1 0.187 0.032 3.26E-09 ALK
15 67056101 T\C 0.1 0.187 0.032 3.26E-09 ALK
15 67061889 G\A 0.1 0.187 0.032 3.26E-09 ALK
15 67081698 C\T 0.1 0.187 0.032 3.26E-09 ALK
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15 67107022 T\C 0.1 0.187 0.032 3.26E-09 ALK
15 67122584 A\G 0.1 0.187 0.032 3.26E-09 ALK
15 67125854 A\C 0.1 0.187 0.032 3.26E-09 ALK
15 67155661 C\A 0.1 0.187 0.032 3.26E-09 ALK
15 67171958 T\G 0.1 0.187 0.032 3.26E-09 ALK
15 67183880 T\C 0.1 0.187 0.032 3.26E-09 ALK
15 67213022 T\C 0.1 0.187 0.032 3.26E-09 ALK
15 67213270 T\C 0.1 0.187 0.032 3.26E-09 ALK
15 67228685 A\C 0.1 0.187 0.032 3.26E-09 ALK
15 67229504 A\G 0.1 0.187 0.032 3.26E-09 ALK
15 67236481 A\G 0.1 0.187 0.032 3.26E-09 ALK
15 67260893 T\C 0.1 0.187 0.032 3.26E-09 ALK
15 67300229 C\T 0.1 0.187 0.032 3.26E-09 ALK
15 67326188 A\G 0.1 0.187 0.032 3.26E-09 ALK
15 66184961 A\C 0.13 0.184 0.031 3.55E-09 LCLAT1
18 8948638 G\A 0.26 0.204 0.035 4.66E-09 TSN
18 9016362 G\A 0.26 0.204 0.035 4.91E-09 NIFK
15 66988869 A\G 0.14 0.182 0.031 5.34E-09 ALK
15 66141154 A\G 0.13 0.181 0.031 7.92E-09 LCLAT1
18 8569273 G\A 0.41 0.191 0.033 8.22E-09 TSN
18 8607534 T\G 0.37 0.184 0.032 9.77E-09 TSN
15 66110588 G\A 0.13 0.178 0.031 1.00E-08 LCLAT1
7 84765240 T\C 0.46 0.18 0.032 1.16E-08 SOX6
18 8917708 C\A 0.26 0.197 0.035 1.56E-08 TSN
15 66029737 G\A 0.16 0.172 0.031 1.81E-08 CAPN13
18 9401773 T\C 0.27 0.193 0.034 1.92E-08 TFCP2L1
18 8981003 A\G 0.26 0.194 0.035 2.20E-08 NIFK
18 8593141 T\G 0.43 0.183 0.033 2.47E-08 TSN
18 8657735 C\T 0.35 0.186 0.033 2.54E-08 TSN
15 66053380 T\C 0.14 0.176 0.032 2.61E-08 LCLAT1
18 8408544 A\G 0.29 0.186 0.033 2.63E-08 TSN
15 66032805 A\G 0.14 0.172 0.031 2.65E-08 CAPN13
18 8547549 C\T 0.48 0.179 0.032 2.70E-08 TSN
18 8649138 A\G 0.34 0.186 0.033 2.72E-08 TSN
1 183663863 G\T 0.19 -0.179 0.032 2.88E-08 DNAAF2
1 183668205 T\C 0.19 -0.179 0.032 2.88E-08 DNAAF2
15 66135520 T\G 0.13 0.173 0.031 3.10E-08 LCLAT1
18 8505327 C\T 0.42 0.185 0.033 3.41E-08 TSN
7 84803850 G\A 0.48 0.174 0.032 3.64E-08 SOX6
2 105684803 G\T 0.11 0.165 0.03 4.03E-08 ADAD1
18 8729227 C\A 0.45 0.174 0.032 4.06E-08 TSN
18 7731541 C\A 0.35 0.176 0.032 4.30E-08 CNTNAP5
2 105698972 A\G 0.1 0.165 0.03 4.44E-08 ADAD1
15 66052656 T\C 0.13 0.173 0.032 4.48E-08 LCLAT1
15 66061042 G\T 0.13 0.173 0.032 4.48E-08 LCLAT1
18 8678717 C\A 0.34 0.183 0.033 4.62E-08 TSN
18 8625323 T\C 0.35 0.183 0.034 4.66E-08 TSN
15 66948962 C\T 0.14 0.171 0.031 4.90E-08 ALK
15 66083987 G\A 0.13 0.17 0.031 5.06E-08 LCLAT1
15 66605848 A\C 0.14 0.172 0.032 5.24E-08 YPEL5
18 8964561 G\A 0.27 0.189 0.035 5.45E-08 TSN
18 8651943 T\C 0.34 0.183 0.034 5.46E-08 TSN
1 184178932 A\G 0.19 -0.173 0.032 5.46E-08 ATP5S
18 7732359 T\C 0.35 0.175 0.032 5.55E-08 CNTNAP5
18 8638988 C\A 0.34 0.182 0.033 5.84E-08 TSN
18 8407744 G\T 0.28 0.181 0.033 5.99E-08 TSN
15 66790529 G\A 0.15 0.172 0.032 6.42E-08 ALK
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1 183675692 C\T 0.19 -0.175 0.032 6.76E-08 POLE2
18 8699152 A\G 0.36 0.181 0.033 6.80E-08 TSN
1 183685920 A\C 0.19 -0.174 0.032 7.11E-08 POLE2
1 183729679 G\A 0.19 -0.174 0.032 7.11E-08 KLHDC1
1 183745396 A\G 0.19 -0.174 0.032 7.11E-08 KLHDC1
1 183791455 C\T 0.19 -0.174 0.032 7.11E-08 NEMF
18 8544905 A\G 0.48 0.172 0.032 7.69E-08 TSN
10 13860272 G\A 0.33 0.163 0.03 7.87E-08 LYPD4
15 66065116 T\C 0.13 0.169 0.031 8.03E-08 LCLAT1
15 66035187 T\C 0.13 0.168 0.031 8.42E-08 LCLAT1
15 66925052 A\G 0.14 0.169 0.031 8.49E-08 ALK
15 66936323 A\G 0.14 0.169 0.031 8.49E-08 ALK
15 66947690 A\G 0.14 0.169 0.031 8.49E-08 ALK
18 9410752 A\C 0.26 0.187 0.035 9.08E-08 TFCP2L1
7 84804729 G\A 0.46 0.168 0.031 9.12E-08 SOX6
18 9407363 C\T 0.31 0.182 0.034 9.27E-08 TFCP2L1
15 66166383 G\A 0.13 0.169 0.032 9.41E-08 LCLAT1
18 9040798 G\A 0.33 0.18 0.034 9.56E-08 CLASP1
15 66138051 C\T 0.13 0.168 0.032 1.04E-07 LCLAT1
18 8651718 C\T 0.34 0.179 0.034 1.05E-07 TSN
18 8440080 A\G 0.24 0.178 0.034 1.27E-07 TSN
18 8409473 T\C 0.28 0.176 0.033 1.38E-07 TSN
18 8997736 C\T 0.34 0.172 0.033 1.49E-07 NIFK
18 7863587 T\G 0.33 0.171 0.033 1.63E-07 TSN
2 105681701 C\A 0.1 0.159 0.03 1.71E-07 ADAD1
18 9090283 G\A 0.31 0.177 0.034 1.73E-07 CLASP1
15 66151620 T\C 0.13 0.165 0.032 1.80E-07 LCLAT1
18 7806575 T\C 0.34 0.169 0.033 1.96E-07 CNTNAP5
18 8388383 A\C 0.24 0.176 0.034 2.10E-07 TSN
18 7826885 T\G 0.33 0.168 0.032 2.16E-07 TSN
18 7827332 C\T 0.33 0.167 0.032 2.60E-07 TSN
1 183865146 C\T 0.19 -0.167 0.032 2.64E-07 ARF6
15 66120688 G\T 0.13 0.161 0.031 2.64E-07 LCLAT1
18 9407244 T\C 0.27 0.177 0.034 2.86E-07 TFCP2L1
18 7757777 T\C 0.33 0.166 0.032 2.96E-07 CNTNAP5
1 183813125 G\A 0.2 -0.166 0.032 2.99E-07 NEMF
18 7824472 G\A 0.33 0.166 0.032 3.11E-07 TSN
18 7758382 C\A 0.35 0.168 0.033 3.20E-07 CNTNAP5
18 7896646 A\G 0.33 0.167 0.033 3.36E-07 TSN
1 183724896 C\A 0.23 -0.164 0.032 3.39E-07 KLHDC1
2 105683559 A\G 0.13 0.162 0.032 3.41E-07 ADAD1
1 183813707 C\T 0.32 -0.161 0.032 3.47E-07 NEMF
18 7770342 T\C 0.33 0.165 0.032 3.56E-07 CNTNAP5
18 8443887 A\G 0.35 0.172 0.034 3.59E-07 TSN
18 7733248 T\G 0.24 0.167 0.033 3.62E-07 CNTNAP5
18 9031138 A\G 0.25 0.175 0.034 3.73E-07 CLASP1
18 8833594 G\A 0.3 0.17 0.034 3.79E-07 TSN
1 183829350 C\T 0.2 -0.164 0.032 3.83E-07 NEMF
1 183840941 C\A 0.2 -0.164 0.032 3.83E-07 NEMF
18 9126396 G\A 0.29 0.175 0.034 3.96E-07 CLASP1
15 65944235 G\A 0.11 0.158 0.031 4.03E-07 CAPN13
15 65776991 G\A 0.09 0.159 0.031 4.21E-07 GALNT14
2 1779499 T\C 0.08 0.155 0.031 4.75E-07 OMA1
2 105711808 C\T 0.1 0.154 0.031 5.46E-07 ADAD1
24 21008374 T\C 0.14 -0.159 0.032 6.14E-07 FLVCR2
18 9079802 G\A 0.28 0.175 0.035 6.30E-07 CLASP1
18 8535293 C\T 0.46 0.162 0.033 6.59E-07 TSN
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15 66022795 G\A 0.15 0.157 0.032 6.63E-07 CAPN13
24 21529408 G\A 0.22 -0.16 0.032 6.66E-07 TGFB3
18 8834248 T\G 0.34 0.165 0.033 6.83E-07 TSN
24 20468564 A\C 0.45 -0.16 0.032 7.40E-07 EIF2B2
18 8701876 G\A 0.5 0.164 0.033 7.41E-07 TSN
18 8538709 T\C 0.46 0.162 0.033 7.51E-07 TSN
18 8542644 G\A 0.46 0.162 0.033 7.51E-07 TSN
18 8729817 G\A 0.43 0.158 0.032 8.19E-07 TSN
10 13465934 A\G 0.45 0.156 0.032 8.57E-07 TMEM145
18 8863197 G\A 0.32 0.161 0.033 8.91E-07 TSN
18 9076539 C\T 0.28 0.172 0.035 9.17E-07 CLASP1
1 164921944 C\T 0.07 -0.154 0.031 9.18E-07 NOVA1
15 65931933 T\C 0.11 0.151 0.031 9.42E-07 CAPN13
18 9292376 G\A 0.31 0.167 0.034 9.77E-07 CLASP1
18 9102040 C\A 0.34 0.171 0.035 9.79E-07 CLASP1
2 105718349 T\C 0.11 0.148 0.03 1.15E-06 ADAD1
24 21015302 C\T 0.29 -0.149 0.031 1.21E-06 FLVCR2
2 105672114 A\C 0.13 0.153 0.032 1.28E-06 ADAD1
1 164883297 A\G 0.08 -0.153 0.032 1.31E-06 NOVA1
18 8547924 G\A 0.48 -0.159 0.033 1.31E-06 TSN
10 13850810 T\C 0.33 0.151 0.031 1.57E-06 LYPD4
15 65879226 C\T 0.11 0.152 0.032 1.57E-06 GALNT14
18 9408052 C\A 0.33 0.161 0.034 1.70E-06 TFCP2L1
30 19352250 T\G 0.09 0.145 0.031 1.98E-06 BRINP3
15 65885117 T\C 0.11 0.149 0.031 2.01E-06 GALNT14
24 21392431 A\G 0.15 -0.154 0.032 2.04E-06 TTLL5
1 183129885 C\T 0.29 0.149 0.031 2.13E-06 RPS29
18 8645466 T\C 0.47 0.157 0.033 2.16E-06 TSN
18 9039740 C\A 0.41 0.153 0.032 2.25E-06 CLASP1
18 8735008 C\T 0.44 0.153 0.032 2.30E-06 TSN
18 9306019 C\A 0.31 0.162 0.034 2.34E-06 CLASP1
18 8683786 A\G 0.4 0.155 0.033 2.58E-06 TSN
1 183808579 C\T 0.28 -0.149 0.032 2.69E-06 NEMF
24 21177322 A\G 0.26 -0.147 0.031 2.75E-06 FLVCR2
1 164735535 A\G 0.13 0.151 0.032 2.96E-06 NOVA1
1 183612813 A\G 0.09 -0.146 0.031 2.97E-06 RPS29
18 9245778 G\A 0.32 0.163 0.035 2.99E-06 CLASP1
1 183691527 G\A 0.28 -0.144 0.031 3.06E-06 POLE2
18 7745107 T\G 0.23 0.154 0.033 3.07E-06 CNTNAP5
18 9041020 C\A 0.34 0.161 0.035 3.12E-06 CLASP1
18 9063071 T\C 0.27 0.161 0.035 3.23E-06 CLASP1
1 164672635 C\T 0.21 -0.142 0.03 3.27E-06 NOVA1
1 164604740 C\T 0.15 0.149 0.032 3.29E-06 NOVA1
18 9152025 C\T 0.32 0.16 0.035 3.38E-06 CLASP1
9 74443615 C\T 0.22 -0.139 0.03 3.40E-06 ST3GAL1
30 20138883 G\A 0.07 0.139 0.03 3.45E-06 BRINP3
11 56669565 A\G 0.21 -0.145 0.031 3.50E-06 HS3ST3B1
1 164741882 G\T 0.12 0.147 0.032 3.51E-06 NOVA1
14 80043766 C\T 0.09 0.146 0.032 3.54E-06 RN7SKP34
14 80059792 G\A 0.09 0.146 0.032 3.54E-06 RN7SKP34
14 80079214 G\A 0.09 0.146 0.032 3.54E-06 RN7SKP34
14 80083457 T\G 0.09 0.146 0.032 3.54E-06 RN7SKP34
14 80121164 G\A 0.09 0.146 0.032 3.54E-06 RN7SKP34
14 80143894 T\G 0.09 0.146 0.032 3.54E-06 RN7SKP34
14 80157090 A\G 0.09 0.146 0.032 3.54E-06 RN7SKP34
14 80169308 T\G 0.09 0.146 0.032 3.54E-06 RN7SKP34
15 66307107 T\C 0.2 0.148 0.032 3.57E-06 LCLAT1
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1 183773554 A\G 0.28 -0.145 0.031 3.60E-06 KLHDC2
18 8695239 T\C 0.45 0.156 0.034 3.67E-06 TSN
10 14225679 A\G 0.42 0.141 0.03 3.73E-06 CD177
7 85044894 T\C 0.12 0.138 0.03 3.78E-06 C11orf58
18 7754632 G\T 0.21 0.15 0.032 3.79E-06 CNTNAP5
1 164863262 G\A 0.06 -0.145 0.031 3.87E-06 NOVA1
1 164879729 A\G 0.07 -0.146 0.032 4.08E-06 NOVA1
15 66891533 A\G 0.17 0.154 0.033 4.08E-06 ALK
9 74555200 C\T 0.11 -0.137 0.03 4.12E-06 ZFAT
15 66810086 C\T 0.17 0.153 0.033 4.21E-06 ALK
24 19986094 A\G 0.1 -0.151 0.033 4.25E-06 ISCA2
18 9227305 T\C 0.31 0.159 0.035 4.51E-06 CLASP1
14 80095754 T\C 0.1 0.144 0.032 4.72E-06 RN7SKP34
1 164686433 T\C 0.15 0.146 0.032 4.86E-06 NOVA1
18 9327923 C\T 0.32 0.157 0.034 4.88E-06 CLASP1
1 183829193 C\T 0.28 -0.145 0.032 5.03E-06 NEMF
24 20660972 T\C 0.38 -0.147 0.032 5.08E-06 FOS
11 56211286 G\A 0.4 -0.135 0.03 5.15E-06 COX10
24 21593980 T\G 0.18 -0.144 0.032 5.16E-06 IFT43
18 8601859 A\G 0.43 -0.156 0.034 5.26E-06 TSN
1 164942346 T\C 0.05 -0.142 0.031 5.30E-06 NOVA1
1 35305763 C\T 0.29 0.144 0.032 5.46E-06 LGI1
1 164712972 T\C 0.14 0.144 0.032 5.67E-06 NOVA1
18 8602353 C\T 0.33 -0.15 0.033 5.78E-06 TSN
1 184259015 G\T 0.08 -0.143 0.032 5.96E-06 MAP4K5
1 164648967 T\C 0.12 0.148 0.033 6.11E-06 NOVA1
11 56150165 A\G 0.35 -0.135 0.03 6.25E-06 COX10
11 56176479 G\A 0.35 -0.135 0.03 6.25E-06 COX10
11 56177741 G\A 0.35 -0.135 0.03 6.25E-06 COX10
11 56188490 T\C 0.35 -0.135 0.03 6.25E-06 COX10
11 56192007 G\A 0.35 -0.135 0.03 6.25E-06 COX10
1 164668494 A\C 0.11 0.144 0.032 6.30E-06 NOVA1
1 164764475 C\A 0.11 0.146 0.032 6.42E-06 NOVA1
1 164698836 C\T 0.12 0.143 0.032 6.45E-06 NOVA1
24 21010123 C\T 0.21 0.14 0.031 6.46E-06 FLVCR2
18 75270775 G\A 0.14 -0.136 0.03 6.47E-06 KCTD18
1 164953244 C\T 0.06 -0.142 0.032 6.51E-06 NOVA1
18 8600593 G\A 0.47 -0.154 0.034 6.80E-06 TSN
1 164717730 T\C 0.23 -0.139 0.031 7.09E-06 NOVA1
1 183910385 T\C 0.09 -0.141 0.031 7.29E-06 ARF6
11 56192263 C\A 0.36 -0.135 0.03 7.29E-06 COX10
1 165022857 C\T 0.17 -0.144 0.032 7.34E-06 NOVA1
24 21009749 C\T 0.21 -0.139 0.031 7.48E-06 FLVCR2
1 183771607 C\A 0.28 -0.141 0.031 7.59E-06 KLHDC2
18 9493407 A\G 0.38 0.146 0.033 7.71E-06 TFCP2L1
2 105649694 C\T 0.11 0.141 0.031 7.79E-06 IL2
18 9189622 G\T 0.32 0.153 0.034 7.83E-06 CLASP1
15 65996462 G\A 0.22 0.14 0.031 7.94E-06 CAPN13
10 14099221 T\C 0.33 0.136 0.03 8.03E-06 CD177
1 164809494 A\G 0.13 0.144 0.032 8.32E-06 NOVA1
1 164685130 T\C 0.12 0.144 0.032 8.34E-06 NOVA1
15 67018469 T\C 0.13 0.143 0.032 8.38E-06 ALK
18 9242801 G\A 0.34 0.156 0.035 8.39E-06 CLASP1
18 9263983 G\T 0.34 0.156 0.035 8.39E-06 CLASP1
18 9275291 A\G 0.34 0.156 0.035 8.39E-06 CLASP1
18 9284287 A\G 0.34 0.156 0.035 8.39E-06 CLASP1
2 1794459 A\C 0.08 0.138 0.031 8.76E-06 OMA1
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9 74571038 C\T 0.12 -0.134 0.03 8.76E-06 ZFAT
30 5917999 G\A 0.44 -0.136 0.031 8.83E-06 CNST
15 66836058 C\T 0.18 0.149 0.033 8.85E-06 ALK
15 66014620 A\G 0.17 0.139 0.031 8.86E-06 CAPN13
9 74557346 T\C 0.11 -0.133 0.03 9.21E-06 ZFAT
24 20894432 G\A 0.1 -0.146 0.033 9.31E-06 BATF
24 20895972 A\G 0.1 -0.146 0.033 9.31E-06 BATF
24 20896831 C\T 0.1 -0.146 0.033 9.31E-06 BATF
24 20899682 T\C 0.1 -0.146 0.033 9.31E-06 BATF
24 21000833 A\G 0.1 -0.146 0.033 9.31E-06 FLVCR2
10 14461597 G\A 0.33 0.133 0.03 9.50E-06 LYPD3
Table D.9: Significance values for all ACTH SNPs above suggestive threshold
chromosome position alleles maf beta standard p-value nearest
estimate error gene
22 37596454 C\T 0.23 0.219 0.033 2.14E-11 SNORD12
22 37601007 T\C 0.23 0.215 0.033 7.51E-11 KCNB1
21 10999900 A\G 0.13 0.223 0.035 1.90E-10 KIF2A
22 37297516 A\C 0.23 0.191 0.034 2.32E-08 ARFGEF2
21 23724278 T\C 0.18 -0.182 0.033 4.04E-08 SEPP1
21 23726763 C\T 0.18 -0.182 0.033 4.04E-08 SEPP1
21 23727790 G\A 0.18 -0.182 0.033 4.04E-08 SEPP1
21 11050713 G\T 0.32 0.184 0.035 9.77E-08 KIF2A
22 37302580 T\C 0.23 0.182 0.034 1.27E-07 ARFGEF2
25 14650611 T\C 0.09 0.164 0.032 4.05E-07 EPB41L4B
22 37594118 C\T 0.31 0.168 0.033 4.07E-07 SNORD12
21 11322078 G\T 0.1 0.174 0.035 6.44E-07 ZSWIM6
21 11206546 C\T 0.08 0.18 0.036 6.74E-07 KIF2A
21 11306260 A\G 0.08 0.18 0.036 6.74E-07 ZSWIM6
21 11318205 C\T 0.08 0.18 0.036 6.74E-07 ZSWIM6
21 11347296 C\T 0.08 0.18 0.036 6.74E-07 ZSWIM6
21 11370637 T\G 0.08 0.18 0.036 6.74E-07 ZSWIM6
21 11392097 A\G 0.08 0.18 0.036 6.74E-07 ZSWIM6
21 11323510 C\T 0.1 0.175 0.035 7.05E-07 ZSWIM6
21 11115562 C\T 0.08 0.181 0.037 7.57E-07 KIF2A
13 24087845 C\T 0.25 0.184 0.037 8.73E-07 SCNN1B
21 10410234 C\T 0.13 0.173 0.035 8.80E-07 IPO11
3 101439577 G\A 0.26 0.167 0.034 9.52E-07 GBA3
21 11135499 G\A 0.08 0.177 0.036 1.01E-06 KIF2A
3 101389612 T\C 0.26 0.169 0.035 1.05E-06 GBA3
22 37213519 C\A 0.24 0.167 0.034 1.21E-06 ARFGEF2
22 37294366 T\C 0.05 0.166 0.034 1.29E-06 ARFGEF2
3 101429436 C\T 0.27 0.165 0.034 1.42E-06 GBA3
3 101435557 T\C 0.27 0.165 0.034 1.42E-06 GBA3
3 101447867 G\A 0.27 0.165 0.034 1.42E-06 GBA3
3 101439891 A\G 0.27 0.165 0.034 1.46E-06 GBA3
3 101457464 C\A 0.27 0.163 0.034 1.57E-06 GBA3
22 37684328 C\T 0.06 0.161 0.034 1.74E-06 KCNB1
20 28706883 T\C 0.22 -0.152 0.032 1.79E-06 OR2H1
3 101426791 C\T 0.32 0.161 0.034 1.98E-06 GBA3
22 38275543 A\G 0.1 0.163 0.035 2.59E-06 TMEM189
3 101445648 G\T 0.26 0.162 0.035 2.73E-06 GBA3
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22 37709717 T\G 0.07 0.153 0.033 3.70E-06 KCNB1
3 101391352 G\T 0.24 0.16 0.035 3.74E-06 GBA3
3 101469263 A\C 0.26 0.16 0.035 3.85E-06 GBA3
21 10995125 C\A 0.16 0.166 0.036 4.18E-06 KIF2A
22 37595803 C\T 0.46 0.151 0.033 4.23E-06 SNORD12
13 24073474 C\A 0.21 0.168 0.037 4.39E-06 SCNN1B
21 11307724 C\T 0.27 0.162 0.035 4.50E-06 ZSWIM6
22 37696602 C\T 0.08 0.153 0.033 4.51E-06 KCNB1
22 38277626 A\G 0.1 0.159 0.035 4.53E-06 TMEM189
22 37340019 A\G 0.21 -0.153 0.033 4.60E-06 ARFGEF2
22 37509740 T\C 0.27 -0.156 0.034 4.67E-06 DDX27
22 37592331 T\C 0.31 0.154 0.034 4.91E-06 SNORD12
22 37350157 C\T 0.21 -0.152 0.033 5.24E-06 ARFGEF2
22 37683894 C\A 0.06 0.152 0.033 5.33E-06 KCNB1
22 37696485 A\G 0.06 0.152 0.033 5.33E-06 KCNB1
22 37251815 G\A 0.05 0.154 0.034 5.43E-06 ARFGEF2
22 37253365 G\A 0.05 0.154 0.034 5.43E-06 ARFGEF2
22 38255100 T\C 0.1 0.155 0.034 5.86E-06 TMEM189
21 10979760 G\A 0.28 0.157 0.035 5.92E-06 KIF2A
3 101429197 T\C 0.27 0.155 0.034 6.72E-06 GBA3
22 40740864 C\A 0.39 0.133 0.03 7.19E-06 TSHZ2
22 37327242 C\T 0.05 0.155 0.035 8.25E-06 ARFGEF2
22 37401442 G\A 0.06 0.15 0.034 8.35E-06 CSE1L
22 37303532 G\A 0.23 -0.151 0.034 8.41E-06 ARFGEF2
22 37751615 G\A 0.07 0.148 0.033 8.52E-06 PTGIS
22 38232323 T\C 0.1 0.154 0.035 8.89E-06 TMEM189
22 37422561 C\A 0.35 -0.149 0.034 9.07E-06 STAU1
20 28682224 G\A 0.22 -0.143 0.032 9.36E-06 UBD
21 23709379 G\A 0.06 0.145 0.033 9.75E-06 SEPP1
21 23736680 C\T 0.06 0.145 0.033 9.75E-06 SEPP1
22 37647086 C\T 0.31 -0.151 0.034 9.78E-06 KCNB1
Table D.10: Significance values for all leptin SNPs above suggestive threshold
chromosome position alleles maf beta standard p-value nearest
estimate error gene
19 49581025 G\A 0.23 -0.187 0.037 5.42E-07 CCDC54
19 48941767 A\G 0.23 -0.182 0.037 1.14E-06 BBX
19 48987630 A\G 0.23 -0.18 0.037 1.31E-06 BBX
19 49102373 T\G 0.24 -0.18 0.037 1.32E-06 BBX
19 48936677 T\C 0.22 -0.179 0.037 1.50E-06 BBX
19 48942697 G\A 0.22 -0.179 0.037 1.50E-06 BBX
19 49011908 C\T 0.23 -0.178 0.037 1.78E-06 BBX
19 49038033 T\C 0.23 -0.178 0.037 1.78E-06 BBX
19 49022570 T\C 0.23 -0.177 0.037 1.98E-06 BBX
19 49050327 C\T 0.23 -0.177 0.037 1.98E-06 BBX
19 49055203 G\A 0.23 -0.177 0.037 1.98E-06 BBX
19 49068376 T\C 0.23 -0.176 0.037 1.99E-06 BBX
19 49500590 A\G 0.22 -0.178 0.038 2.22E-06 CCDC54
19 49444445 A\G 0.23 -0.176 0.037 2.47E-06 CCDC54
19 11111059 T\C 0.42 -0.18 0.038 2.56E-06 RPL22L1
14 47283907 G\A 0.23 0.181 0.039 2.79E-06 MEGF10
19 49601357 T\C 0.23 -0.175 0.037 2.80E-06 CCDC54
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19 49540241 A\C 0.23 -0.175 0.038 3.04E-06 CCDC54
19 49485717 T\C 0.22 -0.175 0.038 3.34E-06 CCDC54
19 49492656 G\A 0.22 -0.174 0.038 3.85E-06 CCDC54
19 49620200 C\A 0.32 -0.168 0.037 4.46E-06 CCDC54
1 54004249 G\A 0.21 0.175 0.038 5.43E-06 CTNNA3
19 49459767 G\T 0.22 -0.17 0.037 5.63E-06 CCDC54
2 51826889 A\G 0.1 0.161 0.036 5.78E-06 RHOBTB2
19 49554094 T\C 0.23 -0.17 0.038 5.82E-06 CCDC54
3 25187849 C\T 0.18 -0.173 0.038 5.92E-06 CNTNAP4
19 49032937 T\C 0.25 -0.167 0.038 9.04E-06 BBX
19 49529333 T\G 0.22 -0.167 0.038 9.15E-06 CCDC54
6 38093791 G\A 0.13 0.155 0.035 9.32E-06 KLRC1
Table D.11: Significance values for all adiponectin SNPs above suggestive threshold
chromosome position alleles maf beta standard p-value nearest
estimate error gene
15 21018128 A\G 0.11 -0.2 0.033 1.85E-09 ST6GALNAC2
15 21026780 A\G 0.11 -0.196 0.033 4.38E-09 ST6GALNAC2
15 21025772 T\C 0.1 -0.193 0.034 8.67E-09 ST6GALNAC2
22 18132778 C\T 0.15 -0.194 0.035 2.83E-08 SLC23A2
15 22055134 G\A 0.07 -0.183 0.034 5.81E-08 RN7SKP218
15 21431973 A\C 0.11 -0.184 0.034 7.33E-08 ST6GALNAC2
15 21500853 C\T 0.12 -0.185 0.035 9.16E-08 ST6GALNAC2
15 21475823 G\A 0.14 -0.186 0.035 9.74E-08 ST6GALNAC2
15 21178845 A\G 0.38 -0.175 0.033 1.09E-07 ST6GALNAC2
15 22054804 G\A 0.09 -0.179 0.034 1.32E-07 RN7SKP218
24 24582154 G\A 0.15 -0.171 0.033 1.88E-07 NRXN3
15 21999784 C\A 0.07 -0.176 0.034 2.36E-07 RN7SKP218
6 68035083 G\A 0.11 0.178 0.035 2.71E-07 DIP2B
15 22035163 G\T 0.08 -0.17 0.033 3.61E-07 RN7SKP218
15 21500312 T\G 0.18 -0.173 0.034 3.84E-07 ST6GALNAC2
22 18140627 T\C 0.15 -0.173 0.034 4.41E-07 SLC23A2
24 24582743 T\C 0.1 -0.16 0.032 5.19E-07 NRXN3
15 21452496 C\T 0.12 -0.17 0.034 7.06E-07 ST6GALNAC2
15 21414572 C\A 0.12 -0.167 0.034 7.33E-07 ST6GALNAC2
15 21271186 C\T 0.14 -0.168 0.034 7.50E-07 ST6GALNAC2
15 22052424 C\T 0.07 -0.169 0.034 8.06E-07 RN7SKP218
2 85771023 G\A 0.17 -0.169 0.034 8.62E-07 TTC29
4 37502360 C\T 0.23 -0.165 0.033 8.96E-07 GNGT1
22 18212199 G\A 0.06 -0.167 0.034 9.26E-07 SLC23A2
15 22026177 C\T 0.08 -0.163 0.033 9.67E-07 RN7SKP218
15 22000800 C\T 0.08 -0.165 0.034 1.07E-06 RN7SKP218
15 21397014 C\A 0.12 -0.165 0.034 1.15E-06 ST6GALNAC2
4 37502144 C\T 0.23 -0.161 0.033 1.31E-06 GNGT1
15 21289677 A\G 0.13 -0.163 0.034 1.75E-06 ST6GALNAC2
15 21366722 G\T 0.16 -0.161 0.034 1.80E-06 ST6GALNAC2
22 18191701 G\A 0.07 -0.164 0.034 1.96E-06 SLC23A2
24 24557290 T\C 0.09 -0.155 0.033 2.21E-06 NRXN3
22 18181290 C\T 0.06 -0.16 0.034 2.38E-06 SLC23A2
20 3585516 G\T 0.35 -0.155 0.033 2.85E-06 RIPK1
22 18135640 C\T 0.06 -0.159 0.034 2.86E-06 SLC23A2
22 18196266 C\A 0.06 -0.16 0.034 3.14E-06 SLC23A2
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15 21631031 G\A 0.06 -0.156 0.033 3.20E-06 RN7SKP218
2 17691609 T\C 0.11 -0.161 0.035 3.91E-06 ZFP69B
15 21380094 C\A 0.16 -0.155 0.033 3.95E-06 ST6GALNAC2
15 21154707 C\T 0.42 -0.155 0.034 4.27E-06 ST6GALNAC2
4 37196258 C\T 0.26 -0.155 0.034 4.79E-06 CALCR
6 68036518 G\A 0.11 0.159 0.035 4.81E-06 DIP2B
4 37412203 C\A 0.44 -0.149 0.033 4.84E-06 GNGT1
19 44097058 C\A 0.1 -0.154 0.034 4.86E-06 GRAMD1C
22 18154533 C\A 0.06 -0.157 0.034 4.90E-06 SLC23A2
15 21281057 C\T 0.22 -0.152 0.033 5.34E-06 ST6GALNAC2
15 21150905 C\T 0.39 -0.155 0.034 6.09E-06 ST6GALNAC2
15 21387001 G\T 0.14 -0.155 0.034 6.11E-06 ST6GALNAC2
15 21331324 T\C 0.16 -0.152 0.034 6.31E-06 ST6GALNAC2
24 24540980 A\G 0.09 -0.146 0.033 7.21E-06 NRXN3
15 80933450 G\A 0.13 -0.151 0.034 8.17E-06 TRIB2
20 3575970 T\C 0.36 -0.15 0.034 8.42E-06 RIPK1
D.2 GWAS results obtained for equine metabolic traits
using the standard linear mixed model algorithm pro-
vided in the GEMMA software.
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Figure D.12: Manhattan plot of GWAS results for neck circumference to height ratio.
Bonferonni threshold : p-value<5.70x10−8; suggestive threshold (dashed line): p-
value<1x10−5.
chromosome position alleles maf beta standard p-value nearest
estimate error gene
24 42014088 T\C 0.06 -0.825 0.167 7.67E-07 EVL
19 1139669 C\T 0.34 -0.426 0.088 1.32E-06 VEPH1
18 59290188 C\T 0.29 0.444 0.094 2.39E-06 CERKL
2 96094409 G\A 0.38 0.475 0.101 2.86E-06 ENO1
1 85323285 T\C 0.08 0.696 0.152 4.73E-06 CCSER2
1 78271748 G\A 0.23 0.459 0.101 5.84E-06 MAP10
23 44703897 A\G 0.09 0.658 0.148 8.78E-06 CAAP1
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Figure D.13: Manhattan plot of GWAS results for girth to height ratio.
Bonferonni threshold : p-value<5.70x10−8; suggestive threshold (dashed line): p-
value<1x10−5.
chromosome position alleles maf beta standard p-value nearest
estimate error gene
1 78254375 G\A 0.25 0.48 0.097 8.50E-07 MAP10
2 63795958 T\C 0.11 -0.618 0.132 2.74E-06 GALNTL6
1 121633670 G\C 0.47 0.413 0.088 2.79E-06 THSD4
2 84992300 T\C 0.31 0.418 0.089 2.83E-06 NR3C2
13 9371403 T\C 0.29 0.423 0.092 4.05E-06 SRRM3
4 3678246 T\C 0.05 -0.816 0.179 5.13E-06 FGL2
2 33817044 T\C 0.08 0.673 0.149 5.94E-06 VWA5B1
1 103364221 C\T 0.21 0.48 0.106 6.19E-06 ARRDC4
25 23370559 C\T 0.07 -0.722 0.161 7.43E-06 BRINP1
X 105199 T\G 0.25 -0.457 0.103 8.68E-06 ZBED1
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Figure D.14: Manhattan plot of GWAS results for fasting glucose.
Bonferonni threshold : p-value<5.70x10−8; suggestive threshold (dashed line): p-
value<1x10−5.
chromosome position alleles maf beta standard p-value nearest
estimate error gene
22 6982098 G\A 0.06 -0.803 0.152 1.36E-07 BANF2
8 9312611 T\C 0.31 0.469 0.092 3.10E-07 CRYBA4
4 3518141 C\T 0.11 -0.661 0.136 1.25E-06 CCDC146
14 26279221 A\G 0.05 -0.885 0.184 1.43E-06 GLRA1
30 14742954 A\G 0.26 -0.503 0.105 1.76E-06 GPATCH2
10 69248486 G\A 0.11 -0.611 0.13 2.58E-06 GJA1
4 18520506 A\G 0.37 -0.412 0.09 4.32E-06 ABCA13
4 27797636 A\G 0.29 0.426 0.093 5.21E-06 PCLO
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Figure D.15: Manhattan plot of GWAS results for fasting insulin.
Bonferonni threshold : p-value<5.70x10−8; suggestive threshold (dashed line): p-
value<1x10−5.
chromosome position alleles maf beta standard p-value nearest
estimate error gene
24 26630151 A\C 0.11 0.646 0.137 2.37E-06 SEL1L
X 21928679 G\A 0.38 0.37 0.079 2.97E-06 MAGEB10
3 74183327 T\G 0.1 0.645 0.138 3.05E-06 IGFBP7
24 3595302 C\T 0.07 0.721 0.156 3.69E-06 ATG14
10 53891179 T\C 0.15 0.516 0.112 3.91E-06 GRIK2
21 20162158 C\A 0.12 -0.573 0.124 4.14E-06 ISL1
19 18465605 G\A 0.19 0.497 0.109 5.41E-06 MFN1
17 7858033 C\A 0.13 -0.547 0.121 6.06E-06 PAN3
20 4274738 T\C 0.36 0.422 0.094 7.44E-06 FAM50B
29 13581131 A\G 0.24 -0.483 0.108 7.70E-06 ARMC3
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Figure D.16: Manhattan plot of GWAS results for glucose 75 minute post-oral sugar
test.
Bonferonni threshold : p-value<5.70x10−8; suggestive threshold (dashed line): p-
value<1x10−5.
chromosome position alleles maf beta standard p-value nearest
estimate error gene
28 26398304 AG 0.06 0.808 0.165 1.05E-06 PAH
6 50244553 CT 0.06 0.845 0.177 1.91E-06 BCAT1
2 66782128 TC 0.17 0.553 0.116 2.01E-06 DDX60
2 62150475 GT 0.06 0.784 0.165 2.05E-06 SCRG1
13 4944861 AG 0.1 0.705 0.15 2.46E-06 FTSJ2
26 22041705 GA 0.14 0.555 0.12 4.15E-06 MIR155
26 37222496 TC 0.31 0.457 0.099 4.37E-06 KRTAP10-
4
2 43256184 AG 0.23 0.489 0.108 5.51E-06 CAMTA1
16 69351494 TC 0.14 -0.596 0.131 5.79E-06 TF
9 24881334 CT 0.07 0.802 0.177 6.19E-06 TOX
7 69006360 CA 0.26 -0.428 0.095 6.34E-06 OR2AT4
2 35518476 GA 0.06 0.807 0.18 7.78E-06 IGSF21
14 29997110 GA 0.24 0.48 0.108 8.09E-06 SPINK5
3 100623132 CA 0.36 -0.423 0.095 9.06E-06 PPARGC1A
2 25319052 GA 0.3 -0.434 0.098 9.13E-06 SNRNP40
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Figure D.17: Manhattan plot of GWAS results for insulin 75 minute post-oral sugar
test.
Bonferonni threshold : p-value<5.70x10−8; suggestive threshold (dashed line): p-
value<1x10−5.
chromosome position alleles maf beta standard p-value nearest
estimate error gene
10 71762350 T\C 0.17 0.573 0.115 5.90E-07 RNF217
6 31912608 C\T 0.17 0.59 0.122 1.44E-06 CCND2
2 22478751 A\G 0.21 0.498 0.105 2.00E-06 GJB5
21 20162158 C\A 0.12 -0.593 0.128 3.70E-06 ISL1
4 52134927 T\C 0.36 0.42 0.091 4.24E-06 MACC1
10 16809864 A\C 0.34 -0.447 0.098 4.90E-06 DACT3
20 42730981 G\T 0.08 0.739 0.162 5.15E-06 VEGFA
20 50773321 C\T 0.15 -0.546 0.12 5.24E-06 GCM1
13 22421004 A\G 0.06 0.827 0.182 5.73E-06 ZKSCAN2
2 1227005 A\C 0.05 0.815 0.182 7.20E-06 JUN
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Figure D.18: Manhattan plot of GWAS results for trigylcerides.
Bonferonni threshold : p-value<5.70x10−8; suggestive threshold (dashed line): p-
value<1x10−5.
chromosome position alleles maf beta standard p-value nearest
estimate error gene
4 4849780 C\T 0.14 -0.603 0.117 2.51E-07 LHFPL3
20 57334198 A\C 0.14 -0.575 0.122 2.37E-06 NOTCH2NL
14 52391270 A\G 0.09 -0.664 0.144 3.93E-06 PRR16
30 16877429 C\T 0.13 -0.596 0.13 4.81E-06 KCTD3
21 56597442 G\A 0.21 -0.457 0.102 6.82E-06 LPCAT1
1 125321360 C\T 0.23 0.473 0.105 7.20E-06 IQCH
30 11310850 A\G 0.27 0.437 0.099 9.49E-06 HLX
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Figure D.19: Manhattan plot of GWAS results for non-esterified fatty acids.
Bonferonni threshold : p-value<5.70x10−8; suggestive threshold (dashed line): p-
value<1x10−5.
chromosome position alleles maf beta standard p-value nearest
estimate error gene
1 164702224 A\G 0.18 0.558 0.107 1.79E-07 NOVA1
2 105698972 A\G 0.1 0.648 0.133 1.05E-06 ADAD1
30 19352250 T\G 0.09 0.677 0.145 3.03E-06 BRINP3
1 183728003 G\A 0.23 -0.467 0.101 3.84E-06 KLHDC1
24 21462649 G\A 0.17 -0.49 0.106 3.91E-06 TTLL5
2 1779499 T\C 0.08 0.71 0.157 5.78E-06 OMA1
5 70713583 T\G 0.13 -0.545 0.123 8.97E-06 ABCD3
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Figure D.20: Manhattan plot of GWAS results for adrenocorticotropin hormone.
Bonferonni threshold : p-value<5.70x10−8; suggestive threshold (dashed line): p-
value<1x10−5.
chromosome position alleles maf beta standard p-value nearest
estimate error gene
18 62046771 T\G 0.05 0.842 0.178 2.27E-06 ZNF804A
21 10410234 C\T 0.13 0.55 0.117 2.50E-06 IPO11
22 37596454 C\T 0.23 0.483 0.104 3.68E-06 SNORD12
10 66817465 T\C 0.1 0.624 0.138 6.03E-06 CEP85L
23 29059985 A\C 0.14 -0.557 0.124 6.44E-06 PTPRD
25 14650611 T\C 0.09 0.617 0.137 7.10E-06 EPB41L4B
8 2823191 A\G 0.11 0.569 0.128 8.32E-06 SLC7A4
13 24073474 C\A 0.21 0.465 0.105 8.75E-06 SCNN1B
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Figure D.21: Manhattan plot of GWAS results for leptin.
Bonferonni threshold : p-value<5.70x10−8; suggestive threshold (dashed line): p-
value<1x10−5.
chromosome position alleles maf beta standard p-value nearest
estimate error gene
19 11111059 T\C 0.42 -0.433 0.091 2.13E-06 RPL22L1
25 27382469 G\T 0.28 -0.409 0.09 5.33E-06 STRBP
9 50462647 G\A 0.19 0.478 0.105 5.49E-06 ZFPM2
19 49581025 G\A 0.23 -0.458 0.101 5.70E-06 CCDC54
14 47283907 G\A 0.23 0.449 0.1 6.79E-06 MEGF10
19 43369395 G\A 0.22 -0.466 0.104 7.95E-06 ZBTB20
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Figure D.22: Manhattan plot of GWAS results for adiponectin.
Bonferonni threshold : p-value<5.70x10−8; suggestive threshold (dashed line): p-
value<1x10−5.
chromosome position alleles maf beta standard p-value nearest
estimate error gene
2 17691609 T\C 0.11 -0.691 0.133 1.85E-07 ZFP69B
6 68035083 G\A 0.11 0.646 0.137 2.25E-06 DIP2B
21 48226552 A\G 0.16 0.551 0.117 2.55E-06 CTNND2
15 21150905 C\T 0.39 -0.406 0.089 4.68E-06 ST6GALNAC2
2 85771023 G\A 0.17 -0.542 0.119 4.96E-06 TTC29
X 6005558 G\A 0.06 0.752 0.167 6.89E-06 GPR143
X 94742024 T\C 0.29 -0.403 0.09 8.17E-06 KIAA1210
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Table D.12: Replication of human GWAS candidate genes for metabolic traits using a
standard linear mixed model
Human metabolic trait associations
Gene
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BANF2 GLU 1.36E-07
NOVA1 NEFA 1.79E-07 X X X
ZFP69B APN 1.85E-07
LHFPL3 TG 2.51E-07 X X X
CRYBA4 GLU 3.10E-07
RNF217 INS OST 5.90E-07 X
EVL NH 7.67E-07
MAP10 GH 8.50E-07
PAH GLU OST 1.05E-06
ADAD1 NEFA 1.05E-06 X
CCDC146 GLU 1.25E-06
VEPH1 NH 1.32E-06 X X
GLRA1 GLU 1.43E-06 X
CCND2 INS OST 1.44E-06
GPATCH2 GLU 1.76E-06 X X X
BCAT1 GLU OST 1.91E-06 X X X
GJB5 INS OST 2.00E-06 X X
DDX60 GLU OST 2.01E-06
SCRG1 GLU OST 2.05E-06 X
RPL22L1 LEP 2.13E-06 X X
DIP2B APN 2.25E-06
ZNF804A ACTH 2.27E-06 X X X
SEL1L INS 2.37E-06
NOTCH2NL TG 2.37E-06
CERKL NH 2.39E-06
FTSJ2 GLU OST 2.46E-06
IPO11 ACTH 2.50E-06
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CTNND2 APN 2.55E-06 X X X X X X
GJA1 GLU 2.58E-06 X
GALNTL6 GH 2.74E-06 X X X X X
THSD4 GH 2.79E-06 X X X
NR3C2 GH 2.83E-06 X
ENO1 NH 2.86E-06
MAGEB10 INS 2.97E-06
BRINP3 NEFA 3.03E-06 X X X X X X
IGFBP7 INS 3.05E-06 X
SNORD12 ACTH 3.68E-06
ATG14 INS 3.69E-06
ISL1 INS OST 3.70E-06 X X
KLHDC1 NEFA 3.84E-06
GRIK2 INS 3.91E-06 X X X X
TTLL5 NEFA 3.91E-06
PRR16 TG 3.93E-06 X X X X
SRRM3 GH 4.05E-06
ISL1 INS 4.14E-06 X X
MIR155 GLU OST 4.15E-06
MACC1 INS OST 4.24E-06
ABCA13 GLU 4.32E-06 X X
KRTAP10-4 GLU OST 4.37E-06
ST6GALNAC2 APN 4.68E-06
CCSER2 NH 4.73E-06
KCTD3 TG 4.81E-06
DACT3 INS OST 4.90E-06
TTC29 APN 4.96E-06 X X
FGL2 GH 5.13E-06
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VEGFA INS OST 5.15E-06 X X X X
PCLO GLU 5.21E-06 X
GCM1 INS OST 5.24E-06 X
STRBP LEP 5.33E-06 X
MFN1 INS 5.41E-06
ZFPM2 LEP 5.49E-06 X X
CAMTA1 GLU OST 5.51E-06 X X X
CCDC54 LEP 5.70E-06 X X X
ZKSCAN2 INS OST 5.73E-06
OMA1 NEFA 5.78E-06 X
TF GLU OST 5.79E-06
MAP10 NH 5.84E-06
VWA5B1 GH 5.94E-06 X X
CEP85L ACTH 6.03E-06
PAN3 INS 6.06E-06 X
ARRDC4 GH 6.19E-06 X X X X X
TOX GLU OST 6.19E-06 X X X X X
OR2AT4 GLU OST 6.34E-06
PTPRD ACTH 6.44E-06 X X X X X X X
MEGF10 LEP 6.79E-06 X X X
LPCAT1 TG 6.82E-06 X
GPR143 APN 6.89E-06
EPB41L4B ACTH 7.10E-06
JUN INS OST 7.20E-06 X X X
IQCH TG 7.20E-06
BRINP1 GH 7.43E-06
FAM50B INS 7.44E-06
ARMC3 INS 7.70E-06 X
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IGSF21 GLU OST 7.78E-06 X X X
ZBTB20 LEP 7.95E-06 X X
SPINK5 GLU OST 8.09E-06
KIAA1210 APN 8.17E-06 X
SLC7A4 ACTH 8.32E-06
ZBED1 GH 8.68E-06
SCNN1B ACTH 8.75E-06
CAAP1 NH 8.78E-06
ABCD3 NEFA 8.97E-06
PPARGC1A GLU OST 9.06E-06 X X X X
SNRNP40 GLU OST 9.13E-06
HLX TG 9.49E-06 X X
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